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ABSTRACT 
 
Despite extensive epidemiological research and plausible biological mechanisms being 
elucidated, it is unclear whether vitamin D reduces risks of cancer incidence and mortality. 
Only for colorectal cancer does the observational evidence seem persuasive, whereas for 
other cancer types an anti-carcinogenic role has not been established convincingly, with 
rarer cancers seldom investigated. Similarly, whether vitamin D has a beneficial role on other 
chronic disease end-points and all-cause mortality remains uncertain, despite extensive 
research. 
 
Prospective studies which directly measure actual circulating 25-hydroxyvitamin D 
(25(OH)D) are viewed as the “gold standard” approach to assess vitamin D-disease 
associations. However, these studies are expensive to carry out (as circulating 25(OH)D 
usually has to be measured in all participants) and a single measurement of circulating 
25(OH)D may not reflect long-term exposures (due to within-person variability). An 
alternative approach, not yet used in European populations, is to create predictor scores of 
circulating 25(OH)D levels. This cost effective approach provides the opportunity to examine 
associations between predicted 25(OH)D and multiple outcomes (including less common 
diseases).  
 
Sex-specific predictor scores were derived in 4,089 participants from the European 
Investigation into Cancer and Nutrition (EPIC) study by quantifying the relationships between 
correlates/determinants of circulating 25(OH)D levels (using multivariable linear regression 
models). The predictor scores were validated in 2,029 participants with measured circulating 
25(OH)D levels. In summary, the predictor scores provided poor estimates of absolute 
circulating 25(OH)D levels but were more successful at ranking individuals similarly by their 
actual and predicted levels. The predictor scores were also able to replicate results from 
previous EPIC colorectal cancer incidence and prostate cancer incidence nested case-
control studies which used actual circulating 25(OH)D measurements. Overall, this evidence 
suggests that the predictor scores may have utility for epidemiological research but not in a 
clinical setting. 
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The predictor scores were then applied to the full EPIC cohort to assess the associations 
between predicted 25(OH)D levels with risks of cancer incidence and mortality, all-cause 
mortality, and cause-specific mortality. In summary, significant inverse predicted 25(OH)D 
score associations were observed for: overall cancer incidence and mortality; colorectal 
cancer incidence; lung cancer incidence and mortality; kidney cancer incidence; stomach 
and oesophageal cancer incidence; pancreatic cancer incidence and mortality; thyroid 
cancer incidence; prostate cancer mortality; all-cause mortality; circulatory disease mortality; 
respiratory disease mortality; and digestive disease mortality. However, due to the 
methodological limitations specific to 25(OH)D predictor scores - such as providing poor 
estimates of absolute levels - and observational epidemiology in general, it is important to 
acknowledge that alternative explanations may explain some or all of these observed 
relationships. 
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1. INTRODUCTION 
 
 
Vitamin D is predominantly known for its role in calcium and phosphorus metabolism but a 
potential anti-carcinogenic role was first proposed by Garland and Garland in 1980 (1). This 
hypothesis was further developed by the identification of the vitamin D receptor (VDR) and 
1α-hydroxylase (the enzyme which converts vitamin D into its most active form) throughout 
the body. Despite extensive epidemiological research and plausible biological mechanisms 
being elucidated, it is unclear whether vitamin D reduces risks of cancer incidence and 
mortality. Only for colorectal cancer does the observational evidence seem persuasive, 
whereas for other cancer types an anti-carcinogenic role has not yet been established 
convincingly. Possible biological roles for vitamin D in other chronic disease end-points have 
also been investigated. For circulatory disease mortality, inverse relationships have usually 
been reported; however, to date, only relatively small studies have been conducted. For 
respiratory disease and digestive disease mortality, little is known about a possible role for 
vitamin D as minimal prospective studies have been carried out. For all-cause mortality, 
previous research is suggestive of elevated risk at lower levels of circulating vitamin D; 
although recent research suggests a J- or U-shaped risk curve may exist, with increased risk 
observed at higher levels of circulating vitamin D. Thus, despite the high volume of research, 
many questions on the role of vitamin D on cancer incidence and mortality, circulatory 
disease, respiratory disease, digestive disease and all-cause mortality remain unanswered.  
 
In the first part of this analysis the relationships between dietary vitamin D intake and all-
cause and cancer caused mortality within the European Prospective Investigation into 
Cancer and Nutrition (EPIC) were investigated. In the second part of this study, data from 
EPIC were used to derive and validate predictor scores of circulating vitamin D status. These 
predictor scores was then applied to the full EPIC cohort to assess risks of cancer incidence 
and mortality, and all-cause mortality, circulatory disease mortality, respiratory disease 
mortality, and digestive disease mortality. 
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1.1 Vitamin D 
 
1.1.1 Production and metabolism of vitamin D 
 
Vitamin D is a fat soluble secosteroid which can be produced endogenously or obtained 
exogenously from dietary or supplementary sources (Figure 1). The two major forms are 
vitamin D2 (ergocalciferol; C28H44O) and D3 (cholecalciferol; C27H44O). Endogenously 
produced Vitamin D3 is produced by UVB (ultraviolet B) radiation (wavelength 290-315 nm) 
converting 7-dehydrocholesterol into previtamin D3. An immediate thermally induced 
isomerisation changes previtamin D3 into vitamin D3. Vitamin D-binding protein then 
transports vitamin D3 into the liver. Exogenous dietary vitamin D exists as either vitamin D2 
or D3. After ingestion these fat soluble compounds are incorporated into chylomicrons, 
absorbed through the lymphatic system, and then transported to the liver. In the liver, both 
endogenous and exogenous vitamin D are converted into 25-hydroxyvitamin D (25(OH)D; 
C27H44O2) in a reaction catalysed by 25-hydroxylase. The biologically active form of the 
vitamin is 1α,25-dihydroxyvitamin D (1,25(OH)2D; C27H44O3), and its formation from 25(OH)D 
is catalysed by the enzyme 1α-hydroxylase. This occurs within the kidney (where it is 
dependent on calcium and parathyroid hormone (PTH) concentrations) and in cells 
throughout the body. Circulating 25(OH)D is the main circulating form of vitamin D and is 
used as an indicator of body status as its half-life is estimated to be three weeks (2). In 
contrast, 1,25(OH)2D has an estimated half-life of less than four hours (3).  
 
The biological actions of 1,25(OH)2D are achieved by binding to the VDR, an intracellular 
hormone receptor, and can be categorised into genomic and rapid responses (4). The 
genomic response is the better understood. Once activated by 1,25(OH)2D, the VDR 
interacts with the retinoid X receptor, which in turn binds with 1,25(OH)2D (5;6). The 
activated VDR then modulates gene transcription by binding up or down to vitamin D 
responsive elements (5;6). Over 2,700 human genome sites have been identified as being 
involved in VDR binding (7). A recent genome wide study identified genes which VDR bind 
to that are associated with various health conditions, including: Crohn’s disease, type-1 
diabetes, and colorectal cancer (7). The expression of up to 229 genes may be affected by 
1,25(OH)2D (6;7). Rapid or non-genomic responses of vitamin D have recently been 
identified. Once more, 1,25(OH)2D actions are mediated through VDR; except this time the 
VDR are membrane bound and associated with caveolae domains, rather than located 
within the nucleus (4). Once membrane bound VDR have been activated, the rapid 
20 
 
responses are instigated through secondary messengers. This response has been proposed 
to explain the function of vitamin D in influencing intestinal absorption of calcium, insulin 
secretion of pancreatic β cells, and calcium entering muscle cells (6). 
 
The VDR is a vital mediator for the cellular effects of vitamin D. The gene encoding VDR is 
located at chromosome 12q13.11. To date, more than 60 polymorphisms of the VDR gene 
have been identified (8), but only a few VDR single nucleotide polymorphisms have been 
extensively studied with regard to cancer and other chronic diseases (9). One of these is the 
rs11568820 polymorphism (aka Cdx-2), which is situated in exon 1e and modulates 
transcription of VDR gene expression. Another is polymorphism rs10735810 (aka Fokl) 
which is located in the coding region of the VDR gene and therefore has an effect on the 
activity of the receptor. Finally the rs1544410 (aka Bsml), rs7675232 (aka Apal) and 
rs731236 (aka Taq1) single nucleotide polymorphisms are located in the 3’ end of the VDR 
gene. These polymorphisms have been hypothesised to alter the risks of colorectal cancer, 
breast cancer and prostate cancer. However, a recent review reported that these VDR 
polymorphisms did not substantially influence disease risk (10). Larger studies which can 
investigate how environmental exposures interact with these polymorphisms are required to 
broaden the understanding of how genetic variation may influence disease risk. 
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Figure 1. Vitamin D production and metabolism 
 
 
 
1.1.2 Biological roles of vitamin D 
 
Skeletal roles 
The skeletal roles of vitamin D are well defined, relative to the non-skeletal roles. In 
summary, vitamin D acts upon the intestine and bone to ensure calcium and phosphorus 
homeostasis (Figure 2). In the intestine, 1,25(OH)2D promotes the absorption of calcium and 
phosphorus. Specifically for calcium, this involves the up regulation of the expression of the 
epithelial calcium channel and calcium binding protein (6). In the bone, 1,25(OH)2D 
stimulates resorption by increasing the number of osteoclasts; this results in an increase of 
calcium and phosphorus into the circulation.   
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Figure 2. The summarised biological roles of Vitamin D related to chronic diseases 
 
 
 
 
Non-skeletal roles 
The biological plausibility of non-skeletal roles for vitamin D has grown from the identification 
of the VDR and 1-α-hydroxylase throughout the body. VDR expression has been identified in 
at least 38 different tissue types, including: adipose, brain, breast cancer cells, colon, liver, 
lung, muscle, ovary, pancreas, prostate, skin, stomach, and thyroid (4;7). Expression of 1α-
hydroxylase, not influenced by PTH and calcium concentration, has been identified in cancer 
and non-cancer cells, such as prostate, colon, lung, endothelial, brain, pancreatic β-cells, 
and monocytes (4;11). Outlined below are proposed effects of vitamin D on cancer, 
immunity, cardiovascular diseases and metabolic disorders (Figure 2). 
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Cancer 
Laboratory research suggests that vitamin D and its metabolites may reduce incidence of 
many types of cancers by mechanisms said to include: suppression of proliferation and 
stimulating differentiation in cancer cells; inducing apoptosis in cancer cells; and inhibiting 
tumour angiogenesis. 
 
Suppression of proliferation, and stimulation of differentiation in cancer cells 
Separate anti-proliferative roles of vitamin D have been proposed. Firstly, 1,25(OH)2D has 
been shown to promote cell cycle arrest by enhancing the expression of Cyclin-dependent 
kinase (CDK) inhibitors (6;12). For instance, elevated p21 and p27 gene expression was 
enhanced by 1,25(OH)2D in squamous cancer cell lines within the head and neck (12). A 
proposed inhibitory mechanism of vitamin D against cellular proliferation is through aiding 
the preservation of gap junction intercellular communication during carcinogenesis; 
consequently strengthening contact inhibition of proliferation (13). Vitamin D has also been 
shown to promote differentiation within pathway target genes (14). 
 
Inducing apoptosis in cancer cells  
Experimental evidence has highlighted a regulatory role for vitamin D on the principal 
mediators of apoptosis in cancer cells (6;15). Specifically, 1,25(OH)2D decreases the 
expression of BCL2 and BCL-XL (anti-apoptotic proteins) and increases the expression of 
BAX, BAK and BAD (pro-apoptotic proteins) (15). Apoptosis in tumour cells has also been 
shown to be constrained by the down regulation of telomerase activity by 1,25(OH)2D; 
leading to swifter telomere shortening (16). 
 
Inhibition of tumour angiogenesis  
In vitro and in vivo models have demonstrated that vitamin D has anti-angiogenic properties. 
In vitro, 1,25(OH)2D has been shown to reduce vascular endothelial growth factor (VEGF) 
induced cell sprouting, elongation and proliferation (17). In vivo, tumour xenografts placed on 
mice, induced to overexpress VEGF, were treated with 1,25(OH)2D and, after 8 weeks, 
reduced vascularisation was observed (17). 
 
Immunity 
Roles for vitamin D on the innate and adaptive immune systems have been discovered. For 
the innate immune system, 1,25(OH)2D has been shown to induce the differentiation of 
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monocytes into macrophages (18). Furthermore, 1,25(OH)2D has been shown to improve 
the chemotactic and phagocytic capabilities of macrophages (19). Antimicrobial actions of 
vitamin D, via 1,25(OH)2D activation of the cathelicidin gene (CAMP) and expression of 
defensin β2, have also been uncovered (20). Vitamin D also influences the adaptive 
immunity response. Activation of the VDR can result in greater production of T regulatory 
cells by providing dendritic cells with their telerogenic properties (19). Also on T-cells, 
1,25(OH)2D has been shown to reduce the production of the Th1 (IL-2 and IFN-γ) and Th17 
cytokines (6). 
 
Cardiovascular disease and metabolic disorders 
Vitamin D may be beneficial for cardiovascular health through blood pressure homeostasis, 
with two separate proposed mechanisms. Firstly, animal models have demonstrated that 
1,25(OH)2D is a negative regulator for the renin-angiotensin system (RAS), which regulates 
blood pressure, by reducing renin synthesis (21). Renin is a protease that hydrolyses 
angiotensinogen into angiotensin I, which in turn is converted into angiotensin II by the 
angiotension-converting enzyme. Angiotensin II elevates blood pressure by constricting 
blood vessels and increasing renal absorption of sodium and water (via aldosterone release) 
(6). A secondary mechanism whereby 1,25(OH)2D lowers blood pressure is through the 
reduction of PTH levels, which have been associated with elevated blood pressure (6). A 
modulatory role for vitamin D on cardiac sarcomere contraction has also been proposed 
(22). Rat models have demonstrated a rapid response (within 2.5 minutes) for 1,25(OH)2D 
on decreasing the contraction of sarcomeres (22). 
 
A role for vitamin D on metabolic disorders, such as insulin resistance, has been proposed. 
Firstly, 1,25(OH)2D treatment has been shown to promote transcription of U-937, the human 
promonocytic cell insulin resistance gene (23). Vitamin D may also indirectly influence insulin 
sensitivity through its role in calcium homeostasis. Calcium is required for insulin mediated 
responses in certain tissues, such as skeletal muscle and adipose tissue (24). Finally, 
vitamin D may also improve insulin sensitivity and promote β-cell survival through the 
modulation of cytokine levels; as elevated cytokine levels may trigger β-cell apoptosis (24). 
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1.1.3 Exogenous dietary sources of vitamin D (including supplements) 
 
Natural dietary sources of vitamin D are limited. Good natural sources include fatty fish (such 
as mackerel and sardines) and egg yolks (Table 1). Fortification of margarine spreads and 
some cereal products with vitamin D2 and D3 mean they are also good sources. Vitamin D 
within foods remains stable through storage, processing, and cooking (25). 
 
In the UK, dietary supplements usually contain 10-25 µg vitamin D3 and are recommended 
by manufacturers to be taken daily. Cod liver oil is also a good source of vitamin D (Table 1). 
The contribution of dietary supplements to vitamin D status is country dependent. For 
instance, amongst Norwegian men and women, supplements contributed 42% and 49% of 
total dietary intake of vitamin D respectively (26). An analysis of 1958 British Birth Cohort, 
conducted in 2007, reported that 13% of men and 20% of women used vitamin D 
supplements (27). 
 
Analyses on quantifying the relationship between intakes of vitamin D and circulating 
25(OH)D has been conducted among men in winter months when endogenous synthesis is 
low (28). From a mean baseline of 70.3 nmol/L, a 1 μg increase in vitamin D3 intake 
increased circulating 25(OH)D by 0.70 nmol/L. From a lower baseline level, 25(OH)D 
increases 1.2 nmol/L for a 1 μg increase in vitamin D3 intake (29). 
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Table 1. Vitamin D content of foods (μg/100g) 
(Sources: Olsen et al., (25); SACN (30)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
                
 
 
 
Milk and milk products 
 
Cow's milk 0.01-0.03 
Human milk 0.04 
Cream 0.1-0.3 
Cheese 0.03-0.05 
Yoghurt Trace-0.04 
 
Eggs 
 
Whole 1.8 
Yolk 4.9 
 
Fats and oils 
 
Butter 0.8 
Cod liver oil 210 
 
Fortified food items 
 
Breakfast cereals 3-8 
Margarines and spreads 5.8-8.0 
 
Meat and meat products 
 
Beef, lamb, pork, veal Trace 
Poultry, game Trace 
Liver 0.2-1.1 
 
Fish and fish products 
 
White fish Trace 
Fatty fish 5-10 
Crustacea and molluscs Trace 
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1.1.4 Deficiency and toxicity 
 
Deficiency 
Deficiency of vitamin D impairs dietary calcium absorption and causes demineralisation of 
the skeleton. Severe deficiency is usually defined as circulating 25(OH)D levels below 25 
nmol/L and at these levels rickets and osteomalacia can occur in children and adults. 
Circulating 25(OH)D levels between 25 and 50 nmol/L have been associated with elevated 
PTH, a biomarker of vitamin D insufficiency (9). Circulating 25(OH)D equal to or above 75 
nmol/L has been quantified as the optimal level for bone health (29). At this level PTH is 
maximally suppressed, calcium absorption is greatest, bone loss rate reduced, and bone 
mineral density is highest. 
 
Toxicity 
The identified effects of vitamin D toxicity result from increased free circulating 1,25(OH)2D, 
which in turn causes increased absorption of dietary calcium and hypercalcaemia. Toxicity 
should not occur from endogenous over-production of vitamin D. This is because excess 
sunlight exposure, beyond what is required to produce maximal previtamin D3, should result 
in biologically inert photoproducts being produced from previtamin D3 and vitamin D3 (3;9). 
Toxicity therefore usually only occurs from high intakes, mainly of supplements containing 
vitamin D. Long-term vitamin D supplementation of less than 25 μg per day has been shown 
to be non-toxic (9). Most studies which tested higher dosages of supplements have only 
been conducted for a short time period. One small intervention study of 12 patients 
administered dosages of vitamin D3 which by the end of the 28 week study resulted in mean 
circulating 25(OH)D concentrations above 386 nmol/L (31). Vieth (32) suggests that adverse 
effects have not been reported with circulating 25(OH)D concentrations up to 140 nmol/L. 
Generally, major gaps exist in the current knowledge regarding the upper limits of toxicity. 
Most of the intervention studies testing this were small and lasted only for short time periods, 
consequently long-term and uncommon effects are unknown.  
 
The picture is further complicated by results from recent prospective epidemiological studies 
where elevated all-cause mortality risks were observed at circulating 25(OH)D levels ranging 
from >93-140 nmol/L when compared against the mid-range reference categories (33-35). 
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Similarly, increased risks of overall cancer (35;36), prostate cancer (37-39) and pancreatic 
cancer (40) have also recently been reported in prospective studies when individuals within 
the highest circulating 25(OH)D levels were compared against those in reference categories 
with lower levels. Thus, intervention studies testing the long-term effects of supplement 
dosages over 25 μg are required.  
 
 
1.1.5 Recommended vitamin D intakes 
 
The recommended vitamin D intakes from the WHO/FAO and selected European countries 
are presented in Table 2. Current recommendations for vitamin D intakes are based on 
preventing rickets in children and osteomalacia in women of childbearing age.  
 
In the UK, where latitudes range from 50-60°N, the majority of the country is unable to 
endogenously produce vitamin D3 in winter months. Despite this, specific recommendations 
for men and non-childbearing women aged between 4 and 65 years are not in place. 
Generally, the different country recommendations are of a similar magnitude and have 
specific guidance for babies, children, pregnant and lactating women and the elderly. 
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Table 2. Recommendations for vitamin D intake from the WHO/FAO, United Kingdom, 
Nordic Countries and Spain 
(Sources:  SACN (30); Doets et al, (41); FAO/WHO (42)  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WHO/FAO Men (µg/day) Women (µg/day) 
0 months to 9 years 5 5 
10 years to 50 years 5 5 
51-65 years 10 10 
65+ years 15 15 
Pregnancy  5 
Lactation  5 
United Kingdom   
0-6 months 8.5 8.5 
7 months to 3 years 7 7 
4 years to 65 years - - 
65+ years 10 10 
Pregnancy - 10 
Lactation, 0-4 months - 10 
Lactation, 4+ months - 10 
 
Nordic countries 
  
9 months 10 10 
5 years to 69 years 7.5 7.5 
70+ years 10 10 
Pregnancy - 10 
Lactation - 10 
 
Spain 
  
0 months to 9 years 10  
10 years to 49 years 5  
50 years 10  
70+ years 15  
Pregnancy  10 
Lactation  10 
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1.2 Correlates and determinants of Vitamin D status 
 
1.2.1 Skin synthesis 
 
Endogenous production of vitamin D3 requires sufficient skin exposure with the appropriate 
UVB radiation (wavelength 290-315 nm). Between mid-October and the start of April at 
latitudes of 52°N and above endogenous production of vitamin D3 is not possible (43). This 
is because, in these months and at those locations, UVB does not reach the earth surface. 
The traditional belief was that the vitamin D endogenously produced in summer provides 
sufficient supplies for the winter months when production is not possible (in northern 
latitudes). Peak circulating 25(OH)D levels are usually observed in the late summer and 
early autumn months, while lowest levels are found at the end of winter months (9). An 
analysis of 7,437 Caucasian men and women from the 1958 British Birth Cohort reported 
lower mean circulating 25(OH)D levels for individuals who had their blood collected in the 
winter and spring months (41.1 nmol/L) compared to those who had blood collected in 
summer and autumn months (60.3 nmol/L) (27). Similarly, a southern Italian study reported 
lower mean 25(OH)D level for participants who had their blood collected in winter (42.7 
nmol/L) compared to summer (84.0 nmol/L) (44). Finally, a small Norwegian cross-sectional 
analysis also reported lower mean 25(OH)D levels for participants who had their blood 
samples collected in March (51.5 nmol/L) compared to September (82.0 nmol/L) (45). 
 
The current best estimates are that a fair skinned person at 40°N latitude requires 5-10 
minutes sunlight exposure (during a sunny summers day) 2-3 times per week to achieve 
maximal previtamin D3 production (9). For dark skinned individuals this time period increases 
to 30 minutes exposure.  
 
Despite endogenous vitamin D3 production not being possible above certain latitudes during 
periods of the year, using latitude as a predictor of vitamin D status seems only appropriate 
when comparing regions within certain European countries. For instance, in the UK, higher 
mean 25(OH)D levels were found among individuals from the southern regions of the 
country (42.6 nmol/L in winter/spring and 62.4 nmol/L in summer/autumn) compared to those 
from Scotland (35.4 nmol/L in winter/spring and 50.9 nmol/L in summer/autumn) (27). A 
similar latitude gradient has also been observed in a French study, where individuals located 
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in the south west of the country (94.0 nmol/L) had higher mean circulating 25(OH)D levels 
than those whose residence was in the north of the country (43.0 nmol/L) (46). However, 
when comparing circulating 25(OH)D levels across different European countries a reverse 
relationship has been observed. A recent systematic review of studies in Western, Northern 
and Southern Europe calculated a mean increase in circulating 25(OH)D of 11.8 nmol/L was 
associated with a 10 degree increase in latitude of country of residence (47).  
 
Other factors which may affect vitamin D biosynthesis include clothing and sunscreen use. 
Covering of skin when exposed to sunlight can reduce the endogenous production of vitamin 
D3. Hatun et al., (48) observed that Turkish teenage girls who followed the Islamic dress 
code and wore a veil had a circulating 25(OH)D level half of that to those who were unveiled. 
Endogenous production of vitamin D is also reduced when sunscreen is used. The capacity 
of the skin to produce vitamin D3 is lowered by up to 95% when sunscreen with sun 
protection factor (SPF) 15 is applied (3). 
 
 
1.2.2 Skin pigmentation and ethnicity/race 
 
Endogenous vitamin D production varies with ethnicity (9). The primary explanation for this is 
that dark skinned people have more melanin than light skinned people. Melanin acts as a 
natural sunscreen filtering out UVB radiation, meaning that darker skinned people need 
extended exposures in the sunlight, in comparison to light skinned people, to produce 
equivalent amounts of vitamin D3. Another possible reason for differences in circulating 
25(OH)D between ethnic groups is the cultural variation in the consumption of foods 
containing vitamin D. 
 
1.2.3 Adiposity 
 
An inverse association between higher body mass index (BMI), waist circumference, or 
obesity and circulating 25(OH)D concentrations has consistently been reported (27;49;50). 
The main biological reason for this is that vitamin D is fat soluble so therefore less 
bioavailable amongst obese people due to deposition in body fat compartments (51). 
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Another potential reason for this difference is that the decreased mobility associated with 
obesity causes less sunlight exposure and ultimately less endogenous vitamin D production. 
 
 
1.2.4 Physical activity 
 
Increased physical activity has been positively associated with increased circulating 
25(OH)D (49;52). Whether this is because physical activity is a surrogate measure for sun 
exposure and a healthier lifestyle, or this is caused by a separate biological effect is not 
known.  
 
 
1.2.5 Sex 
 
Men have higher circulating 25(OH)D levels than women. Scragg et al., (53) in an National 
Health and Nutrition Examination Survey III (NHANES III) analysis reported a mean 
circulating 25(OH)D of 78.8 nmol/L in men compared to 72.6 nmol/L in women. This 
difference in vitamin D status may partially be due to women having more body fat than men 
and circulating 25(OH)D being inversely correlated with adiposity. However, Scragg et al., 
(53) adjusted for BMI and many of the other determinants highlighted in this section and the 
gender difference in circulating 25(OH)D remained. 
 
 
1.2.6 Age 
 
An inverse relationship between age and circulating 25(OH)D has been consistently 
observed. Amongst 6,228 participants of NHANES III, the mean circulating 25(OH)D for 
participants aged 20-39 years and over 60 years was 81 nmol/L and 69.5 nmol/L 
respectively (53). One possible explanation for this age related decline is that sunlight 
exposure and dietary intakes reduce as a person gets older. However, this does not explain 
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the observation that a 70 year old exposed to the same amount of sunlight as a 20 year old 
endogenously produces one quarter of vitamin D (3). This may be caused by an age 
dependent reduction in 7-dehydrocholesterol production in the epidermis of the skin where 
more than 80% of previtamin D3 is produced (54). Another possible biological explanation is 
that renal production of 1,25(OH)2D declines with age (9).  
 
 
1.2.7 Smoking habits 
 
The majority of previous research has reported smokers as having lower vitamin D status 
than non-smokers (49;50). Possible reasons for this difference include: a smoking induced 
increase in liver enzyme activity (55); a reduction in dermal production amongst smokers (9); 
and other differences in sun exposure, diet, and lifestyle factors which may exist between 
smokers and non-smokers.  
 
 
1.2.8 Retinol 
 
Vitamin A and vitamin D compete for the same receptor protein (retinoid X receptor). This 
means that high levels of vitamin A may inhibit vitamin D absorption (9). High intake of 
retinol has been associated with reduced bone mineral density, hip fracture increases, and 
increased fracture risk (56). Whether retinol has any deleterious effects on the anti-
carcinogenic properties of vitamin D is unknown.  
34 
 
1.3 Previous epidemiological research: vitamin D and risks of cancer 
incidence and mortality  
 
Epidemiological research has investigated the vitamin D and cancer association using 
differing approaches to vitamin D exposure assessment. Prospective studies that use 
circulating 25(OH)D measures are often viewed as the "gold standard" (9). This is because 
measurement of this metabolite encompasses endogenously produced vitamin D from UVB 
exposure and dietary/supplementary intakes. The overview of the relevant scientific literature 
below generally focuses on prospective nested case-control and cohort studies which have 
measured actual or predicted circulating 25(OH)D levels.  
 
Note: some of the risk estimates from the previous epidemiological research have been 
inverted so higher levels of actual or predicted circulating 25(OH)D are consistently 
compared against lower levels. 
 
1.3.1 Overall cancer  
 
Incidence 
Few studies have examined the association between vitamin D and risk of total cancer 
incidence and the results are inconsistent. The mixed findings may be due to the 
heterogeneous relationships between vitamin D and the incidences of the individual cancer 
types. Using a model of predicted circulating 25(OH)D in the Health Professionals Follow-Up 
Study (HPFS), Giovannucci et al., (52) reported a 16% lower risk (95% CI: 0.72-0.98) of total 
cancer incidence associated with a 25 nmol/L increment. A recent German cohort analysis 
also observed a reduced overall cancer incidence risk amongst men in the highest quartile of 
circulating 25(OH)D when compared against those in the lowest group (HR 0.75, 95% CI: 
0.60-0.94); although, amongst women, no association was observed (57). In a small 
Swedish cohort, a U-shaped relationship for total cancer incidence was observed (as was for 
cancer mortality and all-cause mortality) (35). In the fully adjusted model a 68% increased 
risk of cancer incidence was observed amongst those in the highest circulating 25(OH)D 
category when compared against the mid-range reference category (>98 vs. 46-93 nmol/L, 
RR 1.68, 95% CI: 1.06-2.65). Increased risk was also observed amongst those in the lowest 
25(OH)D category (<39 vs. 46-93 nmol/L, RR 1.65, 95% CI: 1.08-2.54) (35).  
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One small randomised control trial (RCT) has been conducted where women in the 
intervention group received 27.5 μg of vitamin D3 plus 1.5 g of calcium daily over 4 years 
(58). A suggestive, but statistically non-significant, inverse association was observed for 
vitamin D and risk of cancer incidence (RR 0.59, 95% CI: 0.32-1.10). The association was 
statistically significant when the intention to treat analysis was conducted (P-value <0.03). 
However, the trial methodology has been criticised and results are inconclusive (9). 
 
Mortality 
The limited studies investigating the association between circulating 25(OH)D and overall 
cancer mortality have produced variable results. Especially of interest is the unexpected 
elevated risk of death at high circulating 25(OH)D levels. In an NHANES III analysis, 
Freedman et al., (36) reported an increased risk amongst men with circulating 25(OH)D 
levels above 100 nmol/L when compared versus those with the lowest concentrations (<37.5 
nmol/L) (RR 1.85, 95% CI: 1.02-3.35; P-trend 0.09); although, no such association was 
observed amongst women (RR 0.64, 95% CI: 0.35-1.18; P-trend 0.29). One smaller U.S. 
study reported a near significance 92% increased risk (HR 1.92, 95% CI: 1.00-3.70; P-trend 
0.086) of cancer death amongst men in the highest circulating 25(OH)D exposure category 
when compared against those in the lowest category (>74.9 vs. <49.7 nmol/L) (54). Finally, 
in a small Swedish cohort of elderly men, an increased risk was observed amongst those 
with the highest levels of circulating 25(OH)D (>93 nmol/L) when compared against those in 
the mid-range reference category (46-93 nmol/L) (HR 2.45, 95% CI: 1.36-4.00) (35). A U-
shaped relationship was observed in this study, as a risk estimate of similar magnitude was 
observed when participants in the lowest exposure category (<39 nmol/L) were compared 
against those in the reference group (HR 2.34, 95% CI: 1.36-4.00) (35).  
 
In contrast, several studies have reported that higher levels of actual circulating, or predicted 
25(OH)D, are associated with lower cancer mortality risk. First, in the HPFS, a 29% lower 
cancer mortality risk (HR 0.71, 95% CI: 0.60-0.83) was associated with a 25 nmol/L 
increment in predicted circulating 25(OH)D (52). Most recently, a German prospective 
analysis observed a 30% decreased cancer mortality risk (HR 0.70, 95% CI: 0.53-0.93) 
when those with circulating 25(OH)D levels above 50 nmol/L were compared against those 
with levels below 30 nmol/L (59). Another small cohort analysis reported a significantly 
reduced risk amongst men and women in the highest 25(OH)D exposure category (>57.5 vs. 
<25 nmol/L, HR 0.45, 95% CI: 0.22-0.93) (60). Finally, an analysis of older men within the 
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Whitehall II cohort, reported a near-significance inverse association between circulating 
25(OH)D and cancer mortality risk (61).  
 
The remaining five prospective studies published to date have reported statistically non-
significant associations (62-65). The largest of these studies was a recent analysis in the 
U.S. based Southern Community Cohort Study (Q4 vs. Q1, OR 0.78, 95% CI: 0.47-1.28; P-
trend 0.53) (64). Similarly, in the WHI observational study, a weak non-significant decreased 
cancer mortality risk was observed amongst the post-menopausal women (Q4 vs. Q1, HR 
0.72, 95% CI: 0.46-1.14; P-trend 0.11) (65).  
 
Overall, mixed results have been observed in the prospective studies to date and the role of 
vitamin D on cancer mortality is uncertain. Further studies are required to investigate this 
relationship.  
 
 
1.3.2 Colorectal cancer  
 
Incidence 
The vitamin D-cancer hypothesis was first proposed from the results of an ecological study 
which reported positive associations between latitude and colon cancer mortality (1). Since 
then, numerous studies for colorectal cancer incidence and mortality have been published 
which have used dietary vitamin D or measured circulating 25(OH)D as exposure measures. 
The totality of the epidemiological research suggests that high vitamin D status may lower 
the risk of colorectal cancer incidence.  
 
The majority of dietary studies have reported statistically non-significant reductions in risk. 
For instance, in the E3N cohort of women a non-significant 11% reduced risk (HR 0.89, 95% 
CI: 0.58-1.36) was observed amongst participants with the highest daily intake (>3.23 μg) 
compared with those in the lowest intake category (<1.72 μg) (66). Also, a recent EPIC 
nested case-control study reported non-significant reduced risk amongst participants with 
the highest dietary intakes (≥5.8 vs. <2.1 μg per day, RR 0.84, 95% CI: 0.60-1.17; P-trend 
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0.19) (67). Two cohort studies have reported statistically significant associations amongst 
men but not women. Firstly, in the Cancer Prevention Study II Nutrition Cohort (United 
States) (CPS-II), a reduced risk amongst men in the highest intake quintile (>13.1 μg per 
day) was observed when compared against those in the lowest intake quintile (<2.8 μg per 
day) (RR 0.71, 95% CI: 0.51-0.98; P-trend 0.02) (68); no association was observed for 
women. Similarly, Park et al., (69), in a Multiethnic Cohort Study analysis reported a 28% 
(HR 0.72, 95% CI: 0.51-1.00; P-trend 0.03) reduced risk of colorectal cancer amongst men 
in the highest intake quintile (>6.9 μg per day) versus those in the lowest (<1 μg per day); 
once more, no association observed amongst women. 
 
The largest prospective study which measured circulating 25(OH)D was a nested case-
control study using EPIC data (67). In this analysis circulating 25(OH)D was categorised in 
five pre-defined clinically relevant groups (<25; ≥25 to <50; ≥50 to <75; ≥75 to <100; ≥100 
nmol/L). When colorectal cancer risk was analysed, the estimates did not reach statistical 
significance but were suggestive of elevated risk at lower circulating 25(OH)D levels, and 
reduced risk at higher circulating levels (P-trend <0.001). However, when colon and rectal 
cancer were analysed separately divergent associations were observed. For colon cancer, a 
statistically significant increased risk was observed at the lowest circulating 25(OH)D levels 
(<25 vs. ≥50 to <75 nmol/L, OR 1.90, 95% CI: 1.10-3.29; P-trend <0.001), and a non-
significant reduced risk was observed at the highest level (≥100 vs. ≥50 to <75 nmol/L, OR 
0.71, 95% CI 0.46-1.08); in contrast, no association was observed for rectal cancer (67). A 
similar relationship for colon cancer was also reported in a pooled analysis of the Nurses’ 
Health Study (NHS) and HPFS data (70). When participants in the highest circulating 
25(OH)D group were compared against those in the lowest, a 54% statistically significant 
reduced risk was observed (OR 0.46, 95% CI: 0.24-0.89; P-trend 0.005). Similarly to the 
EPIC study, no associations were reported for rectal cancer (70).  
 
A Multiethnic cohort nested case-control study observed an inverse association for colorectal 
cancer (OR per doubling of circulating 25(OH)D, 0.68; 95% CI: 0.51-0.92) (71). Whereas two 
other nested case-control studies reported non-significant inverse risk estimates for colon 
cancer (72;73). However, no association for colorectal cancer was observed in the 
Physicians’ Health Study (PHS) (Q4 vs. Q1, OR 1.08, 95% CI: 0.62-1.87) (74). Whereas a 
recent Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) nested case-
control study did not observe lower colorectal cancer risk for higher 25(OH)D levels; instead 
a suggestive elevated risk at lower levels was observed (<25 vs. 50-75 nmol/L, OR 0.68, 
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95% CI: 0.45-1.03) (75). Nor was an association observed in a small Japanese nested case-
control study (76). However, overall, in a recent meta-analysis, a 5.9 nmol/L increment in 
circulating 25(OH)D was associated with a 4% lower risk (95% CI: 0.94-0.97) of colorectal 
cancer (77); similar risk estimates were also yielded for colon and rectal cancers. 
 
To date, two RCTs have examined the influence of vitamin D supplementation on colorectal 
cancer risk (78;79). The largest was the Women’s Health Initiative (WHI) clinical trial which 
included 36,282 post-menopausal women (79). During the 7 year duration of the trial, the 
intervention group were given 10 μg of vitamin D plus 1 g of elemental calcium each day. By 
the end of the trial 168 and 154 colorectal cancer cases were reported in the intervention 
and placebo groups respectively, and the final results were null (HR 1.08, 95% CI: 0.86-1.34; 
P-value 0.51). Criticisms of the trial methodology have been used to explain this null result. 
First, the duration of 7 years may be too short a time period for vitamin D to influence 
colorectal cancer occurrence (80). Second, the dosage given to intervention subjects may 
have been too low to differentiate them from the placebo control group (9). Finally, the 
contrast in circulating 25(OH)D levels between the intervention group and the placebo group 
was lower than expected due to a high proportion of women taking non-study supplements 
(80). A small UK RCT which administered vitamin D supplements to examine the prevention 
of osteoporotic fractures, also, in secondary analyses, recorded cases of colon cancer 
amongst subjects (78). The intervention group of the trial was administered with the daily 
equivalent of 41 μg per day over a 5 year period. Once more no reduction in colon cancer 
was observed amongst the intervention group (HR 1.02, 95% CI: 0.60-1.74; P-value 0.94).  
 
Overall, the observational evidence suggests that vitamin D may have a protective colorectal 
cancer role. However, these observations have yet to be confirmed with intervention studies. 
 
Mortality 
Few studies have investigated the relationship between vitamin D and colorectal cancer 
mortality; although the limited available evidence indicates that vitamin D may have an 
important role in limiting tumour progression. Some studies suggest a greater reduction of 
risk at higher exposures to vitamin D for mortality than incidence (80). A U.S. ecological 
study reported higher risk estimates for male colon cancer mortality (RR 1.27 95% CI: 1.24-
1.30) than incidence (RR 1.11, 95% CI: 1.08-1.13) when the northern regions of the country 
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were compared against the southern (81); similar associations were observed for women, 
and also for rectal cancer in both sexes.  
 
Most prospective studies have measured pre-diagnostic circulating 25(OH)D to assess the 
relationship with colorectal cancer mortality. In an NHANES III analysis, a non-significant 
reduced colorectal cancer mortality risk was observed when participants in the highest and 
lowest exposure groups were compared (≥100 vs. <50 nmol/L, RR 0.35, 95% CI: 0.11-1.14; 
P-trend 0.09) (36). Ng et al., (82), in a pooled NHS and HPFS analysis of 304 participants 
with colorectal cancer, reported a non-significant reduced risk of death for participants in the 
highest 25(OH)D quartile when compared against the lowest (Q4 vs. Q1, HR 0.61, 95% CI: 
0.31-1.19; P-trend 0.23). Within EPIC, pre-diagnostic circulating 25(OH)D levels amongst 
participants who developed colorectal cancer were also associated with a subsequent 
reduced mortality risk from the disease (n=444 deaths; Q5 vs. Q1, HR 0.69, 95% CI: 0.50-
0.93; P-trend 0.04) (83). 
 
To date, one small Japanese study has measured post-diagnosis levels of actual circulating 
25(OH)D to assess the relationship (84); amongst the 257 colorectal cancer patients, higher 
levels of 25(OH)D were associated with improved survival (HR per 2.5 nmol/L increment 
0.91, 95% CI: 0.84-0.99). Similarly, a NHS and HPFS analysis, which predicted post-
diagnosis levels of circulating 25(OH)D levels for 1,017 colorectal cancer patients reported a 
50% reduced risk (HR 0.50, 95% CI: 0.26-0.95; P-trend 0.02) for participants within the 
highest category (>77 nmol/L) when compared against those in the lowest category (<64 
nmol/L) (85). 
 
Overall, the limited data does suggest that vitamin D levels are inversely associated with 
colorectal cancer mortality. However, the few previous studies have been small and larger 
analyses are required. 
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1.3.3 Prostate cancer 
 
Incidence 
The large body of evidence investigating the association between vitamin D and prostate 
cancer does not support the hypothesis that high vitamin D exposures can reduce incidence. 
Ecological studies first highlighted an inverse association between UVB radiation and 
prostate cancer mortality (86). Although this association was not supported by dietary intake 
studies, where one cohort (9.2 vs. 2.4 μg, RR 0.80, 95% CI: 0.50-1.30; P-trend 0.86) (87) 
and two case-control studies (88;89) failed to observe any associations. 
 
The vast majority of prostate cancer nested case-control studies which measured circulating 
25(OH)D have yielded null or non-significant positive associations (90-99). In a previous 
EPIC analysis, a suggestive increased risk was observed when the highest versus lowest 
quintiles of circulating 25(OH)D were compared (OR 1.28, 95% CI: 0.88-1.88; P-trend 0.19) 
(97). Significant positive prostate cancer associations have been observed in three Nordic 
nested case-control studies. Firstly, Tuohimaa et al., (37), reported an elevated risk of 
circulating 25(OH)D levels greater than 80 nmol/L, when compared against the mid-range 
(40-59 nmol/L) category (OR 1.70, 95% CI: 1.10-2.40); at low concentrations (≤19 nmol/L), 
increased risk was also reported (OR 1.50, 95% CI: 0.80-2.70), although this association 
was not statistically significant. Secondly, in an ATBC study analysis, a 56% increased 
prostate cancer risk (OR 1.56, 95% CI: 1.15-2.12; P-trend 0.01) was observed when the 
highest and lowest 25(OH)D exposure groups were compared (38). Finally, in the largest 
prospective study to date (n=2,106 cases) which measured circulating 25(OH)D, a 30 nmol/L 
higher increment was associated with a 13% greater (95% CI: 1.02-1.25) prostate cancer 
risk (39). Overall, a recent meta-analysis, which did not include the latter two of these 
studies with positive associations, hinted at a possible weak positive relationship, as a 25 
nmo/L increment in circulating 25(OH)D was associated with an OR of 1.04 (95% CI: 0.99-
1.10) (100). Overall, the evidence is unsupportive of a possible protective role for vitamin D 
on prostate cancer; instead null or non-significant positive associations have usually been 
reported. 
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Mortality 
The effect of vitamin D on prostate cancer mortality has rarely been studied. An NHANES III 
analysis (74 prostate cancer deaths) which used pre-diagnosis circulating 25(OH)D 
measurements did not find an association (80-<100 vs. <50 nmol/L, RR 1.23, 95% CI: 0.50-
3.05; P-trend 0.84) (36). However, a small Norwegian cohort study (52 deaths) which 
collected post-diagnosis circulating 25(OH)D measurements from patients, reported a 67% 
significantly reduced risk (95% CI: 0.14-0.77) of prostate cancer mortality when the medium 
and lowest exposure categories were compared (50-80 vs. <50 nmol/L) (101). Finally, a 
more recent analysis in the HPFS study (114 deaths) used pre-diagnostically measured 
25(OH)D to assess the relationship with lethal prostate cancer and reported inverse linear 
associations (Q4 vs. Q1, OR 0.43, 95% CI:0.24-0.76; P-trend 0.001) (102). Overall, few 
studies have examined vitamin D with prostate cancer mortality end-points and those that 
have been conducted have been small; that said, the results indicate that a possible inverse 
relationship may be present, although larger studies are required to confirm this association. 
 
 
1.3.4 Breast cancer 
 
Incidence 
Ecological studies have reported inverse associations between UVB and breast cancer 
incidence and mortality (103;104). However, mixed results have been observed in 
observational studies. Several case-control studies have reported a significantly reduced 
breast cancer risk at higher circulating 25(OH)D levels (105-109). In a U.S. study of pre- and 
post-menopausal women, a 44% reduced risk (OR 0.56, 95% CI: 0.41-0.78; P-trend 0.004) 
was observed when participants in the highest exposure category were compared against 
those in the lowest (109). A German study in post-menopausal women reported a 
significantly reduced risk when the highest circulating 25(OH)D category was compared 
versus the lowest (≥75 vs. <30 nmol/L, OR 0.31, 95% CI: 0.24-0.42; P-trend <0.0001) (108).  
    
In contrast to these inverse associations, nested case-control studies have generally not 
reported associations, except for two recent smaller studies (110;111). Firstly, a small 
Danish study (n=120 cases) observed reduced risk amongst pre-menopausal women when 
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participants in the highest and lowest tertiles (>84 vs. <60 nmol/L) of circulating 25(OH)D 
were compared (OR 0.38, 95% CI: 0.15-0.97) (110). Secondly, a E3N cohort analysis 
observed a 27% reduced risk (95% CI: 0.55-0.96; P-trend 0.02) amongst participants in the 
highest tertile of 25(OH)D when compared against the lowest tertile (67.4 vs. <49.4 nmol/L) 
(111). However, these inverse significant associations have not been replicated in larger 
nested case-control studies (112-117). For instance, a WHI analysis, which included 1,067 
cases, did not report an association (Q5 vs. Q1, OR 1.22, 95% CI: 0.89-1.67; P-trend 0.20) 
(114). Furthermore, in an EPIC analysis, which was the largest study to date (n=1,391 
cases), no association was observed when the highest and lowest quintiles of circulating 
25(OH)D were compared (>63 vs. ≤39.3 nmol/L, OR 1.07, 95% CI: 0.85-1.36; P-trend 0.67) 
(117). Despite these largely null results of individual nested case-control studies, a recent 
meta-analysis - published prior to the EPIC analysis – reported a pooled OR estimate of 0.87 
(95% CI: 0.77-0.99) for the highest versus the lowest circulating 25(OH)D quintiles (118).  
 
One vitamin D-breast cancer RCT has been conducted. The WHI clinical trial also recorded 
breast cancer incidence amongst subjects. Similarly to colorectal cancer, no reduction in 
breast cancer incidence was observed at the end of the 7 year intervention (HR 0.96, 95% 
CI: 0.85-1.09) (114).  
 
Generally, the results of case-control studies have largely been consistent and indicate a 
possible protective role for vitamin D; whilst the mixed results from nested case-control 
studies require further investigation in larger prospective analyses. 
 
Mortality 
One study which measured pre-diagnosis circulating 25(OH)D levels has been conducted. 
An NHANES III analysis of pre- and post-menopausal women observed a non-significant 
reduced breast cancer mortality risk when individuals with circulating 25(OH)D of 80-<100 
nmol/L were compared against those within the lowest reference category (vs. <50 nmol/L, 
RR 0.65, 95% CI: 0.18-2.38) (36). Other studies have measured circulating 25(OH)D levels 
after diagnosis. Goodwin et al., (119) reported a near-significance HR of 0.63 (95% CI: 0.38-
1.04) when patients in the highest and lowest circulating 25(OH)D categories (>72 vs. <50 
nmol/L) were compared against each other. Similarly, a near significance reduced mortality 
risk was reported amongst German post-menopausal women with high circulating 25(OH)D 
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levels when compared against the mid-range reference category (≥55 vs. <35 nmol/L, HR 
0.65, 95% CI: 0.42-1.00; P-trend 0.07) (120). However, a beneficial prognostic role for 
vitamin D post breast cancer diagnosis was not observed in the Women’s Healthy Eating 
and Living (WHEL) Study, where no association was observed between circulating 25(OH)D 
levels and recurrence of the disease (≥75 vs. 25 nmol/L, OR 0.88, 95% CI: 0.43-1.75) (121).  
 
Overall, whether vitamin D has a role on breast cancer mortality is uncertain as few previous 
studies have been conducted, and those that have been published have generally been 
small. 
 
 
1.3.5 Pancreatic cancer 
 
The prospective data investigating the relationship between circulating 25(OH)D and 
pancreatic cancer risk are inconsistent. An ATBC study of 200 men who smoked, reported 
an OR of 2.92 (95% CI: 1.56-5.48; P-trend 0.001) for participants in the highest circulating 
25(OH)D quintile when compared against those in the lowest quintile (122). This significant 
positive association was not replicated in the United States (U.S.) based Prostate, Lung, 
Colorectal, and Ovarian Screening Trial (PLCO) study (Q5 vs. Q1, OR 1.45, 95% CI: 0.66-
3.15; P-trend 0.49) (123). It was suggested that this inconsistency was due to the Finnish 
ATBC participants being smokers (a major pancreatic cancer risk factor) and living at higher 
latitudes than participants in the U.S. PLCO study (124).  
 
The recent Vitamin D Pooling Project of Rarer Cancers (VDPP) included data from eight 
worldwide prospective cohorts (including the ATBC and PLCO studies). A nested case-
control study from the pooling project used clinically defined circulating 25(OH)D exposure 
categories within their models (40). When the highest and mid-range clinically defined 
exposure categories (≥100 vs. 50-<75 nmol/L) were compared, elevated pancreatic cancer 
risk was observed once more (OR 2.12, 95% CI: 1.23-3.64). No association was found for 
the lowest exposure group when compared against the mid-range (<25 vs. 50-<75 nmol/L, 
OR 0.95, 95% CI: 0.68-1.32). Importantly, when the ATBC cohort was excluded in sensitivity 
analyses, a similar association was observed in the highest circulating 25(OH)D category 
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(≥100 nmol/L) (OR 2.95, 95% CI: 1.47-5.93). Also, when limited to U.S. only cohorts, the 
association remained in the highest exposure group (OR 2.98, 95% CI: 1.48-6.02) (40). 
However, other recent U.S. based prospective analyses have yielded inverse associations 
(124;125). Firstly, predicted circulating 25(OH)D was inversely associated with pancreatic 
cancer risk in the full NHS and HPFS cohorts (RR 0.65, 95% CI: 0.50-0.86; P-trend 0.001) 
(124). More recently, a pooled analysis of five U.S. based nested case-control studies 
(HPFS, NHS, PHS, WHI, and the Women’s Health Study (WHS)) which measured 
circulating 25(OH)D, reported an inverse association when individuals in the highest and 
lowest quintiles were compared (>81 vs. <45 nmol/L, OR 0.67, 95% CI: 0.46-0.97; P-trend 
0.03) (125). In the same analysis, when identical clinically defined exposure categories used 
by the VDPP were used, elevated risk was not observed at 25(OH)D levels above 100 
nmol/L when compared against the mid-range reference category (vs. 50-<75 nmol/L, OR 
1.01, 95% CI: 0.63-1.62).  
 
Overall, the data reveal a mixed and confusing picture for the vitamin D-pancreatic cancer 
relationship, underlying the importance of additional studies. 
 
 
1.3.6 Lung cancer 
 
Null lung cancer results have been observed in the three previous prospective studies which 
measured circulating 25(OH)D. In a small Finnish cohort (n=122 cases), no association was 
observed for lung cancer incidence when the highest and lowest tertile of circulating 
25(OH)D were compared (RR 0.72, 95% CI: 0.43-1.19; P-trend 0.22) (126). Similarly, in the 
ATBC study (n=500 cases), no association was reported (Q5 vs. Q1, OR 1.08, 95% CI: 
0.67-1.75) (127). Finally, an NHANES III analysis observed no association for lung cancer 
mortality (n=258 deaths) when the highest and lowest quartiles of circulating 25(OH)D were 
compared (≥80.3 vs. <44 nmol/L, RR 0.95, 95% CI: 0.62-1.44) (128). The sparse data mean 
that whether vitamin D has any lung cancer role is unknown and further prospective studies 
are required. Importantly, these larger analyses should (where sample size allows) assess 
the vitamin D-lung cancer relationship amongst never smokers, as risk estimates for lung 
cancer may be biased by smoking habits, or alternatively whether any benefit may be 
greater to smokers. 
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1.3.7 Kidney cancer 
 
A VDPP nested case-control study (n=775 cases) reported null results when individuals in 
the low (<25 vs. 50-<75 nmol/L, OR 0.94, 95% CI: 0.64-1.37) and high (≥100 vs. 50-<75 
nmol/L, OR 0.92, 95% CI: 0.44-1.92) circulating 25(OH)D groups were compared against 
those in the mid-range reference group (P-trend 0.86) (129). However, an analysis of the 
NHS and HPFS cohorts (n=408 cases), recently reported that a 25 nmol/L increment in 
predicted circulating 25(OH)D was associated with a 44% lower kidney cancer risk (95% CI: 
0.42-0.74) (130).  
 
 
1.3.8 Stomach and oesophageal cancers 
 
Few studies have analysed the relationships between circulating 25(OH)D and stomach and 
oesophageal cancers. An VDDP nested case-control study reported null results when 
individuals with low levels (<25 vs. 50-<75 nmol/L, OR 0.90, 95% CI: 0.65-1.24) and high 
levels (≥100 vs. 50-<75 nmol/L, OR 0.81, 95% CI: 0.39-1.69) of circulating 25(OH)D were 
compared against the mid-range reference category (131). Similar null results were also 
observed when oesophageal and gastric cancer were analysed separately (131). In contrast, 
a Chinese nested case-control study reported a statistically significant 77% (OR 1.77, 95% 
CI: 1.16-2.70; P-trend 0.003) increased oesophageal squamous cell carcinoma risk amongst 
men when the highest circulating 25(OH)D quartile was compared against the lowest (132); 
although no associations were observed for other oesophageal cancer disease subtypes. 
Finally, in the HPFS cohort, higher predicted circulating 25(OH)D was associated with 
significantly lower risk of oesophageal cancer (HR per 25 nmol/L increment in predicted 
25(OH)D, 0.37, 95% CI: 0.17-0.80) and non-significantly lower risk of stomach cancer (HR 
per 25 nmol/L increment in predicted 25(OH)D, 0.58, 95% CI: 0.26-1.33) (52). 
 
 
1.3.9 Bladder cancer 
 
To date, two prospective nested case-control studies have been conducted with divergent 
results reported within them. Firstly, a significant linear inverse association was observed in 
an ATBC cohort study (≥50 vs. <25 nmol/L OR 0.58, 95% CI: 0.34-0.98; P-trend 0.04) (133). 
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In contrast, an analysis within the PLCO cohort reported no association between circulating 
25(OH)D and bladder cancer risk (Q4 vs. Q1, OR 1.20, 95% CI:0.74-1.92; P-trend 0.56) 
(134). No association was also observed in the HPFS cohort between predicted 25(OH)D 
and bladder cancer (52). 
 
 
1.4.0 Non-Hodgkin’s lymphoma 
 
A VDPP nested case-control analysis, reported null non-Hodgkin lymphoma (NHL) 
associations for participants in the lowest (<25 vs. 50-<75 nmol/L, OR 1.08, 95% CI: 0.78-
1.50) and highest (≥100 vs. 50-<75 nmol/L, OR 0.86, 95% CI: 0.57-1.27) circulating 
25(OH)D category when compared against the mid-range reference group (P-trend 0.68) 
(135). A null result was also reported within the HPFS study when predicted 25(OH)D was 
used to assess vitamin D status (52). While a recent EPIC nested case-control study of 
1,127 cases also observed a null result for overall lymphoid cancers (Q4 vs. Q1, OR 1.05, 
95% CI: 0.81-1.38; P-trend 0.52) (136). However, for B-NHL, the most common disease 
subtype, a significant positive association was observed within EPIC (≥75 vs. 50-<75 nmol/L, 
OR 1.36, 95% CI: 1.00-1.83; P-trend 0.007) (136). 
 
 
1.4.1 Skin cancer 
 
For overall skin cancer incidence, a near significance positive association was observed for 
predicted circulating 25(OH)D in the HPFS study (52). Other studies have stratified skin 
cancer by disease subtype. For melanoma, non-significant positive associations have been 
observed in two previous nested case-control studies (137;138), the largest of which was an 
ATBC analysis (≥50 vs. <25 nmol/L, OR 1.32, 95% CI: 0.64-2.72; P-trend 0.51) (137). For 
the relationship between 25(OH)D and overall non-melanoma skin cancer (NMSC), a small 
study (178 cases) of elderly men reported an inverse association (Q5 vs. Q1, OR 0.54, 95% 
CI: 0.31-0.96; P-trend 0.04) (139). A NHS analysis reported positive associations for both 
basal cell carcinoma (BCC; <75 vs. >50 nmol/L, OR 2.07, 95% CI: 1.58-2.80; P-trend 
<0.0001) and squamous cell carcinoma (SCC; <75 vs. >50 nmol/L, OR 3.77, 95% CI: 1.70-
8.36; P-trend 0.0002) when the highest and lowest quartiles of circulating 25(OH)D were 
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compared (140). However, a smaller Australian study reported a positive association for 
BCC (≥75 vs. <75 nmol/L, OR 1.51, 95% CI: 1.10-2.07), but not SCC (≥75 vs. <75 nmol/L, 
OR 0.67, 95% CI: 0.44-1.03) (138). The contrasting results between studies may be 
influenced by the vitamin D-skin cancer relationship being confounded by sun exposure 
habits/behaviours; the studies highlighted above adjusted for sun exposure covariates to 
varying degrees.   
 
 
1.4.2 Ovarian cancer and endometrial cancer 
 
Four previous nested case-control studies have analysed the relationship between 
circulating 25(OH)D and ovarian cancer risk (141-143). The largest was a VDPP analysis 
which included 516 cases and reported non-significant associations at low (<25 vs. 50-<75 
nmol/L, OR 1.08, 95% CI: 0.64-1.81) and high (≥100 vs. 50-<75 nmol/L, OR 1.11, 95% CI: 
0.61-2.05) circulating 25(OH)D levels when compared against the mid-range reference 
category (P-trend 0.65) (143). Similarly, the other nested case-control studies did not 
observe any associations (141;142). A recent meta-analysis of prospective studies also 
reported a non-significant risk estimate (RR per 50 nmol/L of 25(OH)D, 0.83, 95% CI: 0.63-
1.08) (144). 
 
Data for vitamin D and endometrial cancer are sparse, with only one nested case-control 
study being conducted to date. In this VDPP analysis, non-significant associations were 
reported when individuals in the low (<25 vs. 50-<75 nmol/L, OR 1.02, 95% CI: 0.68-1.53) 
and high (≥100 vs. 50-<75 nmol/L, OR 0.85, 95% CI: 0.47-1.53) circulating 25(OH)D groups 
were compared against those in the mid-range reference group (P-trend 0.81) (145). A null 
result was also reported in an NHS study which used predicted 25(OH)D levels to assess 
status (Q5 vs. Q1, HR 1.00, 95% CI: 0.73-1.36) (146).  
 
 
1.4.3 Other less common cancers  
 
Prospective data on the relationships between vitamin D and other less common cancers in 
Western populations are absent. For instance, no previous nested case-control or cohort 
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analyses have been carried out for liver and thyroid cancers; whilst for brain cancer, the only 
previous analysis was in the HPFS, where a non-significant positive association observed 
with predicted circulating 25(OH)D (52).  
 
 
 
1.5 Previous epidemiological research: vitamin D and risks of all-
cause and cause-specific mortality  
 
1.5.1 All-cause mortality 
 
The available prospective data suggests that a low vitamin D status may contribute to 
elevated all-cause mortality risk. In studies which solely investigated the circulating 
25(OH)D-all-cause mortality relationship using linear models, consistent inverse associations 
have been observed when the high and low exposure groups are compared. One of the 
largest prospective studies to date, in terms of the number of all-cause deaths (n=3,215 
deaths), was of elderly men (mean baseline age of 77 years) who were participants of the 
Whitehall II cohort (61). In this analysis the all-cause mortality HR for a twofold higher 
measure of circulating 25(OH)D was 0.78 (95% CI: 0.72-0.85) (61). Similarly, the Southern 
Community Cohort Study nested case-control study, which included 1,852 all-cause deaths, 
observed a reduced all-cause mortality risk when the highest quartile of circulating 25(OH)D 
was compared against the lowest quartile (OR 0.56, 95% CI: 0.44-0.70) (64); with similar 
associations observed amongst African American and non-African American participants. 
Another larger cohort study (n=1,083 deaths) reported a 40% reduced all-cause mortality 
risk (HR 0.60, 95% CI: 0.50-0.71) when individuals with high and low concentrations of 
circulating 25(OH)D were compared (>50 vs. <30 nmol/L) (59).  
 
Other smaller prospective studies have observed similar inverse linear associations (63;147-
151); although a number of other small studies have reported non-significant associations 
(54;65;152). For instance, in a WHI observational study analysis, a weak non-significant 
reduced all-cause mortality risk was observed amongst the post-menopausal women 
participants (Q4 vs. Q1, HR 0.80, 95% CI: 0.51-1.25; P-trend 0.39) (65).  
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Meta-analyses for all-cause mortality have yielded similar risk estimates despite differing 
study inclusion criteria. A 28% reduced all-cause mortality risk was observed when the 
highest and lowest quartiles were compared (61). Whereas Schöttker et al., (59), in a linear 
dose-response analysis, reported a HR of 0.92 (95% CI: 0.89-0.95) being associated with a 
20 nmol/L higher level of circulating 25(OH)D. 
 
However, three studies with a larger number of deaths and wider ranges of circulating 
25(OH)D levels, have observed a J- or U-shaped relationship, with greater all-cause 
mortality risk at higher as well as lower 25(OH)D levels (33-35). The largest of these studies 
was a Danish retrospective cohort study which included 247,574 participants amongst whom 
15,198 deaths were recorded (33). Within this study, a J-shaped risk curve was observed, 
with a 42% increased all-cause death risk (RR 1.42, 95% CI: 1.31-1.53) found amongst 
participants with circulating 25(OH)D above 140 nmol/L when compared against the 50 
nmol/L reference category (33). While in an NHANES III analysis of the general population, a 
U-shaped risk relationship was present, with a non-significant increased all-cause mortality 
risk observed at circulating levels 25(OH)D above 125 nmol/L when compared against the 
mid-range reference category (75-97.5 nmol/L) (34). Finally, a U-shaped relationship and 
increased risk at higher circulating 25(OH)D was also observed in a Swedish cohort of 
elderly men (35); amongst those with the highest levels of circulating 25(OH)D (>93 nmol/L), 
an increased risk was also observed when compared versus the reference category (vs. 46-
93 nmol/L, HR 1.57, 95% CI: 1.12-2.19) (35).  
 
A meta-analysis of smaller RCT’s in which a supplementary vitamin D intervention was 
administered, reported a significantly reduced occurrence of all-cause mortality (153). 
Amongst the 57,311 participants, 4,777 all-cause deaths occurred across the 18 studies, 
and a summary RR of 0.93 (95% CI: 0.87-0.99) was reported for participants who received 
vitamin D supplements.  
 
Generally, in smaller studies, reduced all-cause death risks have been consistently observed 
with higher levels of circulating 25(OH)D, and this observational evidence has been further 
supported by the aforementioned meta-analysis of small RCT’s. However, three larger 
observational studies have observed J- or U-shaped relationships, with increased all-cause 
50 
 
mortality risks associated with higher 25(OH)D levels. This possible detrimental effect of 
higher levels of vitamin D requires further investigation in other large prospective studies. 
 
 
1.5.2 Circulatory disease mortality 
 
The relationships between circulating 25(OH)D and circulatory/cardiovascular disease 
mortality have been studied frequently in prospective studies. In the largest study to date 
(n=1,358 vascular deaths) - an analysis of older men in the Whitehall II cohort - the vascular 
mortality HR for a twofold higher measure of circulating 25(OH)D was 0.80 (95% CI: 0.70-
0.91); with similar risk estimates observed for ischaemic heart disease, strokes and other 
vascular deaths, when analysed separately (61). A similar inverse association was also 
observed in a Finnish cohort analysis in which 933 cardiovascular disease deaths were 
recorded amongst the men and women participants during the follow-up period (Q5 vs. Q1, 
HR 0.76, 95% CI: 0.61-0.95; P-trend 0.005) (154). In the NHANES III study, a reduced 
cardiovascular disease mortality risk was observed when the highest and lowest quartiles of 
circulating 25(OH)D were compared (>80 vs. <45 nmol/L. HR 0.78, 95% CI: 0.68-0.90) (34). 
Other smaller studies have also observed significant inverse associations between 
circulating 25(OH)D and circulatory disease mortality end-points (64;155;156). In the U.S. 
based Southern Community Cohort Study (n=531 circulatory disease deaths), reduced 
circulatory disease mortality risks were reported amongst African American (OR 0.63, 95% 
CI: 0.47-0.83; P-trend 0.003) and non-African American (OR 0.47, 95% CI: 0.31-0.72; P-
trend <0.001) participants in the highest quartile of circulating 25(OH)D when compared 
against individuals in the lowest quartile (64).  
 
Non-significant associations have also been observed in a number of smaller studies 
(35;54;59;63;65;157). Most recently, a prospective German analysis (n=350 cardiovascular 
disease deaths) reported a non-significant reduced cardiovascular disease mortality when 
participants with the highest and lowest levels of circulating 25(OH)D were compared (>50 
vs. <30 nmol/L, HR 0.78, 95% CI: 0.57-1.06) (59). However, a recent meta-analysis of 18 
prospective studies, many of which are detailed above, reported a 21% reduced overall 
vascular mortality risk (RR 0.79, 95% CI: 0.72-0.87) when the highest and lowest quartiles 
were compared (61).  
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Overall, the prospective evidence is indicative of an inverse relationship between circulating 
25(OH)D and circulatory disease deaths. However, the studies conducted to date have been 
relatively small, with only two having more than 1,000 circulatory disease deaths recorded 
during the follow-up period. Thus, larger studies are warranted as the association can then 
be analysed across subgroups of other circulatory disease risk factors which many confound 
(e.g. smoking habits, BMI and age) the relationship. 
 
 
1.5.3 Digestive disease mortality 
 
The relationship between vitamin D and digestive disease mortality has seldom been 
studied. One small Danish cohort analysis, with just 34 digestive disease deaths, reported 
an inverse association with circulating 25(OH)D (Q4 vs. Q1, HR 0.28, 95% CI: 0.10-0.78; P-
trend 0.004) (62). For liver disease mortality, a non-significant inverse association was also 
observed with circulating 25(OH)D among 75 patients with chronic liver failure (158). Other 
small studies have also reported vitamin D deficiency amongst liver disease patients (159-
161), but whether this is a causal association or a consequence of the disease – due to 
compromised digestive and liver functions – is unclear. Larger studies, with sufficient cases 
and longer follow-up times are required to further scrutinise this relationship. 
 
 
1.5.4 Respiratory disease mortality 
 
To date, only three prospective studies have analysed the association between circulating 
25(OH)D and respiratory disease mortality; with inverse associations observed within them 
all. The largest (497 respiratory disease deaths) was from the UK based Whitehall II study, 
where a HR of 0.69 (95% CI: 0.56-0.85) was observed for a twofold higher measure of 
circulating 25(OH)D (61). Two recent smaller cohort studies also observed inverse 
associations between circulating 25(OH)D and respiratory disease mortality (59;62). Firstly, 
in a Danish cohort analysis in which 47 respiratory deaths were recorded (Q4 vs. Q1, HR 
0.26, 95% CI: 0.09-0.75; P-trend 0.0042) (62). Most recently, a prospective German analysis 
reported reduced respiratory disease mortality when participants with the highest and lowest 
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levels of circulating 25(OH)D were compared (>50 vs. <30 nmol/L, HR 0.40, 95% CI: 0.18-
0.89) (59). Generally, further larger prospective analyses are required to investigate the 
circulating 25(OH)D-respiratory disease mortality relationship. 
 
 
 
1.6 Previous circulating 25-hydroxyvitamin D predictor scores  
 
While directly measuring circulating 25(OH)D is viewed as the “gold standard” approach in 
prospective epidemiological studies to assess vitamin D-disease associations, the 
availability, collection and laboratory analysis of blood samples on a large-scale may be 
prohibitively expensive. Instead case-control studies nested within prospective cohorts are 
usually undertaken. However, nested case-control datasets are specific for a disease or 
disease subtype as the control participants, usually selected using incidence density 
sampling, are uniquely matched to cases by follow-up time, time of year of blood collection, 
age, and other criteria. This means that the relationships between vitamin D and other 
disease end-points cannot be carried out without creating a new disease-specific nested 
case-control dataset.  
 
A further weakness of studies which directly measure circulating 25(OH)D is that blood 
samples have usually only been collected on one occasion (usually at baseline of the study). 
This means that within-person variation in circulating levels of 25(OH)D (half-life of ~3 
weeks) is usually not taken into account. Vitamin D status at a given point in time is reflective 
of recent sun exposures and behaviours (e.g. beach holiday, season, sunbathing habits), as 
well as dietary/supplementary intakes. Correlations between circulating 25(OH)D levels 
within individuals has been shown to be fairly stable over 2-3 years (correlation coefficients 
of ~0.70) (52;162). However, studies which have investigated the reproducibility of 
circulating 25(OH)D levels over longer time periods (5 years plus) have observed 
attenuations in correlation coefficients to ~0.50 (163;164), suggesting that a single measure 
of circulating 25(OH)D may not be an optimal reflection of long-term vitamin D status.  
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An alternative approach to measuring actual circulating 25(OH)D, which has previously been 
used to assess disease risks in the U.S. based HPFS and Framingham Offspring cohorts, is 
to derive predicted circulating 25(OH)D scores (52;165). In both studies, actual circulating 
25(OH)D measurements - available for a subset of cohort participants - were modelled in 
multiple regression models with predictors/correlates of vitamin D status, such as: location of 
residence, vitamin D intake, physical activity, and body size. Then the validated predictor 
scores were applied to the full cohorts, creating a predicted circulating 25(OH)D value for 
each participant. This variable was then used to assess risks of either cancer incidence and 
mortality (52) or type-2 diabetes (165). In validation analyses in the NHS and HPFS cohorts, 
similar associations for colorectal, pancreatic and prostate cancers, type-2 diabetes and 
hypertension were observed when the predicted 25(OH)D and actual circulating 25(OH)D 
measurements were used to assess vitamin D status (164). This approach is cost-effective 
as actual circulating 25(OH)D measurements to derive the predictor score are only required 
from a subset of cohort participants. Furthermore, once the scores have been created they 
can be applied to all cohort participants (minus those whose samples were used in predictor 
score derivation), meaning that multiple disease end-points can be assessed. Another 
advantage is that predictor scores may provide more stable long-term indicators of vitamin D 
status, than actual measurements of circulating 25(OH)D, as the constituent model variables 
used to derive the scores are relatively stable over time (e.g. BMI or region of residence) 
(9;52). Predictor scores of 25(OH)D status have only been previously used twice in U.S. 
cohorts to assess chronic disease risk. Whether this analytical approach is appropriate for 
European populations is unknown.  
 
 
 
1.7 Other prediction scores derived in prospective cohort studies 
 
While predictor scores of 25(OH)D have been previously used to estimate vitamin D 
exposures, most previous prediction scores derived from prospective cohort data have been 
used to directly predict dichotomous chronic disease outcomes. Most notably, the 
Framingham cardiovascular disease risk score (derived from the Framingham Heart Study) 
was developed to identify individuals at high-risk of developing the disease (166). Exposures 
included when calculating an individual’s Framingham score are: age, blood cholesterol 
levels, smoking status and duration, blood pressure, and the presence of diabetes (166). In 
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the UK, the Framingham score has been adopted into clinical practice, as a patient’s risk of 
a cardiovascular event (within 10 years) can be calculated in all electronic patient record 
systems (167).  
 
Multiple prediction scores have also been derived from prospective cohort data for type 2 
diabetes risk (167). The components of these scores usually were: age, anthropometric 
measurements, family history of diabetes, smoking status, hypertension, blood triglyceride 
and cholesterol levels, and in some scores, diet, alcohol consumption and physical activity 
(167). To date, none of the type 2 diabetes prediction scores have been used in a clinical 
setting to identify high and low-risk individuals (167). 
 
 
1.8 Summary  
 
Despite the large amount of recent research that has investigated the associations between 
vitamin D and cancer incidence and mortality, cause-specific mortality, and all-cause 
mortality, many uncertainties remain. The best evidence for a reduced incidence of disease 
is for colorectal cancer, while for other cancer types, heterogeneous results have emerged. 
For prostate cancer, previous research is non-supportive of an inverse association, with 
some recent studies even reporting an elevated risk with higher circulating 25(OH)D levels. 
While for breast cancer, the prospective data does not support a role for vitamin D in 
lowering disease risk. Other rarer cancers have been studied less frequently or not at all 
(e.g. thyroid cancer and liver cancer).  
 
For other chronic disease end-points, such as circulatory disease mortality, prospective 
studies which measured circulating 25(OH)D levels have usually reported inverse 
associations; however, these studies were relatively small in terms of the number of 
recorded deaths. For respiratory disease mortality and digestive disease mortality few 
previous studies have been carried out. 
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Many of these previous studies contain small numbers of incidence cases/deaths, and have 
adjusted for other risk factors which may confound the vitamin D-cancer relationships to 
varying extents. Measurements of actual and predicted 25(OH)D levels may be especially 
vulnerable to residual confounding from other chronic disease risk factors as higher 
25(OH)D levels are usually correlated with lower adiposity/BMI, higher physical activity 
levels, younger age, and not smoking (as detailed in Section 1.2). Due to these concerns, 
analyses in cohorts with a large number of recorded incident cases and deaths, and in which 
information on possible confounding variables have been extensively collected, are required.   
 
More data are also required to investigate the unexpected elevated risks previously 
observed for prostate cancer incidence, pancreatic cancer incidence and total cancer 
mortality associated with higher levels of circulating 25(OH)D. Similarly, for the vitamin D-all-
cause mortality relationship, the J- and U-shaped associations observed in previous studies 
require further investigation. Understanding the relationships between circulating 25(OH)D 
and chronic disease and all-cause mortality end-points is paramount in setting dosage 
regimens for future intervention studies and ultimately shaping public health policy. Further 
prospective research is required to aid understanding of these relationships.  
 
Prospective studies directly measuring actual circulating 25(OH)D are viewed as the “gold 
standard” approach to assess the vitamin D associations. However, these studies are 
expensive to carry out (as circulating 25(OH)D has to be measured in all participants), 
disease specific (when used in nested case-control studies), and the single measurement of 
circulating 25(OH)D may not reflect long-term exposures. An alternative approach, not yet 
used in European populations, is to create predictor scores for circulating 25(OH)D. This 
cost effective approach means associations between predicted 25(OH)D and multiple 
outcomes (including rarer diseases) can be investigated. 
 
This EPIC research used circulating 25(OH)D measures taken from a subset of the cohort to 
derive and validate predictor scores of 25(OH)D status. These predictor scores were then 
applied to the full EPIC cohort (minus those individuals whose circulating samples were used 
to derive the score) and used to assess risks of cancer incidence and mortality, circulatory 
disease mortality, respiratory disease mortality, digestive disease mortality, and all-cause 
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mortality. Prior to predictor score derivation, the relationships between dietary vitamin D and 
all-cause and cancer caused mortality within the full EPIC cohort were also assessed.  
 
 
 
1.9 Aims 
 
The aims of these analyses were: (1) to assess the relationships between dietary vitamin D 
and all-cause and cancer caused mortality in EPIC; (2) to derive and validate predictor 
25(OH)D scores using correlates/determinants of vitamin D status; (3) to apply the validated 
predictor 25(OH)D scores to the full EPIC cohort to assess the incidence risks of overall 
cancer and individual cancers; (4) to apply the validated predictor 25(OH)D scores to the full 
EPIC cohort to assess the risks of cancer mortality, circulatory disease mortality, respiratory 
disease mortality, digestive disease mortality, and all-cause mortality.  
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2. METHODS 
 
2.1 Dietary vitamin D intake and all-cause and cause-specific mortality 
 
2.1.1 Study population 
 
EPIC is an on-going multicentre prospective cohort study designed to investigate the 
association between diet, lifestyle, genetic and environmental factors and various types of 
cancer. A detailed description of the methods employed has previously been described 
(168;169). In summary, 521,448 participants (~70% women) mostly aged 35 years or above 
were recruited between 1992 and 2000. Participants were recruited from 23 study centres in 
ten European countries: Denmark (Aarhus and Copenhagen); France; Germany (Heidelberg 
and Potsdam); Greece; Italy (Florence, Naples, Ragusa, Turin, and Varese); the 
Netherlands (Bilthoven and Utrecht); Norway (Tromso); Spain (Asturias, Granada, Murcia, 
Navarra, and San Sebastian); Sweden (Malmö and Umea); and the United Kingdom (UK; 
Cambridge and Oxford).  
 
Participants were recruited from the general population of their respective countries, with the 
following exceptions: the French cohort were teacher health insurance programme 
members; the Italian and Spanish cohorts included members of blood donor associations 
and the general population; the Utrecht (the Netherlands) and Florence (Italy) cohorts 
contained participants from mammographic screening programs; the Oxford (UK) cohort 
included a large proportion of vegetarians, vegans, and low meat eaters; finally, only women 
participated in the cohorts of France, Norway, Naples (Italy) and Utrecht (the Netherlands).   
Written informed consent was provided by all study participants. Ethical approval for the 
EPIC study was provided from the review boards of the International Agency for Research 
on Cancer (IARC) and local participating centres.  
 
Exclusions prior to the onset of the analyses, included: participants with missing dietary 
vitamin D intake (n=6,837); participants in the highest and lowest 1% of the distribution for 
the ratio between energy intake to estimated energy requirement (n=10,242); participants 
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who had cancer at baseline (n=23,412); participants who self-reported a history of heart 
disease (n=11,163), stroke (n=3,258), or diabetes (n=11,438) at baseline; and finally, 
participants with missing follow-up information (n=2,381). This analysis therefore included 
452,717 participants (130,564 men and 322,153 women). 
 
 
2.1.2 Diet, lifestyle, and anthropometric information collection 
 
Dietary information over the previous 12 months was obtained at study baseline using 
validated country/centre specific dietary questionnaires. In Malmö (Sweden), a dietary 
questionnaire was combined with a 7-day food registration and interview. In Greece, two 
Italian centres, and Spain, interviewers administered the dietary questionnaires. In all other 
centres/countries, the questionnaires were self-administered. In Spain, France, and Ragusa 
(Italy) questions were structured by meals, while in other countries the structure was by food 
groups. Intakes of dietary vitamin D were obtained from the EPIC Nutrient Data Base 
(ENDB); in which the nutritional composition of foods across the different countries has been 
standardised (170).  
 
Lifestyle questionnaires were used to obtain information on education (used as a proxy for 
socioeconomic status), smoking habits (status, intensity and duration), alcohol consumption, 
and physical activity levels. Height and weight were measured at the baseline examination in 
all centres apart from part of Oxford and all of the Norway and France cohorts, where 
measurements were self-reported via the lifestyle questionnaire (168;169). BMI (kg/m2) was 
calculated from these height and weight measures. Medication and information on 
reproductive history was obtained via questionnaires. Menopausal status at enrolment was 
calculated from an algorithm using information on menstrual history, menopause type, oral 
contraceptive and menopausal hormone use. 
 
 
2.1.3 Assessment of mortality 
 
Vital statuses, causes, and dates of death were obtained from record linkages with cancer 
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registries, boards of health, and death indexes (Denmark, Italy, the Netherlands, Norway, 
Spain, Sweden, and the United Kingdom). For Germany, Greece, and France participants 
were actively followed-up through a combination of methods: by mail or telephone directly; or 
through municipal registries, regional health departments, physicians, and hospitals. Data on 
causes of deaths were coded in accordance with the International Classification of Diseases, 
10th Revision (ICD-10). Because of time differences across participating centres in reporting 
the causes of deaths, follow-up dates were truncated to when 80% of causes were known. 
Truncated follow-up dates were: 30 June 2005 for Cambridge (UK); 31 December 2006 for 
Denmark, France, Naples (Italy), Turin (Italy), Varese (Italy), Granada (Spain), Murcia 
(Spain), and Malmö (Sweden); 31 December 2007 for Florence (Italy), Norway, San 
Sebastian (Spain), and Umea (Sweden); 31 December 2008 for the Netherlands, Ragusa 
(Italy), Asturias (Spain), and Navarra (Spain); 30 June 2009 for Oxford (UK); and the actual 
date of last contact for Germany and Greece. Where the cause of death was coded with the 
qualifier “underlying” this was taken as the originating cause of death. Where one cause of 
death was given, this was used as the originating cause of death. If two or more recorded 
causes of death were given, with one being “antecedent” and one of the others being 
“immediate”, the former was used as the cause of death. Finally, if deaths were classified 
with two or more causes including: “other significant conditions”; “not distinguished”; or 
“immediate”, the latter cause was used. The underlying causes of death were used to 
estimate the risks of the following causes of death: cancer (ICD-10: C00-D48), circulatory 
diseases (I00-I99), respiratory diseases (J30-J98), and digestive diseases (K00-K93). 
Cancer deaths were further divided into digestive and non-digestive system cancers, based 
on the a priori hypothesis that the former would be more sensitive to vitamin D status. 
Digestive system cancers were oesophagus (C15); stomach (C16); colorectal cancer (C18-
C20); anus and anal canal (C21); liver and intrahepatic bile acids (C22); gallbladder (C23); 
other and unspecified parts of biliary tract (C24); pancreas (C25); and other ill-defined 
digestive organs (C26). Non-digestive system cancers were all other cancers. Deaths 
caused from colorectal cancer (C18-C20), pancreatic cancer (C25), lung cancer (C34), 
prostate cancer (C61), and breast cancer (C50) were also investigated. Mortality risk caused 
by external causes (S00-Y98), such as accidents, was examined as negative controls. 
 
 
2.1.4 Statistical analysis 
 
Hazard ratios and 95% confidence intervals (CIs) were estimated using Cox proportional 
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hazards models; with age as the primary time variable in all models. Time at entry was age 
at recruitment. Exit time was age at death or the last date at which follow-up was considered 
complete in each centre. Models were stratified by study centre to control for differing follow-
up procedures, questionnaire design, and other differences across centres. Models were 
also stratified by sex and age at recruitment in 1-year categories. Possible non-
proportionality was assessed using an analysis of Schoenfeld residuals (171); with no 
evidence of non-proportionality detected.  
 
Dietary intakes of vitamin D were modelled using sex-specific quintiles and as continuous 
variables (HR expressed per increment of 2.5 µg/day). Trend tests across quintiles were 
calculated by assigning the median value of each intake quintile and modelling as 
continuous terms into Cox regression models. Analyses were conducted for both sexes 
combined and separately. All models were adjusted for total energy intake, using the 
standard model, to obtain isocaloric risk estimates and partly control for measurement error 
of vitamin D intake estimates. All models were additionally adjusted for: BMI (<22, 22-24.9, 
25-29.9, 30-34.9, or 35+ kg/m2); physical activity index (inactive, moderately inactive, 
moderately active, active, or missing); smoking status and intensity (never; current , 1-15 
cigarettes per day; current, 16-25 cigarettes per day; current, 25+ cigarettes per day; former, 
quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, 
pipe/cigar/occasional; current/former, missing; or unknown); smoking duration (<10, 10-<20, 
20-<30, 30-<40, 40+ years, or smoking duration unknown); education level (none/primary 
school completed, technical/professional school, secondary school, longer education - 
including university, or unknown); menopausal status (premenopausal, postmenopausal, 
perimenopausal/unknown menopausal status, or surgical postmenopausal); ever use of oral 
contraceptive (yes, no, or unknown); ever use of menopausal hormone therapy (yes, no, or 
unknown); and intakes of alcohol (non-consumers, <5, 5-14.9, 15-29.9, or 30+ g/day), red 
and processed meats (continuous, g/day), fruits and vegetables (continuous, g/day), dietary 
calcium (continuous, mg/day), and polyunsaturated fatty acids (continuous, g/day). The 
colorectal cancer mortality analyses were additionally adjusted for cereal fibre intake 
(continuous, g/day); whilst the breast cancer mortality analysis was additionally adjusted for 
age at menarche (<12, 12-<15, 15+ years old, or unknown) and age at first pregnancy (<21, 
21-<30, 30+ years old, no children, or not specified). 
 
To determine whether the all-cause mortality association differed according to 
anthropometric and lifestyle characteristics, interaction terms (multiplicative scale) were 
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included in the models. The statistical significance of the cross-product terms were 
evaluated using the likelihood ratio test. Interaction terms inputted into the statistical model 
were intakes of dietary vitamin D (continuous) with sex, smoking status (never, former, or 
current); BMI (underweight-normal weight = <25; overweight = 25-29.9; obese = 30+ kg/m2); 
and physical activity index (inactive, moderately inactive, moderately active, active). The 
heterogeneity across countries was explored by taking a meta-analytic approach (172). How 
the associations differed according to length of follow-up time was also explored (<5, 5-10, 
or ≥10 years). Follow-up time of <5 years included the person-time and incident events 
within this time period only. Follow-up time for 5-10 and ≥10 years included only the person-
time and incident events within these respective time periods. To evaluate possible reverse 
causality, cases diagnosed within the first 5 years of follow-up were excluded from the 
analyses. 
 
Statistical tests used in the analysis were all two-sided and a P-value of <0.05 was 
considered statistically significant. All analyses were performed using Stata version 11.0. 
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2.2 Derivation and validation of European Prospective Investigation 
into Cancer and Nutrition 25-hydroxyvitamin D predicted score 
 
 
2.2.1 Study population and data collection 
 
The study involved secondary analysis of subjects circulating 25(OH)D measures from 
previous EPIC colorectal cancer (n=2,388) (67), prostate cancer (n=1,077) (97), lymphoma 
(n=2,248) (136) and breast cancer (n=1,395, all controls) (117) nested case-control studies. 
Cases for the nested case-control studies were sourced from the full EPIC cohort as 
described in Section 2.1.1. In the colorectal cancer study, cases were not selected from 
Norway or the Malmö (Sweden) centre (67). In the prostate cancer study, the women only 
cohorts were excluded (France, Norway, Utrecht (the Netherlands), and Naples (Italy)); 
cases were also not selected from the Denmark and Malmö (Sweden) cohorts (97). In the 
lymphoma nested case-control analysis, the France cohort was excluded (136). Only control 
samples were available for predictor score derivation from the breast cancer nested case-
control study (117). In all studies, controls were match 1:1 with cases by age, sex, centre, 
timing of blood collection. Cases and controls in the colorectal and prostate cancer studies 
were additionally matched by fasting status of blood collection; whilst additional matching 
criteria in the breast cancer and lymphoma was length of follow-up and blood donor status 
(lymphoma study only). 
 
Participants with incomplete dietary intake information were excluded (n=24). Due to the 
incompatibly of the physical activity index information with the remainder of the cohort, 
participants from the Umea centre were excluded (n=310). Participants with missing data for 
physical activity index (n=134), smoking status and intensity (n=37), and waist circumference 
(n=485) were also excluded from the predictor score datasets. This meant that 6,118 
participants (2,966 men and 3,152 women) with circulating 25(OH)D measurements were 
used for the derivation and validation of the predictor score.  
 
Information on dietary intakes, physical activity, smoking status, education level and alcohol 
intake was obtained from participants as described in Section 2.1.2. Dietary intakes were 
adjusted for energy using the residual method (173). Additionally, waist circumference was 
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measured at recruitment from participants at ether the narrowest circumference of the torso 
or at the mid-point between ribs ad iliac chest.  
 
 
2.2.2 Blood collection and laboratory measures 
 
Blood samples were collected from 385,747 of the 521,448 EPIC participants at recruitment, 
prior to disease diagnosis. Samples were stored in liquid nitrogen tanks at IARC (Lyon, 
France) at -196°C, except for samples from Denmark (-150°C, nitrogen vapour). Circulating 
25(OH)D levels for participants in the prostate cancer study were determined by enzyme 
immunoassay (OCTEIA 25-Hydroxy Vitamin D kit; Immunodiagnostic Systems, Limited, 
Boldon, Tyne and Wear, UK) in the MRC Research Laboratories in Cambridge (97). 
Laboratory personnel were blinded as to case or control status of participants. The same 
enzyme immunoassay kit was used for colorectal cancer participant blood samples (67). 
These analyses were conducted at the laboratory for Health Protection Research, National 
Institute for Public Health and the Environment, the Netherlands. Circulating samples in the 
breast cancer and lymphoma studies were analysed with the fully automated IDS-iSYS 
25(OH)D (Immunodiagnostic systems Ltd, Boldon, UK). For quantification of 25(OH)D in 
EDTA-samples a OCTEIA 25-hydroxyvitamin D enzyme immunoassay (IDS, 
Immunodiagnostic systems Ltd, Boldon, UK) was used (117;136).  
 
 
2.2.3 Derivation and validation of predicted 25-hydroxyvitamin D scores 
 
Derivation of predicted 25-hydroxyvitamin D scores 
For each sex, random two-third subsets of participants with blood measurements (n=1,982 
for men and n=2,107 for women) were used to investigate the relationship between 
circulating 25(OH)D and dietary, lifestyle, geographical, age at blood collection, and timing of 
blood collection variables, forming the basis of the predictor 25(OH)D scores. Blood samples 
from the remaining third of men and women participants (n=984 for men and n=1,045 for 
women) were used to validate the predictor scores.  
 
64 
 
Multiple linear regression modelling was used with circulating 25(OH)D as the dependent 
variable and potential correlates/determinants as independent variables. To meet the model 
assumptions of a linear relationship between independent and dependent variables, 
circulating measurements of 25(OH)D were naturally log-transformed. When multiplied by 
100 the loge β coefficients from the linear regression analysis can be interpreted as the 
mean percentage difference compared with the reference category (categorical variables), or 
as the mean percentage difference in circulating 25(OH)D for a one unit increase in the 
predictor variable (continuous) (174).  
 
Independent variables/correlates/determinants considered for inclusion in the predictor 
scores, in addition to sex, were chosen based on a prior knowledge of their relationships 
with circulating 25(OH)D. These were split into the following categories: age at blood 
collection and timing of blood collection, dietary variables, anthropometric variables, lifestyle 
variables, reproductive variables, and location of residence. 
 
Age at blood collection and timing of blood collection variables 
Variables considered for inclusion in the predictor scores were: age at blood collection 
(years; continuous); month of blood collection (January, February, March, April, May, June, 
July, August, September, October, November, or December); season of blood collection 
(spring, summer, autumn, or winter); and year of blood collection (1992, 1993, 1994, 1995, 
1996, 1997, 1998, or 1999). 
 
Dietary variables 
Variables considered for inclusion were: dietary intakes of vitamin D (µg/day; continuous), 
calcium (mg/day; continuous), and retinol (µg/day; continuous). 
 
Anthropometric variables 
Variables considered as indicators of adiposity were: waist circumference (cm; continuous), 
BMI (kg/m2; continuous); height (cm; continuous); weight (kg; continuous); and waist-to-hip 
ratio (continuous). 
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Lifestyle variables 
Variables considered for inclusion were: physical activity index level (inactive, moderately 
inactive, moderately active, or active); recreational physical activity (METs; continuous); 
smoking status and intensity (never; current, 1-15 cigarettes per day; current, 16-25 
cigarettes per day; current, 25+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 
years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; or 
unknown); education level (no education, primary school completed, technical/professional 
school, secondary school, longer education including university, or not specified); and 
alcohol consumption (g/day; continuous). 
 
Reproductive variables 
Variables considered for inclusion in the women’s predictor score were: menopausal status 
(premenopausal, postmenopausal, perimenopausal/unknown menopausal status, or surgical 
postmenopausal); ever use of menopausal hormone therapy (yes, no, or unknown); ever use 
of contraceptive pill (yes, no, or unknown); and whether women participants had live born 
children (no or yes).  
 
Location of residence 
Country of residence was included in the predictor scores (Denmark, Germany, Greece, 
Italy, the Netherlands, Spain, or the UK). 
 
Univariate linear regression models were fit for each of these independent variables. All 
variables with P-values <0.05 were then included in multivariable linear regression models; 
these models were adjusted for age at blood collection, and source study and batch of 
circulating sample analysis. One at a time, non-significant variables with the largest P-values 
(≥0.05) were removed from the multivariable models, until all remaining predictors were 
statistically significant. Also, taken into consideration at this stage was the amount of 
additional variance in loge 25(OH)D that was explained by the inclusion of predictor variables 
in the models. A significant sex interaction (P-value <0.001) was observed and as a 
consequence separate predictor scores were derived for men and women  
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The predictor scores assumed that: loge 25(OH)D = β0 + βiXi + βiXi …, where β0 represents 
the intercept and βi represents coefficient values associated with the value of the 
independent variable 25(OH)D predictor, Xi. 
 
The final correlates/determinants included within the separate men and women’s predictor 
scores were: age at blood collection, dietary vitamin D intake, waist circumference, physical 
activity index, month of blood collection, country of residence, smoking status and intensity, 
ever use of menopausal hormone therapy, and source study and batch of serum samples. 
The rationale for the inclusion of these correlates/determinants (and the exclusion of the 
other variables considered) is outlined in the results section. The final circulating 25(OH)D 
predictor scores for men and women explained 34% and 28% of the overall variance in 
circulating 25(OH)D respectively (Table 11).  
 
Age at blood collection and smoking status and intensity were not used when the predictor 
scores were applied to the validation datasets (i.e. used only as covariates in predictor score 
derivation); as both are major risk factors for chronic disease incidence and mortality, and 
excluding them at this stage meant that they could be used as confounders when assessing 
disease risk (164). This minimised risk of statistical over-adjustment of these variables on 
the analyses. The timing of blood collection reflects recent sun or dietary exposures, and 
does not determine long-term average between person variation in circulating 25(OH)D, 
which is of interest when assessing disease risk; because of this month of blood collection 
was also excluded when the predictor score was applied. The predictor scores were also 
adjusted for source study and batch of circulating sample analysis as the serum samples 
were sourced from four different studies and analysed at different times and in different 
laboratories. 
 
Validation of predicted 25-hydroxyvitamin D scores 
 
The predictor scores were validated primarily using the blood samples from the remaining 
third of men and women participants (n=984 for men and n=1,045 for women). The predictor 
scores were applied in the validation datasets with actual 25(OH)D measurements, creating 
a predicted circulating 25(OH)D value for each participant. The various validation stages are 
outlined below: 
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Correlations between predicted 25-hydroxyvitamin D and actual circulating 25-
hydroxyvitamin D 
Firstly, Pearson and Spearman correlation coefficients (adjusted by source study and batch 
of circulating samples) were used to assess agreement between actual and predicted 
circulating 25(OH)D values.  
 
Actual 25-hydroxyvitaminD measurements by quantile of predicted 25-hydroxyvitamin D 
Next, the actual circulating 25(OH)D measurements according to quintile and decile of 
predicted 25(OH)D scores for men and women were examined.  
 
Cross-classifications of participants by predicted and actual circulating 25-hydroxyvitamin D 
categories 
Participants were also cross-classified by quintiles, tertiles and three or five biologically 
relevant pre-defined categories (three: <50 nmol/L deficiency, 50-<75 nmol/L insufficient, 
and 75+ nmol/L sufficient; five: <25 nmol/L severe deficiency, 25-<50 nmol/L deficiency, 50-
<75 nmol/L insufficient, 75-<100 nmol/L sufficient, and 100+ nmol/L optimal) of both 
predicted and actual circulating 25(OH)D. 
 
Assessment of colorectal cancer risk in the nested case-control dataset 
The next validation stage was to assess colorectal cancer risk using the predictor scores in 
the colorectal nested case-control dataset; to find out if a similar inverse association was 
observed to the published analysis which used actual circulating 25(OH)D measurements 
(67). Firstly, to ensure independence of circulating 25(OH)D measures, participants whose 
serum samples were sourced from the colorectal cancer nested case-control study were 
excluded from the datasets used to derive the predictor scores (this left n=1,234 samples for 
men and n=1,372 samples for women). The predictor scores were then re-derived and 
applied to the colorectal cancer nested case-control dataset. In this dataset the controls 
were matched to cases on a 1:1 basis, by: age at recruitment; sex; study centre; time of day 
of blood collection; and women were further matched for menopausal status, phase of 
menstrual cycle, and usage of menopausal hormone therapy. Predicted circulating 25(OH)D 
was split into quintiles based on the distribution in the control participants within the dataset. 
Linear trends across these quintiles were assessed by assigning a score variable with 
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values from 1 to 5, dependent on quintile categorisation. Conditional logistic regression 
models were then used - stratified by case-control set - and adjusted for the same 
confounders as the published nested case-control analysis: BMI, smoking status and 
intensity, alcohol consumption, education, and intakes of total energy, fruits and vegetables, 
and meats or meat products. Multivariable models also included adjustment for physical 
activity index, although this inclusion may have caused statistical over-adjustment as 
physical activity index was also a key determinant of 25(OH)D included within the predictor 
scores. Due to this concern, separate risk estimates for multivariable models with and 
without physical activity index adjustment were assessed. Due to the close correlations 
between waist circumference (the marker of adiposity included within the predictor scores) 
and BMI, separate risk estimates for the multivariable model minus BMI adjustment were 
also assessed.  
 
Assessment of colorectal cancer risk in the full European Prospective Investigation into 
Cancer and Nutrition cohort 
The associations between predicted 25(OH)D and colorectal cancer were also assessed in 
the full EPIC cohort. Here the full datasets used to derive the predictor scores (containing 
n=1,982 men and n=2,107 women) were applied to the full EPIC cohort (minus participants 
with actual circulating 25(OH)D measurements who were used in the derivation and 
validation of predictor scores). Hazard ratios and 95% CIs were estimated using Cox 
proportional hazards models; with age as the primary time variable in all models. Time at 
entry was age at recruitment. Exit time was age at whichever of the following came first: 
cancer diagnosis, death, or the last date at which follow-up was considered complete in each 
centre. Predicted circulating 25(OH)D values were modelled using sex specific quintiles 
defined across cohort participants or as continuous variables (HR expressed per increment 
of 5.9 nmol/L, which is equivalent to 100 IU/L). Trend tests across quintiles of exposure were 
calculated by assigning the median value of each intake category and modelling as 
continuous terms into Cox regression models. These validation analyses used the same 
confounding variables as were controlled for in the published nested case-control analysis 
(67). The Cox regression models were stratified by age at recruitment, sex, and centre, and 
adjusted for BMI, total energy intake, education, smoking status and intensity, and intakes of 
alcohol, fruits and vegetables and meat and meat products. Once more, the multivariable 
model was also assessed with and without additional adjustment for physical activity index 
and BMI. 
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Assessment of prostate cancer risk in the full European Prospective Investigation into 
Cancer and Nutrition cohort 
The predictor scores were also applied to the full EPIC cohort to assess prostate cancer risk. 
A non-significant suggestive positive association was observed in the published nested 
case-control study (97). The full dataset used to build the predictor score (containing 
n=1,982 men) was applied to the full EPIC cohort (minus participants with actual circulating 
25(OH)D measurements who were used in the derivation and validation of the predictor 
score). The associations were assessed using Cox regression models, stratified by age at 
recruitment and centre, and adjusted for BMI, education, smoking status and intensity, 
marital status, and alcohol intake. Once more, the multivariable model was also assessed 
with and without additional adjustment for physical activity index and BMI. Predicted 
circulating 25(OH)D values were modelled using sex specific quintiles defined across cohort 
participants or as continuous variables (HR expressed per increment of 25 nmol/L). Trend 
tests across quintiles of exposure were calculated by assigning the median value of each 
intake category and modelling as a continuous term into Cox regression models.   
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2.3 Application and validation of the Health Professionals Follow-Up 
Study derived 25-hydroxyvitamin D score in the European 
Prospective Investigation into Cancer and Nutrition  
 
2.3.1 Application of the Health Professionals Follow-Up Study derived 25-
hydroxyvitamin D score in the European Prospective Investigation into Cancer 
and Nutrition 
 
 
To test whether prediction models derived in different cohorts can be applied to other study 
populations, we applied the HPFS predictor score of Giovannucci et al., (52) to men in EPIC 
with circulating 25(OH)D measurements available. The HPFS predictor score included the 
following correlates/determinants of circulating 25(OH)D: race; residence location; quintile of 
leisure-time physical activity; BMI; dietary vitamin D intake; supplementary vitamin D intake; 
and season of blood collection. 
 
Residence in the HPFS predictor score was split into three groups: South, Midwest/West, 
and Northeast/Mid-Atlantic. The latitudes of these locations span from approximately 37°N to 
47°N; whilst the latitude range of EPIC constituent countries is approximately 36°N to 63°N. 
Participants in EPIC countries located outside the HPFS latitude ranges were excluded from 
the analysis, these were: Denmark (n=472), Germany (n=683), the Netherlands (n=79), and 
the UK (n=684). This meant that 823 circulating 25(OH)D measurements were available for 
application of the HPFS score within EPIC. The remaining centres were split into southern 
and northern European categories, with equivalent HPFS coefficients for Northeast/Mid-
Atlantic and the South used for these categories. The centres categorised as the southern 
Europe reference category were: Ragusa (36°N; Italy), Granada (37°N; Spain), Greece 
(37°N, Athens), Murcia (37°N; Spain), Navarra (42°N; Spain), Asturias (43°N; Spain), and 
San Sebastian (43°N; Spain). Centres categorised as northern European were Florence 
(43°N; Italy), Turin (45°N; Italy), and Varese (45°N; Italy). For quintiles of leisure-time 
physical activity, the EPIC recreational physical activity variable split into quintiles was used. 
Dietary vitamin D was categorised into five intake groups: ≥400; 200-399; 100-199; and 
<100 IU/day. Three HPFS determinants were excluded when the predictor score was 
applied within EPIC. Firstly, supplementary vitamin D was not included as intake information 
was unavailable for EPIC participants. Secondly, race was excluded as participants within 
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EPIC are believed to be all Caucasian. Finally, season was excluded as this timing of blood 
collection reflects recent exposures and not long-term between person variation in 25(OH)D. 
This meant that final HPFS predictor score for application within EPIC included four 
determinants of circulating 25(OH)D: residence, quintile of leisure-time/recreational physical 
activity, BMI, and dietary vitamin D intake (Table 3). 
 
Table 3. Correlates/determinants of circulating 25-hydroxyvitamin D included in the Health 
Professionals Follow-up study (52) and the adapted coefficient values used when applied 
within the European Prospective Investigation into Cancer and Nutrition cohort 
 
§  Participants within EPIC are solely Caucasian.  
β  Residence locations in U.S. based HPFS range from latitudes of ~37° - 47°; compared to EPIC pan-European latitude range ~36° - 63°. 
Greece, Italy, and Spain the only EPIC countries included.  
Ω  Recreational physical activity quintiles used within EPIC.  
‡  Dietary vitamin D energy adjusted using the residual method, and converted into IU/day from µg/day (1  µg of vitamin D=40 IU). 
Ф  Dietary supplement information not available within EPIC.  
¥  Season excluded when predictor score applied as not a factor in determining long-term between person variation.  
 
Determinants
Change in 25(OH)D (nmol/L) 
as per HPFS
Change in 25(OH)D (nmol/L) 
adapted for EPIC N 
Intercept 90.8 90.8 -
Residence  β
South REF REF 283
Midwest/West −2.4 - -
Northeast/Mid-Atlantic −6.4 -6.4 540
Quintile of leisure-time physical activity  Ω
5 REF REF 133
4 −4.5 −4.5 157
3 −7.7 −7.7 125
2 −9.0 −9.0 176
1 −13.5 −13.5 232
Body mass index (kg/m
2
)
<22 REF REF 28
22–24.9 −1.0 −1.0 148
25–29.9 −4.5 −4.5 448
30–34.9 −6.5 −6.5 168
≥35 −8.6 −8.6 31
Dietary vitamin D (IU/day)  ‡
≥400 REF REF 22
300–399 −3.5 −3.5 28
200–299 −2.6 −2.6 104
100–199 −7.2 −7.2 316
<100 −10.4 −10.4 353
Supplementary vitamin D (IU/day)  Ф
≥400 IU/day REF REF -
200–399 IU/day −1.8 - -
100–199 IU/day 2.4 - -
<100 IU/day −2.1 - -
Race  §    
White REF REF 823
African American −12.8 - -
Asian −13.3 - -
Season of blood collection  ¥  
Autumn REF REF -
Summer −1.8 - -
Spring −12.1 - -
Winter −13.5 - -
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2.3.2 Validation of the Health Professionals Follow-Up Study derived 25-
hydroxyvitamin D score in the European Prospective Investigation into Cancer 
and Nutrition 
 
The HPFS predictor score performance was validated within EPIC using a four stage 
process: (1) Pearson and Spearman correlation coefficients (adjusted by source study and 
batch of circulating samples) between actual and predicted circulating 25(OH)D values were 
calculated; (2) actual circulating 25(OH)D measurements according to decile of predicted 
25(OH)D scores were examined; (3) participants were cross-classified by quintile of 
predicted and actual circulating 25(OH)D, and the agreement between these categorisations 
was assessed; and finally (4) assessment of colorectal cancer risk amongst men in the full 
EPIC cohort. 
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2.4 Application of predicted 25-hydroxyvitamin D scores to assess 
cancer incidence risk 
 
 
2.4.1 Study population 
 
The EPIC study population was sourced as described above (Section 2.1.1). Participants 
used in the derivation of the predictor score were excluded from the analyses (n=7,108). 
Also excluded were participants with missing information for any of the predictor score 
correlates/determinants: dietary vitamin D intake (n=6,821); physical activity index 
(n=44,507); waist circumference (n=78,027); and smoking status and intensity (n=2,926). 
Participants from Sweden were excluded as they were not included within the predictor 
score datasets (n=27,722). Other exclusions prior to the onset of the analyses, included: 
participants in the highest and lowest 1% of the distribution for the ratio between energy 
intake to estimated energy requirement (n=6,982); and participants with prevalent cancer at 
baseline (n=16,931). This analysis therefore included 330,424 participants (112,957 men 
and 217,467 women). 
 
 
2.4.2 Diet, lifestyle, and anthropometric information collection 
 
Dietary, lifestyle, and anthropometric information were collected from participants as detailed 
in Section 2.1.2. 
 
 
2.4.3 Assessment of cancer incidence 
 
Population cancer registries were used in Denmark, Italy, the Netherlands, Norway, Spain, 
Sweden and the United Kingdom to identify incident cancer diagnoses. In France, Germany 
and Greece cancer cases during follow-up were identified by a combination of methods 
including: health insurance records, cancer and pathology registries, and by active follow-up 
directly through study participants or through next-of-kin. Complete follow-up censoring 
dates varied amongst centres, ranging between 2005 and 2010. 
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Cancer incidence data were coded using the 10th Revision of the International Classification 
of Diseases (ICD-10) and the second revision of the International Classification of Disease 
for Oncology (ICDO-2). Only the first primary neoplasm was included in the analyses. 
Cancer incidence end-points considered in this analysis were: overall cancer incidence 
(C00-C97); colorectal cancer (C18-C20); lung cancer (C34); kidney cancer (C64-C65); 
stomach and oesophageal cancers (C15-C16); bladder cancer (C67); pancreatic cancer 
(C25); liver cancer (C22-C24); brain cancer (C70- C72); skin cancer (C44); thyroid cancer 
(C73); prostate cancer (C61); breast cancer (C50); ovarian cancer (C48, C56-C57); 
endometrial cancer (C54); and non-Hodgkin’s lymphoma (Originally classified according to 
ICD-O-2, but were reclassified according to the WHO classification of haematopoietic and 
lymphoid tissues, third edition (171). The conversion was performed using a program 
available on the United States National Cancer Institute Surveillance, Epidemiology and End 
Results (SEER) website (http://seer.cancer.gov/) and by the expertise of pathologists). 
Cancer cases were additionally split into digestive system (Colorectal, upper aero-digestive 
tract, stomach, oesophageal, pancreatic and liver cancers) and non-digestive system 
cancers (all other cancers). Similarly, cases were split into smoking related (Lung, bladder, 
upper aero-digestive tract, kidney, stomach, oesophageal, pancreatic, liver, and colorectal 
cancers) and non-smoking related cancers (all other cancers). 
 
 
2.4.4 Statistical analysis 
 
Hazard ratios and 95% confidence intervals (CIs) were estimated using Cox proportional 
hazards models; with age as the primary time variable in all models. Time at entry was age 
at recruitment. Exit time was age at cancer diagnosis, or the last date at which follow-up was 
considered complete in each centre. To control for differing follow-up procedures, 
questionnaire design, and other differences across centres, models were stratified by study 
centre. Models were also stratified by sex and age at recruitment in 1-year categories. 
Possible non-proportionality was assessed using an analysis of Schoenfeld residuals (171); 
with no evidence of non-proportionality detected.  
 
Predicted circulating 25(OH)D exposures were modelled using sex-specific quintiles and as 
continuous variables (HR expressed per increment of 25 nmol/L). Trend tests across 
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quintiles were calculated by assigning the median value of each intake quintile and 
modelling as continuous terms into Cox regression models. Analyses were conducted for 
both sexes combined and separately. All models were adjusted for: BMI (<22, 22-24.9, 25-
29.9, 30-34.9, or 35+ kg/m2); smoking status and intensity (never; current, 1-15 cigarettes 
per day; current, 16-25 cigarettes per day; current, 25+ cigarettes per day; former, quit ≤10 
years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; or unknown); smoking duration (<10, 10-<20, 20-<30, 30-<40, 40+ 
years, or smoking duration unknown); education level (none/primary school completed, 
technical/professional school, secondary school, longer education - including university, or 
unknown); menopausal status (premenopausal, postmenopausal, perimenopausal/unknown 
menopausal status, or surgical postmenopausal); ever use of oral contraceptive (yes, no, or 
unknown); and intakes of total energy (continuous, kcal/day), alcohol (non-consumers, <5, 5-
14.9, 15-29.9, or 30+ g/day), red and processed meats (continuous, g/day), fruits and 
vegetables (continuous, g/day), and dietary calcium (continuous, mg/day). The colorectal 
cancer analyses were additionally adjusted for cereal fibre intake (continuous, g/day); whilst 
the breast cancer, ovarian cancer, and endometrial cancer analyses were additionally 
adjusted for age at menarche (<12, 12-<15, 15+ years old, or unknown) and age at first 
pregnancy (<21, 21-<30, 30+ years old, no children, or not specified). Physical activity index 
was an important correlate/determinant in the 25(OH)D predictor scores, and also an 
important risk factor/confounder for cancer. Inclusion of physical activity index in both the 
predictor score and as a confounder in the mortality models may be deemed as statistical 
over-adjustment. Therefore, risk estimates for all models were presented with and without 
this additional adjustment for physical activity index (inactive, moderately inactive, 
moderately active, active, or missing). Similarly, due to the close correlations between waist 
circumference (the marker of adiposity included within the predictor scores) and BMI, 
inclusion of the latter within the cancer incidence models could be deemed as statistical 
over-adjustment. Therefore, separate risk estimates for the multivariable model minus BMI 
adjustment are also presented in the appendix.  
 
To determine whether cancer incidence associations differed according to anthropometric, 
lifestyle, and dietary characteristics, interaction terms (multiplicative scale) were included in 
the models. The statistical significance of these cross-product terms was evaluated using the 
likelihood ratio test. Interaction terms inputted into the statistical model were predicted 
circulating 25(OH)D (continuous) with: sex; age at recruitment (<55, 55-<65 or ≥65 years 
old); smoking status (never, former, or current); BMI (underweight-normal weight = <25; 
overweight = 25-29.9; obese = 30+ kg/m2); physical activity index (inactive, moderately 
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inactive, moderately active, or active); alcohol consumption (non-consumers, <15, 15-29.9, 
or ≥30 g/day); menopausal status (premenopausal, postmenopausal, perimenopausal, or 
surgical postmenopausal); ever use of the contraceptive pill (yes/no); and above and below 
median dietary intakes of red and processed meat (median=68.6 g/day), fruits and 
vegetables (median=412 g/day), fish (median=23.5 g/day), calcium (median=959 mg/day), 
fibre (median=22.4 g/day), and retinol (median=557 µg/day). How the associations differed 
according to length of follow-up time was also explored (<5, 5-10, or ≥10 years). Follow-up 
time of <5 years included the person-time and incident events within this time period only. 
Follow-up time for 5-10 and ≥10 years included only the person-time and incident events 
within these respective time periods. To evaluate possible reverse causality, cases 
diagnosed within the first 5 years of follow-up were excluded from the analyses. To be able 
to determine the relative importance of the predictor score correlates/determinants on the 
risk of overall cancer incidence, mutually adjusted analyses for dietary vitamin D, physical 
activity index, waist circumference, country, and ever use of menopausal hormone therapy 
were conducted. These models were also adjusted for the same covariates as the main 
cancer incidence models. The heterogeneity across countries was explored by taking a 
meta-analytic approach (172).  
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2.5 Application of predicted 25-hydroxyvitamin D scores to assess all-
cause and cause specific mortality risk 
 
 
2.5.1 Study population 
 
The EPIC study population was sourced as described above (Section 2.1.1). Participants 
used in the derivation of the predictor score were excluded from the analyses (n=7,108). 
Also excluded were participants with missing information for any of the predictor score 
correlates/determinants: dietary vitamin D intake (n=6,821); physical activity index 
(n=44,507); waist circumference (n=78,027); and smoking status and intensity (n=2,926). 
Participants from Sweden were excluded as they were not included within the predictor 
score (n=27,722). Other exclusions prior to the onset of the analyses, included: participants 
in the highest and lowest 1% of the distribution for the ratio between energy intake to 
estimated energy requirement (n=6,086); participants who had cancer at baseline 
(n=12,994); participants who self-reported a history of heart disease (n=9,684), stroke 
(n=2,680), or diabetes (n=9,240) at baseline; and finally, participants with missing follow-up 
information (n=2,896). This analysis therefore included 310,757 participants (103,251 men 
and 207,506 women). 
 
 
2.5.2 Diet, lifestyle, and anthropometric information collection 
 
Dietary, lifestyle, and anthropometric information were collected from participants as detailed 
in Section 2.1.2. 
 
 
2.5.3 Assessment of all-cause and cause-specific mortality deaths 
 
Assessment of all-cause and cause specific mortality cases is detailed in Section 2.1.3.  
The underlying causes of death were used to estimate the risks of the following causes of 
death: cancer (ICD-10: C00-D48), circulatory diseases (I00-I99), respiratory diseases (J30-
J98), and digestive diseases (K00-K93). Cancer deaths were further divided into digestive 
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and non-digestive system cancers, based on the a priori hypothesis that the former would be 
more sensitive to vitamin D status. Digestive system cancers were: oesophagus (C15); 
stomach (C16); colorectal (C18-C20); anus and anal canal (C21); liver and intrahepatic bile 
acids (C22); gallbladder (C23); other and unspecified parts of biliary tract (C24); pancreas 
(C25); and other ill-defined digestive organs (C26). Non-digestive system cancers were all 
other cancers. Cancer deaths were additionally split by smoking and non-smoking related 
cancers. Smoking related cancers were: oral cavity (C01-C06, C08); oropharynx (C09, C10, 
C12-C14); nasopharynx (C11); oesophagus (C15); stomach (C16); colorectal (C18-C20); 
liver (C22); pancreas (C25); nasal cavity and sinuses (C300, C31); larynx (C32); lung (C34); 
kidney (C64); bladder (C65, C67); and myeloid leukemia (C92). Non-smoking related 
cancers were all other cancers. Deaths caused from colorectal cancer (C18-C20), pancreatic 
cancer (C25), lung cancer (C34), skin cancer (C43-C44), prostate cancer (C61), and breast 
cancer (C50) were also investigated. Mortality risk caused by external causes (S00-Y98), 
such as accidents, was examined as negative controls. 
 
 
2.5.4 Statistical analysis 
 
Hazard ratios and 95% confidence intervals (CIs) were estimated using Cox proportional 
hazards models; with age as the primary time variable in all models. Time at entry was age 
at recruitment. Exit time was age at death or the last date at which follow-up was considered 
complete in each centre. To control for differing follow-up procedures, questionnaire design, 
and other differences across centres, models were stratified by study centre. Models were 
also stratified by sex and age at recruitment in 1-year categories. Possible non-
proportionality was assessed using an analysis of Schoenfeld residuals (171); with no 
evidence of non-proportionality detected.  
 
Predicted circulating 25(OH)D exposures were modelled using sex-specific quintiles and as 
continuous variables (HR expressed per increment of 25 nmol/L). Trend tests across 
quintiles were calculated by assigning the median value of each intake quintile and 
modelling as continuous terms into Cox regression models. Analyses were conducted for 
both sexes combined and separately. All models were adjusted for: BMI (<22, 22-24.9, 25-
29.9, 30-34.9, or 35+ kg/m2); smoking status and intensity (never; current, 1-15 cigarettes 
per day; current, 16-25 cigarettes per day; current, 25+ cigarettes per day; former, quit ≤10 
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years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; or unknown); smoking duration (<10, 10-<20, 20-<30, 30-<40, 40+ 
years, or smoking duration unknown); education level (none/primary school completed, 
technical/professional school, secondary school, longer education - including university, or 
unknown); menopausal status (premenopausal, postmenopausal, perimenopausal/unknown 
menopausal status, or surgical postmenopausal); ever use of oral contraceptive (yes, no, or 
unknown); and intakes of total energy (continuous, kcal/day), alcohol (non-consumers, <5, 5-
14.9, 15-29.9, or 30+ g/day), red and processed meats (continuous, g/day), fruits and 
vegetables (continuous, g/day), and dietary calcium (continuous, mg/day). The colorectal 
cancer mortality analyses were additionally adjusted for cereal fibre intake (continuous, 
g/day); whilst the breast cancer analyses were additionally adjusted for age at menarche 
(<12, 12-<15, 15+ years old, or unknown) and age at first pregnancy (<21, 21-<30, 30+ 
years old, no children, or not specified). 
 
Physical activity index was an important determinant of the circulating 25(OH)D predictor 
score and also an important confounder for chronic disease mortality. Inclusion of physical 
activity index in both the predictor score and as a confounder in the mortality models may be 
deemed as statistical over-adjustment. Therefore, risk estimates for all models were 
presented with and without additional adjustment for physical activity index (inactive, 
moderately inactive, moderately active, active, or missing). Similarly, due to the close 
correlations between waist circumference (the marker of adiposity included within the 
predictor scores) and BMI, inclusion of the latter within the mortality models could be 
deemed as statistical over-adjustment. Therefore, separate risk estimates for the 
multivariable model minus BMI adjustment are presented in the appendix.  
 
To determine whether the mortality associations differed according to lifestyle, demographic, 
anthropometric, and dietary characteristics, interaction terms (multiplicative scale) were 
included in the models. The statistical significance of these cross-product terms was 
evaluated using the likelihood ratio test. Interaction terms inputted into the statistical model 
were predicted circulating 25(OH)D (continuous) with: sex; age at recruitment (<55, 55-<65 
or ≥65 years old); smoking status (never, former, or current); BMI (underweight-normal 
weight = <25; overweight = 25-29.9; obese = 30+ kg/m2); physical activity index (inactive, 
moderately inactive, moderately active, or active); alcohol consumption (non-consumers, 
<15, 15-29.9, or ≥30 g/day); menopausal status (premenopausal, postmenopausal, 
perimenopausal, or surgical postmenopausal); ever use of the contraceptive pill (yes/no); 
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and above and below median dietary intakes of red and processed meat (median=68.5 
g/day), fruits and vegetables (median=411 g/day), fish (median=23.1 g/day), calcium 
(median=961 mg/day), fibre (median=22.4 g/day), and retinol (median=559.2 µg/day). 
Follow-up time of <5 years included the person-time and incident events within this time 
period only. Follow-up time for 5-10 and ≥10 years included only the person-time and 
incident events within these respective time periods. To evaluate possible reverse causality, 
cases diagnosed within the first 5 years of follow-up were excluded from the analyses. To be 
able to determine the relative importance of the predictor score correlates/determinants on 
the risk of death, mutually adjusted analyses for dietary vitamin D, physical activity index, 
waist circumference, country, and ever use of menopausal hormone therapy were 
conducted. These models were also adjusted for the same covariates as the main mortality 
models. The heterogeneity across countries was explored by taking a meta-analytic 
approach (172).  
 
Statistical tests used in the analysis were all two-sided and a P-value of <0.05 was 
considered statistically significant. All analyses were performed using Stata version 11.0. 
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3. RESULTS 
 
3.1 Dietary vitamin D and all-cause and cancer caused mortality 
 
3.1.1 Characteristics of cohort participants 
 
After a mean (SD) follow-up of 12.7 (2.4) years, 24,997 all-cause mortality death were 
recorded amongst the 452,717 participants. The total person-years and distribution of all-
cause mortality deaths by country are shown in Table 4. The 130,564 men contributed 
1,610,859 years of follow-up and 11,118 all-cause deaths. The 322,153 women contributed 
4,140,966 years of follow-up and 13,879 all-cause deaths. Intakes of dietary vitamin D 
amongst men and women were relatively low in Italy and Greece; whilst high intakes were 
reported in Sweden, Spain, and Norway (women only). Mortality rates were calculated per 
10,000 person-years and age adjusted to the European standard population (175). Amongst 
men and women, the age adjusted mortality rates were 98 and 62 cases per 10,000 person-
years respectively. 
 
Table 4. Cohort characteristics by sex and country of participants included in the dietary 
vitamin D-mortality analyses 
 
* Data are intake information collected from 24-hour dietary recalls (n=32,221 participants) 
 
Country Men Women Men Women Men Women Men Women
Denmark 23,864 27,331 276,093 323,395 2,518 1,808 5.6 (11.1) 3.8 (6.4)
France - 65,605 - 978,205 - 2,833 - 2.7 (4.5)
Germany 19,225 26,288 216,129 298,323 1,188 655 4.1 (8.1) 3.2 (7.3)
Greece 9,355 13,646 87,710 135,843 760 518 3.4 (4.8) 2.6 (3.5)
Italy 13,424 29,517 168,539 358,788 580 814 2.5 (4.2) 1.8 (3.3)
Norway - 34,517 - 378,323 - 739 - 4.2 (5.9)
Spain 13,968 23,362 188,597 319,849 932 611 6.1 (9.2) 3.9 (5.9)
Sweden 20,892 25,609 288,222 358,617 2,403 1,724 8.6 (6.1) 6.1 (4.7)
The Netherlands 9,272 25,767 121,748 337,610 443 1,395 5.6 (5.3) 3.8 (4.5)
United Kingdom 20,564 50,511 263,822 652,014 2,294 2,782 4.4 (4.4) 3.2 (4.0)
All EPIC 130,564 322,153 1,610,859 4,140,966 11,118 13,879 5.5 (7.7) 3.6 (5.2)
N  of participants
Mean (SD) total 
dietary vitamin D 
intake (µg/day) *
Total person-years
N  all-cause 
deaths
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3.1.2 Dietary sources of vitamin D amongst cohort participants 
 
Amongst men and women, the greatest proportion of dietary vitamin D was consumed from 
fish and shellfish (Figure 3). Other common dietary sources of vitamin D were added fats 
(such as margarines) and eggs and egg products. 
 
Figure 3. Dietary sources of vitamin D in the European Prospective Investigation into 
Cancer and Nutrition 
 
* Intake information collected from 24-hour dietary recalls (n=32,221 participants) 
 
 
3.1.3 Baseline characteristics by dietary vitamin D intake quintiles 
 
A higher proportion of current smokers were observed amongst men in the lowest and 
women in the highest vitamin D intake quintiles (Table 5). The lowest proportion of men 
classified as physically active was observed amongst those in the lowest vitamin D intake 
quintile. Compared to those in the lower intake quintiles, men and women with higher 
reported dietary vitamin D intakes also reported higher intakes of total energy, red and 
processed meats, calcium, and polyunsaturated fatty acids (Table 5).  
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Table 5. Baseline characteristics of study participants included in the mortality analyses by 
categories (quintiles) of total dietary vitamin D intake 
Mean and standard deviation (in parenthesis) for continuous variables, or percentages for categorical variables (‡). 
 
 
Characteristic
Q1 Q2 Q3 Q4 Q5
Dietary vitamin D intake range 
(μg/day) <2.3 2.3-<3.4 3.4-<4.7 4.7-<6.5 ≥6.5
N 26,113  26,113     26,113  26,113   26,112   
N  all-cause deaths 1,996    1,835       2,154    2,353     2,780     
Age at recruitment (years) 50.8 (10.9) 50.6 (9.9) 51.5 (9.7) 52.1 (9.5) 52.5 (10.0)
Body mass index (kg/m2) 26.6 (3.7) 26.4 (3.6) 26.4 (3.6) 26.3 (3.6) 26.3 (3.6)
Education  ‡
Longer education including 
University (%) 26.5 27.4 28.5 27.9 25.6       
Smoking status and intensity  ‡
Current (%) 30.8 30.2 29.6 29.0 28.8
Physical activity  ‡
Active (%) 21.5 24.9 26.5 26.1 25.5
Total energy intake (kcal/day) 2094 (565) 2330 (626) 2412 (633) 2520 (633) 2783 (651)
Red and processed meat 
consumption (g/day) 67.8 (50.0) 92.5 (54.0) 104.2 (58.8) 108.6 (64.5) 114.1 (66.3)
Fruit & vegetable consumption 
(g/day) 511.8 (340.1) 410.9 (294.7) 356.8 (244.3) 344.9 (228.7) 359.3 (240.4)
Calcium intake (mg/day) 902.9 (356.7) 1013 (412.0) 1030 (422.7) 1078 (428.7) 1201 (457.4)
Polyunsaturated fat intake 
(g/day) 12.2 (6.1) 13.9 (6.3) 14.9 (6.3) 16.2 (6.7) 18.5 (7.2)
Alcohol intake  (g/day) 19.6 (23.3) 21.5 (23.2) 21.4 (22.9) 20.8 (22.9) 19.3 (22.4)
Dietary vitamin D intake range 
(μg/day) <1.9 1.9-<2.7 2.7-<3.6 3.6-<5.1 ≥5.1
N 64,431  64,431     64,430  64,431   64,430   
N  all-cause deaths 2,699    2,516       2,761    2,866     3,037     
Age at recruitment (years) 50.3 (10.9) 50.4 (9.6) 50.5 (9.4) 50.6 (9.4) 50.7 (9.2)
Body mass index (kg/m2) 25.0 (4.6) 24.6 (4.3) 24.7 (4.2) 25.0 (4.3) 25.0 (4.3)
Education  ‡
Longer education including 
University (%) 24.4 25.2 24.2 22.3 19.4       
Smoking status and intensity  ‡
Current (%) 17.2 18.1 18.8 20.5 23.9
Physical activity  ‡
Active (%) 12.4 14.4 15.8 16.1 12.0
Total energy intake (kcal/day) 1657 (438) 1883 (492) 1981 (533) 2055 (558) 2100 (550)
Red and processed meat 
consumption (g/day) 47.7 (37.1) 64.7 (40.4) 70.3 (42.9) 72.8 (43.9) 69.9 (42.5)
Fruit & vegetable consumption 
(g/day) 507.7 (298.9) 467.2 (263.7) 452.1 (247.8) 444.4 (248.0) 432.1 (252.2)
Calcium intake (mg/day) 855.9 (346.9) 960.2 (376.2) 1003 (396.2) 1029 (415.1) 1015 (428.2)
Polyunsaturated fat intake 
(g/day) 10.3 (5.0) 11.9 (5.1) 12.9 (5.2) 13.8 (5.7) 14.9 (6.2)
Alcohol intake  (g/day) 6.9 (11.1) 8.5 (12.0) 9.0 (12.2) 8.5 (12.1) 6.9 (10.2)
Ever use of contraceptive pill  ‡
Yes (%) 51.3 59.1 62.0 60.5 57.2
Ever use of menopausal 
hormone therapy  ‡
Yes (%) 19.3 23.8 25.0 25.7 27.4
Menopausal status  ‡
Postmenopausal (%) 42.9 41.3 41.3 42.3 43.6
Quintile of dietary vitamin D intake
Men
Women
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3.1.4 Dietary vitamin D and risk of all-cause mortality 
 
Dietary vitamin D intake was not associated with all-cause mortality risk in the multivariable 
model (Q5 vs. Q1, HR 0.96, 95% CI: 0.91-1.01; P-trend 0.65) (Table 6). Similar associations 
were observed for men and women (P-interaction 0.65). The dietary vitamin D and all-cause 
mortality associations did not differ across different strata of smoking status (P-interaction 
0.31), physical activity index (P-interaction 0.07), and BMI (P-interaction 0.23). Although, an 
inverse all-cause mortality association was observed amongst former smokers (Q5 vs. Q1, 
HR 0.88, 95% CI: 0.79-0.98; P-trend 0.04), but not amongst never and current smokers. This 
significant association was not present in the continuous models (HR per 2.5 µg/day 
increase, 0.98, 95% CI: 0.96-1.01). There was evidence of significant heterogeneity across 
participant countries (P-heterogeneity 0.007) (Figure 4). Positive associations (significant in 
France and Germany) were observed in half of the participant countries. A similar null 
association in the sexes combined analysis was observed when deaths recorded within the 
first 5 years of follow-up were excluded (eliminating 5,250 deaths: Q5 vs. Q1, HR 0.96, 95% 
CI: 0.90-1.02; P-trend 0.78). 
 
 
3.1.5 Dietary vitamin D and risk of cause-specific mortality 
 
During the follow-up period, cause-specific mortality end-points analysed included: cancer 
(n=10,157), circulatory diseases (n=5,083), respiratory diseases (n=744), and digestive 
diseases (n=682).  
 
Cancer mortality 
Similar null associations (P-interaction 0.61) were observed between dietary vitamin D intake 
and deaths caused by cancer in men (Q5 vs. Q1, HR 1.01, 95% CI: 0.89-1.16; P-trend 0.93) 
and women (Q5 vs. Q1, HR 0.92, 95% CI: 0.83-1.03; P-trend 0.24) (Table 7). Significant 
heterogeneity was observed across participant countries for the risk of cancer death in the 
sexes combined analysis (P-heterogeneity 0.026); with non-significant risk estimates 
observed for all countries except a positive association for Germany (HR per 2.5 µg/day, 
1.06, 95% CI: 1.02-1.10) and an inverse association for the Netherlands (HR per 2.5 µg/day, 
0.74, 95% CI: 0.61-0.90).  
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Circulatory disease mortality 
For deaths caused by circulatory diseases, no associations were observed for men (Q5 vs. 
Q1, HR 1.05, 95% CI: 0.89-1.25; P-trend 0.35) and women (Q5 vs. Q1, HR 1.01, 95% CI: 
0.84-1.21; P-trend 0.86) (P-interaction 0.61) (Table 7). Differences in associations were 
observed across countries (P-heterogeneity 0.03), with non-significant risk estimates 
observed for all countries except Denmark (HR per 2.5 µg/day, 0.90, 95% CI: 0.82-0.99), 
Germany (HR per 2.5 µg/day, 1.06, 95% CI: 1.01-1.12), and the Netherlands (HR per 2.5 
µg/day, 1.34, 95% CI: 1.06-1.71).  
 
Respiratory disease and digestive disease mortality 
Null associations were also observed for deaths caused by respiratory diseases in men (Q5 
vs. Q1, HR 1.09, 95% CI: 0.67-1.80; P-trend 0.73) and women (Q5 vs. Q1, HR 1.02, 95% CI: 
0.66-1.57; P-trend 0.38) (P-interaction 0.60) (Table 7). Similarly, for digestive disease 
mortality, no associations were observed among men (Q5 vs. Q1, HR 0.95, 95% CI: 0.60-
1.50; P-trend 0.85) and women (Q5 vs. Q1, HR 0.99, 95% CI: 0.62-1.60; P-trend 0.85) (P-
interaction 0.09). 
 
 
3.1.6 Dietary vitamin D and risks of digestive system and non-digestive system 
cancer mortality 
Based on an a priori hypothesis that cancers within the digestive system will be the most 
responsive to vitamin D exposures, deaths were split into digestive system and non-
digestive cancers. Overall, no difference was observed in the associations between digestive 
and non-digestive cancers, with no associations observed in the cancers of both locations 
(P-heterogeneity 0.54) (Table 8). For digestive system cancers, non-significant inverse and 
positive associations in the categorical models were observed amongst men and women 
respectively; although this difference was non-significant (P-interaction 0.74). Divergent risk 
estimates were also observed between men and women for non-digestive cancers, with a 
non-significant positive association observed amongst men and a significant inverse 
association observed amongst women. This difference by sex was non-significant (P-
interaction 0.36). 
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3.1.7 Dietary vitamin D and risks of mortality of individual cancers 
 
Colorectal cancer mortality 
Associations between dietary vitamin D intake and risks of death from individual cancers are 
shown in Table 9. No association was observed for colorectal cancer mortality (Q5 vs. Q1, 
HR 0.96, 95% CI: 0.75-1.24; P-trend 0.53) in analysis of men and women combined. Non-
significant results were also observed in separate men and women analyses (P-interaction 
0.75).  
 
Pancreatic cancer mortality 
For pancreatic cancer mortality, a non-significant association was observed for men and 
women combined (Q5 vs. Q1, HR 1.05, 95% CI: 0.77-1.44; P-trend 0.93) and analysed 
separately (Table 9). Contrasting non-significant inverse and positive associations were 
observed amongst men and women respectively; although this difference was not significant 
(P-interaction 0.22). 
 
Lung cancer mortality 
For lung cancer mortality, no association was observed in the sexes combined model (Table 
9). These associations did not differ by sex (P-interaction 0.22).  
 
Prostate cancer and breast cancer mortality 
Non-significant associations were also observed for prostate cancer mortality (Q5 vs. Q1, 
HR 0.87, 95% CI: 0.55-1.38; P-trend 0.66) and breast cancer mortality (Q5 vs. Q1, HR 1.15, 
95% CI: 0.85-1.55; P-trend 0.30) (Table 9). 
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Table 6. Risk (hazard ratios) of death from all causes associated with dietary vitamin D intake 
 
*  Basic model - Cox regression using total energy intake (continuous), and stratified by age (1-year categories), sex, and centre. 
†  Multivariable model - Cox regression using total energy intake (continuous), body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none, primary school completed, technical/professional school, secondary 
school, longer education including university, or not specified), physical activity index (inactive, moderately inactive, moderately active, active, or missing), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 
16-25 cigarettes per day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), smoking duration (<10; 10-<20; 20-
<30; 30-<40; 40+ years; smoking duration unknown), ever use of contraceptive pill (yes, no, or unknown), ever use of menopausal hormone therapy (yes, no, or unknown), menopausal status (premenopausal, postmenopausal, 
perimenopausal/unknown menopausal status, or surgical postmenopausal), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), and intakes of fruits and vegetables (g/day), red and processed meats (g/day), calcium 
(mg/day), and polyunsaturated fatty acids (g/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
Dietary vitamin D intake range (μg/day) 1 2 3 4 5
Men <2.3 2.3-<3.4 3.4-<4.7 4.7-<6.5 ≥6.5
Women <1.9 1.9-<2.7 2.7-<3.6 3.6-<5.1 ≥5.1 P -trend P -interaction
Total all cause mortality
Overall risk
N deaths 4,695            4,351                    4,915                   5,219                  5,817                    
Person-years 1,123,765      1,159,949              1,163,799             1,158,856           1,145,457             
Basic model - HR (95% CI) * 1.00              0.91 (0.87-0.96) 0.95 (0.91-0.99) 0.92 (0.88-0.97) 0.91 (0.87-0.96) 0.03 1.00 (0.98-1.01)
Multivariable model - HR (95% CI) † 1.00              0.93 (0.89-0.98) 0.97 (0.93-1.02) 0.96 (0.91-1.00) 0.96 (0.91-1.01) 0.65 1.00 (0.99-1.02)
Sex 0.65
Men 1.00              0.93 (0.87-1.00) 0.97 (0.91-1.05) 0.97 (0.90-1.05) 0.97 (0.90-1.06) 0.88 1.01 (0.99-1.03)
Women 1.00              0.93 (0.88-0.99) 0.97 (0.92-1.03) 0.95 (0.89-1.01) 0.95 (0.88-1.02) 0.47 1.00 (0.98-1.02)
Follow-up 0.85
<5 years 1.00              0.95 (0.86-1.05) 0.97 (0.88-1.07) 0.97 (0.87-1.08) 0.94 (0.83-1.06) 0.44 1.01 (0.98-1.04)
5-10 years 1.00              0.92 (0.86-0.99) 0.95 (0.89-1.03) 0.95 (0.88-1.03) 0.96 (0.88-1.04) 0.93 1.00 (0.98-1.02)
≥10 years 1.00              0.93 (0.87-1.00) 0.97 (0.90-1.04) 0.94 (0.87-1.01) 0.95 (0.87-1.04) 0.54 1.00 (0.98-1.03)
Smoking status 0.31
Never smoked 1.00              0.94 (0.88-1.01) 1.00 (0.93-1.08) 0.98 (0.90-1.06) 1.03 (0.94-1.13) 0.22 1.03 (1.00-1.05)
Former smoker 1.00              0.91 (0.84-0.99) 0.98 (0.90-1.08) 0.92 (0.84-1.01) 0.88 (0.79-0.98) 0.04 0.98 (0.96-1.01)
Current smoker 1.00              0.94 (0.86-1.02) 0.93 (0.86-1.01) 0.96 (0.88-1.05) 0.96 (0.88-1.06) 0.90 1.01 (0.99-1.03)
Body mass index 0.23
<25 kg/m2 1.00              0.91 (0.85-0.97) 0.96 (0.90-1.02) 0.91 (0.85-0.98) 0.93 (0.85-1.01) 0.29 0.99 (0.97-1.01)
25.0-29.9 kg/m2 1.00              0.95 (0.89-1.03) 0.99 (0.92-1.07) 1.01 (0.93-1.09) 1.00 (0.92-1.10) 0.49 1.01 (0.99-1.04)
≥30 kg/m2 1.00              0.97 (0.78-1.09) 0.98 (0.87-1.10) 0.95 (0.84-1.08) 0.97 (0.85-1.11) 0.80 1.02 (0.98-1.05)
Physical activity 0.07
Inactive 1.00 0.94 (0.87-1.02) 1.01 (0.93-1.09) 0.96 (0.88-1.05) 0.99 (0.89-1.09) 0.98 1.00 (0.97-1.03)
Moderately inactive 1.00 0.92 (0.85-0.99) 0.99 (0.91-1.08) 0.94 (0.87-1.03) 0.94 (0.85-1.04) 0.42 1.00 (0.98-1.03)
Moderately active 1.00 0.95 (0.85-1.06) 0.93 (0.84-1.04) 0.92 (0.82-1.03) 0.94 (0.83-1.08) 0.66 1.03 (0.99-1.06)
Active 1.00 0.93 (0.82-1.06) 0.96 (0.85-1.09) 1.03 (0.91-1.17) 1.02 (0.88-1.18) 0.34 1.02 (0.98-1.06)
Sex specific quintile of dietary vitamin D intake
HR (95% CI) per 
2.5 μg/day 
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Figure 4. Multivariable hazard ratios and 95% confidence intervals of all-cause mortality risk 
by country, per 2.5 µg/day increase in dietary vitamin D intake 
 
Multivariable model - Cox regression using total energy intake (continuous), body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), 
education status (none, primary school completed, technical/professional school, secondary school, longer education including university, or not 
specified), physical activity index (inactive, moderately inactive, moderately active, active, or missing), smoking status and intensity (never; 
current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 
years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), smoking duration (<10; 10-<20; 20-<30; 30-<40; 
40+ years; smoking duration unknown), ever use of contraceptive pill (yes, no, or unknown), ever use of menopausal hormone therapy (yes, no, 
or unknown), menopausal status (premenopausal, postmenopausal, perimenopausal/unknown menopausal status, or surgical postmenopausal), 
alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), and intakes of fruits and vegetables (g/day), red and processed meats 
(g/day), calcium (mg/day), and polyunsaturated fatty acids (g/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
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Table 7. Risk (hazard ratios) of cause-specific deaths associated with dietary vitamin D intake 
 
*  Basic model - Cox regression using total energy intake (continuous), and stratified by age (1-year categories), sex, and centre. 
†  Multivariable model - Cox regression using total energy intake (continuous), body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none, primary school completed, technical/professional school, secondary 
school, longer education including university, or not specified), physical activity index (inactive, moderately inactive, moderately active, active, or missing), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 
Causes of Death (ICD-10) N deaths 1 2 3 4 5
Men <2.3 2.3-<3.4 3.4-<4.7 4.7-<6.5 ≥6.5
Women <1.9 1.9-<2.7 2.7-<3.6 3.6-<5.1 ≥5.1 P -trend Sex P -interaction
Cancer (C00-D48) 0.61
Men
Basic model - HR (95% CI) * 4,307 1.00    0.99 (0.88-1.10) 1.01 (0.90-1.13) 1.00 (0.89-1.13) 0.93 (0.82-1.06) 0.20
Multivariable model - HR (95% CI) † 4,307 1.00    1.01 (0.91-1.13) 1.05 (0.94-1.18) 1.07 (0.95-1.21) 1.01 (0.89-1.16) 0.93 1.02 (0.99-1.05)
Women
Basic model - HR (95% CI) * 5,850 1.00    0.92 (0.84-1.00) 1.01 (0.92-1.10) 0.98 (0.89-1.08) 0.92 (0.83-1.03) 0.27
Multivariable model - HR (95% CI) † 5,850 1.00    0.92 (0.84-1.01) 1.01 (0.92-1.10) 0.98 (0.89-1.07) 0.92 (0.83-1.03) 0.24 0.99 (0.96-1.01)
Circulatory diseases (I00-I99) 0.81
Men
Basic model - HR (95% CI) * 2,780 1.00    1.00 (0.87-1.15) 0.93 (0.81-1.08) 0.96 (0.83-1.12) 1.02 (0.87-1.20) 0.63
Multivariable model - HR (95% CI) † 2,780 1.00    1.00 (0.87-1.15) 0.94 (0.81-1.09) 0.98 (0.84-1.14) 1.05 (0.89-1.25) 0.35 1.00 (0.96-1.04)
Women
Basic model - HR (95% CI) * 2,303 1.00    1.01 (0.88-1.17) 1.00 (0.86-1.16) 1.14 (0.97-1.32) 1.05 (0.88-1.26) 0.46
Multivariable model - HR (95% CI) † 2,303 1.00    1.01 (0.87-1.17) 0.97 (0.84-1.13) 1.09 (0.93-1.28) 1.01 (0.84-1.21) 0.86 1.00 (0.95-1.06)
Respiratory diseases (J30-J98) 0.60
Men
Basic model - HR (95% CI) * 338 1.00    0.86 (0.57-1.30) 0.98 (0.65-1.49) 0.89 (0.58-1.37) 0.86 (0.54-1.39) 0.63
Multivariable model - HR (95% CI) † 338 1.00    0.96 (0.63-1.46) 1.20 (0.78-1.83) 1.09 (0.70-1.71) 1.09 (0.67-1.80) 0.73 1.04 (0.94-1.16)
Women
Basic model - HR (95% CI) * 406 1.00    0.67 (0.47-0.96) 0.83 (0.59-1.17) 0.88 (0.62-1.26) 0.80 (0.53-1.20) 0.78
Multivariable model - HR (95% CI) † 406 1.00    0.73 (0.51-1.05) 0.90 (0.63-1.29) 1.02 (0.70-1.47) 1.02 (0.66-1.57) 0.38 1.10 (0.95-1.27)
Digestive diseases (K00-K93) 0.09
Men
Basic model - HR (95% CI) * 350 1.00    0.78 (0.55-1.12) 0.72 (0.50-1.05) 0.75 (0.51-1.10) 0.61 (0.40-0.95) 0.06
Multivariable model - HR (95% CI) † 350 1.00    0.86 (0.60-1.24) 0.91 (0.62-1.33) 1.02 (0.69-1.51) 0.95 (0.60-1.50) 0.85 1.02 (0.91-1.14)
Women
Basic model - HR (95% CI) * 332 1.00    1.04 (0.72-1.51) 1.09 (0.75-1.58) 1.02 (0.69-1.53) 1.01 (0.64-1.59) 0.92
Multivariable model - HR (95% CI) † 332 1.00    1.04 (0.71-1.51) 1.07 (0.73-1.56) 0.99 (0.66-1.50) 0.99 (0.62-1.60) 0.85 0.92 (0.77-1.10)
External causes (S00-Y98) 0.14
Men
Basic model - HR (95% CI) * 575 1.00    0.73 (0.54-0.99) 1.05 (0.78-1.41) 0.92 (0.68-1.26) 0.82 (0.58-1.16) 0.46
Multivariable model - HR (95% CI) † 575 1.00    0.76 (0.55-1.03) 1.10 (0.82-1.49) 1.00 (0.73-1.37) 0.91 (0.64-1.29) 0.91 0.97 (0.89-1.06)
Women
Basic model - HR (95% CI) * 473 1.00    0.95 (0.71-1.27) 0.89 (0.66-1.21) 0.73 (0.52-1.02) 1.16 (0.81-1.66) 0.38
Multivariable model - HR (95% CI) † 473 1.00    0.98 (0.73-1.31) 0.93 (0.69-1.27) 0.75 (0.54-1.06) 1.21 (0.84-1.74) 0.30 1.09 (0.99-1.20)
Sex specific quintile of dietary vitamin D intake
HR (95% CI) per 
2.5 μg/day 
increase 
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16-25 cigarettes per day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), smoking duration (<10; 10-<20; 20-
<30; 30-<40; 40+ years; smoking duration unknown), ever use of contraceptive pill (yes, no, or unknown), ever use of menopausal hormone therapy (yes, no, or unknown), menopausal status (premenopausal, postmenopausal, 
perimenopausal/unknown menopausal status, or surgical postmenopausal), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), and intakes of fruits and vegetables (g/day), red and processed meats (g/day), calcium 
(mg/day), and polyunsaturated fatty acids (g/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
 
 
 
Table 8. Risk (hazard ratios) of digestive system and non-digestive system deaths associated with dietary vitamin D intake 
 
*  Basic model - Cox regression using total energy intake (continuous), and stratified by age (1-year categories), sex, and centre. 
†  Multivariable model - Cox regression using total energy intake (continuous), body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none, primary school completed, technical/professional school, secondary 
school, longer education including university, or not specified), physical activity index (inactive, moderately inactive, moderately active, active, or missing), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 
16-25 cigarettes per day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), smoking duration (<10; 10-<20; 20-
<30; 30-<40; 40+ years; smoking duration unknown), ever use of contraceptive pill (yes, no, or unknown), ever use of menopausal hormone therapy (yes, no, or unknown), menopausal status (premenopausal, postmenopausal, 
perimenopausal/unknown menopausal status, or surgical postmenopausal), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), and intakes of fruits and vegetables (g/day), red and processed meats (g/day), calcium 
(mg/day), and polyunsaturated fatty acids (g/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
Digestive system cancers were oesophagus (C15), stomach (C16), colon and rectum (C18, C19, C20), anus and anal canal (C21), liver and intrahepatic bile acids (C22), gallbladder (C23), other and unspecified parts of biliary tract 
(C24), pancreas (C25), and other ill-defined digestive organs (C26). Non-digestive system cancers (all other cancers).  
Dietary vitamin D intake range (μg/day) 1 2 3 4 5
Men <2.3 2.3-<3.4 3.4-<4.7 4.7-<6.5 ≥6.5 HR (95% CI) per 
Women N deaths <1.9 1.9-<2.7 2.7-<3.6 3.6-<5.1 ≥5.1 P -trend 2.5 μg/day increase 
Digestive system cancers
Overall risk
Basic model - HR (95% CI) * 2,674 1.00 0.96 (0.83-1.10) 1.08 (0.94-1.24) 1.10 (0.95-1.27) 0.97 (0.83-1.15) 0.74
Multivariate model - HR (95% CI) † 2,674 1.00 0.97 (0.84-1.11) 1.09 (0.95-1.25) 1.11 (0.96-1.29) 1.00 (0.85-1.18) 0.95 0.99 (0.95-1.03)
Sex
Men 1,276 1.00 0.90 (0.74-1.10) 1.00 (0.82-1.23) 1.10 (0.89-1.36) 0.90 (0.71-1.15) 0.66 1.00 (0.94-1.06)
Women 1,398 1.00 1.02 (0.84-1.23) 1.17 (0.97-1.42) 1.12 (0.92-1.37) 1.09 (0.87-1.37) 0.62 0.98 (0.92-1.04)
Non-digestive system cancers
Overall risk
Basic model - HR (95% CI) * 7,483 1.00 0.94 (0.86-1.01) 0.97 (0.90-1.06) 0.94 (0.87-1.03) 0.90 (0.82-0.99) 0.04
Multivariate model - HR (95% CI) † 7,483 1.00 0.95 (0.88-1.03) 1.00 (0.92-1.08) 0.97 (0.89-1.06) 0.94 (0.85-1.04) 0.28 1.00 (0.98-1.03)
Sex
Men 3,031 1.00 1.07 (0.93-1.22) 1.07 (0.93-1.23) 1.06 (0.92-1.22) 1.07 (0.91-1.25) 0.69 1.02 (0.99-1.06)
Women 4,452 1.00 0.90 (0.81-0.99) 0.96 (0.87-1.07) 0.94 (0.84-1.04) 0.88 (0.77-0.99) 0.10 0.99 (0.96-1.02)
Sex specific quintile of dietary vitamin D intake
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Table 9. Risk (hazard ratios) of cancer deaths associated with dietary vitamin D intake 
 
*  Basic model - Cox regression using total energy intake (continuous), and stratified by age (1-year categories), sex, and centre. 
†  Multivariable model - Cox regression using total energy intake (continuous), body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none, primary school completed, technical/professional school, secondary 
school, longer education including university, or not specified), physical activity index (inactive, moderately inactive, moderately active, active, or missing), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 
16-25 cigarettes per day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), smoking duration (<10; 10-<20; 20-
<30; 30-<40; 40+ years; smoking duration unknown), ever use of contraceptive pill (yes, no, or unknown), ever use of menopausal hormone therapy (yes, no, or unknown), menopausal status (premenopausal, postmenopausal, 
perimenopausal/unknown menopausal status, or surgical postmenopausal), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), and intakes of fruits and vegetables (g/day), red and processed meats (g/day), calcium 
(mg/day), and polyunsaturated fatty acids (g/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
Dietary vitamin D intake range (μg/day) 1 2 3 4 5
Men <2.3 2.3-<3.4 3.4-<4.7 4.7-<6.5 ≥6.5 HR (95% CI) per 
Women N deaths <1.9 1.9-<2.7 2.7-<3.6 3.6-<5.1 ≥5.1 P -trend 2.5 μg/day increase Sex P -interaction
Colorectal cancer (C18-C20)
Overall risk
Basic model - HR (95% CI) * 1,145 1.00 1.02 (0.83-1.26) 1.11 (0.90-1.37) 1.10 (0.88-1.37) 0.96 (0.75-1.23) 0.52
Multivariate model - HR (95% CI) †¥ 1,145 1.00 1.02 (0.82-1.25) 1.10 (0.89-1.36) 1.09 (0.88-1.37) 0.96 (0.75-1.24) 0.53 0.96 (0.90-1.02)
Sex 0.75
Men 497 1.00 0.92 (0.67-1.27) 0.90 (0.65-1.25) 1.04 (0.74-1.46) 0.82 (0.56-1.21) 0.46 0.97 (0.88-1.07)
Women 648 1.00 1.08 (0.82-1.44) 1.28 (0.97-1.70) 1.13 (0.84-1.52) 1.08 (0.77-1.52) 0.98 0.95 (0.87-1.03)
Pancreatic cancer (C25)
Overall risk
Basic model - HR (95% CI) * 758 1.00 1.02 (0.79-1.33) 1.17 (0.90-1.52) 1.16 (0.88-1.53) 1.05 (0.77-1.43) 0.93
Multivariate model - HR (95% CI) † 758 1.00 1.02 (0.78-1.33) 1.16 (0.89-1.52) 1.16 (0.88-1.53) 1.05 (0.77-1.44) 0.93 1.00 (0.92-1.08)
Sex 0.22
Men 339 1.00 0.99 (0.67-1.47) 1.16 (0.78-1.73) 1.03 (0.68-1.58) 0.89 (0.55-1.44) 0.47 0.95 (0.84-1.07)
Women 419 1.00 1.04 (0.73-1.48) 1.16 (0.81-1.66) 1.26 (0.87-1.82) 1.20 (0.79-1.84) 0.41 1.04 (0.94-1.16)
Lung cancer (C34)
Overall risk
Basic model - HR (95% CI) * 1,919 1.00 0.96 (0.82-1.13) 1.00 (0.85-1.18) 0.96 (0.81-1.14) 0.90 (0.74-1.09) 0.25
Multivariate model - HR (95% CI) † 1,919 1.00 1.00 (0.85-1.18) 1.03 (0.87-1.22) 1.02 (0.86-1.22) 1.01 (0.83-1.23) 0.99 1.04 (0.99-1.08)
Sex 0.40
Men 1,042 1.00 1.12 (0.89-1.40) 1.25 (0.98-1.58) 1.12 (0.87-1.44) 1.19 (0.90-1.57) 0.46 1.06 (1.01-1.10)
Women 877 1.00 0.89 (0.70-1.13) 0.85 (0.67-1.08) 0.95 (0.74-1.21) 0.87 (0.65-1.16) 0.62 1.01 (0.95-1.08)
Prostate cancer (C61)
Overall risk
Basic model - HR (95% CI) * 392 1.00 0.90 (0.61-1.35) 0.90 (0.60-1.34) 0.81 (0.53-1.22) 0.85 (0.54-1.33) 0.55
Multivariate model - HR (95% CI) † 392 1.00 0.91 (0.61-1.35) 0.91 (0.61-1.35) 0.82 (0.54-1.25) 0.87 (0.55-1.38) 0.66 0.96 (0.86-1.08)
Breast cancer (C50)
Overall risk
Basic model - HR (95% CI) * 741 1.00 0.92 (0.72-1.18) 1.11 (0.87-1.43) 0.98 (0.75-1.27) 1.11 (0.83-1.49) 0.37
Multivariate model - HR (95% CI) †Ф 741 1.00 0.93 (0.72-1.19) 1.13 (0.88-1.46) 1.00 (0.76-1.31) 1.15 (0.85-1.55) 0.30 1.07 (1.00-1.13)
Sex specific quintile of dietary vitamin D intake
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†¥  Multivariable model – plus adjustment for cereal fibre intake (g/day, continuous). 
†Ф  Multivariable model – plus adjustment for age at first pregnancy (<21; 21-<30; 30+ years old; no children; or not specified) and age at menarche (<12; 12-<15; 15+ years old; or not specified). 
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3.2 Derivation and validation of a predictor 25-hydroxyvitamin D score     
within the European Prospective Investigation into Cancer and Nutrition 
 
3.2.1 Participant characteristics 
 
Characteristics of the participants used in the derivation and validation of the predictor 
25(OH)D score are shown in Table 10. The derivation and validation datasets for men and 
women were similar across all of the characteristics considered. 
 
Table 10. Characteristics of study participants included in the derivation and validation of the 
predictor circulating 25-hydroxyvitamin D score 
 
Mean and standard deviation (in parenthesis) unless stated otherwise. 
§  P-values for differences between the 25(OH)D derivation and validation subsamples were calculated using linear regression (continuous 
characteristic variables) and chi-square tests (categorical characteristic variables). 
 
Characteristic
P -value  § P -value  §
1,982 984 2,107 1,045
59.2 (7.0) 59.3 (7.2) 0.90 55.5 (8.0) 55.0 (8.8) 0.65
0.82 0.60
Denmark 23.8 24.9 22.5 22.6
France - - 6.9 5.7
Italy 11.1 11.6 17.0 16.9
Spain 14.2 12.9 9.2 11.3
United Kingdom 22.2 22.9 16.5 14.8
The Netherlands 2.4 3.2 14.4 14.6
Greece 2.5 3.3 2.4 3.0
Germany 23.9 21.3 11.1 11.1
4.5 (2.6) 4.4 (2.3) 0.78 3.4 (1.8) 3.3 (1.8) 0.28
96.2 (9.9) 96.4 (9.8) 0.87 81.2 (11.0) 81.8 (11.6) 0.67
0.31 0.46
Inactive 25.1 24.0 23.7 25.5
Moderately inactive 28.7 30.8 35.0 34.2
Moderately active 23.4 22.6 22.1 20.2
Active 22.8 22.6 19.3 20.2
0.21 0.70
Never smoker 27.4 24.5 52.0 52.0
Current, 1-15 cigarettes/day 8.1 8.7 13.4 12.7
Current, 16-25 cigarettes/day 6.0 7.3 5.9 5.6
Current, 26+ cigarettes/day 2.6 2.4 1.0 1.1
Former, quit ≤10 years 12.9 13.0 7.1 9.4
Former, quit 11-20 years 11.7 12.1 7.2 6.8
Former, quit 20+ years 18.0 18.2 7.9 7.8
Current, pipe/cigar/ocassional 10.5 11.9 4.0 4.0
Current/Former, missing 2.9 1.8 1.6 0.8
0.58 0.41
December 6.6 7.2 5.7 6.7
January 8.8 8.5 7.6 9.2
February 10.2 9.2 10.3 8.6
March 11.2 11.7 10.9 11.5
April 8.3 7.7 9.1 8.4
May 8.9 9.0 9.1 8.5
June 8.0 6.5 7.9 9.1
July 7.6 7.7 7.1 5.9
August 6.3 5.9 4.8 4.9
September 7.4 9.0 8.2 7.9
October 7.9 7.1 8.7 9.1
November 8.9 10.4 10.6 10.2
- 0.54
No - - 69.2 67.6
Yes - - 27.3 28.4
Unknown - - 3.5 4.0
0.91 0.34
Colorectal cancer 37.7 37.7 34.9 36.5
Prostate cancer 33.9 33.2 - -
Non-Hodgkin lymphomas 28.4 29.1 26.7 24.6
Breast cancer - - 38.4 39.0
Ever use of menopausal 
hormone therapy (%)
Source study (%)
Month of blood draw (%)
Smoking status and intensity (%)
Physical activity (%)
Waist circumference (cm)
Dietary vitamin D intake (µg/day)
Country (%)
Age at blood collection (years)
N
Men Women
 Sample for the 
derivation of the 
predictor score 
Sample for the 
validation of 
predictor score
 Sample for the 
derivation of the 
predictor score 
Sample for the 
validation of 
predictor score
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3.2.2 Derivation and validation of predictor 25-hydroxyvitamin D scores 
 
Predictor circulating 25-hydroxyvitaminD score derivation 
Correlates/determinants of circulating 25(OH)D considered for inclusion in the predictor 
score were split into the following categories: age at blood collection and timing of blood 
collection, dietary variables, anthropometric variables, lifestyle variables, reproductive 
variables, location of residence, and adjustment for different laboratories and assays. The 
final 25(OH)D predictor scores for men and women explained 34% and 28% of the overall 
variance in circulating 25(OH)D respectively (Table 11). Correlates/determinants included 
within the predictor scores were: age at blood collection, dietary vitamin D intake, waist 
circumference, physical activity index, month of blood collection, country of residence, 
smoking status and intensity, ever use of menopausal hormone therapy, and source study 
and batch of serum samples. The rationale for the inclusion of these correlates/determinants 
(and the exclusion of the other variables considered) is outlined in the section below. 
 
Age at blood collection and timing of blood collection variables 
Age at blood collection was a near statistically significant predictor in men and women. 
Weak divergent associations were observed in men (1 year age increase associated with a 
0.003% higher mean 25(OH)D) and women (1 year increase associated with a -0.002% 
lower mean 25(OH)D level) (Table 11). Despite these weak associations, age at blood 
collection remained in both predictor scores as it is a known determinant of vitamin D status. 
However, when the predictor scores were applied to the validation datasets, age was 
excluded to minimise the risk of statistical over-adjustment; as age is also an important risk 
factor (and therefore confounder) for chronic disease incidence and mortality, as well as a 
correlate/determinant of vitamin D status. 
 
Of the timing of blood collection variables considered, only month of blood collection was 
included in the predictor scores. Month of blood collection explained the most variance in 
circulating 25(OH)D in the men (16%) and women’s (12%) predictor scores. Using 
December as the reference category, the highest mean circulating 25(OH)D was found 
amongst those participants who had their blood collected in August in men (41% higher) and 
August and September in women (both 29% higher) (Table 11 and Figure 5). For both 
sexes, participants whose blood was collected in March had the lowest mean circulating 
25(OH)D levels when compared against the December reference category (16% lower in 
men and 17% lower in women). Month of blood collection reflects recent exposures 
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impacting on vitamin D status and is not a factor in determining long-term between person 
variance; because of this, month of blood collection was excluded when the predictor scores 
were applied to the validation datasets.  
 
Month of blood collection was selected ahead of season of blood collection as the latter 
variable explained less variance in circulating 25(OH)D (0.05% less in men and 0.03% less 
in women). Year of blood collection was not significant (P-value >0.05% in men and women) 
when included in the predictor scores and as a consequence was excluded. 
 
Dietary variables 
Dietary variables considered a priori for inclusion in the predictor scores were intakes of 
vitamin D, calcium and retinol. For dietary vitamin D, amongst both men and women, a 1 
µg/day increment in intake was statistically significantly associated with mean 2% higher 
circulating 25(OH)D levels. In men, 1% of the variance of circulating 25(OH)D levels was 
explained by dietary vitamin D intakes; whilst negligible variance was explained in women. 
(Table 11) Dietary calcium intake was not significantly associated with circulating 25(OH)D in 
men (P-value 0.62) and women (P-value 0.60); in both sexes zero additional variance in 
circulating 25(OH)D was explained by the addition of dietary calcium to the final predictor 
scores. Similarly, dietary retinol intake was not associated with circulating 25(OH)D (men: P-
value 0.63; women P-value 0.45),and no additional variance in circulating 25(OH)D was 
explained by its inclusion in the final predictor scores. Of the dietary intake variables 
considered, only vitamin D was included in the predictor scores. 
 
Anthropometric variables 
The anthropometric variables considered for inclusion in the predictor scores as indicators of 
adiposity were waist circumference, BMI, height, weight, and waist-to-hip ratio. Waist 
circumference was significantly associated with circulating 25(OH)D in both men and women 
(P-value <0.001). For both sexes, a 1 cm increase in waist circumference was associated 
with a mean 1% reduction in circulating 25(OH)D. Waist circumference explained more of 
the variance in circulating 25(OH)D among women (3%) than in men (1%) (Table 11). BMI 
was also significantly associated with circulating 25(OH)D when included in the predictor 
scores instead of waist circumference (P-value <0.001); however, slightly less variance was 
explained in the predictor scores than when waist circumference was included (0.01% less 
for men and 0.003% less for women). The close correlation between BMI and waist 
circumference (Pearson r =0.85 in men; r =0.86 in women) meant that only waist 
circumference was included in the final predictor scores. 
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Height (men P-value 0.94; women P-value 0.06) and weight (men P-value 0.26; women P-
value 0.90) were non-significant when included, in addition to waist circumference, in the 
final predictor scores; negligible additional variance in circulating 25(OH)D was explained by 
their inclusion. Similarly, waist-to-hip ratio was non-significant (men P-value 0.91; women P-
value 0.17), and did not explain any additional variance in circulating 25(OH)D when added 
to the final predictor scores. 
 
In summary, waist circumference was included as the indicator of adiposity as it was of 
greater statistical significance and/or explained more variance in circulating 25(OH)D than 
BMI, weight, or waist-to-hip-ratio.  
 
Lifestyle variables 
The a priori lifestyle variables considered for inclusion were physical activity, smoking status 
and intensity, educational level, alcohol consumption, and ever use of menopausal hormone 
therapy. Amongst men and women, increasing physical activity index levels were associated 
with higher circulating 25(OH)D levels (Table 11). Men, categorised as being physically 
‘active’ had mean 17% higher circulating 25(OH)D levels than those categorised as 
physically ‘inactive’. Amongst women, ‘active’ participants had a mean circulating 25(OH)D 
levels 12% higher than those classified as ‘inactive’. For both men and women, 1% of the 
variance in circulating 25(OH)D was explained by the inclusion of physical activity index 
within the predictor scores. The physical activity index variable was included within the 
predictor scores to act as a surrogate measure for sun exposure. The physical activity index 
variable encompasses all occupational and recreational activity.  
 
For smoking status and intensity, amongst both men and women, never smokers had higher 
circulating 25(OH)D status than current smokers (Table 11). The lowest circulating 25(OH)D 
levels were observed amongst current smokers of 16-25 cigarettes/day (men: 23% lower 
mean 25(OH)D compared to never smokers; women: 12% lower compared to never 
smokers). The highest circulating 25(OH)D levels were observed amongst men and women 
former smokers, who had quit for 11-20 years (men: 5% higher mean 25(OH)D compared to 
never smokers; women: 8% higher mean compared to never smokers). Smoking status and 
intensity explained 2% of circulating 25(OH)D variance in men and 1% in women. Due to 
smoking behaviour being an important risk factor/confounder in chronic disease/mortality risk 
models, as well as a significant correlate of circulating 25(OH)D levels, smoking status and 
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intensity was excluded when the predictor scores were applied to the validation datasets to 
minimise the risk of statistical over-adjustment. 
 
Education level was not included in the final predictor scores as was non-significant (P-value 
>0.05 in men and women) and explained zero additional variance in circulating 25(OH)D. 
Alcohol consumption was not significantly associated with circulating 25(OH)D in men (P-
value 0.81); while amongst women, this association was significant (P-value 0.01), but zero 
additional variance in circulating 25(OH)D was explained by its inclusion. As a consequence 
alcohol consumption was excluded from both sexes final predictor scores.   
 
Reproductive variables 
Women who had previously used menopausal hormone therapy had a mean 5% higher 
circulating 25(OH)D levels than never users (Table 11). Menopausal status (P-value >0.05), 
ever use of the contraceptive pill (P-value >0.05) and whether women had live born children 
(P-value 0.62) were excluded from the final predictor scores as all were non-significantly 
associated with circulating 25(OH)D in women. 
 
Location of residence 
Country of residence explained 1% and 2% of the variance in circulating 25(OH)D amongst 
men and women respectively. Men from Italy and Germany had the highest and lowest 
mean circulating 25(OH)D respectively when compared against participants from Denmark 
(reference category) (Table 11 and Figure 6). Men from Spain had a lower mean circulating 
25(OH)D levels than those from the UK and the Netherlands. Amongst women, the highest 
mean circulating 25(OH)D levels were observed amongst participants from Denmark 
(reference category); with the lowest observed in participants from Germany (27% lower 
than Denmark), Greece (22% lower), and Italy (21% lower). 
 
Adjustment for different laboratories and assays 
The source study and batch of circulating sample analysis was adjusted for in the final 
model, but excluded when the predictor score was applied to the validation datasets. 
Amongst both men and women, inclusion of this adjustment within the predictor scores 
explained 7% of the overall variances in circulating 25(OH)D (Table 11). 
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Table 11. Predictors of circulating 25-hydroxyvitamin D included in the scores. Analyses 
were completed in the derivation datasets of 1,982 men and 2,107 women 
 
‡  Age at blood collection and smoking status and intensity were excluded when predictor score was applied to the validation and full cohort 
datasets, so these variables can be used as confounders (avoiding statistical over-adjustment) when assessing disease risk with the predictor 
score. 
§  Month of blood collection was excluded when predictor score applied to the validation and full cohort datasets, as timing of blood collection 
reflects recent sun and diet/supplements exposures and is not a factor in determining long-term average between person variation. 
**  Adjusted for source study and batch of circulating 25(OH)D samples (colorectal cancer, prostate cancer, breast cancer or lymphoma) but 
excluded when predictor score applied to validation and full cohort datasets. 
 
 
 
 
Predictor N Loge β-coeff. P -value R
2 N Loge β-coeff. P -value R
2
N 1,982  - - - 2,107  - - -
Age at blood collection (years) ‡ 1,982  0.003 0.09 0.001 2,107  -0.002 0.05 0.001
1,982  0.02 <0.001 0.01 2,107  0.02 <0.001 0.00
1,982  -0.01 <0.001 0.01 2,107  -0.01 <0.001 0.03
Physical activity index 0.01 0.01
Inactive 497     REF REF 499     REF REF
Moderately inactive 569     0.08 0.001         737     0.09 <0.001
Moderately active 464     0.11 <0.001 465     0.10 <0.001
Active 452     0.17 <0.001 406     0.12 <0.001
Month of blood collection § 0.16 0.12
December 174     REF REF 120     REF REF
January 202     -0.03 0.56           159     -0.05 0.31
February 221     -0.15 <0.001 216     -0.16 <0.001
March 165     -0.16 <0.001 230     -0.17 <0.001
April 176     -0.07 0.12           191     -0.15 0.001
May 158     0.06 0.23           192     -0.05 0.29
June 150     0.19 <0.001 167     0.09 0.04
July 124     0.23 <0.001 150     0.18 <0.001
August 147     0.41 <0.001 102     0.29 <0.001
September 157     0.39 <0.001 173     0.29 <0.001
October 177     0.26 <0.001 184     0.16 <0.001
November 131     0.07 0.11           223     0.01 0.78
Country 0.01 0.02
Denmark 472     REF REF 473     REF REF
France - - - 145     -0.16 0.01
Italy 219     0.05 0.37           359     -0.21 <0.001
Spain 281     0.01 0.80           193     -0.03 0.54
United Kingdom 439     0.03 0.56           348     -0.17 0.001
The Netherlands 48       0.04 0.55           304     -0.12 0.02
Greece 50       0.04 0.58           51       -0.22 0.004
Germany 473     -0.10 0.04           234     -0.27 <0.001
Smoking status and intensity ‡ 0.02 0.01
Never smoker 542     REF REF 1,095  REF REF
Current, 1-15 cigarettes/day 161     -0.05 0.14 282     -0.06 0.04
Current, 16-25 cigarettes/day 118     -0.23 <0.001 124     -0.12 0.01
Current, 26+ cigarettes/day 52       -0.15 0.06 22       -0.07 0.43
Former, quit ≤10 years 255     -0.001 0.99 149     0.05 0.18
Former, quit 11-20 years 232     0.05 0.07 151     0.08 0.03
Former, quit 20+ years 357     0.01 0.71 166     0.02 0.55
Current, pipe/cigar/ocassional 208     -0.08 0.03 85       -0.05 0.24
Current/Former, missing 57       0.09 0.10 33       -0.11 0.09
Ever use of menopausal hormone therapy - 0.002
No - - - 1,458  REF REF
Yes - - - 576     0.05 0.01
Unknown - - - 73       0.04 0.46
Source study and batch of serum samples ** 0.07 0.07
Full model 0.34 0.28
Men Women
Dietary vitamin D intake (µg/day) 
Waist circumference (cm)
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Figure 5. Geometric mean (95% CI) monthly variation in circulating 25-hydroxyvitamin D in 
men and women in the European Prospective Investigation into Cancer and Nutrition 
Adjusted for other correlates/determinants of circulating 25-hydroxyvitamin D detailed in 
Table 11. Analyses were done in the derivation datasets of 1,982 men and 2,107 women. 
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Figure 6. Geometric mean (95% CI) country variation in circulating 25-hydroxyvitamin D in 
men and women in the European Prospective Investigation into Cancer and Nutrition 
Adjusted for other correlates/determinants of circulating 25-hydroxyvitamin D detailed in 
Table 11. Analyses were done in the derivation datasets of 1,982 men and 2,107 women. 
 
 
 
 
Predictor 25-hydroxyvitamin D scores validation 
The separate predictor scores for men and women were then applied to the validation 
datasets which had actual circulating 25(OH)D measurements for the participants (n=984 in 
men; and n=1,045 in women). Application of the predictor scores created a predicted 
25(OH)D value for each participant. 
 
Correlations between predicted 25-hydroxyvitamin D and actual circulating 25-
hydroxyvitamin D 
For men, the mean (SD) predicted 25(OH)D level was 46.1 (4.6) nmol/L, compared to an 
actual circulating 25(OH)D mean of 59.6 (24.6) after adjusting for source study and batch of 
101 
 
laboratory analysis. The Pearson and Spearman correlation coefficients between these 
variables were identical: 0.20 (95% CI: 0.14-0.26). When the actual circulating 25(OH)D 
measurements were further adjusted for month of blood collection and age of blood 
collection (mean actual 25(OH)D: 58.7 (22.3) nmol/L), the correlations increased slightly 
(Pearson: 0.21, 95% CI: 0.15-0.27; Spearman: 0.21, 95% CI: 0.14-0.26). Amongst women, 
the mean (SD) predicted 25(OH)D level was 55.2 (8.4) nmol/L, compared to an actual 
circulating 25(OH)D mean of 52.9 (21.9) nmol/L after adjusting for source study and batch of 
laboratory analysis. The Pearson and Spearman correlation coefficients were 0.19 (95% CI: 
0.13-0.25) and 0.20 (95% CI: 0.14-0.26) respectively. Similarly to men, further adjusting the 
actual 25(OH)D levels for month of blood collection and age at blood collection slightly 
increased these correlations (mean actual 25(OH)D: 52.1 (19.5) nmol/L; Pearson: 0.20, 95% 
CI: 0.14-0.26; Spearman: 0.21, 95% CI: 0.16-0.27). 
 
Actual 25-hydroxyvitaminD measurements by quantile of predicted 25-hydroxyvitamin D 
For both men and women actual measurements generally increased with increasing quintile 
and decile of predicted 25(OH)D levels (Figure 7). The differences between the extreme 
predicted quintiles of mean actual 25(OH)D was 18.3 nmol/L in men and 13.2 nmol/L in 
women, with incremental increases in actual 25(OH)D generally observed in the 
intermediate categories (P-trends <0.0001) (Figure 7A). Across deciles of predicted 
25(OH)D, linear increases in mean actual 25(OH)D measurements were observed in men 
and women (P-trends <0.0001). The differences in mean actual 25(OH)D between the 
extreme predicted 25(OH)D deciles was 23.3 nmol/L in men and 15.2 nmol/L in women. For 
both men and women, higher mean actual 25(OH)D values were generally yielded across 
incremental increases in predicted 25(OH)D deciles (Figure 7B).  
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Figure 7. Mean actual circulating 25-hydroxyvitamin D level by: (A) quintile; (B) decile of 
predicted 25-hydroxyvitamin D score in the European Prospective Investigation into Cancer 
and Nutrition 
Analyses were done in the validation datasets of 984 men and 1,045 women. 
 
(A) 
 
(B) 
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Cross-classifications of participants by predicted and actual circulating 25-hydroxyvitamin D 
categories 
How well the predictor scores categorised participants according to clinically relevant levels 
of circulating 25(OH)D, tertiles, and quintiles is shown in Figure 8. Figure 8A shows the 
agreement between participants’ predicted and actual 25(OH)D using three clinically 
relevant categories: <50; 50 to <75; and ≥75 nmol/L. Of the 384 men classified as having a 
deficiency in vitamin D status (<50 nmol/L) using their actual 25(OH)D measurements, 
85.4% (n=328) of them were classified into the corresponding predicted 25(OH)D category. 
In the mid-range exposure category, 19.7% (n=74) of men were similarly classified into 
matching predicted and actual 25(OH)D categories. Of the 225 men in the ≥75 nmol/L actual 
25(OH)D category, none were similarly classified into the equivalent predicted 25(OH)D 
category. Amongst the 525 women, classified in the <50 nmol/L actual circulating 25(OH)D 
category, 35.4% were classified into the corresponding predicted 25(OH)D category (Figure 
8A). Of the 354 women classified in the actual 25(OH)D 50 to <75 nmol/L category, 77.7% 
(n=275) were classified in the analogous predicted 25(OH)D category. Finally, of the 166 
women classified in the ≥75 nmol/L actual 25(OH)D category, just 2.4% (n=4) were 
classified into the equivalent predicted 25(OH)D category. 
 
In epidemiological studies assessing the circulating 25(OH)D-disease relationships five pre-
defined clinically relevant categories are used when analysing the associations: <25; 25 to 
<50; 50 to <75; 75 to <100; ≥100 nmol/L (67;176). The outermost categories reflect the 
extremes of severe deficiency (<25 nmol/L) through to high exposure status (≥100 nmol/L). 
Using the predictor scores, such extremes of exposure within EPIC could not be identified as 
participants were solely classified into the 25 to <50 and 50 to <75 nmol/L categories. 
 
Another approach to analyse relationships in epidemiological studies is to categorise the 
exposures into quantiles. In Figure 8B, the agreement between participants classified into 
predicted and actual circulating 25(OH)D tertiles is shown. Of the 328 men and 349 women 
classified in the lowest exposure tertile of actual circulating 25(OH)D, 41.2% and 45.6% 
were similarly classified into the parallel lowest tertile of predicted 25(OH)D. One-third of 
participants (32.9% in men and 33.9% in women) were jointly classified in the same 
predicted and actual circulating 25(OH)D second tertile. Agreement in participant’s 
classification between predicted tertile 3 to actual circulating 25(OH)D tertile 3 was 42.1% in 
men and 41.4% in women. Overall, across all tertiles of actual 25(OH)D, 39% and 40% of 
men and women were classified into the corresponding predicted 25(OH)D tertile. 
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Figure 8C shows the proportion of participants classified by quintiles of actual and predicted 
25(OH)D. Of men classified in the first actual circulating 25(OH)D quintile: 32.2% were 
classified into predicted 25(OH)D quintile 1; 51.3% were classified into predicted 25(OH)D 
quintile 1 or 2; and 10.6% were classified into predicted 25(OH)D quintile 5. Of those men 
classified into the highest actual circulating 25(OH)D quintile: 30.8% were classified into the 
corresponding predicted 25(OH)D quintile; 51.3% were classified either in quintiles 4 and 5 
of predicted 25(OH)D; and 11.3% were classified into the lowest predicted 25(OH)D quintile. 
Of women classified in the lowest quintile of actual circulating 25(OH)D: 31.1% were 
classified into the equivalent predicted 25(OH)D category; 52.6% were classified into 
predicted quintiles 1 and 2; and 15.8% were classified into quintile 5 of predicted 25(OH)D. 
Amongst women who were classified into the highest actual circulating 25(OH)D quintile: 
25.4% were classified into the analogous predicted 25(OH)D category; 52.6% were 
classified into predicted 25(OH)D quintiles 4 and 5; and 11.5% were classified into the 
lowest predicted 25(OH)D quintile. For men and women, 46.3% and 45.8% were 
respectively classified into equivalent or parallel quintiles of actual and predicted 25(OH)D 
(Figure 9).  
 
Assessment of colorectal cancer risk in the nested case-control dataset 
The next stage in the validation process was to assess the risks of colorectal cancer 
incidence using the predictor scores and then to compare these results against previously 
published studies within EPIC. A nested case-control study carried out by Jenab et al., (67) 
previously reported 38% reduced colorectal cancer incidence risk (95% CI: 0.47-0.81) when 
the highest and lowest quintiles of circulating 25(OH)D were compared (Table 12). This 
association was linear (P-trend <0.001) and standardised for month of blood collection. In 
the continuous model, a 4% lower colorectal cancer risk (95% CI: 0.94-0.98) was observed 
per higher 5.9 nmol/L (100 IU/L) increase in circulating 25(OH)D. When the predictor scores 
(re-derived with the samples sourced from the colorectal cancer nested case-control study 
excluded) were applied to the nested case-control dataset significant inverse associations 
were also observed (Table 12). These associations were stronger than when actual 
circulating 25(OH)D measurements were used in the models. In the categorical multivariable 
model, a 50% reduced colorectal cancer risk was observed amongst participants in the 
highest predicted 25(OH)D quintile when compared against those in the lowest quintile; this 
association was linear (P-trend 0.03). In the continuous model, a 20% lower colorectal 
cancer risk (95% CI: 0.68-0.93) was observed per increment of 5.9 nmol/L (100 IU/L). 
Additional adjustment for physical activity index may be deemed as statistical over-
adjustment as was an important component of the predictor scores, serving as a proxy 
indicator of sun exposures; however, when adjusted for in the multivariable models similar 
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associations were observed. When the multivariable model was not adjusted for BMI (due to 
its close correlation with waist circumference (r =78) – the marker of adiposity used within 
the predictor scores - a slightly stronger significant inverse association was observed. 
 
Assessment of colorectal cancer risk in the full European Prospective Investigation into 
Cancer and Nutrition cohort 
When the predictor scores were applied to the full EPIC cohort - minus the participants 
whose samples were used in the derivation of the predictor scores - similar inverse results 
were also observed to the Jenab et al., (67) analysis. With men and women analysed jointly, 
a 25% reduced risk of colorectal cancer incidence was observed in the multivariable model 
(Table 13). This association was linear (P-trend 0.009); and in the continuous model, a 6% 
lower colorectal cancer incidence risk was observed per 5.9 nmol/L higher predicted 
25(OH)D. This statistical model adjusted for identical covariates as the Jenab et al., (67) 
models, except for the timing of blood collection (not a relevant factor in determining long-
term between person variation) and physical activity. However, for completeness, the results 
with this additional adjustment are presented. In the continuous models, the risk estimates 
were attenuated with statistical significance lost (HR per 5.9 nmol/L increment in predicted 
25(OH)D, 0.97, 95% CI: 0.89-1.05). Conversely, when the multivariable model was not 
adjusted for BMI, stronger inverse associations were observed. 
 
Assessment of prostate cancer risk in the full European Prospective Investigation into 
Cancer and Nutrition cohort 
The association between circulating 25(OH)D and prostate cancer incidence has previously 
been investigated within EPIC in a nested case-control study by Travis et al., (97). In this 
analysis, a non-significant suggestive positive association was observed in the multivariable 
models standardised by month of blood collection (Q5 vs. Q1, OR 1.28, 95% CI: 0.88-1.88). 
This association was non-linear (P-trend 0.19) and in the continuous models, a non-
significant 5% higher prostate cancer risk was observed per 25 nmol/L increment in 
circulating 25(OH)D. After the predictor scores were applied to the full EPIC cohort, a non-
significant weak positive association was observed in the multivariable model (Q5 vs. Q1, 
OR 1.08, 95% CI: 0.92-1.26) (Table 14). In the continuous model, a 7% greater prostate 
cancer risk was observed per 25 nmol/L higher circulating 25(OH)D. Identical covariate 
adjustments were made as in the Travis et al., (97) analysis; except for the variables 
reflecting the timing of blood collection and, once more, physical activity. When the 
multivariable models were additionally adjusted for physical activity, and not adjusted for 
BMI, similar risk estimates were observed.  
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Figure 8. The percentage of participants who were classified into predicted circulating 25-
hyrdroxyvitamin D by their actual circulating 25(OH)D categories 
Analyses were done in the validation datasets of 984 men and 1,045 women. Categories: 
(A) Three clinically defined categories (<50; 50 to <75; ≥75 nmol/L); (B) tertiles; and (C) 
quintiles. Red box denotes the percentage of participants whose predicted category 
corresponds to their actual circulating 25(OH)D category. 
Men Women 
(A) 
 
 
 
 
 
 
Men 
 
 
 
Women 
(B) 
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Women 
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Figure 9. The percentage of participants (by sex) classified by quintiles of actual and 
predicted circulating 25-hydroxyvitamin D 
Analyses were done in the validation datasets of 984 men and 1,045 women.  
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Table 12. Assessment of colorectal cancer incidence risk using the predictor 25-hydroxyvitamin D score in the colorectal nested case-control dataset, 
compared with a previous published analysis within the European Prospective Investigation into Cancer and Nutrition (67) 
 
†  Matched by centre, sex, age at recruitment, and time of day of blood collection. 
ɸ  Multivariable model - adjusted for BMI, smoking, alcohol intake, education, physical activity, total energy intake, and intakes of total fruits and vegetables, meats/meat products, and alcohol. 
 
 
 
 
 
 
 
Non-standardised 
Q1 Q2 Q3 Q4 Q5
Jenab et al. , 2010 ≤40.2 >40.2-≤53 >53-≤64.2 >64.2-≤79.8 >79.8
1.00 0.82 (0.65-1.05) 0.78 (0.60-1.00) 0.63 (0.49-0.82) 0.61 (0.47-0.79) <0.001
1.00 0.80 (0.62-1.03) 0.78 (0.60-1.01) 0.62 (0.48-0.82) 0.62 (0.47-0.81) <0.001 0.96 (0.94-0.98)
Predicted 25(OH)D score Q1 Q2 Q3 Q4 Q5 P -trend RR per 100 IU/L (5.9 nmol/L)
Excluding colorectal cancer serum samples ≤42.0 >42.0-≤46.1 >46.1-≤52.8 >52.8-≤61.5 >61.5
1.00 0.66 (0.49-0.89) 0.59 (0.42-0.83) 0.55 (0.34-0.88) 0.42 (0.24-0.72) 0.001
1.00 0.67 (0.49-0.91) 0.60 (0.42-0.86) 0.55 (0.34-0.89) 0.41 (0.24-0.72) 0.001 0.79 (0.70-0.89)
1.00 0.70 (0.51-0.96) 0.65 (0.44-0.96) 0.63 (0.36-1.09) 0.50 (0.26-0.97) 0.03 0.80 (0.68-0.93)
1.00 0.72 (0.51-1.01) 0.68 (0.45-1.04) 0.64 (0.35-1.18) 0.51 (0.24-1.07) 0.07 0.79 (0.66-0.95)
RR per 100 IU/L (5.9 nmol/L)
Matching variables only  †
Multivariable model  ɸ
Matching variables only  †
Multivariable model  ɸ
Multivariable model ɸ plus physical activity adjustment
Multivariable model ɸ minus BMI
Standardised by month
P -trend
109 
 
Table 13. Assessment of colorectal cancer incidence risk within the full European Prospective Investigation into Cancer and Nutrition cohort using the 
predictor 25-hydroxyvitamin D score 
Analyses were done in the full cohort containing 112,957 men and 217,467 women. 
 
 
§  Basic model - stratified by age of recruitment (1 year categories) and centre. 
¶  Multivariable model - stratified by age of recruitment (1 year categories) and centre and adjusted for BMI, total energy intake, education, smoking status and intensity, and intakes of alcohol, fruits and vegetables, and meat and meat 
products. 
 
 
  
Predicted 25(OH)D score Q1 Q2 Q3 Q4 Q5
Men <42.8 42.8-45.6 45.7-48.1 48.2-50.9 ≥51.0
Women <48.0 48.0-52.4 52.5-56.1 56.2-60.3 ≥60.4
Both sexes
N  cases 517 426 396 392 381
Basic model § 1.00 0.78 (0.68-0.89) 0.74 (0.64-0.86) 0.76 (0.66-0.89) 0.65 (0.55-0.76) <0.001 0.89 (0.84-0.93)
Multivariable model ¶ minus BMI 1.00 0.78 (0.68-0.90) 0.75 (0.65-0.87) 0.78 (0.67-0.91) 0.66 (0.56-0.79) <0.001 0.89 (0.85-0.94)
Multivariable model ¶ 1.00 0.82 (0.71-0.95) 0.80 (0.69-0.94) 0.85 (0.72-1.01) 0.75 (0.62-0.91) 0.009 0.94 (0.88-0.99)
Multivariable model ¶ plus physical activity 1.00 0.85 (0.73-0.98) 0.85 (0.71-1.01) 0.90 (0.74-1.10) 0.80 (0.63-1.01) 0.12 0.97 (0.89-1.05)
By sex
Men
N  cases 251 187 178 182 145
Basic model § 1.00 0.72 (0.59-0.87) 0.67 (0.55-0.83) 0.73 (0.59-0.91) 0.62 (0.49-0.79) 0.001 0.83 (0.76-0.92)
Multivariable model ¶ minus BMI 1.00 0.73 (0.60-0.89) 0.69 (0.56-0.86) 0.76 (0.61-0.95) 0.67 (0.53-0.84) 0.002 0.86 (0.78-0.95)
Multivariable model ¶ 1.00 0.79 (0.64-0.97) 0.77 (0.62-0.96) 0.88 (0.69-1.11) 0.79 (0.61-1.03) 0.29 0.94 (0.84-1.05)
Multivariable model ¶ plus physical activity 1.00 0.82 (0.66-1.03) 0.84 (0.64-1.09) 0.96 (0.70-1.30) 0.85 (0.59-1.22) 0.85 0.98 (0.83-1.16)
Women
N  cases 266 239 218 210 236
Basic model § 1.00 0.84 (0.69-1.01) 0.81 (0.66-0.99) 0.79 (0.64-0.98) 0.66 (0.52-0.85) 0.003 0.91 (0.85-0.97)
Multivariable model ¶ minus BMI 1.00 0.84 (0.69-1.01) 0.80 (0.66-0.98) 0.79 (0.64-0.98) 0.66 (0.52-0.85) 0.002 0.91 (0.85-0.97)
Multivariable model ¶ 1.00 0.85 (0.70-1.04) 0.83 (0.67-1.04) 0.82 (0.64-1.05) 0.70 (0.52-0.95) 0.048 0.92 (0.85-0.99)
Multivariable model ¶ plus physical activity 1.00 0.87 (0.71-1.07) 0.86 (0.68-1.10) 0.86 (0.64-1.14) 0.75 (0.53-1.05) 0.18 0.94 (0.85-1.03)
HR per 100 IU/L (5.9 nmol/L)P -trend
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Table 14. Assessment of prostate cancer incidence risk using the predictor 25-hydroxyvitamin D score (A) compared with a previous published 
analysis (97) (B) within the European Prospective Investigation into Cancer and Nutrition 
Analyses were done in the full cohort containing 112,957 men.  
 
(A) 
 
§  Basic model - stratified by age of recruitment (1 year categories) and centre. 
¶  Multivariable model - stratified by age of recruitment (1 year categories) and centre and adjusted for BMI, education, smoking status and intensity, marital status, and intake of alcohol. 
 
 
(B) 
 
†  Matched by centre, age at recruitment, time of day of blood collection, and time between blood collection and last consumption of food and drink. 
ɸ  Multivariable model - adjusted for BMI, smoking, alcohol intake, education, marital status, and physical activity. 
 
 
 
Predicted 25(OH)D score Q1 Q2 Q3 Q4 Q5
<42.8 42.8-45.6 45.7-48.1 48.2-50.9 ≥51.0 P -trend HR per 25 nmol/L
Men
N  cases 581 568 522 448 434
Basic model § 1.00 1.10 (0.97-1.24) 1.07 (0.94-1.22) 0.99 (0.86-1.13) 1.09 (0.95-1.26) 0.53 1.09 (0.86-1.38)
Multivariable model ¶ minus BMI 1.00 1.08 (0.96-1.22) 1.05 (0.92-1.20) 0.97 (0.84-1.11) 1.07 (0.93-1.23) 0.70 1.05 (0.83-1.34)
Multivariable model ¶ 1.00 1.09 (0.96-1.23) 1.06 (0.92-1.21) 0.98 (0.84-1.13) 1.08 (0.92-1.26) 0.70 1.07 (0.81-1.41)
Multivariable model ¶ plus physical activity 1.00 1.09 (0.95-1.25) 1.06 (0.90-1.25) 0.98 (0.81-1.19) 1.12 (0.90-1.39) 0.53 1.18 (0.80-1.72)
Travis et al ., 2009
Q1 Q2 Q3 Q4 Q5
≤40.4 >40.4-≤50.4 >50.4-≤59.1 >59.1-≤70.8 >70.8 P -trend RR per 25 nmol/L
1.00 1.24 (0.88-1.74) 1.15 (0.82-1.62) 1.01 (0.71-1.45) 1.24 (0.87-1.79) 0.27
1.00 1.27 (0.89-1.81) 1.23 (0.85-1.76) 1.06 (0.73-1.55) 1.28 (0.88-1.88) 0.19 1.05 (0.93-1.19)
Standardised by month
Matching variables only  †
Multivariable adjusted  ɸ
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Sensitivity analyses for predictor 25-hydroxyvitamin D scores derivations 
Various sensitivity analyses were carried out to assess the impact of certain decisions made 
during the derivation of the predictor 25(OH)D scores: 
 
1) Due to smoking behaviour being an important risk factor/confounder in chronic 
disease/mortality risk models, as well as a significant correlate of circulating 25(OH)D 
levels, smoking status and intensity was excluded when the predictor scores were 
applied to the validation datasets to minimise the risk of statistical over-adjustment. In 
the sensitivity analysis, smoking status and intensity was excluded from the predictor 
scores and all validations were re-run. 
2) Similarly, age is an important risk factor/confounder in chronic disease/mortality risk 
models, as well as an important determinant of circulating 25(OH)D levels. Age at 
blood collection was excluded when the predictor scores were applied to the 
validation datasets to minimise the risk of statistical over-adjustment. In the sensitivity 
analysis, age at blood collection was excluded from the predictor scores and all 
validations were re-run. 
3) The predictor scores were derived using case and control samples from previous 
EPIC nested case-control studies. Cases were not excluded as blood samples were 
collected prospectively prior to the onset of disease. In sensitivity analyses, the 
predictor scores were derived using samples from control participants only to assess 
the impact of samples from cases being used. 
 
Sensitivity analysis - correlations between actual and predicted 25-hydroxyvitamin D values  
For the final men and women’s predictor scores, the Pearson and Spearman correlation 
coefficients between actual and predicted 25(OH)D levels in the validation datasets ranged 
from 0.20 to 0.21. Similar correlations were observed when: (1) smoking status and intensity 
variable was excluded from the predictor scores at the derivation stage (Spearman: r =0.21 
for men and r =0.20 for women); (2) age at blood collection was excluded from the predictor 
scores at the derivation stage (Spearman: r =0.20 for men and r =0.20 for women); and (3) 
when the predictor scores were derived using samples from control participants (Spearman: 
r =0.21 for men and r =0.19 for women). 
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Sensitivity analysis - actual circulating 25(OH)D measurements according to quintiles and 
deciles of predicted 25-hydroxyvitamin D levels  
In the final predictor scores, actual circulating 25(OH)D measurements generally increased 
with increasing decile of predicted 25(OH)D levels in the validation datasets. The differences 
in mean actual 25(OH)D between the extreme predicted 25(OH)D deciles was 23.3 nmol/L 
for men and 15.2 nmol/L for women. Similar results were observed in the sensitivity analyses 
when: (1) the smoking status and intensity variable was excluded from the predictor scores 
at the derivation stage (P-trend <0.001; differences in extreme deciles 24.7 nmol/L for men 
and 15.1 nmol/L for women); and (2) age at blood collection was excluded from the predictor 
scores at the derivation stage (P-trend <0.001; differences in extreme deciles 24.7 nmol/L 
for men and 15.6 nmol/L for women). When samples from control participants were used to 
derive the predictor scores (3), once more, actual measurements increased with increasing 
decile of predicted 25(OH)D levels. However, compared to the final predictor scores, the 
difference between the extreme deciles was lower for men (19.8 nmol/L) but higher for 
women (20.1 nmol/L) 
 
Sensitivity analysis - cross-classifications of participants into categories of predicted and 
actual 25-hydroxyvitamin D levels 
In the final predictor scores, for men and women, 46.3% and 45.8% were respectively 
classified into equivalent or parallel quintiles of actual and predicted 25(OH)D in the 
validation datasets. Similar classifications were made when: (1) smoking status and intensity 
variable was excluded from the predictor scores at the derivation stage (45.6% men and 
46.5% women); (2) age at blood collection was excluded from the predictor scores at the 
derivation stage (46.3% men and 46.0% women); and (3) when the predictor scores were 
derived using samples from control participants (44.5% men and 44.8% women). 
 
Sensitivity analysis - assessment of colorectal cancer incidence risk using predicted 25-
hydroxyvitamin D score 
Colorectal cancer incidence risk was assessed using the predictor scores in the nested 
case-control datasets (with the circulating samples sourced from the colorectal cancer 
nested case-control study excluded). In the final predictor score sexes combined 
multivariable model, a 20% lower colorectal cancer risk (OR 0.80, 95% CI: 0.68-0.93) was 
observed per increment of 5.9 nmol/L (100 IU/L). In sensitivity analyses, similar inverse 
associations were observed when: (1) smoking status and intensity variable was excluded 
from the predictor scores at the derivation stage (HR per 5.9 nmol/L increment in predicted 
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25(OH)D, 0.80, 95% CI: 0.68-0.93); (2) age at blood collection was excluded from the 
predictor scores at the derivation stage (HR per 5.9 nmol/L increment in predicted 25(OH)D, 
0.77, 95% CI: 0.66-0.91); and (3) when the predictor scores were derived using samples 
from control participants (HR per 5.9 nmol/L increment in predicted 25(OH)D, 0.80, 95% CI: 
0.68-0.93) (Table 15). Similar associations were observed for all versions of the predictor 
scores when not adjusted for BMI in the multivariable models, and when additionally 
adjusted for physical activity index. 
 
 
Table 15. Assessment of colorectal cancer incidence risk in the colorectal nested case-
control dataset using the: 25-hydroxyvitamin D final predictor scores, (1) final predictor 
scores minus smoking, (2) final predictor scores minus age at blood collection, and (3) final 
predictor scores using control samples only 
 
†  Matched by centre, sex, age at recruitment, and time of day of blood collection. 
ɸ  Multivariable model - adjusted for BMI, smoking, alcohol intake, education, physical activity, total energy intake, and intakes of total fruits and 
vegetables, meats/meat products, and alcohol. 
1  Excluding smoking status and intensity from predictor score derivation. 
2  Excluding age at blood collection from predictor score derivation. 
3  Predictor scores derived using 25(OH)D samples from control participants only (i.e. excluding cases from lymphoma and prostate cancer 
nested case-control studies). 
 
 
 
 
 
 
 
Predicted 25(OH)D score
0.79 (0.70-0.89) 0.79 (0.70-0.89) 0.78 (0.69-0.88) 0.79 (0.70-0.89)
0.80 (0.68-0.93) 0.80 (0.68-0.93) 0.77 (0.66-0.91) 0.80 (0.68-0.93)
0.79 (0.66-0.95) 0.79 (0.65-0.95) 0.76 (0.62-0.93) 0.79 (0.66-0.95)
RR per 100 IU/L (5.9 nmol/L)
Smoking 
excluded from 
predictor scores 1
Multivariable model ɸ minus BMI
Multivariable model  ɸ
Multivariable model ɸ plus 
physical activity adjustment
Final predictor 
scores
Control samples only 
predictor scores 3
Age at blood 
collection excluded 
from predictor 
scores 2
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3.3 Application and validation of the Health Professionals Follow-Up 
Study derived 25-hydroxyvitamin D score in the European 
Prospective Investigation into Cancer and Nutrition 
 
3.3.1 Validation of the Health Professionals Follow-Up Study derived 25-
hydroxyvitamin D score in the European Prospective Investigation into Cancer 
and Nutrition 
The U.S. based HPFS predictor score (52) was applied to the EPIC validation dataset of 823 
men who lived at similar latitudes. Application of the predictor score created a predicted 
25(OH)D value for each participant. 
 
Correlations between actual and predicted 25-hydroxyvitamin D values 
The mean (SD) of the HPFS predicted 25(OH)D score was 69.4 (6.7) nmol/L; compared to 
mean (SD) of actual circulating 25(OH)D measurements (adjusted for course source study 
and batch of laboratory analysis, month of blood collection, and age of blood collection) of 
57.2 (22.7) nmol/L. The correlations between actual circulating 25(OH)D measurements and 
the HPFS score were lower than for the EPIC derived score; with identical Pearson and 
Spearman correlation coefficients (0.05, 95% CI: 0.02-0.12) yielded between the HPFS 
predicted 25(OH)D values and actual circulating 25(OH)D measurements. 
 
Actual circulating 25(OH)D measurements according to quintiles and deciles of Health 
Professional Follow-Up Study predicted 25-hydroxyvitamin D levels  
Mean actual circulating 25(OH)D levels were changeable across increasing quintiles and 
deciles of HPFS predicted 25(OH)D levels (Figure 10). Unlike the EPIC derived predictor 
scores, linear increases in actual 25(OH)D across quintiles (P-trend 0.17) and deciles (P-
trend 0.18) of HPFS predicted 25(OH)D were not observed. Furthermore, the differences 
across the extreme HPFS predicted quantiles of mean actual 25(OH)D were narrower than 
from the EPIC derived score (5.0 nmol/L for quintiles vs. 18.3 nmol/L using the EPIC derived 
score; and 5.8 nmol/L for deciles vs. 23.3 nmol/L using the EPIC derived score).  
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Cross-classifications of participants into categories of Health Professional Follow-Up 
Study predicted and actual 25-hydroxyvitamin D levels 
Figure 11 shows the proportion of participants classified by quintiles of actual and HPFS 
predicted 25(OH)D. Of men classified in the first actual circulating 25(OH)D quintile: 25.9% 
were classified into predicted 25(OH)D quintile 1; 44.6% were classified into predicted 
25(OH)D quintile 1 or 2; and 18.1% were classified into predicted 25(OH)D quintile 5. Of 
those men classified into the highest actual circulating 25(OH)D quintile: 21.5% were 
classified into the corresponding predicted 25(OH)D quintile; 36.8% were classified either in 
quintiles 4 and 5 of predicted 25(OH)D; 27.0% were classified into predicted quintile 3; and 
17.2% were classified into the lowest predicted 25(OH)D quintile. Overall, 42.1% of men 
were classified into equivalent or parallel quintiles of actual and predicted 25(OH)D. 
 
Assessment of colorectal cancer incidence risk using the Health Professionals 
Follow-Up Study predicted 25-hydroxyvitamin D score 
The next stage in the validation process of the predicted 25(OH)D scores was to assess the 
risks of colorectal cancer and then compare these results against previously published 
studies with EPIC. Unlike the inverse associations observed in the Jenab et al., (67) and 
when using the EPIC derived predictor score, non-significant associations were observed 
when the HPFS predictor score was applied to the full EPIC cohort dataset to assess 
colorectal cancer incidence risk (multivariable model: HR per 5.9 nmol/L increment, 1.08, 
95% CI: 0.88-1.33). Similarly, in the categorical models, when the highest and lowest 
quintiles were compared, a non-significant 23% increased risk (HR 1.23, 95% CI: 0.76-1.99) 
was observed, without a linear trend between quintiles (P-trend 0.49). Analysis of the HPFS 
predictor score within the colorectal cancer nested case-control dataset was not possible as, 
after exclusions (including circulating samples sourced from the colorectal cancer nested 
case-control study), just 4 cases remained in the dataset of 558 men. 
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Figure 10. Mean actual circulating 25-hydroxyvitamin D level by: (A) quintile; (B) decile of 
predicted 25-hydroxyvitamin D score derived in the Health Professionals Follow-Up Study 
but applied in the European Prospective Investigation into Cancer and Nutrition 
Analyses were done in the validation dataset of 823 men. 
 
(A) 
 
(B) 
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Figure 11. The percentage of participants who were classified into predicted circulating 25-
hyrdroxyvitamin D by their actual circulating 25(OH)D quintiles using the Health 
Professionals Follow-Up Study predictor score 
Analyses were done in the validation dataset of 823 men.  
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3.4 Application of the predicted 25-hydroxyvitamin D score within the 
European Prospective Investigation into Cancer and Nutrition to 
assess cancer incidence risk 
 
3.4.1 Characteristics of cohort participants 
 
The cohort characteristics by country and sex are shown in Table 16. The highest predicted 
circulating 25(OH)D levels were observed in the Netherlands for men and Denmark for 
women. The lowest predicted 25(OH)D levels for men and women were observed amongst 
participants from Germany and Greece respectively. The crude overall cancer incidence 
rates for men and women were 80 and 72 cases per 10,000 person-years respectively. After 
adjustment for age, using the European standard population (175), incidence rates for men 
and women were 67 and 58 cases per 10,000 person-years respectively. 
 
Table 16. Cohort characteristics by sex and country of participants included in the predicted 
25(OH)D-cancer incidence analyses 
 
 
 
3.4.2 Baseline characteristics by predicted 25-hydroxyvitamin D quintiles 
 
The characteristics of the participants included in the analyses of cancer incidence by 
quintiles of predicted 25(OH)D are shown in Table 17. Compared to participants in the 
lowest quintile, those participants in the highest quintile of predicted 25(OH)D were more 
likely to be younger, physically active, and have a lower BMI. Men in the highest predicted 
25(OH)D quintile had lower intakes of red and processed meat and higher intakes of total 
energy and fruits and vegetables than those in the lowest quintile. Conversely, women in the 
Country Men Women Men Women Men Women Men Women
Denmark 25,504 27,945 278,258 309,429 3,086 3,240 48.0 (4.0) 65.0 (6.8)
France - 19,087 - 204,184 - 1,976 - 54.4 (4.8)
Germany 20,457 27,017 203,323 268,491 1,881 1,915 42.7 (4.2) 49.1 (5.8)
Greece 10,149 14,468 93,279 141,453 473 507 44.8 (3.7) 44.1 (5.2)
Italy 13,472 29,977 153,720 336,257 1,003 2,286 48.5 (3.7) 49.3 (5.1)
Spain 14,737 24,532 179,334 296,363 1,089 1,271 46.7 (4.5) 56.3 (6.9)
The Netherlands 7,342 23,668 84,805 273,899 354 2,129 50.7 (4.0) 56.2 (5.0)
United Kingdom 21,296 50,773 237,872 567,815 2,009 3,861 48.8 (4.3) 55.7 (5.3)
All EPIC 112,957 217,467 1,230,590 2,397,890 9,895 17,185 47.0 (4.8) 54.4 (7.9)
N  of participants Total person-years
N  overall cancer 
cases
Mean (SD) predicted 
25(OH)D level (nmol/L)
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highest predicted 25(OH)D quintile had higher red and processed meat intakes and lower 
intakes of total energy and fruits and vegetables than those in the lowest quintile. Women in 
the highest predicted 25(OH)D quintile were more likely to be current smokers than those in 
the lowest quintile. Current smokers were relatively evenly distributed in men across the 
predicted 25(OH)D quintiles. Women in the lowest predicted 25(OH)D quintile were less 
likely to have used the contraceptive pill than those in the higher quintiles. 
 
Table 17. Baseline characteristics of study participants included in the cancer incidence 
analyses by categories (quintiles) of predicted 25-hydroxyvitamin D score 
 
Mean and standard deviation (in parenthesis) for continuous variables, or percentages for categorical variables (‡). 
Characteristic
Q1 Q2 Q3 Q4 Q5
Predicted 25(OH)D range 
(nmol/L) <42.8 42.8-45.7 45.8-48.1 48.2-50.9 ≥51.0
N 22,592 22,591 22,592 22,591 22,591
N  overall cancer cases 2397 2118 1993 1813 1574
Age at recruitment (years)  55.2 (8.8) 53.7 (9.2) 52.4 (9.3) 51.1 (9.6) 48.7 (10.8)
Body mass index (kg/m2) 29.3 (3.9) 27.4 (3.4) 26.6 (3.1) 25.6 (2.9) 24.3 (2.8)
Education  ‡
Longer education including 
University (%) 29 27.6 27.3 28.5 27.6
Smoking status and intensity  ‡
Current (%) 30.1 31.9 31.4 31.2 30.4
Physical activity  ‡
Active (%) 2.9 9.7 17.5 32.9 67.9
Total energy intake (kcal/day) 2334 (671) 2389 (662) 2427 (643) 2454 (644) 2511 (660)
Red and processed meat 
consumption (g/day) 108.1 (65.4) 101.0 (61.4) 98.3 (60.8) 97.0 (62.1) 94.6 (63.5)
Fruit & vegetable consumption 
(g/day) 392.5 (299.0) 436.9 (307.2) 448.8 (293.2) 439.2 (274.7) 432.0 (265.3)
Vitamin D intake (μg/day) 3.2 (1.8) 3.7 (2.1) 3.9 (2.2) 4.3 (2.4) 5.5 (3.9)
Calcium intake (mg/day) 943.9 (405.0) 1003 (414.6) 1044 (413.4) 1076 (421.3) 1124 (438.7)
Alcohol intake  (g/day) 24.3 (27.8) 23.3 (24.9) 23.1 (23.7) 22.3 (22.3) 19.7 (20.6)
Predicted 25(OH)D range 
(nmol/L) <48.0 48.0-52.4 52.5-56.1 56.2-60.3 ≥60.4
N 43,494 43,493 43,494 43,493 43,493
N  overall cancer cases 3260 3495 3331 3273 3826
Age at recruitment (years) 54.2 (10.1) 50.9 (10.3) 49.2 (10.6) 47.8 (11.3) 51.3 (9.8)
Body mass index (kg/m2) 29.9 (5.1) 26.0 (4.1) 24.5 (3.7) 23.6 (3.5) 23.4 (3.2)
Education  ‡
Longer education including 
University (%) 12.5 21.4 26.8 29.0 19.4
Smoking status and intensity  ‡
Current (%) 17.1 18.4 17.4 18.0 25.9
Physical activity  ‡
Active (%) 4.2 9.6 14.9 22.9 34.2
Total energy intake (kcal/day) 1950 (575) 1962 (549) 1957 (535) 1935 (510) 1921 (482)
Red and processed meat 
consumption (g/day) 65.9 (42.9) 64.8 (43.2) 61.0 (44.9) 57.3 (44.7) 67.0 (40.4)
Fruit & vegetable consumption 
(g/day) 530.3 (306.4) 483.2 (283.9) 486.0 (264.3) 487.4 (264.0) 451.0 (246.2)
Vitamin D intake (μg/day) 2.5 (1.5) 2.8 (1.6) 3.0 (1.7) 3.3 (1.8) 4.5 (2.7)
Calcium intake (mg/day) 947.2 (377) 993.4 (395) 1019 (394) 1032 (388) 1041 (409)
Alcohol intake  (g/day) 6.4 (11.3) 8.1 (11.9) 8.6 (11.8) 8.6 (11.5) 10.5 (12.6)
Ever use of contraceptive pill  ‡
Yes (%) 37.7 54.8 63.7 68.5 64.1
Menopausal status  ‡
Postmenopausal (%) 54.7 42.7 37.2 36.3 52.1
Quintile of predicted 25(OH)D (nmol/L)
Men
Women
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3.4.3 Predicted 25-hydroxyvitamin D levels and overall cancer incidence risk 
 
After a mean (SD) follow-up of 11.0 (2.6) years, 27,080 incident cases of any cancer 
accrued. In the basic models (adjusted for age, sex, and centre), a linear (P-trend <0.001) 
inverse association was observed between predicted 25(OH)D level and overall cancer 
incidence risk in the men and women’s combined analysis (Table 18). This association 
attenuated after multivariable adjustments (Q5 vs. Q1, HR 0.89, 95% CI 0.84-0.94), but a 
linear relationship remained (P-trend <0.001). In the continuous model, a 13% lower overall 
cancer incidence risk was observed per increment in predicted 25 nmol/L of 25(OH)D. After 
adjustment for physical activity index, the associations attenuated further, and statistical 
significance was lost in the continuous, but not the categorical models. Similar significant 
inverse associations were observed when participants whose follow-up time was less than 5 
years were excluded from the analyses. The statistically significant association observed 
amongst men (HR per 25 nmol/L increment in predicted 25(OH)D, 0.81, 95% CI: 0.70-0.93) 
was slightly stronger than that observed amongst women (HR per 25 nmol/L increment in 
predicted 25(OH)D, 0.88, 95% CI: 0.81-0.96); however, this difference was not statistically 
significant (P-interaction 0.12). 
 
Obesity is both a risk factor for cancer and correlated with vitamin D status. To examine 
whether the associations were driven largely by obesity, models with and without predicted 
circulating 25(OH)D variables were run. Similar associations for BMI were observed with 
(BMI 35+ vs. 22-24.9 kg/m2, HR 1.13, 95% CI: 1.06-1.22) and without (BMI 35+ vs. 22-24. 9 
kg/m2, HR 1.18, 95% CI: 1.11-1.27) predicted 25(OH)D in the multivariable model. This 
indicates that the predicted vitamin D-overall cancer incidence association is largely 
independent of obesity. 
 
No statistically significant interactions were observed for predicted 25(OH)D levels and 
overall cancer incidence across strata of lifestyle, demographic, anthropometric, and dietary 
variables (Table 19). The inverse associations were constant across strata of age, follow-up 
time, menopausal status, ever use of contraceptive pills and dietary intakes of red and 
processed meats, fruits and vegetables, fish, calcium, fibre, and retinol. For alcohol, a 
stronger and significant reduced risk was observed amongst non-consumers, although this 
difference to the other consumption categories was non-significant (P-interaction 0.12). No 
association was observed amongst never smokers which may indicate possible residual 
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confounding; because of this the associations between predicted 25(OH)D levels and 
smoking and non-smoking cancers were investigated. 
 
The mutually adjusted HRs for total overall cancer incidence associated with the individual 
components of the applied predictor scores are shown in Table 20. After multivariable 
adjustments, waist circumference, country, and ever use of menopausal hormone therapy 
were significantly associated with overall cancer risk. In contrast, dietary vitamin D intake 
and physical activity were not significantly associated with overall cancer incidence risk 
 
The associations between predicted 25(OH)D and overall cancer incidence by country are 
shown in Figure 12. The inverse association for overall cancer incidence was relatively 
consistent across countries (P-heterogeneity 0.08), with only Germany yielding a risk 
estimate >1.  
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Table 18. Risk (hazard ratios) of overall cancer incidence associated with predicted 25-hydroxyvitamin D level 
 
†  Basic model - Cox regression stratified by age (1-year categories), sex, and centre. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active).
1 2 3 4 5
Men <42.8 42.8-45.6 45.7-48.1 48.2-50.9 ≥51.0
Women <48.0 48.0-52.4 52.5-56.1 56.2-60.3 ≥60.4 P -trend
Overall cancer incidence
Both sexes
N cases 5,657 5,613 5,324 5,086 5,400
Person-years 686,034   716,725            734,411            743,941            747,370            
Basic model - HR (95% CI) † 1.00        0.94 (0.90-0.98) 0.89 (0.86-0.93) 0.87 (0.84-0.91) 0.84 (0.80-0.88) <0.001 0.80 (0.76-0.85) 0.77 (0.72-0.83)
Multivariable model - HR (95% 
CI) ‡ 1.00        0.97 (0.93-1.01) 0.93 (0.89-0.97) 0.91 (0.87-0.96) 0.89 (0.84-0.94) <0.001 0.87 (0.80-0.92) 0.84 (0.77-0.92)
Multivariable model + physical 
activity adj - HR (95% CI) ɸ 1.00        0.98 (0.94-0.94) 0.95 (0.90-0.99) 0.94 (0.89-0.99) 0.92 (0.86-0.99) 0.012 0.92 (0.84-1.01) 0.85 (0.76-0.95)
Men
N cases 2,397 2,118 1,993 1,813 1,574
Person-years 229,777   241,938            249,081            252,868            256,927            
Basic model - HR (95% CI) * 1.00        0.91 (0.86-0.97) 0.88 (0.82-0.94) 0.85 (0.79-0.91) 0.82 (0.77-0.89) <0.001 0.69 (0.61-0.78)
Multivariable model - HR (95% 
CI) † 1.00        0.95 (0.89-1.01) 0.94 (0.88-1.01) 0.91 (0.85-0.98) 0.90 (0.83-0.97) 0.006 0.81 (0.70-0.93)
Multivariable model + physical 
activity adj - HR (95% CI) † 1.00        0.96 (0.90-1.03) 0.96 (0.88-1.04) 0.94 (0.85-1.03) 0.93 (0.83-1.04) 0.21 0.86 (0.70-1.06)
Women
N cases 3,260 3,495 3,331 3,273 3,826
Person-years 456,257   474,787            485,330            491,073            490,443            
Basic model - HR (95% CI) * 1.00        0.96 (0.91-1.01) 0.90 (0.86-0.95) 0.89 (0.84-0.94) 0.86 (0.80-0.91) <0.001 0.84 (0.79-0.90)
Multivariable model - HR (95% 
CI) † 1.00        0.98 (0.93-1.03) 0.92 (0.87-0.98) 0.91 (0.85-0.97) 0.89 (0.82-0.96) 0.001 0.88 (0.81-0.96)
Multivariable model + physical 
activity adj - HR (95% CI) † 1.00        0.99 (0.94-1.05) 0.95 (0.89-1.01) 0.95 (0.88-1.02) 0.93 (0.85-1.01) 0.06 0.94 (0.85-1.04)
Per 25 nmol/L 
increase
Quintile of predicted 25(OH)D (nmol/L)
Per 25 nmol/L 
increase
<5 years 
excluded
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Table 19. Risk (hazard ratios) of overall cancer incidence associated with a 25 nmol/L 
increment of predicted 25-hydroxyvitamin D level across strata of lifestyle, demographic, 
anthropometric, and dietary variables 
 
*  Median intakes:  red and processed meat=93.3 g/day in men and 59.0 g/day in women; fruit and vegetable=356 g/day in men and 438 g/day in 
women; fish consumption=27.1 g/day in men and 21.9 g/day in women; calcium=972 mg/day in men and 952 mg/day in women; fibre=23.9 g/day 
in men and 21.7 g/day in women; retinol=691 µg/day in men and 509 µg/day in women. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
Both sexes P  interaction
Stratification variable Predicted 25(OH)D
HR (95% CI), per 25 nmol/L ‡
Overall 0.87 (0.80-0.92)
Sex 0.12
Men 0.81 (0.70-0.93)
Women 0.88 (0.81-0.96)
Age at recruitment 0.15
<55 years old 0.86 (0.77-0.97)
55-<65 years old 0.89 (0.80-0.99)
≥65 years old 0.76 (0.60-0.96)
Follow-up 0.40
<5 years 0.93 (0.81-1.05)
5-10 years 0.90 (0.81-1.00)
≥10 years 0.81 (0.69-0.95)
Smoking status 0.15
Never smoked 0.98 (0.87-1.09)
Former smoker 0.79 (0.69-0.91)
Current smoker 0.70 (0.61-0.81)
Body mass index 0.12
<24.9 kg/m2 0.94 (0.84-1.05)
<25.0-29.9 kg/m2 0.84 (0.75-0.95)
≥30 kg/m2 0.69 (0.58-0.82)
Physical activity 0.06
Inactive 0.75 (0.62-0.92)
Moderately inactive 1.01 (0.86-1.18)
Moderately active 1.06 (0.88-1.27)
Active 0.88 (0.72-1.08)
Alcohol consumption 0.12
Non-consumers 0.66 (0.54-0.82)
<15 g/day 0.90 (0.82-0.99)
15-29.9 g/day 0.97 (0.79-1.19)
≥30 g/day 0.86 (0.71-1.04)
Red and processed meat consumption * 0.38
Below median 0.92 (0.83-1.03)
Above median 0.82 (0.74-0.91)
Fruit and vegetable consumption * 0.31
Below median 0.85 (0.77-0.94)
Above median 0.88 (0.79-0.99)
Fish consumption * 0.98
Below median 0.73 (0.65-0.84)
Above median 0.91 (0.83-0.99)
Calcium intake * 0.99
Below median 0.85 (0.76-0.94)
Above median 0.90 (0.81-0.99)
Fibre intake * 0.92
Below median 0.84 (0.75-0.93)
Above median 0.90 (0.81-1.01)
Retinol intake * 0.69
Below median 0.87 (0.78-0.98)
Above median 0.86 (0.78-0.95)
Menopausal status 0.28
Premenopausal 0.85 (0.70-1.04)
Postmenopausal 0.90 (0.81-1.01)
Perimenopausal 0.85 (0.66-1.09)
Surgical postmenopausal 0.74 (0.48-1.14)
Ever use of contraceptive pill 0.68
No 0.88 (0.78-1.01)
Yes 0.87 (0.77-0.99)
Overall cancer incidence
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completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per 
day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary 
calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
 
 
Table 20. Risk (hazard ratios) of overall cancer incidence associated with the 
correlates/determinants of circulating 25(OH)D used in the predictor scores (mutually 
adjusted) 
 
Multivariable model - Cox regression with predictor score determinants mutually adjusted for each other, plus additional adjustment for body mass 
index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary 
school; longer education including university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking 
status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; former, quit ≤10 
years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 
10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of contraceptive pill (yes; no; or unknown), menopausal status 
(premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy 
(kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-
year categories), sex, and centre. 
 
 
 
 
 
Predictor score HR (95% CI) P -trend
1.00 (0.99-1.02)
0.94
Inactive 1.00
Moderately inactive 0.99 (0.96-1.02)
Moderately active 1.01 (0.97-1.05)
Active 0.99 (0.95-1.03)
1.01 (1.00-1.02)
0.01
Denmark 1.00
UK 0.97 (0.93-1.02)
The Netherlands 0.91 (0.87-0.96)
France 1.22 (1.14-1.30)
Germany 1.13 (1.08-1.18)
Greece 0.49 (0.45-0.53)
Italy 0.94 (0.90-0.99)
Spain 0.77 (0.72-0.81)
<0.001
No 1.00
Yes 1.18 (1.13-1.22)
Overall cancer
Both sexes
Dietary vitamin D (Per 2.5 µg/day)
Physical activity
Waist circumference (Per 1 cm)
Country
Ever use of menopausal hormone 
therapy
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Figure 12. Risk (hazard ratios) of overall cancer incidence, by country, associated with a 25 
nmol/L increment of predicted 25-hydroxyvitamin D level 
Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; 
technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-consumers; 
<5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 
16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, 
missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of contraceptive pill (yes; 
no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical 
postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium 
(mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre.  
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3.4.4 Predicted 25-hydroxyvitamin D levels and smoking related and non-smoking 
related cancer incidences 
 
Smoking related cancers 
The associations between predicted 25(OH)D and incidence of smoking related cancers are 
shown in Table 21. In the sexes combined multivariable model, a 24% reduced smoking 
related cancer risk (95% CI: 0.69-0.83) was observed when the highest and lowest quintiles 
of predicted circulating 25(OH)D were compared (P-trend <0.001). In the equivalent 
continuous model, a 35% lower smoking related cancer risk (95% CI: 0.56-0.74) was 
observed per 25 nmol/L higher predicted 25(OH)D. The association was similar when the 
first 5 years of follow-up were excluded. When analysed by sex, similar strength inverse 
associations were observed (P-interaction 0.35) amongst men (HR per 25 nmol/L increment 
in predicted 25(OH)D, 0.67, 95% CI: 0.55-0.82) and women (HR per 25 nmol/L increment in 
predicted 25(OH)D, 0.61, 95% CI: 0.51-0.73) (Table 21).  
 
In sub-group analyses by strata of lifestyle, demographic, anthropometric, and dietary 
variables, a significant interaction was observed only for smoking status (P-interaction 0.01) 
(Table 22). This may indicate residual confounding by smoking impacted upon the results. 
However, significant inverse associations were observed across all categories of smoking 
status, including amongst never smokers, where a 29% lower (95% CI: 0.55-0.92) risk was 
observed per 25 nmol/L increment in predicted 25(OH)D. Inverse associations were 
observed across all countries (P-heterogeneity 0.14); with significant associations observed 
in Denmark, the Netherlands, and the UK (general population) cohorts (Figure 13A). 
 
Non-smoking related cancers 
No associations were observed for non-smoking related cancers in the sexes combined 
categorical (Q5 vs. Q1, HR 0.98, 95% CI 0.91-1.05; P-trend 0.26) and continuous (HR per 
25 nmol/L increment in predicted 25(OH)D, 0.98, 95% CI: 0.89-1.07) models (Table 21). 
Similar non-significant risk estimates were observed when men and women were analysed 
separately (P-interaction 0.06).  
 
Non-significant estimates were observed across all countries (P-heterogeneity 0.38) (Figure 
13B). The heterogeneous relationships between predicted 25(OH)D and smoking and non-
smoking related cancers was significant (P-heterogeneity <0.001). 
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Table 21. Risk (hazard ratios) of smoking related and non-smoking related cancer incidences associated with predicted 25-hydroxyvitamin D level 
 
†  Basic model - Cox regression stratified by age (1-year categories), sex, and centre. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
1 2 3 4 5
Men <42.8 42.8-45.6 45.7-48.1 48.2-50.9 ≥51.0
Women <48.0 48.0-52.4 52.5-56.1 56.2-60.3 ≥60.4 P -trend
Smoking related cancers
Both sexes
N  cases 2,125 1,808 1,584 1,513 1,626
Basic model - HR (95% CI) † 1.00          0.86 (0.80-0.92) 0.78 (0.72-0.84) 0.77 (0.71-0.83) 0.69 (0.63-0.75) <0.001 0.59 (0.52-0.66) 0.54 (0.47-0.62)
Multivariable model - HR (95% CI) ‡ 1.00          0.90 (0.84-0.97) 0.84 (0.78-0.91) 0.84 (0.77-0.91) 0.76 (0.69-0.83) <0.001 0.65 (0.56-0.74) 0.63 (0.54-0.74)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          0.93 (0.86-0.99) 0.88 (0.81-0.96) 0.88 (0.80-0.97) 0.80 (0.71-0.90) <0.001 0.69 (0.58-0.82) 0.66 (0.54-0.81)
Men
N  cases 1283 1058 945 887 706
Multivariable model - HR (95% CI) ‡ 1.00          0.92 (0.84-1.00) 0.87 (0.79-0.96) 0.88 (0.80-0.98) 0.81 (0.72-0.91) <0.001 0.67 (0.55-0.82)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          0.94 (0.85-1.03) 0.90 (0.80-1.02) 0.91 (0.80-1.04) 0.83 (0.71-0.97) 0.04 0.67 (0.50-0.92)
Women
N  cases 842 750 639 626 920
Multivariable model - HR (95% CI) ‡ 1.00          0.88 (0.78-0.98) 0.79 (0.69-0.89) 0.75 (0.66-0.87) 0.66 (0.56-0.78) <0.001 0.61 (0.51-0.73)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          0.90 (0.80-1.01) 0.82 (0.72-0.94) 0.80 (0.68-0.93) 0.71 (0.59-0.86) <0.001 0.66 (0.53-0.82)
Non-smoking related cancers
Both sexes
N  cases 3,532 3,805 3,740 3,573 3,774
Basic model - HR (95% CI) † 1.00          0.99 (0.94-1.04) 0.96 (0.91-1.01) 0.93 (0.88-0.99) 0.94 (0.88-0.99) 0.01 0.92 (0.85-0.98) 0.91 (0.83-0.99)
Multivariable model - HR (95% CI) ‡ 1.00          1.01 (0.96-1.06) 0.98 (0.93-1.04) 0.96 (0.91-1.02) 0.98 (0.91-1.05) 0.26 0.98 (0.89-1.07) 0.96 (0.86-1.07)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          1.02 (0.96-1.07) 1.00 (0.94-1.06) 0.98 (0.92-1.05) 1.00 (0.92-1.09) 0.82 1.03 (0.93-1.14) 0.95 (0.83-1.09)
Men
N  cases 1114 1060 1048 926 868
Multivariable model - HR (95% CI) ‡ 1.00          0.98 (0.90-1.08) 1.01 (0.91-1.11) 0.94 (0.85-1.05) 0.98 (0.88-1.10) 0.61 0.96 (0.79-1.17)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          0.98 (0.89-1.08) 1.01 (0.90-1.13) 0.95 (0.83-1.09) 1.02 (0.88-1.19) 0.88 1.05 (0.80-1.39)
Women
N  cases 2418 2745 2692 2647 2906
Multivariable model - HR (95% CI) ‡ 1.00          1.01 (0.95-1.08) 0.97 (0.90-1.04) 0.96 (0.89-1.04) 0.97 (0.89-1.05) 0.27 0.98 (0.89-1.09)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          1.03 (0.96-1.10) 0.99 (0.92-1.07) 0.99 (0.91-1.08) 1.00 (0.91-1.10) 0.81 1.05 (0.93-1.17)
Quintile of predicted 25(OH)D (nmol/L) <5 years 
excluded
Per 25 nmol/L 
increase
Per 25 nmol/L 
increase
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use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
Smoking related cancers were lung, bladder, upper aero-digestive, kidney, stomach, pancreatic, liver, colon, and rectum. Non-smoking related cancers were skin (non-melanoma), breast, endometrial, ovarian, prostate, brain, spinal 
cord/central nervous system, and thyroid. 
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Table 22. Risk (hazard ratios) of smoking related cancer incidence associated with a 25 
nmol/L increment of predicted 25-hydroxyvitamin D level across strata of lifestyle, 
demographic, anthropometric, and dietary variables 
 
 
*  Median intakes:  red and processed meat=93.3 g/day in men and 59.0 g/day in women; fruit and vegetable=356 g/day in men and 438 g/day in 
women; fish consumption=27.1 g/day in men and 21.9 g/day in women; calcium=972 mg/day in men and 952 mg/day in women; fibre=23.9 g/day 
Both sexes P  interaction
Stratification variable Predicted 25(OH)D
HR (95% CI), per 25 nmol/L ‡
Overall 0.65 (0.56-0.74)
Sex 0.62
Men 0.67 (0.55-0.82)
Women 0.61 (0.51-0.73)
Age at recruitment 0.83
<55 years old 0.68 (0.54-0.86)
55-<65 years old 0.64 (0.54-0.77)
≥65 years old 0.61 (0.41-0.90)
Follow-up 0.80
<5 years 0.72 (0.56-0.92)
5-10 years 0.65 (0.53-0.79)
≥10 years 0.70 (0.54-0.92)
Smoking status 0.01
Never smoked 0.71 (0.55-0.92)
Former smoker 0.58 (0.45-0.75)
Current smoker 0.53 (0.43-0.65)
Body mass index 0.23
<24.9 kg/m2 0.76 (0.61-0.94)
<25.0-29.9 kg/m2 0.60 (0.49-0.75)
≥30 kg/m2 0.54 (0.40-0.74)
Physical activity 0.77
Inactive 0.59 (0.42-0.85)
Moderately inactive 0.84 (0.62-1.15)
Moderately active 0.65 (0.44-0.96)
Active 0.70 (0.48-1.03)
Alcohol consumption 0.63
Non-consumers 0.55 (0.37-0.81)
<15 g/day 0.62 (0.51-0.75)
15-29.9 g/day 0.93 (0.65-1.32)
≥30 g/day 0.62 (0.46-0.84)
Red and processed meat consumption * 0.32
Below median 0.68 (0.55-0.84)
Above median 0.64 (0.54-0.77)
Fruit and vegetable consumption * 0.13
Below median 0.66 (0.55-0.78)
Above median 0.64 (0.52-0.79)
Fish consumption * 0.97
Below median 0.49 (0.39-0.62)
Above median 0.70 (0.59-0.83)
Calcium intake * 0.11
Below median 0.69 (0.57-0.83)
Above median 0.62 (0.51-0.75)
Fibre intake * 0.07
Below median 0.68 (0.57-0.82)
Above median 0.62 (0.51-0.76)
Retinol intake * 0.86
Below median 0.67 (0.54-0.83)
Above median 0.63 (0.53-0.75)
Menopausal status 0.13
Premenopausal 0.50 (0.28-0.92)
Postmenopausal 0.60 (0.48-0.74)
Perimenopausal 0.53 (0.29-0.95)
Surgical postmenopausal 0.98 (0.47-2.08)
Ever use of contraceptive pill 0.48
No 0.62 (0.48-0.80)
Yes 0.59 (0.45-0.78)
Smoking related cancer incidence
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in men and 21.7 g/day in women; retinol=691 µg/day in men and 509 µg/day in women. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per 
day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary 
calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
Smoking related cancers were lung, bladder, upper aero-digestive, kidney, stomach, pancreatic, liver, colon, and rectum. Non-smoking related 
cancers (all other cancers). 
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Figure 13. Risk (hazard ratios) of smoking related (A) and non-smoking related (B) cancer 
incidences, by country, associated with a 25 nmol/L increment of predicted 25-
hydroxyvitamin D level 
(A) 
 
(B) 
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Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; 
technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-consumers; 
<5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 
16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, 
missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of contraceptive pill (yes; 
no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical 
postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium 
(mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
Smoking related cancers were lung, bladder, upper aero-digestive, kidney, stomach, pancreatic, liver, colon, and rectum. Non-smoking related 
cancers (all other cancers). 
 
 
3.4.5 Predicted 25-hydroxyvitamin D levels and digestive and non-digestive cancer 
incidences 
Based on a priori hypothesis that cancers within the digestive system would be most 
responsive to vitamin D exposures, cases were split into digestive system and non-digestive 
cancers.  
 
Digestive system cancers 
The associations between predicted 25(OH)D and incidences of digestive system cancers 
are shown in Table 23. In the sexes combined multivariable model, a 25% reduced risk (95% 
CI: 0.66-0.85) of digestive system cancer incidence was observed when the highest and 
lowest quintiles of predicted circulating 25(OH)D were compared (P-trend <0.001). In the 
equivalent continuous model, a 37% lower digestive system cancer risk (95% CI: 0.52-0.76) 
was observed per 25 nmol/L higher predicted 25(OH)D. Similar risk estimates were 
observed after additional adjustment for physical activity index. The association observed 
amongst men (HR per 25 nmol/L increment in predicted 25(OH)D, 0.65, 95% CI: 0.48-0.86) 
was slightly weaker than observed amongst women (HR per 25 nmol/L increment in 
predicted 25(OH)D, 0.59, 95% CI: 0.46-0.76); however, this difference was not significant (P-
interaction 0.35). Similar associations were observed when participants whose follow-up was 
less than 5 years were excluded from the analyses.  
 
In sub-group analyses, consistent inverse associations were observed across the different 
levels of lifestyle, demographic, anthropometric, and dietary variables considered, with the 
exception of alcohol consumption, where no association was observed amongst participants 
who consumed 15-29.9 g/day (Table 24); although this interaction was non-significant when 
assessed statistically (P-interaction 0.21). The sexes combined associations for digestive 
system cancers were consistent across countries (P-heterogeneity 0.13), with only Spain not 
observing an inverse association (Figure 14A). 
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Non-digestive system cancers 
For non-digestive system cancers, a weaker significant inverse association was observed in 
the multivariable models when men and women were analysed together (HR per 25 nmol/L 
increment in predicted 25(OH)D, 0.92, 95% CI: 0.85-0.99) (Table 23). This difference in the 
strength of associations with digestive system cancers was significant (P-heterogeneity 
<0.001). When men and women were analysed separately, similar strength non-significant 
risk estimates were observed in the continuous and categorical models (P-interaction 0.48). 
 
In the sexes combined country specific analyses (Figure 14B), non-significant associations 
were observed across all constituent countries. Null or positive associations were observed 
for Denmark, France, Germany, and the UK (health conscious) cohorts. Despite this 
observed heterogeneity, these differences in risk estimates across countries were non-
significant (P-heterogeneity 0.23).  
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Table 23. Risk (hazard ratios) of digestive and non-digestive cancer incidences amongst associated with predicted 25-hydroxyvitamin D level 
 
†  Basic model - Cox regression stratified by age (1-year categories), sex, and centre. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
1 2 3 4 5
Men <42.8 42.8-45.6 45.7-48.1 48.2-50.9 ≥51.0
Women <48.0 48.0-52.4 52.5-56.1 56.2-60.3 ≥60.4 P -trend
Digestive system cancer incidence
Both sexes
N cases 1,168 1,001 821 821 814
Basic model - HR (95% CI) † 1.00          0.86 (0.79-0.95) 0.74 (0.67-0.81) 0.77 (0.69-0.85) 0.67 (0.60-0.75) <0.001 0.55 (0.48-0.65) 0.49 (0.41-0.59)
Multivariable model - HR (95% CI) ‡ 1.00          0.91 (0.83-1.00) 0.80 (0.72-0.89) 0.84 (0.75-0.94) 0.75 (0.66-0.85) <0.001 0.63 (0.52-0.76) 0.59 (0.48-0.73)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          0.92 (0.83-1.01) 0.81 (0.72-0.91) 0.85 (0.74-0.97) 0.74 (0.63-0.87) <0.001 0.61 (0.48-0.77) 0.54 (0.41-0.72)
Men
N cases 626 549 430 444 359
Multivariable model - HR (95% CI) ‡ 1.00          0.97 (0.86-1.10) 0.80 (0.69-0.92) 0.88 (0.76-1.02) 0.80 (0.68-0.94) 0.003 0.65 (0.48-0.86)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          0.94 (0.82-1.07) 0.76 (0.64-0.89) 0.80 (0.66-0.97) 0.69 (0.55-0.87) 0.001 0.46 (0.30-0.73)
Women
N cases 542 452 391 377 455
Multivariable model - HR (95% CI) ‡ 1.00          0.85 (0.74-0.98) 0.80 (0.68-0.94) 0.80 (0.67-0.96) 0.69 (0.56-0.85) 0.001 0.59 (0.46-0.76)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          0.88 (0.76-1.01) 0.85 (0.71-1.01) 0.86 (0.70-1.05) 0.75 (0.59-0.95) 0.03 0.63 (0.47-0.84)
Non-digestive system cancers incidence
Both sexes
N  cases 4,489 4,612 4,503 4,265 4,586
Basic model - HR (95% CI) † 1.00          0.96 (0.92-1.00) 0.93 (0.89-0.97) 0.90 (0.86-0.94) 0.89 (0.84-0.93) <0.001 0.86 (0.81-0.92) 0.85 (0.78-0.92)
Multivariable model - HR (95% CI) ‡ 1.00          0.98 (0.94-1.03) 0.96 (0.91-1.01) 0.93 (0.88-0.98) 0.93 (0.87-0.99) 0.005 0.92 (0.85-0.99) 0.91 (0.82-1.00)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          1.00 (0.95-1.04) 0.98 (0.93-1.04) 0.96 (0.90-1.03) 0.97 (0.90-1.04) 0.27 0.99 (0.90-1.09) 0.93 (0.82-1.05)
Men
N  cases 1771 1569 1563 1369 1215
Multivariable model - HR (95% CI) ‡ 1.00          0.94 (0.88-1.01) 0.99 (0.91-1.07) 0.93 (0.85-1.01) 0.93 (0.85-1.02) 0.13 0.87 (0.74-1.02)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          0.97 (0.89-1.04) 1.03 (0.94-1.13) 0.98 (0.88-1.10) 1.02 (0.90-1.16) 0.69 1.03 (0.82-1.30)
Women
N  cases 2718 3043 2940 2896 3371
Multivariable model - HR (95% CI) ‡ 1.00          1.00 (0.95-1.06) 0.94 (0.88-1.01) 0.93 (0.87-1.00) 0.92 (0.85-1.00) 0.019 0.93 (0.85-1.03)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00          1.02 (0.96-1.08) 0.97 (0.90-1.04) 0.96 (0.89-1.04) 0.96 (0.87-1.05) 0.22 1.00 (0.89-1.11)
Quintile of predicted 25(OH)D (nmol/L) <5 years 
excluded
Per 25 nmol/L 
increase
Per 25 nmol/L 
increase
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ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
Digestive system cancers were stomach, colon and rectum, upper aero-digestive, liver, and pancreatic. Non-digestive system cancers (all other cancers). 
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Table 24. Risk (hazard ratios) of digestive system cancer incidence associated with a 25 
nmol/L increment of predicted 25-hydroxyvitamin D level across strata of lifestyle, 
demographic, anthropometric, and dietary variables 
 
*  Median intakes:  red and processed meat=93.3 g/day in men and 59.0 g/day in women; fruit and vegetable=356 g/day in men and 438 g/day in 
women; fish consumption=27.1 g/day in men and 21.9 g/day in women; calcium=972 mg/day in men and 952 mg/day in women; fibre=23.9 g/day 
Both sexes P  interaction
Stratification variable Predicted 25(OH)D
HR (95% CI), per 25 nmol/L ‡
Overall 0.63 (0.52-0.76)
Sex 0.35
Men 0.65 (0.48-0.86)
Women 0.59 (0.46-0.76)
Age at recruitment 0.68
<55 years old 0.62 (0.45-0.85)
55-<65 years old 0.64 (0.50-0.83)
≥65 years old 0.63 (0.38-1.06)
Follow-up 0.43
<5 years 0.80 (0.55-1.16)
5-10 years 0.59 (0.45-0.78)
≥10 years 0.68 (0.48-0.97)
Smoking status 0.11
Never smoked 0.71 (0.53-0.96)
Former smoker 0.53 (0.38-0.75)
Current smoker 0.54 (0.39-0.75)
Body mass index 0.19
<24.9 kg/m2 0.72 (0.54-0.97)
<25.0-29.9 kg/m2 0.59 (0.44-0.80)
≥30 kg/m2 0.52 (0.35-0.79)
Physical activity 0.54
Inactive 0.68 (0.42-1.10)
Moderately inactive 0.70 (0.46-1.06)
Moderately active 0.51 (0.30-0.87)
Active 0.59 (0.35-0.99)
Alcohol consumption 0.21
Non-consumers 0.50 (0.30-0.84)
<15 g/day 0.66 (0.51-0.85)
15-29.9 g/day 1.02 (0.62-1.66)
≥30 g/day 0.52 (0.34-0.80)
Red and processed meat consumption * 0.31
Below median 0.63 (0.48-0.83)
Above median 0.66 (0.51-0.84)
Fruit and vegetable consumption * 0.19
Below median 0.68 (0.53-0.86)
Above median 0.57 (0.43-0.76)
Fish consumption * 0.93
Below median 0.56 (0.41-0.77)
Above median 0.60 (0.48-0.77)
Calcium intake * 0.33
Below median 0.64 (0.50-0.83)
Above median 0.62 (0.47-0.81)
Fibre intake * 0.52
Below median 0.71 (0.55-0.92)
Above median 0.57 (0.43-0.74)
Retinol intake * 0.83
Below median 0.66 (0.50-0.87)
Above median 0.61 (0.47-0.78)
Menopausal status 0.93
Premenopausal 0.51 (0.24-1.08)
Postmenopausal 0.63 (0.47-0.84)
Perimenopausal 0.36 (0.16-0.79)
Surgical postmenopausal 0.92 (0.34-2.49)
Ever use of contraceptive pill 0.72
No 0.59 (0.42-0.83)
Yes 0.58 (0.40-0.85)
Digestive system cancer incidence
137 
 
in men and 21.7 g/day in women; retinol=691 µg/day in men and 509 µg/day in women. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per 
day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary 
calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
Digestive system cancers were stomach, colon and rectum, upper aero-digestive, liver, and pancreatic.  
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Figure 14. Risk (hazard ratios) of digestive system (A) and non-digestive system (B) cancer 
incidences (sexes combined), by country, associated with a 25 nmol/L increment of 
predicted 25-hydroxyvitamin D level 
(A) 
 
(B) 
 
Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; 
technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-consumers; 
<5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 
16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, 
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missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of contraceptive pill (yes; 
no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical 
postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium 
(mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
Digestive system cancers were stomach, colon and rectum, upper aero-digestive, liver, and pancreatic. Non-digestive system cancers (all other 
cancers). 
 
 
3.4.6 Predicted 25-hydroxyvitamin D levels and incidence of individual cancers 
 
Colorectal cancer 
As was revealed in the validation stage of the predictor scores, significant inverse 
associations in the sexes combined categorical (n=2,112 cases; Q5 vs. Q1, HR 0.74, 95% 
CI: 0.61-0.90; P-trend 0.005) and continuous (HR per 25 nmol/L increment in predicted 
25(OH)D, 0.75, 95% CI: 0.57-0.97) multivariable models were observed for colorectal cancer 
incidence. No significant heterogeneity was seen for the associations between predicted 
25(OH)D with colon (n=1,345 cases; HR per 25 nmol/L increment in predicted 25(OH)D, 
0.74, 95% CI: 0.53-1.04) and rectal cancers (n=767 cases; HR per 25 nmol/L increment in 
predicted 25(OH)D, 0.75, 95% CI: 0.54-1.05) (P-heterogeneity 0.83).The association was 
similar when participants whose follow-up time was less than 5 years were excluded from 
the analyses (Table 25). When men and women were analysed separately, similar inverse 
colorectal cancer risk estimates were observed in the highest quintiles of predicted 25(OH)D 
when compared against quintile 1 (a 25% reduced risk in men and a 28% reduced risk in 
women). In the continuous models, the inverse associations were slightly stronger amongst 
men (HR per 25 nmol/L increment in predicted 25(OH)D, 0.68, 95% CI: 0.43-1.09) than in 
women (HR per 25 nmol/L increment in predicted 25(OH)D, 0.74, 95% CI: 0.53-1.04) 
(Tables 26 and 27) (P-interaction 0.04).  
 
The inverse colorectal cancer association was consistent across constituent countries, with 
inverse associations (HRs ranging from 0.21-0.76) observed in all countries except Spain, 
where a non-significant positive association was observed (P-heterogeneity 0.34).  
 
Lung cancer 
In the categorical sexes combined multivariable model (n=2,124 cases), a 24% reduced lung 
cancer incidence risk (95% CI: 0.63-0.92) was observed when the extreme quintiles of 
predicted circulating 25(OH)D were compared (P-trend 0.002). Inverse associations were 
observed in the equivalent continuous model (HR per 25 nmol/L increment in predicted 
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25(OH)D, 0.64, 95% CI: 0.49-0.84) (Table 25). The association was similar when 
participants whose follow-up time was less than 5 years were excluded from the analyses. 
This inverse association was stronger and only significant amongst women (HR per 25 
nmol/L increment in predicted 25(OH)D, 0.59, 95% CI: 0.41-0.85) and not men (HR per 25 
nmol/L increment in predicted 25(OH)D, 0.72, 95% CI: 0.48-1.08), and this difference was 
significant (P-interaction 0.004) (Tables 26 and 27). However, the inverse lung cancer 
incidence association was absent when the multivariable model was not adjusted for BMI 
(both sexes: HR per 25 nmol/L increment in predicted 25(OH)D, 1.01, 95% CI: 0.81-1.26) 
(Table A1 – appendix). 
 
When the sexes combined association was analysed by smoking status, inverse 
associations of similar strength were observed amongst never smokers (HR per 25 nmol/L 
increment in predicted 25(OH)D, 0.62, 95% CI: 0.26-1.52), former smokers (HR per 25 
nmol/L increment in predicted 25(OH)D, 0.68, 95% CI: 0.40-1.18) and current smokers (HR 
per 25 nmol/L increment in predicted 25(OH)D, 0.66, 95% CI: 0.48-0.93). Overall the 
association across strata of smoking status was non-significant (P-interaction 0.45). Near 
significance heterogeneity was observed across countries with inverse associations 
observed across all countries, except France, Germany and Greece (P-heterogeneity 0.06).  
 
Kidney cancer 
During the follow-up period 623 kidney cancers accrued. A 42% reduced kidney cancer risk 
(95% CI: 0.40-0.83) was observed in the sexes combined multivariable model (P-trend 
0.005) (Table 25). In the equivalent continuous model, a 53% lower kidney cancer risk (95% 
CI: 0.28-0.79) was observed per 25 nmol/L increment in predicted 25(OH)D. The association 
was similar when participants whose follow-up time was less than 5 years were excluded 
from the analyses. This association was stronger and significant amongst men (HR per 25 
nmol/L increment in predicted 25(OH)D, 0.33, 95% CI: 0.15-0.72) as compared to women 
(HR per 25 nmol/L increment in predicted 25(OH)D, 0.64, 95% CI: 0.31-1.30) (P-interaction 
0.03) (Tables 26 and 27). 
 
Stomach and oesophageal cancers 
Over the follow-up period, 862 stomach and oesophageal cancer cases were recorded. In 
the categorical multivariable model, a non-significant inverse association was observed 
(sexes combined: Q5 vs. Q1, HR 0.78, 95% CI: 0.58-1.05; P-trend 0.12) (Table 25). 
However, in the equivalent continuous model, a 40% lower risk (95% CI: 0.39-0.94) per 25 
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nmol/L of predicted 25(OH)D score was observed. An inverse association of similar 
magnitude (albeit non-significant) was observed when participants whose follow-up time was 
less than 5 years were excluded from the analyses. When men and women were analysed 
separately, non-significant inverse associations were observed (P-interaction 0.66) (Tables 
26 and 27). However, when the sexes combined multivariable model was not adjusted for 
BMI, the inverse association attenuated and was no longer significant (HR per 25 nmol/L 
increment in predicted 25(OH)D, 0.74, 95% CI: 0.51-1.07) (Table A1 – appendix). 
 
Bladder cancer 
Non-significant associations were observed for bladder cancer incidence (n=363 cases) 
when men and women were analysed collectively (multivariable model: Q5 vs. Q1, HR 0.87, 
95% CI: 0.69-1.11; P-trend 0.59) (Table 25). When analysed separately, similar associations 
were observed (P-interaction 0.97) (Tables 26 and 27).  
 
Pancreatic cancer 
Inverse associations for pancreatic cancer incidence (n=337 cases) were observed in the 
sexes combined continuous multivariable model (HR per 25 nmol/L increment in predicted 
25(OH)D, 0.52, 95% CI: 0.32-0.84) (Table 25). The inverse association was slightly stronger 
when participants whose follow-up time was less than 5 years were excluded from the 
analyses. The association was significant only for women, where a significant 58% lower risk 
(95% CI: 0.22-0.80) was observed per 25 nmol/L of predicted 25(OH)D score; amongst men, 
a non-significant 30% lower risk was observed for a same increment in predicted 25(OH)D 
score (Tables 26 and 27). This difference in association between the sexes was non-
significant (P-interaction 0.78). Non-significant inverse associations were observed in all of 
the categorical models. 
 
Liver cancer 
Non-significant inverse associations were observed in the sexes combined multivariable 
model for liver cancer incidence (n=205 cases; Q5 vs. Q1, HR 0.80, 95% CI: 0.52-1.24; P-
trend 0.17) (Table 25). Non-significant associations were also observed when men and 
women were analysed separately (P-interaction 0.78) (Tables 26 and 27). When the sexes 
combined multivariable model was not adjusted for BMI, the inverse association 
strengthened and became significant (HR per 25 nmol/L increment in predicted 25(OH)D, 
0.52, 95% CI: 0.31-0.87) (Table A1 – appendix). 
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Non-Hodgkin’s lymphoma 
Non-significant associations were observed for non-Hodgkin’s lymphoma incidence (n=626 
cases) in the sexes combined multivariable model (Q5 vs. Q1, HR 0.79, 95% CI: 0.56-1.12; 
P-trend 0.25) (Table 25). Similar non-significant associations were also observed for men 
and women (P-interaction 0.35) (Tables 26 and 27). 
 
Brain cancer 
In the sexes combined categorical multivariable model, a near significance 25% reduced risk 
(95% CI: 0.54-1.04) of brain cancer incidence (n=764 cases) was observed amongst those 
in the highest predicted 25(OH)D quintile when compared versus those in the lowest quintile 
(P-trend 0.07) (Table 25). A non-significant inverse association was also observed in the 
equivalent continuous model. The inverse association, although once more non-significant, 
was more apparent amongst men (Q5 vs. Q1, HR 0.63, 95% CI: 0.40-1.01; P-trend 0.05) as 
compared to women (Q5 vs. Q1, HR 0.84, 95% CI: 0.52-1.36; P-trend 0.38); however, this 
difference was non-significant (P-interaction 0.72) (Tables 26 and 27). 
 
Skin cancer 
Predicted circulating 25(OH)D was positively associated with the risk of skin cancer 
incidence (n=1,550 cases) in the sexes combined multivariable model (Q5 vs. Q1, HR 1.25, 
95% CI: 1.03-1.51; P-trend 0.02) (Table 25). In the continuous models, a 26% higher skin 
cancer risk (95% CI: 1.00-1.60) was associated with higher predicted 25(OH)D, although this 
association did not reach the significance threshold. Higher skin cancer risks were also 
observed when the participants whose follow-up time was less than 5 years were excluded 
from the analyses. Positive associations were observed amongst men and women (P-
interaction 0.26); although, in women these associations were stronger and significant (Q5 
vs. Q1, HR 1.40, 95% CI: 1.08-1.83; P-trend 0.01) (Tables 26 and 27). 
  
Thyroid cancer 
In the sexes combined multivariable model, a 50% lower risk of thyroid cancer incidence 
(95% CI: 0.26-0.97) was observed per 25 nmol/L of predicted 25(OH)D (n=325 cases) 
(Table 25). Similar inverse associations were observed when the first 5 years of follow-up 
was excluded from the analyses. In the equivalent categorical model a non-significant 
inverse association was observed (Q5 vs. Q1, HR 0.72, 95% CI: 0.43-1.21; P-trend 0.20). 
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Similar strength, albeit non-significant, inverse associations were observed for men and 
women when analysed separately (P-interaction 0.31) (Tables 26 and 27). When the sexes 
combined multivariable model was not adjusted for BMI, the inverse association weakened 
and became non-significant (HR per 25 nmol/L increment in predicted 25(OH)D, 0.69, 95% 
CI: 0.41-1.15) (Table A1 – appendix). 
 
Prostate cancer 
As was revealed in the validation stages of the predictor scores, a non-significant positive 
association was observed for risk of prostate cancer incidence (n=2,553 cases) in the 
multivariable models (Q5 vs. Q1, 1.11, 95% CI: 0.95-1.30; P-trend 0.51) (Table 26). 
 
Breast, ovarian and endometrial cancers 
Null associations were observed for risk of breast cancer (n=7,144 cases: Q5 vs. Q1, 0.97, 
95% CI: 0.86-1.10; P-trend 0.33) and ovarian cancer (n=811 cases: Q5 vs. Q1, 1.00, 95% 
CI: 0.70-1.42; P-trend 0.93) incidences in the multivariable models (Table 27). 
 
For endometrial cancer incidence (n=893 cases), a non-significant inverse association was 
observed when the extreme quintiles of predicted circulating 25(OH)D were compared (Q5 
vs. Q1, HR 0.85, 95% CI: 0.61-1.19; P-trend 0.31) (Table 27). For the equivalent continuous 
model a non-significant 8% lower endometrial cancer incidence risk (95% CI: 0.63-1.35) was 
observed per 25 nmol/L increment in predicted 25(OH)D. However, when the multivariable 
model was not adjusted for BMI, the inverse association strengthened and became 
significant (HR per 25 nmol/L increment in predicted 25(OH)D, 0.36, 95% CI: 0.27-0.49) 
(Table A1 – appendix). 
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Table 25. Risk (hazard ratios) for incidence of specific cancer types amongst men and women 
by predicted 25-hydroxyvitamin D categories 
†  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; 
current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium 
(mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre.  
¥  Multivariable model – plus adjustment for cereal fibre intake (g/day). 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
 
Both sexes
1 2 3 4 5
Men <42.8 42.8-45.6 45.7-48.1 48.2-50.9 ≥51.0
Women <48.0 48.0-52.4 52.5-56.1 56.2-60.3 ≥60.4 P -trend
Colorectal cancer  
N cases 517 426 396 392 381
Multivariable model - HR (95% CI) † ¥ 1.00      0.82 (0.71-0.94) 0.80 (0.68-0.93) 0.84 (0.71-0.99) 0.74 (0.61-0.90) 0.005 0.75 (0.57-0.97) 0.65 (0.49-0.88)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.84 (0.72-0.97) 0.83 (0.70-0.99) 0.88 (0.72-1.07) 0.77 (0.61-0.97) 0.06 0.83 (0.59-1.15) 0.71 (0.49-1.03)
Lung cancer
N cases 473 415 376 350 510
Multivariable model - HR (95% CI) † 1.00      0.92 (0.80-1.07) 0.85 (0.73-1.00) 0.79 (0.66-0.93) 0.76 (0.63-0.92) 0.002 0.64 (0.49-0.84) 0.63 (0.45-0.87)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.97 (0.83-1.13) 0.93 (0.77-1.11) 0.87 (0.71-1.07) 0.87 (0.69-1.10) 0.19 0.77 (0.55-1.08) 0.77 (0.51-1.15)
Kidney cancer
N cases 185 132 131 89 86
Multivariable model - HR (95% CI) † 1.00      0.83 (0.65-1.06) 0.93 (0.71-1.22) 0.69 (0.50-0.94) 0.58 (0.40-0.83) 0.005 0.47 (0.28-0.79) 0.49 (0.26-0.93)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.83 (0.64-1.08) 0.94 (0.69-1.28) 0.70 (0.48-1.02) 0.61 (0.39-0.95) 0.04 0.47 (0.24-0.92) 0.43 (0.19-0.99)
Stomach & oesophageal cancer
N cases 215 191 165 148 143
Multivariable model - HR (95% CI) † 1.00      0.97 (0.78-1.20) 0.94 (0.74-1.20) 0.89 (0.69-1.16) 0.78 (0.58-1.05) 0.12 0.60 (0.39-0.94) 0.65 (0.63-1.18)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.98 (0.78-1.23) 0.96 (0.73-1.26) 0.90 (0.66-1.23) 0.76 (0.52-1.11) 0.19 0.53 (0.30-0.94) 0.49 (0.24-0.98)
Bladder cancer
N cases 77 82 64 62 78
Multivariable model - HR (95% CI) † 1.00      0.91 (0.76-1.09) 0.97 (0.80-1.18) 1.04 (0.84-1.27) 0.87 (0.69-1.11) 0.59 0.89 (0.62-1.28) 1.01 (0.66-1.55)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.96 (0.79-1.17) 1.07 (0.85-1.34) 1.17 (0.91-1.51) 1.02 (0.75-1.38) 0.56 1.11 (0.70-1.75) 1.29 (0.77-2.17)
Pancreatic cancer
N cases 82 69 51 60 75
Multivariable model - HR (95% CI) † 1.00      1.02 (0.79-1.31) 0.71 (0.53-0.95) 0.90 (0.66-1.22) 0.77 (0.55-1.09) 0.11 0.52 (0.32-0.84) 0.39 (0.22-0.70)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.06 (0.81-1.38) 0.75 (0.54-1.05) 0.97 (0.67-1.39) 0.83 (0.54-1.28) 0.39 0.50 (0.27-0.94) 0.34 (0.16-0.72)
Liver cancer
N cases 74 36 34 27 34
Multivariable model - HR (95% CI) † 1.00      0.85 (0.64-1.13) 0.71 (0.50-0.99) 0.79 (0.54-1.15) 0.80 (0.52-1.24) 0.17 0.80 (0.41-1.43) 0.77 (0.36-1.65)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.82 (0.61-1.12) 0.66 (0.45-0.98) 0.71 (0.46-1.11) 0.68 (0.40-1.16) 0.09 0.69 (0.31-1.51) 0.66 (0.25-1.73)
Non-Hodgkin's lymphoma
N cases 133 113 127 117 136
Multivariable model - HR (95% CI) † 1.00      0.76 (0.58-1.00) 0.87 (0.65-1.16) 0.79 (0.58-1.09) 0.79 (0.56-1.12) 0.25 0.87 (0.54-1.43) 0.95 (0.56-1.59)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.73 (0.55-0.98) 0.81 (0.59-1.13) 0.72 (0.50-1.05) 0.71 (0.46-1.09) 0.14 0.81 (0.44-1.48) 0.76 (0.40-1.46)
Brain cancer
N cases 185 178 153 131 117
Multivariable model - HR (95% CI) † 1.00      0.99 (0.79-1.25) 0.92 (0.71-1.19) 0.83 (0.62-1.11) 0.75 (0.54-1.04) 0.07 0.77 (0.49-1.22) 0.82 (0.46-1.46)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.05 (0.82-1.33) 1.00 (0.74-1.33) 0.92 (0.66-1.29) 0.84 (0.56-1.25) 0.39 1.01 (0.59-1.72) 0.91 (0.45-1.83)
Skin cancer
N cases 181 298 344 392 335
Multivariable model - HR (95% CI) † 1.00      1.12 (0.96-1.31) 1.16 (0.99-1.37) 1.22 (1.03-1.44) 1.25 (1.03-1.51) 0.02 1.26 (1.00-1.60) 1.18 (0.87-1.60)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.11 (0.95-1.31) 1.15 (0.96-1.38) 1.20 (0.99-1.47) 1.23 (0.98-1.55) 0.07 1.20 (0.89-1.61) 1.03 (0.70-1.50)
Thyroid cancer
N cases 90 83 70 49 33
Multivariable model - HR (95% CI) † 1.00      0.90 (0.66-1.24) 0.83 (0.58-1.20) 0.81 (0.53-1.23) 0.72 (0.43-1.21) 0.20 0.50 (0.26-0.97) 0.52 (0.23-1.18)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.98 (0.70-1.37) 0.96 (0.63-1.44) 0.95 (0.59-1.55) 0.88 (0.49-1.60) 0.72 0.61 (0.27-1.36) 0.64 (0.23-1.72)
Quintile of predicted 25(OH)D (nmol/L) <5 years 
excluded
Per 25 nmol/L 
increase
Per 25 nmol/L 
increase
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Table 26. Risk (hazard ratios) for incidence of specific cancer types amongst men by 
predicted 25-hydroxyvitamin D categories 
†  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; 
current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); and intakes of total 
energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by 
age (1-year categories) and centre.  
¥  Multivariable model – plus adjustment for cereal fibre intake (g/day). 
1 2 3 4 5
Men <42.8 42.8-45.6 45.7-48.1 48.2-50.9 ≥51.0 P -trend
Colorectal cancer  
N cases 251 187 178 182 145
Multivariable model - HR (95% CI) † ¥ 1.00      0.78 (0.63-0.95) 0.75 (0.60-0.94) 0.84 (0.67-1.06) 0.75 (0.58-0.97) 0.08 0.68 (0.43-1.09)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.80 (0.64-0.99) 0.79 (0.61-1.03) 0.88 (0.65-1.19) 0.75 (0.52-1.07) 0.24 0.72 (0.36-1.44)
Lung cancer
N cases 325 252 254 197 177
Multivariable model - HR (95% CI) † 1.00      0.89 (0.75-1.07) 0.99 (0.82-1.20) 0.83 (0.67-1.03) 0.87 (0.69-1.09) 0.19 0.72 (0.48-1.08)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.98 (0.81-1.19) 1.16 (0.92-1.46) 1.01 (0.76-1.32) 1.07 (0.78-1.48) 0.66 1.05 (0.59-1.86)
Kidney cancer
N cases 112 83 71 57 32
Multivariable model - HR (95% CI) † 1.00      0.89 (0.65-1.21) 0.84 (0.59-1.18) 0.74 (0.50-1.09) 0.49 (0.31-0.79) 0.004 0.33 (0.15-0.72)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.92 (0.66-1.29) 0.89 (0.59-1.35) 0.83 (0.51-1.35) 0.60 (0.33-1.12) 0.15 0.43 (0.13-1.43)
Stomach & oesophageal cancer
N cases 127 129 98 96 75
Multivariable model - HR (95% CI) † 1.00      1.11 (0.85-1.44) 0.93 (0.68-1.25) 0.95 (0.69-1.31) 0.84 (0.59-1.20) 0.24 0.67 (0.36-1.24)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.07 (0.80-1.42) 0.87 (0.61-1.25) 0.87 (0.57-1.31) 0.74 (0.45-1.20) 0.16 0.47 (0.18-1.21)
Bladder cancer
N cases 220 174 192 189 138
Multivariable model - HR (95% CI) † 1.00      0.82 (0.66-1.02) 0.93 (0.74-1.16) 1.02 (0.80-1.28) 0.88 (0.68-1.15) 0.87 0.87 (0.55-1.39)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.86 (0.68-1.09) 1.01 (0.77-1.32) 1.13 (0.83-1.54) 1.02 (0.71-1.47) 0.49 1.04 (0.54-2.02)
Pancreatic cancer
N cases 74 78 48 62 47
Multivariable model - HR (95% CI) † 1.00      1.20 (0.85-1.69) 0.74 (0.49-1.11) 0.98 (0.65-1.48) 0.85 (0.54-1.35) 0.34 0.70 (0.32-1.56)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.05 (0.72-1.53) 0.60 (0.37-0.97) 0.76 (0.44-1.30) 0.62 (0.33-1.17) 0.09 0.34 (0.10-1.20)
Liver cancer
N cases 82 58 29 33 29
Multivariable model - HR (95% CI) † 1.00      1.03 (0.71-1.48) 0.62 (0.39-1.00) 0.81 (0.50-1.33) 0.94 (0.55-1.62) 0.47 0.74 (0.28-1.93)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.94 (0.62-1.43) 0.54 (0.31-0.95) 0.65 (0.34-1.23) 0.69 (0.33-1.45) 0.20 0.42 (0.09-1.90)
Non-Hodgkin's lymphoma
N cases 64 54 60 53 53
Multivariable model - HR (95% CI) † 1.00      0.80 (0.54-1.19) 0.89 (0.59-1.33) 0.77 (0.49-1.20) 0.84 (0.53-1.35) 0.52 0.83 (0.36-1.94)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.72 (0.47-1.10) 0.73 (0.45-1.20) 0.60 (0.34-1.06) 0.63 (0.33-1.22) 0.20 0.51 (0.14-1.89)
Brain cancer
N cases 75 66 70 54 46
Multivariable model - HR (95% CI) † 1.00      0.86 (0.60-1.22) 0.92 (0.63-1.35) 0.73 (0.48-1.11) 0.63 (0.40-1.01) 0.05 0.47 (0.20-1.07)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.93 (0.63-1.36) 1.06 (0.67-1.67) 0.86 (0.50-1.48) 0.76 (0.40-1.44) 0.41 0.74 (0.22-2.48)
Skin cancer
N cases 148 165 188 170 160
Multivariable model - HR (95% CI) † 1.00      1.03 (0.81-1.30) 1.17 (0.92-1.50) 1.10 (0.85-1.43) 1.09 (0.82-1.44) 0.52 1.19 (0.74-1.91)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.01 (0.79-1.30) 1.14 (0.86-1.52) 1.08 (0.77-1.50) 1.08 (0.74-1.58) 0.70 1.19 (0.59-2.38)
Thyroid cancer
N cases 11 11 10 14 9
Multivariable model - HR (95% CI) † 1.00      0.87 (0.33-2.14) 0.71 (0.26-1.91) 1.07 (0.40-2.90) 0.83 (0.27-2.59) 0.92 0.39 (0.05-3.08)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.93 (0.35-2.48) 0.80 (0.24-2.66) 1.35 (0.37-4.97) 1.24 (0.26-5.900 0.64 0.30 (0.01-8.52)
Prostate cancer
N cases 581 568 522 448 434
Multivariable model - HR (95% CI) † 1.00      1.09 (0.96-1.23) 1.06 (0.92-1.21) 0.98 (0.85-1.14) 1.11 (0.95-1.30) 0.51 1.12 (0.86-1.47)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.10 (0.96-1.25) 1.08 (0.92-1.27) 1.02 (0.84-1.23) 1.19 (0.96-1.47) 0.24 1.30 (0.91-1.85)
Quintile of predicted 25(OH)D (nmol/L)
Per 25 nmol/L 
increase
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ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
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Table 27. Risk (hazard ratios) for incidence of specific cancer types amongst women by 
predicted 25-hydroxyvitamin D categories 
 
1 2 3 4 5
Women <48.0 48.0-52.4 52.5-56.1 56.2-60.3 ≥60.4 P -trend
Colorectal cancer  
N cases 266 239 218 210 236
Multivariable model - HR (95% CI) † ¥ 1.00      0.86 (0.71-1.05) 0.84 (0.67-1.05) 0.84 (0.66-1.07) 0.72 (0.54-0.97) 0.05 0.74 (0.53-1.04)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.88 (0.71-1.07) 0.87 (0.68-1.10) 0.87 (0.66-1.14) 0.76 (0.55-1.06) 0.15 0.80 (0.54-1.18)
Lung cancer
N cases 148 163 122 153 333
Multivariable model - HR (95% CI) † 1.00      0.91 (0.70-1.17) 0.59 (0.44-0.80) 0.61 (0.45-0.83) 0.53 (0.38-0.76) <0.001 0.59 (0.41-0.85)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.90 (0.69-1.17) 0.59 (0.43-0.81) 0.61 (0.44-0.85) 0.54 (0.36-0.80) 0.001 0.64 (0.42-0.98)
Kidney cancer
N cases 73 49 60 32 54
Multivariable model - HR (95% CI) † 1.00      0.77 (0.51-1.15) 1.13 (0.73-1.75) 0.65 (0.38-1.13) 0.76 (0.41-1.42) 0.40 0.64 (0.31-1.30)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.74 (0.48-1.13) 1.07 (0.66-1.73) 0.61 (0.33-1.11) 0.69 (0.34-1.40) 0.30 0.51 (0.22-1.19)
Stomach & oesophageal cancer
N cases 88 62 67 52 68
Multivariable model - HR (95% CI) † 1.00      0.77 (0.53-1.11) 0.99 (0.66-1.48) 0.82 (0.51-1.30) 0.70 (0.40-1.21) 0.29 0.55 (0.29-1.04)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.82 (0.56-1.20) 1.10 (0.71-1.70) 0.92 (0.55-1.54) 0.80 (0.42-1.49) 0.59 0.57 (0.27-1.21)
Bladder cancer
N cases 77 82 64 62 78
Multivariable model - HR (95% CI) † 1.00      1.12 (0.79-1.59) 1.05 (0.70-1.57) 1.03 (0.66-1.62) 0.77 (0.45-1.32) 0.36 0.80 (0.44-1.45)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.20 (0.84-1.72) 1.17 (0.76-1.82) 1.19 (0.72-1.96) 0.93 (0.51-1.70) 0.79 1.00 (0.50-1.98)
Pancreatic cancer
N cases 82 69 51 60 75
Multivariable model - HR (95% CI) † 1.00      0.85 (0.59-1.24) 0.67 (0.44-1.04) 0.82 (0.52-1.30) 0.70 (0.40-1.20) 0.22 0.42 (0.22-0.80)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.97 (0.66-1.43) 0.84 (0.52-1.34) 1.08 (0.64-1.80) 0.98 (0.53-1.82) 0.95 0.56 (0.27-1.19)
Liver cancer
N cases 74 36 34 27 34
Multivariable model - HR (95% CI) † 1.00      0.66 (0.42-1.03) 0.78 (0.47-1.310 0.76 (0.42-1.37) 0.64 (0.31-1.33) 0.25 0.55 (0.24-1.28)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.66 (0.41-1.05) 0.79 (0.45-1.37) 0.76 (0.39-1.46) 0.63 (0.28-1.42) 0.32 0.52 (0.19-1.40)
Non-Hodgkin's lymphoma
N cases 69 59 67 64 83
Multivariable model - HR (95% CI) † 1.00      0.74 (0.50-1.09) 0.86 (0.57-1.31) 0.82 (0.52-1.30) 0.74 (0.43-1.27) 0.41 0.87 (0.47-1.60)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.73 (0.49-1.10) 0.85 (0.54-1.34) 0.81 (0.49-1.36) 0.73 (0.40-1.34) 0.43 0.88 (0.43-1.79)
Brain cancer
N cases 110 112 83 77 71
Multivariable model - HR (95% CI) † 1.00      1.11 (0.82-1.50) 0.91 (0.64-1.31) 0.92 (0.62-1.38) 0.84 (0.52-1.36) 0.38 0.98 (0.58-1.67)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.15 (0.84-1.58) 0.97 (0.66-1.43) 0.99 (0.64-1.56) 0.92 (0.54-1.58) 0.65 1.15 (0.68-1.92)
Skin cancer
N cases 181 298 344 392 335
Multivariable model - HR (95% CI) † 1.00      1.19 (0.97-1.46) 1.18 (0.95-1.46) 1.31 (1.04-1.64) 1.40 (1.08-1.83) 0.01 1.26 (0.95-1.66)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.19 (0.96-1.47) 1.18 (0.93-1.49) 1.31 (1.01-1.69) 1.39 (1.03-1.88) 0.03 1.19 (0.85-1.66)
Thyroid cancer
N cases 90 83 70 49 33
Multivariable model - HR (95% CI) † 1.00      0.92 (0.65-1.29) 0.86 (0.58-1.28) 0.76 (0.48-1.22) 0.70 (0.39-1.26) 0.19 0.55 (0.27-1.11)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.00 (0.70-1.44) 0.99 (0.64-1.54) 0.90 (0.53-1.53) 0.86 (0.44-1.67) 0.63 0.71 (0.31-1.63)
Breast cancer
N cases 1,234 1,485 1,440 1,364 1,621
Multivariable model - HR (95% CI) † ¶ 1.00      1.04 (0.96-1.14) 0.98 (0.89-1.08) 0.95 (0.86-1.06) 0.97 (0.86-1.10) 0.33 1.02 (0.89-1.17)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      1.06 (0.97-1.16) 1.01 (0.91-1.12) 0.99 (0.88-1.11) 1.02 (0.89-1.17) 0.87 1.12 (0.96-1.31)
Ovarian cancer
N cases 169 164 151 157 170
Multivariable model - HR (95% CI) † ¶ 1.00      1.03 (0.80-1.31) 0.99 (0.75-1.31) 1.10 (0.81-1.48) 1.00 (0.70-1.42) 0.93 1.25 (0.85-1.85)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.99 (0.77-1.28) 0.94 (0.70-1.27) 1.03 (0.74-1.44) 0.92 (0.62-1.38) 0.75 1.22 (0.77-1.93)
Endometrial cancer
N cases 221 186 163 141 182
Multivariable model - HR (95% CI) † ¶ 1.00      0.94 (0.75-1.17) 0.92 (0.72-1.19) 0.86 (0.65-1.14) 0.85 (0.61-1.19) 0.31 0.92 (0.63-1.35)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00      0.91 (0.72-1.14) 0.88 (0.67-1.15) 0.80 (0.59-1.10) 0.77 (0.53-1.12) 0.16 0.83 (0.53-1.30)
Quintile of predicted 25(OH)D (nmol/L)
Per 25 nmol/L 
increase
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†  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; 
current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium 
(mg/day) (all continuous), and stratified by age (1-year categories) and centre.  
¥  Multivariable model – plus adjustment for cereal fibre intake (g/day). 
¶  Multivariable model – plus adjustment for age at first pregnancy (<21; 21-<30; 30+ years old; no children; or not specified); and age at menarche 
(<12; 12-<15; 15+ years old; or not specified). 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
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3.5 Application of the predicted 25-hydroxyvitamin D score within the 
European Prospective Investigation into Cancer and Nutrition to 
assess mortality risk 
 
3.5.1 Characteristics of cohort participants 
The cohort characteristics by country and sex are shown in Table 28. The highest predicted 
circulating 25(OH)D levels were observed in the Netherlands for men and Denmark for 
women. The lowest predicted circulating 25(OH)D levels for men and women were observed 
amongst participants from Germany and Greece respectively. After adjustment for age, 
using the European standard population (175), the all-cause mortality rates for men and 
women were 94 and 60 cases per 10,000 person-years respectively. 
 
Table 28. Cohort characteristics by sex and country of participants included in the predicted 
25(OH)D-all-cause mortality analyses 
 
 
 
3.5.2 Baseline characteristics by predicted 25-hydroxyvitamin D quintiles 
 
The characteristics of the participants included in the analyses of mortality by quintiles of 
predicted circulating 25(OH)D are shown in Table 29. Compared to participants in the lowest 
quintile, those participants in the highest quintile of predicted 25(OH)D were more likely to be 
younger, physically active and have a lower BMI. Men in the highest predicted 25(OH)D 
quintile had lower intakes of red and processed meat and higher intakes of total energy and 
fruits and vegetables than those in the lowest quintile. Conversely, women in the highest 
Country Men Women Men Women Men Women Men Women
Denmark 23,143 26,594 268,367 314,974 2,305 1,692 48.1 (4.0) 65.2 (6.7)
France - 18,518 - 279,154 - 618 - 54.5 (4.7)
Germany 18,622 25,922 209,411 294,134 1,103 629 42.8 (4.1) 49.3 (5.8)
Greece 8,768 12,931 82,210 128,805 718 505 45.1 (3.7) 44.5 (5.2)
Italy 12,891 29,001 162,061 352,568 522 757 48.6 (3.7) 49.2 (5.0)
Spain 13,599 23,057 183,829 315,870 848 566 46.8 (4.5) 56.5 (6.8)
The Netherlands 7,068 22,667 89,267 292,321 277 1,192 50.7 (4.0) 56.4 (4.9)
United Kingdom 19,160 48,816 247,064 630,676 1,965 2,564 49.0 (4.2) 55.8 (5.2)
All EPIC 103,251 207,506 1,242,208 2,608,501 7,738 8,523 47.1 (4.7) 54.6 (7.8)
N  of participants Total person-years
N  all-cause 
deaths
Mean (SD) predicted 
25(OH)D level (nmol/L)
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predicted 25(OH)D quintile had higher red and processed meat intakes and lower intakes of 
total energy and fruits and vegetables than those in the lowest quintile. Women in the 
highest predicted 25(OH)D quintile were more likely to be current smokers than those in the 
lowest quintile; whereas amongst men, current smokers were relatively evenly distributed 
across the predicted 25(OH)D categories. 
 
Table 29. Baseline characteristics of study participants included in the all-cause mortality 
analyses by categories (quintiles) of predicted 25-hydroxyvitamin D score 
 
Mean and standard deviation (in parenthesis) for continuous variables, or percentages for categorical variables (‡). 
Characteristic
Q1 Q2 Q3 Q4 Q5
Predicted 25(OH)D range (g/day) <43.0 43.0-45.9 46.0-48.3 48.4-51.1 ≥51.2
N 20,651 20,650 20,650 20,650 20,650
N  all-cause deaths 2155 1784 1476 1286 1037
Age at recruitment (years) 54.2 (8.7) 52.9 (9.0) 51.7 (9.2) 50.5 (9.5) 48.2 (10.7)
Body mass index (kg/m2) 29.1 (3.9) 27.4 (3.4) 26.5 (3.1) 25.6 (2.9) 24.3 (2.7)
Education  ‡
Longer education including 
University (%) 30.3 28.5 28.3 29.0 27.9
Smoking status and intensity  ‡
Current (%) 31.1 32.2 31.7 31.5 30.6
Physical activity  ‡
Active (%) 3.3 10.6 18.1 34.3 69.1
Total energy intake (kcal/day) 2371 (671) 2414 (662) 2442 (641) 2466 (644) 2523 (662)
Red and processed meat 
consumption (g/day) 109.3 (64.4) 101.7 (61.7) 98.2 (61.1) 96.8 (61.7) 94.6 (63.8)
Fruit & vegetable consumption 
(g/day) 384.9 (296.3) 435.4 (307.7) 445.9 (291.0) 438.5 (274.3) 430.0 (264.5)
Vitamin D intake (μg/day) 3.3 (1.8) 3.7 (2.1) 3.9 (2.2) 4.3 (2.4) 5.5 (3.8)
Calcium intake (mg/day) 945.3 (405) 1005.7 (415) 1045 (415) 1078 (423) 1126 (439)
Alcohol intake  (g/day) 25.1 (27.7) 23.7 (25.0) 23.4 (23.6) 22.5 (22.3) 19.8 (20.1)
Predicted 25(OH)D range (g/day) <48.3 48.3-52.6 52.7-56.2 56.3-60.4 ≥60.5
N 41,503 41,500 41,501 41,501 41,501
N  all-cause deaths 2180 1762 1473 1365 1743
Age at recruitment (years) 53.4 (10.1) 50.5 (10.2) 48.8 (10.6) 47.6 (11.3) 51.2 (9.8)
Body mass index (kg/m2) 29.6 (5.1) 25.9 (3.9) 24.4 (3.7) 23.6 (3.5) 23.4 (3.1)
Education  ‡
Longer education including 
University (%) 13.4 22.1 27.5 29.4 19.6
Smoking status and intensity  ‡
Current (%) 17.9 18.8 17.4 18.0 26
Physical activity  ‡
Active (%) 4.5 9.9 15.2 23.4 34.5
Total energy intake (kcal/day) 1970 (572) 1968 (550) 1958 (534) 1936 (509) 1921 (481)
Red and processed meat 
consumption (g/day) 66.4 (42.8) 64.6 (43.2) 60.7 (44.9) 57.1 (44.7) 66.9 (40.3)
Fruit & vegetable consumption 
(g/day) 527.8 (309.6) 482.2 (283.8) 485.2 (263.0) 486.9 (263.4) 450.0 (245.4)
Vitamin D intake (μg/day) 2.5 (1.5) 2.8 (1.5) 3.0 (1.7) 3.3 (1.8) 4.5 (2.6)
Calcium intake (mg/day) 952.0 (377) 995.2 (396) 1019.7 (392) 1031.6 (385) 1039.7 (408)
Alcohol intake  (g/day) 6.8 (11.5) 8.2 (11.9) 8.7 (11.9) 8.7 (11.9) 10.5 (12.6)
Ever use of contraceptive pill  ‡
Yes (%) 39.6 56.0 64.7 69.0 64.3
Ever use of menopausal hormone 
therapy  ‡
Yes (%) 13.4 18.5 19.6 23.8 39.6
Menopausal status  ‡
Postmenopausal (%) 51.9 41.2 36.0 35.6 51.7
Men
Women
Quintile of predicted 25(OH)D
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3.5.3 Predicted 25-hydroxyvitamin D levels and all-cause mortality risk 
 
In the sexes combined categorical model, higher levels of predicted 25(OH)D were 
associated with a reduced all-cause mortality (Q5 vs. Q1, HR 0.65, 95% CI: 0.61-0.70; P-
trend <0.001) (Table 30). In the equivalent continuous model, a 52% lower all-cause 
mortality risk (95% CI: 0.43-0.53) was observed per 25 nmol/L increment of predicted 
25(OH)D. Similar associations were observed when participants whose follow-up times were 
less than 5 years were excluded from the analyses. When analysed by sex, similar inverse 
associations were observed for men (HR per 25 nmol/L increment in predicted 25(OH)D, 
0.46, 95% CI: 0.39-0.54) and women (HR per 25 nmol/L increment in predicted 25(OH)D, 
0.47, 95% CI: 0.41-0.53) were observed in the multivariable models (P-interaction 0.84).  
 
Significant predicted 25(OH)D-all-cause mortality associations were observed across strata 
of all lifestyle, demographic, anthropometric, and dietary variables considered (Table 31). 
For BMI, a significant interaction was observed (P-interaction 0.001); however, significant 
associations were observed across all categories of BMI. 
 
The mutually adjusted HRs for all-cause mortality associated with the individual components 
of the applied predictor scores are shown in Table 32. After multivariable adjustment, waist 
circumference, country, and physical activity index, were significantly associated with risk of 
all-cause death. In contrast, dietary vitamin D intake and ever use of menopausal hormones 
were not significantly associated with all-cause mortality risk. 
 
Significant inverse associations were observed across all countries; although the strength of 
the relationships varied (P-heterogeneity <0.001), with the strongest association observed 
for the Netherlands (HR per 25 nmol/L increment in predicted 25(OH)D, 0.20, 95% CI: 0.14-
0.29) and the weakest observed for participants from Spain (HR per 25 nmol/L increment in 
predicted 25(OH)D, 0.68, 95% CI: 0.50-0.92) (Figure 15). 
 
When analyses were limited to individuals who self-reported at baseline being in ‘excellent’ 
or ‘good’ health (n=65,390), similar associations were observed (sexes combined 
multivariable model: HR per 25 nmol/L increment in predicted 25(OH)D, 0.57, 95% CI: 0.46-
0.72). 
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Table 30. Risk (hazard ratios) of all-cause mortality amongst men and women associated with predicted 25-hydroxyvitamin D level 
 
†  Basic model - Cox regression stratified by age (1-year categories), sex, and centre. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
 
1 2 3 4 5
Men <43.0 43.0-45.9 46.0-48.3 48.4-51.1 ≥51.2
Women <48.3 48.3-52.6 52.7-56.2 56.3-60.4 ≥60.5 P -trend
Total all-cause mortality
Both sexes
N cases 4,335 3,546 2,949 2,651 2,780
Person-years 721,056   762,567                 787,833                  798,436                 780,817                 
Basic model - HR (95% CI) † 1.00         0.81 (0.77-0.85) 0.71 (0.68-0.75) 0.66 (0.63-0.70) 0.60 (0.56-0.64) <0.001 0.44 (0.41-0.48) 0.43 (0.39-0.47)
Multivariable model - HR (95% CI) ‡ 1.00         0.87 (0.83-0.92) 0.78 (0.74-0.83) 0.72 (0.68-0.77) 0.65 (0.61-0.70) <0.001 0.48 (0.43-0.53) 0.48 (0.42-0.53)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00         0.92 (0.87-0.97) 0.86 (0.81-0.92) 0.82 (0.76-0.88) 0.75 (0.69-0.82) <0.001 0.57 (0.50-0.64) 0.57 (0.49-0.66)
Men
N cases 2,155 1,784 1,476 1,286 1,037
Person-years 235,309   244,354                 250,077                  253,573                 258,895                 
Basic model - HR (95% CI) † 1.00         0.82 (0.77-0.88) 0.72 (0.67-0.78) 0.67 (0.62-0.72) 0.62 (0.57-0.67) <0.001 0.35 (0.30-0.41) 0.35 (0.29-0.41)
Multivariable model - HR (95% CI) ‡ 1.00         0.90 (0.84-0.96) 0.82 (0.76-0.89) 0.77 (0.71-0.84) 0.69 (0.63-0.76) <0.001 0.46 (0.39-0.54) 0.48 (0.40-0.58)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00         0.94 (0.88-1.02) 0.89 (0.81-0.98) 0.85 (0.76-0.94) 0.77 (0.68-0.87) <0.001 0.49 (0.38-0.64) 0.53 (0.40-0.71)
Women
N cases 2,180 1,762 1,473 1,365 1,743
Person-years 485,747   518,213                 537,756                  544,863                 521,922                 
Basic model - HR (95% CI) † 1.00         0.80 (0.75-0.86) 0.70 (0.65-0.76) 0.65 (0.60-0.70) 0.58 (0.53-0.63) <0.001 0.49 (0.45-0.54) 0.48 (0.43-0.54)
Multivariable model - HR (95% CI) ‡ 1.00         0.83 (0.77-0.89) 0.73 (0.67-0.79) 0.67 (0.61-0.73) 0.59 (0.53-0.65) <0.001 0.47 (0.41-0.53) 0.45 (0.39-0.52)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00         0.88 (0.82-0.95) 0.81 (0.74-0.88) 0.76 (0.69-0.84) 0.70 (0.62-0.78) <0.001 0.57 (0.49-0.66) 0.55 (0.47-0.65)
Quintile of predicted 25(OH)D (nmol/L)
<5 years excluded
Per 25 nmol/L 
increase
Per 25 nmol/L 
increase
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Table 31. Risk (hazard ratios) of all-cause mortality associated with a 25 nmol/L increment 
of predicted 25-hydroxyvitamin D level across strata of lifestyle, demographic, 
anthropometric, and dietary variables 
 
*  Median intakes:  red and processed meat=93.8 g/day in men and 59.1 g/day in women; fruit and vegetable=353 g/day in men and 436 g/day in 
women; fish consumption=26.6 g/day in men and 21.7 g/day in women; calcium=974 mg/day in men and 954 mg/day in women; fibre=23.9 g/day 
in men and 22.7 g/day in women; retinol=698 µg/day in men and 512 µg/day in women. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per 
Stratification variable
P  interaction
Overall 0.48 (0.43-0.53)
Sex 0.84
Men 0.46 (0.39-0.54)
Women 0.47 (0.41-0.53)
Age at recruitment 0.61
<55 years old 0.59 (0.49-0.70)
55-<65 years old 0.46 (0.40-0.53)
≥65 years old 0.39 (0.32-0.48)
Follow-up 0.69
<5 years 0.48 (0.39-0.60)
5-10 years 0.53 (0.46-0.62)
≥10 years 0.49 (0.41-0.57)
Smoking status 0.79
Never smoked 0.50 (0.42-0.59)
Former smoker 0.46 (0.38-0.55)
Current smoker 0.47 (0.40-0.55)
Body mass index 0.001
<25.0 kg/m2 0.52 (0.45-0.61)
25.0-29.9 kg/m2 0.49 (0.42-0.58)
≥30 kg/m2 0.33 (0.26-0.41)
Physical activity 0.11
Inactive 0.47 (0.38-0.60)
Moderately inactive 0.59 (0.47-0.74)
Moderately active 0.61 (0.46-0.82)
Active 0.71 (0.53-0.95)
Alcohol consumption 0.94
Non-consumers 0.50 (0.38-0.64)
<15 g/day 0.45 (0.40-0.52)
15-29.9 g/day 0.58 (0.43-0.77)
≥30 g/day 0.45 (0.36-0.58)
Red and processed meat consumption * 0.53
Below median 0.54 (0.47-0.63)
Above median 0.43 (0.37-0.49)
Fruit and vegetable consumption * 0.79
Below median 0.47 (0.41-0.54)
Above median 0.49 (0.42-0.57)
Fish consumption * 0.05
Below median 0.35 (0.29-0.41)
Above median 0.55 (0.48-0.62)
Calcium intake * 0.25
Below median 0.51 (0.44-0.59)
Above median 0.45 (0.39-0.52)
Fibre intake * 0.58
Below median 0.47 (0.41-0.54)
Above median 0.49 (0.43-0.57)
Retinol intake * 0.58
Below median 0.49 (0.42-0.57)
Above median 0.47 (0.41-0.53)
Menopausal status 0.47
Premenopausal 0.60 (0.41-0.90)
Postmenopausal 0.44 (0.38-0.51)
Perimenopausal 0.63 (0.41-0.99)
Surgical postmenopausal 0.36 (0.20-0.64)
Ever use of contraceptive pill 0.10
No 0.43 (0.37-0.51)
Yes 0.51 (0.42-0.63)
Predicted 25(OH)D HR (95% CI), 
per 25 nmol/L ‡
Total all-cause mortality
Both sexes
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day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary 
calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
 
 
Table 32. Risk (hazard ratios) of all-cause mortality associated with the 
correlates/determinants of circulating 25(OH)D used in the predictor scores (mutually 
adjusted) 
 
Multivariable model - Cox regression with predictor score determinants mutually adjusted for each other, plus additional adjustment for body mass 
index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary 
school; longer education including university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking 
status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; former, quit ≤10 
years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 
10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of contraceptive pill (yes; no; or unknown), menopausal status 
(premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy 
(kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-
year categories), sex, and centre. 
Predictor score HR (95% CI) P -trend
1.00 (0.99-1.02)
<0.001
Inactive 1.00
Moderately inactive 0.84 (0.81-0.88)
Moderately active 0.82 (0.78-0.86)
Active 0.80 (0.76-0.84)
1.02 (1.01-1.02)
<0.001
Denmark 1.00
UK 0.84 (0.79-0.89)
The Netherlands 0.84 (0.79-0.90)
France 0.55 (0.50-0.61)
Germany 0.90 (0.85-0.96)
Greece 0.72 (0.66-0.79)
Italy 0.60 (0.56-0.65)
Spain 0.63 (0.58-0.68)
0.41
No 1.00
Yes 0.98 (0.93-1.03)
Country
Dietary vitamin D (Per 2.5 µg/day)
Physical activity
Waist circumference (Per 1 cm)
Ever use of menopausal hormone 
therapy
Both sexes
Total all-cause mortality
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Figure 15. Risk (hazard ratios) of all-cause mortality, by country, associated with a 25 
nmol/L increment of predicted 25-hydroxyvitamin D level 
 
Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; 
technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-consumers; 
<5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 
16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, 
missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of contraceptive pill (yes; 
no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical 
postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium 
(mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre.  
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3.5.4 Predicted 25-hydroxyvitamin D levels and cause specific mortality risk 
 
Cancer mortality 
Elevated predicted circulating 25(OH)D was associated with a reduced cancer mortality risk 
in the sexes combined multivariable model (n=6,710 deaths: Q5 vs. Q1, HR, 0.77, 95% CI: 
0.69-0.86; P-trend <0.001) (Table 33). In the continuous models, a 25 nmol/L higher 
predicted 25(OH)D level was associated with a 35% lower cancer mortality risk (95% CI: 
0.56-0.75). When participants whose follow-up time was less than 5 years were excluded, 
similar risk estimates were observed. When the associations were assessed in men and 
women separately, identical significant 35% lower cancer mortality risks for both per 
increment in predicted 25(OH)D were observed (P-interaction 0.88) (Tables 34 and 35). 
When the overall cancer mortality analysis was limited to individuals who self-reported being 
in ‘excellent’ or ‘good’ health at baseline (n=65,390 participants), a slightly weaker non-
significant inverse association was observed (HR per 25 nmol/L increment in predicted 
25(OH)D, 0.76, 95% CI: 0.52-1.10). 
 
Inverse predicted 25(OH)D-cancer mortality associations were observed across strata of all 
lifestyle, demographic, anthropometric, and dietary variables considered (Table 36). The 
interaction terms for predicted 25(OH)D with BMI and ever use of contraceptive pill were 
significant when inputted into the cancer mortality models. Inverse associations were 
observed in all countries, with risk estimates ranging from 0.31 to 0.87 per 25 nmol/L of 
predicted 25(OH)D (P-heterogeneity 0.016) (Figure 16).  
 
Circulatory diseases mortality 
At the end of the follow-up period, 3,641 circulatory disease deaths were recorded. In the 
multivariable models, a 41% reduced risk (95% CI: 0.50-0.68) of circulatory disease mortality 
was observed in the sexes combined models, when participants in the highest predicted 
25(OH)D quintile were compared against those in the lowest quintile (P-trend <0.001) (Table 
33). In the continuous models, a 61% lower circulatory disease mortality risk (95% CI: 0.31-
0.48) was observed per 25 nmol/L increment in predicted 25(OH)D. The inverse 
associations were similar when participants whose follow-up time was less than 5 years 
were excluded. A slightly stronger inverse association was observed for women (HR per 25 
nmol/L increment in predicted 25(OH)D, 0.32, 95% CI: 0.24-0.43) compared to men (HR per 
25 nmol/L increment in predicted 25(OH)D, 0.42, 95% CI: 0.30-0.59); although, this 
difference was not significant (P-interaction 0.16) (Tables 34 and 35). When the circulatory 
disease mortality analysis was limited to individuals who self-reported being in ‘excellent’ or 
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‘good’ health at baseline (n=65,390 participants), a slightly weaker inverse relationship was 
observed (both sexes multivariable model: HR per 25 nmol/L increment in predicted 
25(OH)D, 0.56, 95% CI: 0.34-0.94). 
 
When circulatory disease deaths were further sub-categorised, similar associations in the 
sexes combined models were observed for ischaemic heart disease mortality (HR per 25 
nmol/L increment in predicted 25(OH)D, 0.39, 95% CI: 0.27-0.55) and cerebrovascular 
disease mortality (HR per 25 nmol/L increment in predicted 25(OH)D, 0.35, 95% CI: 0.23-
0.53) in the multivariable models. 
 
Table 36 shows the circulatory mortality associations across strata of lifestyle, demographic, 
anthropometric, and dietary variables. Significant interactions were observed for predicted 
25(OH)D with age at recruitment, smoking status, BMI, and alcohol consumption; however, 
the risk estimates for the across the strata of these variables were all within confidence 
intervals of each other and all of the associations were inverse. Inverse associations were 
observed in all countries, with risk estimates ranging from 0.13 to 0.79 per 25 nmol/L of 
predicted 25(OH)D (P-heterogeneity 0.08). 
 
Respiratory diseases mortality 
Over the follow-up period, 544 deaths caused by respiratory disease were recorded. Higher 
predicted 25(OH)D was associated with reduced risk of respiratory disease death (Q5 vs. 
Q1, HR 0.32, 95% CI: 0.22-0.48) in the sexes combined multivariable model (P-trend 
<0.001) (Table 33). In the equivalent continuous model, an 88% lower risk of respiratory 
disease mortality (95% CI: 0.07-0.21) was observed per 25 nmol/L increment in predicted 
25(OH)D. Similar strong associations were observed when men (HR per 25 nmol/L 
increment in predicted 25(OH)D, 0.13, 95% CI: 0.05-0.34) and women (HR per 25 nmol/L 
increment in predicted 25(OH)D, 0.14, 95% CI: 0.07-0.28) were analysed separately (P-
interaction 0.43) (Tables 34 and 35).  
 
When the analysis was limited to individuals who self-reported being in ‘excellent’ or ‘good’ 
health at baseline (n=65,390 participants), a similar inverse relationship was observed (both 
sexes multivariable model: HR per 25 nmol/L increment in predicted 25(OH)D, 0.16, 95% CI: 
0.03-0.90). When the multivariable model was not adjusted for BMI, the inverse association 
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weakened but remained significant (HR per 25 nmol/L increment in predicted 25(OH)D, 0.38, 
95% CI: 0.25-0.59). 
 
A significant interaction was observed for predicted 25(OH)D with smoking status (P-
interaction 0.02); although, strong inverse associations were observed amongst never 
smokers (HR per 25 nmol/L increment in predicted 25(OH)D, 0.26, 95% CI: 0.08-0.87) and 
current smokers (HR per 25 nmol/L increment in predicted 25(OH)D, 0.13, 95% CI: 0.06-
0.29). When analysing by country no heterogeneity in the relationship was detected (P-
heterogeneity 0.87).  
 
Digestive diseases mortality 
At the end of the follow-up period, 511 digestive disease deaths had accrued. A 79% 
significantly reduced digestive disease mortality risk (95% CI: 0.14-0.32) was observed in 
the sexes combined multivariable model when individuals in the highest quintile of predicted 
25(OH)D were compared versus those in the lowest (P-trend <0.001) (Table 33). In the 
continuous model, an 89% lower risk (95% CI: 0.06-0.20) was observed per 25 nmol/L 
increment in predicted 25(OH)D. When analysed by sex, the inverse association was slightly 
stronger for men (HR per 25 nmol/L increment in predicted 25(OH)D, 0.08, 95% CI: 0.03-
0.18), compared to women (HR per 25 nmol/L increment in predicted 25(OH)D, 0.12, 95% 
CI: 0.06-0.26) (P-interaction 0.02) (Tables 34 and 35).  
 
When the analysis was limited to individuals who self-reported being in ‘excellent’ or ‘good’ 
health at baseline (n=65,390 participants), a similar inverse relationship was observed (both 
sexes multivariable model: HR per 25 nmol/L increment in predicted 25(OH)D, 0.06, 95% CI: 
0.02-0.27). 
 
A significant interaction was observed for predicted 25(OH)D with smoking status (P-
interaction 0.02); although, strong inverse associations were observed amongst never 
smokers (HR per 25 nmol/L increment in predicted 25(OH)D, 0.05, 95% CI: 0.02-0.15) and 
current smokers (HR per 25 nmol/L increment in predicted 25(OH)D, 0.16, 95% CI: 0.06-
0.39). When analysed by country, similar associations were observed (P-heterogeneity 
0.96).  
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External causes mortality 
The associations between predicted 25(OH)D levels and deaths caused by external causes 
(n=313 deaths) (i.e. accidents and injuries) were investigated to act as “negative controls”; 
whereby, the exposure (predicted circulating 25(OH)D) and the end-points have no plausible 
mechanism for a causal effect. No association was observed in the sexes combined 
multivariable model (Q5 vs. Q1, HR 0.97, 95% CI: 0.71-1.32; P-trend 0.77) (Table 33). Null 
associations were also observed in the men (Q5 vs. Q1, HR 0.84, 95% CI: 0.57-1.23; P-
trend 0.61) and women’s (Q5 vs. Q1, HR 1.17, 95% CI: 0.68-2.01; P-trend 0.70) 
multivariable models (P-interaction 0.20) (Tables 34 and 35). 
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Table 33. Risk (hazard ratios) of cause-specific mortality amongst men and women associated with predicted 25-hydroxyvitamin D level 
 
†  Basic model - Cox regression stratified by age (1-year categories), sex, and centre. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
1 2 3 4 5
Men <43.0 43.0-45.9 46.0-48.3 48.4-51.1 ≥51.2
Women <48.3 48.3-52.6 52.7-56.2 56.3-60.4 ≥60.5 P -trend
Person-years 698,807      726,295             744,828               752,787            726,586            
Cancer (C00-D48)
N deaths 1,609 1,388 1,245 1,163 1,305
Basic model - HR (95% CI) † 1.00           0.88 (0.82-0.95) 0.81 (0.75-0.88) 0.77 (0.71-0.84) 0.73 (0.66-0.80) <0.001 0.62 (0.55-0.70) 0.65 (0.55-0.76)
Multivariable model - HR (95% CI) ‡ 1.00           0.93 (0.86-1.00) 0.87 (0.79-0.95) 0.82 (0.75-0.91) 0.77 (0.69-0.86) <0.001 0.65 (0.56-0.75) 0.70 (0.57-0.84)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00           0.95 (0.88-1.04) 0.91 (0.82-1.00) 0.87 (0.78-0.98) 0.82 (0.72-0.94) 0.002 0.69 (0.57-0.83) 0.74 (0.59-0.95)
Circulatory diseases (I00-I99)
N deaths 1,227 857 628 501 428
Basic model - HR (95% CI) † 1.00           0.76 (0.69-0.84) 0.63 (0.57-0.70) 0.54 (0.48-0.61) 0.46 (0.40-0.52) <0.001 0.26 (0.21-0.31) 0.26 (0.21-0.32)
Multivariable model - HR (95% CI) ‡ 1.00           0.87 (0.79-0.96) 0.76 (0.68-0.86) 0.68 (0.60-0.77) 0.59 (0.50-0.68) <0.001 0.39 (0.31-0.48) 0.39 (0.30-0.51)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00           0.91 (0.82-1.02) 0.83 (0.73-0.94) 0.75 (0.64-0.87) 0.65 (0.54-0.79) <0.001 0.43 (0.33-0.58) 0.44 (0.31-0.61)
Respiratory diseases (J30-J98)
N deaths 166 131 69 65 113
Basic model - HR (95% CI) † 1.00           0.81 (0.63-1.04) 0.44 (0.32-0.60) 0.41 (0.29-0.56) 0.45 (0.32-0.63) <0.001 0.27 (0.18-0.41) 0.22 (0.13-0.35)
Multivariable model - HR (95% CI) ‡ 1.00           0.78 (0.60-1.02) 0.42 (0.30-0.58) 0.36 (0.25-0.51) 0.32 (0.22-0.48) <0.001 0.12 (0.07-0.21) 0.12 (0.06-0.22)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00           0.94 (0.71-1.24) 0.59 (0.41-0.84) 0.56 (0.38-0.84) 0.60 (0.38-0.97) 0.007 0.28 (0.14-0.55) 0.23 (0.11-0.50)
Digestive diseases (K00-K93)
N deaths 191 98 83 78 61
Basic model - HR (95% CI) † 1.00           0.47 (0.36-0.60) 0.38 (0.29-0.50) 0.36 (0.27-0.48) 0.20 (0.14-0.29) <0.001 0.11 (0.07-0.18) 0.13 (0.07-0.22)
Multivariable model - HR (95% CI) ‡ 1.00           0.51 (0.39-0.66) 0.43 (0.32-0.57) 0.40 (0.29-0.55) 0.21 (0.14-0.32) <0.001 0.11 (0.06-0.20) 0.17 (0.09-0.34)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00           0.57 (0.43-0.76) 0.52 (0.37-0.73) 0.50 (0.34-0.75) 0.28 (0.17-0.47) <0.001 0.19 (0.09-0.40) 0.27 (0.11-0.66)
External causes (S00-Y98)
N deaths 174 132 159 122 155
Basic model - HR (95% CI) † 1.00           0.81 (0.64-1.03) 1.07 (0.84-1.36) 0.83 (0.63-1.09) 1.04 (0.79-1.37) 0.85 1.00 (0.68-1.48) 0.71 (0.43-1.19)
Multivariable model - HR (95% CI) ‡ 1.00           0.81 (0.63-1.04) 1.05 (0.81-1.36) 0.79 (0.59-1.06) 0.97 (0.71-1.32) 0.77 0.84 (0.53-1.33) 0.71 (0.39-1.29)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00           0.79 (0.61-1.03) 1.02 (0.76-1.36) 0.76 (0.54-1.08) 0.94 (0.64-1.39) 0.73 0.75 (0.42-1.35) 0.65 (0.30-1.40)
Quintile of predicted 25(OH)D (nmol/L)
Per 25 nmol/L 
increase
<5 years 
excluded
Per 25 nmol/L 
increase
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use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
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Table 34. Risk (hazard ratios) of cause-specific mortality amongst men associated with predicted 25-hydroxyvitamin D level 
 
†  Basic model - Cox regression stratified by age (1-year categories) and centre. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown), and 
1 2 3 4 5
Men <43.0 43.0-45.9 46.0-48.3 48.4-51.1 ≥51.2 P -trend
Person-years 228,411      232,172             234,695               236,178            240,852            
Cancer (C00-D48)
N deaths 776 636 583 515 413
Basic model - HR (95% CI) † 1.00            0.86 (0.77-0.96) 0.84 (0.74-0.94) 0.80 (0.70-0.90) 0.73 (0.64-0.84) <0.001 0.56 (0.44-0.71)
Multivariable model - HR (95% CI) ‡ 1.00            0.92 (0.82-1.03) 0.91 (0.81-1.03) 0.87 (0.76-0.99) 0.79 (0.68-0.91) 0.002 0.65 (0.50-0.85)
Multivariable model + physical 
activity adj - HR (95% CI) ɸ 1.00            0.95 (0.84-1.07) 0.95 (0.82-1.11) 0.91 (0.77-1.09) 0.83 (0.68-1.02) 0.10 0.70 (0.47-1.04)
Circulatory diseases (I00-I99)
N deaths 626 492 343 293 218
Basic model - HR (95% CI) † 1.00            0.81 (0.71-0.91) 0.63 (0.54-0.73) 0.58 (0.50-0.68) 0.50 (0.42-0.59) <0.001 0.21 (0.15-0.28)
Multivariable model - HR (95% CI) ‡ 1.00            0.95 (0.84-1.08) 0.80 (0.69-0.93) 0.78 (0.66-0.92) 0.69 (0.57-0.84) <0.001 0.42 (0.30-0.59)
Multivariable model + physical 
activity adj - HR (95% CI) ɸ 1.00            0.98 (0.85-1.13) 0.84 (0.70-1.01) 0.83 (0.67-1.02) 0.73 (0.57-0.95) 0.011 0.39 (0.23-0.65)
Respiratory diseases (J30-J98)
N deaths 75 74 35 31 32
Basic model - HR (95% CI) † 1.00            1.05 (0.75-1.47) 0.57 (0.37-0.88) 0.57 (0.36-0.90) 0.74 (0.47-1.17) 0.018 0.29 (0.13-0.66)
Multivariable model - HR (95% CI) ‡ 1.00            0.97 (0.68-1.38) 0.50 (0.32-0.80) 0.48 (0.29-0.79) 0.51 (0.31-0.86) 0.001 0.13 (0.05-0.34)
Multivariable model + physical 
activity adj - HR (95% CI) ɸ 1.00            1.11 (0.75-1.63) 0.64 (0.37-1.10) 0.69 (0.37-1.28) 0.87 (0.42-1.78) 0.37 0.23 (0.05-1.03)
Digestive diseases (K00-K93)
N deaths 117 58 48 39 21
Basic model - HR (95% CI) † 1.00            0.48 (0.34-0.66) 0.39 (0.27-0.55) 0.32 (0.22-0.48) 0.19 (0.12-0.31) <0.001 0.04 (0.02-0.10)
Multivariable model - HR (95% CI) ‡ 1.00            0.55 (0.39-0.78) 0.48 (0.33-0.71) 0.41 (0.26-0.62) 0.22 (0.13-0.37) <0.001 0.08 (0.03-0.18)
Multivariable model + physical 
activity adj - HR (95% CI) ɸ 1.00            0.60 (0.41-0.87) 0.55 (0.35-0.87) 0.45 (0.26-0.79) 0.23 (0.11-0.47) <0.001 0.08 (0.02-0.34)
External causes (S00-Y98)
N deaths 107 70 99 77 76
Basic model - HR (95% CI) † 1.00            0.70 (0.51-0.96) 1.06 (0.79-1.44) 0.85 (0.61-1.19) 0.89 (0.63-1.26) 0.79 0.89 (0.48-1.62)
Multivariable model - HR (95% CI) ‡ 1.00            0.70 (0.51-0.96) 1.07 (0.78-1.47) 0.83 (0.58-1.19) 0.84 (0.57-1.23) 0.61 0.79 (0.40-1.54)
Multivariable model + physical 
activity adj - HR (95% CI) ɸ 1.00            0.68 (0.48-0.97) 1.04 (0.70-1.52) 0.81 (0.51-1.27) 0.84 (0.49-1.42) 0.73 0.73 (0.27-1.97)
Quantile of predicted 25(OH)D (nmol/L)
Per 25 nmol/L 
increase
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intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), and centre. 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
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Table 35. Risk (hazard ratios) of cause-specific mortality amongst women associated with predicted 25-hydroxyvitamin D level 
 
†  Basic model - Cox regression stratified by age (1-year categories) and centre. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
1 2 3 4 5
Women <48.3 48.3-52.6 52.7-56.2 56.3-60.4 ≥60.5 P -trend
Person-years 470,397           494,123             510,133               516,610            485,734            
Cancer (C00-D48)
N deaths 833 752 662 648 892
Basic model - HR (95% CI) † 1.00                0.89 (0.80-0.99) 0.79 (0.70-0.88) 0.75 (0.66-0.85) 0.72 (0.63-0.82) <0.001 0.65 (0.56-0.75)
Multivariable model - HR (95% CI) ‡ 1.00                0.92 (0.82-1.03) 0.82 (0.72-0.93) 0.78 (0.68-0.89) 0.74 (0.63-0.87) <0.001 0.65 (0.54-0.78)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00                0.95 (0.85-1.07) 0.87 (0.76-1.00) 0.83 (0.72-0.97) 0.81 (0.67-0.97) 0.01 0.70 (0.57-0.87)
Circulatory diseases (I00-I99)
N deaths 601 365 285 208 210
Basic model - HR (95% CI) † 1.00                0.71 (0.61-0.82) 0.63 (0.53-0.74) 0.49 (0.40-0.59) 0.39 (0.31-0.49) <0.001 0.29 (0.23-0.37)
Multivariable model - HR (95% CI) ‡ 1.00                0.77 (0.66-0.90) 0.71 (0.59-0.84) 0.55 (0.44-0.67) 0.45 (0.35-0.57) <0.001 0.32 (0.24-0.43)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00                0.81 (0.69-0.95) 0.78 (0.64-0.95) 0.62 (0.50-0.78) 0.53 (0.40-0.70) <0.001 0.38 (0.27-0.55)
Respiratory diseases (J30-J98)
N deaths 91 57 34 34 81
Basic model - HR (95% CI) † 1.00                0.58 (0.40-0.83) 0.31 (0.20-0.49) 0.27 (0.17-0.42) 0.27 (0.17-0.42) <0.001 0.26 (0.16-0.43)
Multivariable model - HR (95% CI) ‡ 1.00                0.55 (0.38-0.82) 0.30 (0.19-0.48) 0.22 (0.13-0.37) 0.18 (0.10-0.32) <0.001 0.14 (0.07-0.28)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00                0.66 (0.44-0.98) 0.42 (0.26-0.70) 0.35 (0.20-0.62) 0.36 (0.19-0.68) 0.001 0.39 (0.18-0.85)
Digestive diseases (K00-K93)
N deaths 74 40 35 39 40
Basic model - HR (95% CI) † 1.00                0.45 (0.30-0.68) 0.38 (0.24-0.59) 0.41 (0.26-0.64) 0.22 (0.13-0.38) <0.001 0.19 (0.11-0.35)
Multivariable model - HR (95% CI) ‡ 1.00                0.44 (0.28-0.67) 0.35 (0.22-0.57) 0.37 (0.22-0.62) 0.18 (0.09-0.35) <0.001 0.12 (0.06-0.26)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00                0.49 (0.31-0.77) 0.44 (0.26-0.74) 0.50 (0.28-0.89) 0.27 (0.13-0.58) 0.002 0.19 (0.07-0.48)
External causes (S00-Y98)
N deaths 67 62 60 45 79
Basic model - HR (95% CI) † 1.00                1.01 (0.69-1.48) 1.09 (0.73-1.65) 0.81 (0.51-1.29) 1.34 (0.84-2.13) 0.33 1.09 (0.66-1.82)
Multivariable model - HR (95% CI) ‡ 1.00                0.97 (0.65-1.45) 1.03 (0.66-1.61) 0.74 (0.44-1.23) 1.17 (0.68-2.01) 0.70 0.87 (0.46-1.64)
Multivariable model + physical activity 
adj - HR (95% CI) ɸ 1.00                0.95 (0.62-1.43) 0.99 (0.61-1.60) 0.70 (0.40-1.24) 1.11 (0.60-2.05) 0.79 0.77 (0.36-1.63)
Quintile of predicted 25(OH)D (nmol/L)
Per 25 nmol/L 
increase
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former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), and centre. 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
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Table 36. Risk (hazard ratios) of cancer and circulatory disease mortality associated with a 
25 nmol/L increment of predicted 25-hydroxyvitamin D level across strata of lifestyle, 
demographic, anthropometric, and dietary variables 
 
*  Median intakes:  red and processed meat=93.8 g/day in men and 59.1 g/day in women; fruit and vegetable=353 g/day in men and 436 g/day in 
women; fish consumption=26.6 g/day in men and 21.7 g/day in women; calcium=974 mg/day in men and 954 mg/day in women; fibre=23.9 g/day 
in men and 22.7 g/day in women; retinol=698 µg/day in men and 512 µg/day in women. 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per 
day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
Stratification variable
P  interaction P  interaction
Overall 0.65 (0.56-0.75) 0.39 (0.31-0.48)
Sex 0.88 0.16
Men 0.65 (0.50-0.85) 0.42 (0.30-0.59)
Women 0.65 (0.54-0.78) 0.32 (0.24-0.43)
Age at recruitment 0.62 0.04
<55 years old 0.73 (0.57-0.94) 0.45 (0.28-0.72)
55-<65 years old 0.63 (0.51-0.77) 0.33 (0.24-0.45)
≥65 years old 0.58 (0.39-0.87) 0.45 (0.31-0.65)
Follow-up 0.80 0.82
<5 years 0.62 (0.45-0.84) 0.38 (0.25-0.58)
5-10 years 0.69 (0.56-0.86) 0.45 (0.33-0.62)
≥10 years 0.71 (0.53-0.94) 0.42 (0.27-0.65)
Smoking status 0.92 0.001
Never smoked 0.75 (0.58-0.96) 0.29 (0.20-0.42)
Former smoker 0.60 (0.44-0.80) 0.41 (0.27-0.61)
Current smoker 0.61 (0.47-0.78) 0.46 (0.32-0.67)
Body mass index 0.02 0.02
<25.0 kg/m2 0.77 (0.61-0.96) 0.33 (0.23-0.47)
25.0-29.9 kg/m2 0.71 (0.56-0.91) 0.42 (0.30-0.60)
≥30 kg/m2 0.36 (0.25-0.52) 0.26 (0.17-0.41)
Physical activity 0.36 0.03
Inactive 0.51 (0.35-0.75) 0.39 (0.24-0.64)
Moderately inactive 0.73 (0.52-1.02) 0.67 (0.40-1.13)
Moderately active 0.79 (0.51-1.20) 0.28 (0.14-0.56)
Active 0.80 (0.53-1.20) 0.41 (0.20-0.87)
Alcohol consumption 0.45 0.02
Non-consumers 0.73 (0.49-1.09) 0.17 (0.09-0.32)
<15 g/day 0.60 (0.49-0.73) 0.42 (0.32-0.56)
15-29.9 g/day 0.70 (0.46-1.08) 0.41 (0.22-0.77)
≥30 g/day 0.70 (0.49-0.99) 0.39 (0.22-0.70)
Red and processed meat consumption * 0.51 0.52
Below median 0.78 (0.63-0.97) 0.37 (0.27-0.51)
Above median 0.54 (0.44-0.67) 0.42 (0.31-0.57)
Fruit and vegetable consumption * 0.75 0.57
Below median 0.70 (0.57-0.85) 0.39 (0.29-0.53)
Above median 0.59 (0.47-0.75) 0.40 (0.29-0.55)
Fish consumption * 0.87 0.35
Below median 0.52 (0.40-0.68) 0.29 (0.21-0.42)
Above median 0.71 (0.59-0.87) 0.43 (0.33-0.58)
Calcium intake * 0.93 0.60
Below median 0.66 (0.54-0.82) 0.41 (0.30-0.56)
Above median 0.63 (0.51-0.78) 0.37 (0.27-0.50)
Fibre intake * 0.67 0.68
Below median 0.77 (0.63-0.95) 0.36 (0.27-0.49)
Above median 0.54 (0.44-0.68) 0.42 (0.31-0.58)
Retinol intake * 0.96 0.09
Below median 0.71 (0.56-0.89) 0.33 (0.24-0.46)
Above median 0.59 (0.49-0.73) 0.43 (0.32-0.58)
Menopausal status 0.91 0.12
Premenopausal 0.68 (0.41-1.13) 0.31 (0.08-1.11)
Postmenopausal 0.62 (0.49-0.77) 0.30 (0.22-0.42)
Perimenopausal 0.80 (0.43-1.46) 1.04 (0.29-3.79)
Surgical postmenopausal 0.64 (0.27-1.54) 0.56 (0.14-2.23)
Ever use of contraceptive pill 0.02 0.30
No 0.50 (0.39-0.65) 0.36 (0.25-0.51)
Yes 0.81 (0.62-1.06) 0.25 (0.15-0.43)
Predicted 25(OH)D HR 
(95% CI), per 25 nmol/L ‡
Predicted 25(OH)D HR 
(95% CI), per 25 nmol/L ‡
Cancer mortality Circulatory disease mortality
Both sexesBoth sexes
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surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary 
calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
 
 
Figure 16. Risk (hazard ratios) of cancer mortality, by country, associated with a 25 nmol/L 
increment of predicted 25-hydroxyvitamin D level 
 
Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; 
technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-consumers; 
<5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 
16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, 
missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of contraceptive pill (yes; 
no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical 
postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary calcium 
(mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre.  
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3.5.5 Predicted 25-hydroxyvitamin D levels and smoking related and non-smoking 
related cancer mortality 
 
Smoking related cancer mortality 
Elevated predicted circulating 25(OH)D was associated with a reduced risk of smoking 
related cancer deaths (n=3,681 deaths: Q5 vs. Q1, HR 0.73, 95% CI: 0.63-0.84) in the sexes 
combined multivariable model (P-trend <0.001) (Table 37). In the continuous models, a 38% 
lower risk (95% CI: 0.51-0.77) of smoking related cancer mortality was observed, and similar 
associations were also observed when participants whose follow-up time was less than 5 
years were excluded from the analysis. A stronger inverse association was observed 
amongst women (HR per 25 nmol/L increment in predicted 25(OH)D, 0.55, 95% CI: 0.41-
0.72) than for men (HR per 25 nmol/L increment in predicted 25(OH)D, 0.73, 95% CI: 0.53-
1.00); although this difference was non-significant (P-interaction 0.21). 
 
When the association was analysed by smoking status, similar inverse associations were 
observed amongst never smokers (HR per 25 nmol/L increment in predicted 25(OH)D, 0.67, 
95% CI: 0.44-1.00); former smokers (HR per 25 nmol/L increment in predicted 25(OH)D, 
0.67, 95% CI: 0.45-0.99) and current smokers (HR per 25 nmol/L increment in predicted 
25(OH)D, 0.60, 95% CI: 0.45-0.82) (P-interaction 0.88). No heterogeneity between countries 
was found (P-heterogeneity 0.20), with risk estimates below 1 observed in all countries (HRs 
per 25 nmol/L increment in predicted 25(OH)D ranging from HR 0.23 to 0.96). 
 
Non-smoking related cancer mortality 
A 16% reduced risk (95% CI: 0.71-0.99) of non-smoking related cancer mortality (n=3,029 
deaths) was observed in the sexes combined multivariable model (P-trend 0.017) (Table 37). 
In the equivalent continuous model, a 32% lower risk (95% CI: 0.55-0.85) was observed per 
25 nmol/L increment in predicted circulating 25(OH)D. Inverse associations of similar 
magnitude were observed when participants whose follow-up times were less than 5 years 
were excluded. The inverse association was stronger for men (HR per 25 nmol/L increment 
in predicted 25(OH)D, 0.51, 95% CI: 0.32-0.82) than for women (HR per 25 nmol/L 
increment in predicted 25(OH)D, 0.74, 95% CI: 0.58-0.95), although this difference was non-
significant (P-interaction 0.15). Inverse associations of similar magnitude were observed 
across all countries (P-heterogeneity 0.36). 
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Table 37. Risk (hazard ratios) of smoking related and non-smoking related cancer mortality associated with predicted 25-hydroxyvitamin D level 
 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
Smoking related cancers were: oral cavity (C01-C06, C08); oropharynx (C09, C10, C12-C14); nasopharynx (C11); oesophagus (C15); stomach (C16); colorectal (C18-C20); liver (C22); pancreas (C25); nasal cavity and sinuses (C300, 
C31); larynx (C32); lung (C34); kidney (C64); bladder (C65, C67); and myeloid leukemia (C92). Non-smoking related cancers were all other cancers.  
1 2 3 4 5
Men <43.0 43.0-45.9 46.0-48.3 48.4-51.1 ≥51.2
Women <48.3 48.3-52.6 52.7-56.2 56.3-60.4 ≥60.5 P -trend
Smoking related cancers *
Both sexes
N deaths 919 757 687 611 707
Multivariable model - HR (95% CI) ‡ 1.00               0.91 (0.82-1.02) 0.87 (0.78-0.98) 0.80 (0.70-0.90) 0.73 (0.63-0.84) <0.001 0.62 (0.51-0.77) 0.69 (0.53-0.89)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00               0.94 (0.84-1.05) 0.92 (0.80-1.05) 0.83 (0.71-0.97) 0.76 (0.63-0.91) 0.002 0.67 (0.51-0.87) 0.78 (0.56-1.07)
Men
N deaths 541 437 401 337 271
Multivariable model - HR (95% CI) ‡ 1.00               0.96 (0.84-1.10) 0.96 (0.82-1.11) 0.88 (0.75-1.03) 0.82 (0.68-0.98) 0.02 0.73 (0.53-1.00)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00               0.98 (0.84-1.14) 0.99 (0.82-1.19) 0.90 (0.73-1.11) 0.81 (0.63-1.04) 0.10 0.76 (0.47-1.22)
Women
N deaths 378 320 286 274 436
Multivariable model - HR (95% CI) ‡ 1.00               0.83 (0.70-0.98) 0.74 (0.61-0.90) 0.66 (0.53-0.81) 0.58 (0.46-0.74) <0.001 0.55 (0.41-0.72)
1.00               0.86 (0.72-1.02) 0.79 (0.64-0.97) 0.71 (0.56-0.89) 0.64 (0.48-0.84) 0.001 0.61 (0.44-0.84)
Non-smoking related cancers *
Both sexes
N deaths 690 631 558 552 598
Multivariable model - HR (95% CI) ‡ 1.00               0.95 (0.84-1.07) 0.86 (0.75-0.98) 0.87 (0.75-1.00) 0.84 (0.71-0.99) 0.017 0.68 (0.55-0.85) 0.72 (0.54-0.97)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00               0.98 (0.86-1.11) 0.90 (0.78-1.05) 0.92 (0.78-1.09) 0.90 (0.74-1.10) 0.26 0.72 (0.55-0.93) 0.71 (0.49-1.02)
Men
N deaths 235 199 182 178 142
Multivariable model - HR (95% CI) ‡ 1.00               0.85 (0.69-1.04) 0.82 (0.66-1.02) 0.84 (0.66-1.06) 0.73 (0.57-0.95) 0.03 0.51 (0.32-0.82)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00               0.87 (0.70-1.08) 0.85 (0.65-1.12) 0.91 (0.67-1.23) 0.84 (0.59-1.20) 0.47 0.55 (0.27-1.13)
Women
N deaths 455 432 376 374 456
Multivariable model - HR (95% CI) ‡ 1.00               1.01 (0.87-1.17) 0.88 (0.75-1.05) 0.88 (0.73-1.06) 0.89 (0.72-1.11) 0.18 0.74 (0.58-0.95)
1.00               1.04 (0.89-1.22) 0.94 (0.78-1.13) 0.95 (0.77-1.17) 0.97 (0.76-1.24) 0.65 0.79 (0.59-1.06)
<5 years 
excluded
Per 25 nmol/L 
increase
Per 25 nmol/L 
increase
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Quintile of predicted 25(OH)D (nmol/L)
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3.5.6 Predicted 25-hydroxyvitamin D levels and digestive system and non-digestive 
system cancer mortality 
 
Digestive system cancer mortality 
Higher predicted circulating 25(OH)D was associated with a non-significant reduced 
digestive system cancer mortality risk in the sexes combined multivariable model (n=1,629 
deaths: Q5 vs. Q1, HR 0.81, 95% CI: 0.65-1.01), with a near significance linear trend (P-
trend 0.06) (Table 38). In the equivalent continuous model, a 25 nmol/L higher predicted 
25(OH)D level was associated with a 33% lower digestive system cancer mortality risk (95% 
CI: 0.49-0.91). When participants whose follow-up time was less than 5 years were 
excluded, similar risk estimates were yielded. This association was stronger and significant 
for women (HR per 25 nmol/L increment in predicted 25(OH)D, 0.57, 95% CI: 0.38-0.84) 
compared to men (HR per 25 nmol/L increment in predicted 25(OH)D, 0.79, 95% CI: 0.47-
1.29); although this difference was not significant (P-interaction 0.25). No heterogeneity was 
observed by country for the inverse association observed (P-heterogeneity 0.84). 
 
Non-digestive cancer mortality 
In the sexes combined multivariable model, a 24% reduced (95% CI: 0.67-0.86) non-
digestive system mortality risk (n=5,074 deaths) was observed when participants in the 
highest and lowest predicted circulating 25(OH)D quintiles were compared (Table 38). In the 
equivalent continuous models, a 36% lower risk (95% CI: 0.54-0.76) was also observed per 
25 nmol/L increment in predicted 25(OH)D. Inverse associations of similar magnitude were 
observed when participants whose follow-up time was less than 5 years were excluded. 
Similar associations were observed when men (HR per 25 nmol/L increment in predicted 
25(OH)D, 0.60, 95% CI: 0.44-0.82) and women (HR per 25 nmol/L increment in predicted 
25(OH)D, 0.67, 95% CI: 0.54-0.83) were analysed separately (P-interaction 0.57). Significant 
heterogeneity was observed in the inverse associations when analysed by country (P-
heterogeneity 0.007); although HRs below 1 per 25 nmol/L increment in predicted 25(OH)D 
were observed in all countries (ranging from HR 0.25 to 0.95). 
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Table 38. Risk (hazard ratios) of digestive and non-digestive cancer mortality associated with predicted 25-hydroxyvitamin D level 
 
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
1 2 3 4 5
Men <43.0 43.0-45.9 46.0-48.3 48.4-51.1 ≥51.2
Women <48.3 48.3-52.6 52.7-56.2 56.3-60.4 ≥60.5 P -trend
Digestive system cancers *
Both sexes
N deaths 410 354 293 284 288
Multivariable model - HR (95% CI) ‡ 1.00               0.97 (0.83-1.14) 0.88 (0.74-1.05) 0.90 (0.75-1.09) 0.81 (0.65-1.01) 0.06 0.67 (0.49-0.91) 0.68 (0.47-0.99)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00               1.02 (0.86-1.20) 0.95 (0.77-1.16) 0.97 (0.78-1.22) 0.86 (0.66-1.13) 0.32 0.70 (0.48-1.03) 0.73 (0.46-1.17)
Men
N deaths 202 198 136 135 120
Multivariable model - HR (95% CI) ‡ 1.00               1.13 (0.91-1.39) 0.85 (0.66-1.08) 0.91 (0.70-1.18) 0.92 (0.70-1.23) 0.28 0.79 (0.47-1.29)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00               1.08 (0.86-1.37) 0.79 (0.59-1.06) 0.82 (0.58-1.15) 0.78 (0.52-1.15) 0.10 0.56 (0.26-1.20)
Women
N deaths 208 156 157 149 168
Multivariable model - HR (95% CI) ‡ 1.00               0.81 (0.64-1.03) 0.89 (0.69-1.16) 0.87 (0.65-1.16) 0.68 (0.49-0.96) 0.07 0.57 (0.38-0.84)
1.00               0.89 (0.70-1.14) 1.04 (0.78-1.38) 1.06 (0.77-1.45) 0.86 (0.58-1.27) 0.65 0.70 (0.44-1.12)
Non-digestive system cancers *
Both sexes
N deaths 1199 1034 952 872 1017
Multivariable model - HR (95% CI) ‡ 1.00               0.91 (0.83-0.99) 0.86 (0.78-0.95) 0.80 (0.72-0.89) 0.76 (0.67-0.86) <0.001 0.64 (0.54-0.76) 0.70 (0.56-0.88)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00               0.93 (0.84-1.03) 0.90 (0.80-1.01) 0.84 (0.74-0.95) 0.80 (0.69-0.94) 0.003 0.68 (0.55-0.84) 0.74 (0.56-0.98)
Men
N deaths 574 438 447 380 293
Multivariable model - HR (95% CI) ‡ 1.00               0.85 (0.74-0.97) 0.93 (0.80-1.07) 0.85 (0.73-0.99) 0.74 (0.62-0.88) 0.003 0.60 (0.44-0.82)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ 1.00               0.89 (0.77-1.03) 1.01 (0.85-1.20) 0.95 (0.78-1.16) 0.85 (0.67-1.09) 0.35 0.76 (0.48-1.21)
Women
N deaths 625 596 505 499 724
Multivariable model - HR (95% CI) ‡ 1.00               0.96 (0.84-1.09) 0.80 (0.69-0.93) 0.75 (0.64-0.88) 0.76 (0.63-0.91) <0.001 0.67 (0.54-0.83)
1.00               0.97 (0.85-1.11) 0.82 (0.70-0.96) 0.78 (0.65-0.93) 0.79 (0.64-0.97) 0.01 0.70 (0.55-0.90)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Quintile of predicted 25(OH)D (nmol/L) <5 years 
excluded
Per 25 nmol/L 
increase
Per 25 nmol/L 
increase
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ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
Digestive system cancers were: oesophagus (C15); stomach (C16); colorectal (C18-C20); anus and anal canal (C21); liver and intrahepatic bile acids (C22); gallbladder (C23); other and unspecified parts of biliary tract (C24); pancreas 
(C25); and other ill-defined digestive organs (C26). Non-digestive system cancers were all other cancers.  
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3.5.7 Predicted 25-hydroxyvitamin D levels and mortality from individual cancers 
 
Colorectal cancer mortality 
By the end of the follow-up period, 491 colorectal cancer deaths had been recorded. In the 
sexes combined multivariable model, a non-significant 20% reduced colorectal cancer 
mortality risk (95% CI: 0.53-1.21) was observed amongst participants in the highest quintile 
when compared against those in the lowest quintile of predicted circulating 25(OH)D (P-
trend 0.35) (Table 39). A non-significant 24% lower risk per 25 nmol/L increment in predicted 
circulating 25(OH)D was observed in the continuous model. When analysed separately, 
similar non-significant inverse associations were observed for men (HR per 25 nmol/L 
increment in predicted 25(OH)D, 0.78, 95% CI: 0.28-2.19) and women (HR per 25 nmol/L 
increment in predicted 25(OH)D, 0.67, 95% CI: 0.34-1.30) (P-interaction 0.84). 
 
Pancreatic cancer mortality 
Higher predicted 25(OH)D levels were associated with a 35% reduced risk (95% CI: 0.44-
0.95) of pancreatic cancer mortality (n=540 deaths) (P-trend 0.036) (Table 39). Significant 
inverse associations were also observed in the continuous models; with similar associations 
observed when participants whose follow-up times were less than 5 years were excluded. 
When analysed by sex, non-significant inverse associations of similar strength were 
observed for men (n=248 deaths; HR per 25 nmol/L increment in predicted 25(OH)D, 0.66, 
95% CI: 0.27-1.61) and women (n=292 deaths; HR per 25 nmol/L increment in predicted 
25(OH)D, 0.52, 95% CI: 0.27-1.02) (P-interaction 0.72). 
 
Lung cancer mortality 
Over the follow-up period, 1,480 lung cancer deaths were recorded. In the sexes combined 
multivariable model, a 30% reduced lung cancer mortality risk (95% CI: 0.56-0.88) was 
observed when participants in the highest and lowest quintiles of predicted circulating 
25(OH)D were compared (P-trend 0.002) (Table 39). In the equivalent continuous model, a 
non-significant 24% lower risk (95% CI: 0.55-1.05) was observed per 25 nmol/L increment in 
predicted 25(OH)D levels. Similar associations were observed when participants whose 
follow-up times were less than 5 years were excluded. Stronger inverse associations were 
observed amongst women (HR per 25 nmol/L increment in predicted 25(OH)D, 0.69, 95% 
CI: 0.45-1.06) than in men (HR per 25 nmol/L increment in predicted 25(OH)D, 0.83, 95% 
CI: 0.51-1.34), although this difference was non-significant (P-interaction 0.59).  
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However, the inverse lung cancer incidence association was absent when the multivariable 
model was not adjusted for BMI (both sexes: HR per 25 nmol/L increment in predicted 
25(OH)D, 1.22, 95% CI: 0.94-1.58) (Table A2 – appendix). 
 
When the association was analysed by smoking status, non-significant inverse associations 
were observed amongst never smokers (HR per 25 nmol/L increment in predicted 25(OH)D, 
0.76, 95% CI: 0.27-2.14) and current smokers (HR per 25 nmol/L increment in predicted 
25(OH)D, 0.72, 95% CI: 0.49-1.08); whilst a non-significant positive association was 
observed amongst former smokers (HR per 25 nmol/L increment in predicted 25(OH)D, 
1.10, 95% CI: 0.57-2.11). Overall the association across strata of smoking status was non-
significant (P-interaction 0.67). 
 
Prostate cancer mortality 
A 50% reduced (95% CI: 0.30-0.85) prostate cancer mortality risk (n=228 deaths) was 
observed in the categorical multivariable model (P-trend 0.02) (Table 39). In the equivalent 
continuous model, a 68% lower risk (95% CI: 0.12-0.84) was observed per 25 nmol/L 
increment in predicted circulating 25(OH)D. A stronger inverse association was observed 
when men with follow-up time less than 5 years were excluded (HR per 25 nmol/L increment 
in predicted 25(OH)D, 0.31, 95% CI: 0.09-1.09). 
 
Breast cancer mortality 
In the multivariable model, when the highest and lowest quintiles of predicted circulating 
25(OH)D were compared, a non-significant 15% reduced risk (95% CI: 0.57-1.29) of breast 
cancer mortality (n=575 deaths) was observed (P-trend 0.44) (Table 39). In the continuous 
models, a non-significant 26% lower risk was observed per 25 nmol/L increment in predicted 
circulating 25(OH)D.  
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Table 39. Risk (hazard ratios) for mortality of specific cancer types amongst men and women by predicted 25-hydroxyvitamin D (25(OH)D) 
categories 
  
‡  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school completed; technical/professional school; secondary school; longer education including 
university; or not specified), alcohol consumption (non-consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per day; current, 16+ cigarettes per day; 
former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever 
use of contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or surgical postmenopausal), and intakes of total energy (kcal/day), red and 
processed meat (g/day), fruits and vegetables (g/day), and dietary calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre. 
¥  Multivariable model – plus adjustment for cereal fibre intake (g/day). 
¶  Multivariable model – plus adjustment for age at first pregnancy (<21; 21-<30; 30+ years old; no children; or not specified); and age at menarche (<12; 12-<15; 15+ years old; or not specified). 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
 
Both sexes
1 2 3 4 5
Men <43.0 43.0-45.9 46.0-48.3 48.4-51.1 ≥51.2
Women <48.3 48.3-52.6 52.7-56.2 56.3-60.4 ≥60.5 P -trend
Colorectal cancer (C18-C20)
N deaths 120 103 96 86 86
Multivariable model - HR (95% CI) ‡ ¥ 1.00               0.95 (0.70-1.27) 0.97 (0.70-1.34) 0.92 (0.64-1.32) 0.80 (0.53-1.21) 0.35 0.76 (0.44-1.32) 0.84 (0.44-1.59)
1.00               1.03 (0.75-1.40) 1.12 (0.78-1.61) 1.09 (0.72-1.66) 0.97 (0.59-1.58) 0.97 1.00 (0.52-1.94) 1.33 (0.63-2.83)
Pancreatic cancer (C25)
N deaths 142 112 87 103 96
Multivariable model - HR (95% CI) ‡ 1.00               0.85 (0.64-1.12) 0.68 (0.50-0.94) 0.84 (0.60-1.16) 0.65 (0.44-0.95) 0.036 0.58 (0.34-0.99) 0.50 (0.26-0.95)
1.00               0.89 (0.66-1.19) 0.73 (0.51-1.04) 0.89 (0.60-1.31) 0.68 (0.43-1.08) 0.15 0.65 (0.33-1.25) 0.53 (0.23-1.18)
Lung cancer (C34)
N deaths 335 267 295 243 340
Multivariable model - HR (95% CI) ‡ 1.00               0.85 (0.71-1.01) 0.94 (0.78-1.14) 0.75 (0.61-0.92) 0.70 (0.56-0.88) 0.002 0.76 (0.55-1.05) 0.81 (0.54-1.21)
1.00               0.87 (0.72-1.04) 0.97 (0.79-1.20) 0.78 (0.61-0.99) 0.73 (0.55-0.97) 0.03 0.91 (0.61-1.36) 1.02 (0.62-1.67)
Prostate cancer (C61)
N deaths 61 49 41 47 30
Multivariable model - HR (95% CI) ‡ 1.00               0.71 (0.47-1.07) 0.60 (0.39-0.95) 0.70 (0.45-1.10) 0.50 (0.30-0.85) 0.02 0.32 (0.12-0.84) 0.31 (0.09-1.09)
1.00               0.70 (0.45-1.10) 0.59 (0.34-1.02) 0.67 (0.36-1.24) 0.48 (0.23-1.00) 0.08 0.25 (0.05-1.18) 0.09 (0.01-0.73)
Breast cancer (C50)
N deaths 120 106 110 98 141
Multivariable model - HR (95% CI) ‡ ¶ 1.00               0.88 (0.65-1.18) 0.90 (0.65-1.25) 0.78 (0.54-1.12) 0.85 (0.57-1.29) 0.44 0.74 (0.46-1.19) 0.82 (0.37-1.79)
1.00               0.96 (0.71-1.31) 1.05 (0.74-1.50) 0.94 (0.63-1.41) 1.07 (0.67-1.70) 0.78 0.95 (0.55-1.63) 0.91 (0.36-2.27)
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Multivariable model + physical activity adj - 
HR (95% CI) ɸ
Quintile of predicted 25(OH)D (nmol/L)
Per 25 nmol/L 
increase
<5 years 
excluded
Per 25 nmol/L 
increase
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4. DISCUSSION 
 
4.1 Dietary vitamin D intake and all-cause mortality, cancer mortality 
and cause-specific mortality  
 
This analysis investigated the relationships between dietary vitamin D intake and all-cause 
mortality, cancer mortality and cause-specific mortality risk amongst participants in the EPIC 
cohort.  
 
No associations were observed for dietary vitamin D intake and all of mortality end-points 
considered. The methodological limitations of using dietary intakes as a surrogate marker of 
vitamin D status are probably the cause of these null results. Firstly, as the EPIC derived 
vitamin D predictor scores suggest, intake of vitamin D from food sources contributes little to 
serum 25(OH)D status (1% of variance in circulating 25(OH)D for men and negligible 
variance for women). Secondly, recorded dietary vitamin D intakes within EPIC are low. For 
instance, men and women in the highest intake quintile had vitamin D intakes over 6.5 
µg/day and 5.1 µg/day respectively. Such daily intakes would have little impact on 
endogenous vitamin D levels, with 1 µg of vitamin D intake being shown to increase 
circulating 25(OH)D by just 0.70 nmol/L (from a mean 25(OH)D baseline of 70.3 nmol/L) 
(29). Finally, using dietary intake of vitamin D to assess status also fails to take into account 
endogenous production, so exposures are misclassified and probably underestimated.   
 
An EPIC specific limitation of using dietary intakes as a surrogate indicator of vitamin D 
status is that detailed dietary supplement intake information from the complete cohort is 
unavailable. More comprehensive data are available from a subset of the cohort (n=36,034) 
who had additional intake measurements collected via 24-hour recalls. This information 
highlighted the importance of dietary supplements, particularly in northern European 
participants (177). For instance, the highest intakes were found amongst participants from 
Denmark where 51.8% of men and 65.8% of women reported consuming dietary 
supplements the previous day. Similar high levels were reported amongst participants from 
Sweden, UK, and Norway. Vitamin D was a frequently used ingredient within supplements 
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consumed in these countries, partly because cod liver oil intake is often recommended to 
prevent vitamin D deficiency, as endogenous production is relatively low (177). This higher 
recorded consumption of dietary supplements for northern European countries is also 
probably a contributory factor to latitude being such a poor indicator of vitamin D status as 
was revealed during the derivation of the predictor 25(OH)D scores. For instance, women 
from Denmark had the highest mean circulating 25(OH)D across all countries. 
 
A more general limitation of all epidemiological dietary analyses, which may have also 
contributed to the null results observed, is dietary assessment measurement error (random 
and systematic). This may have caused the dietary intake information collected from 
participants at baseline to be under- or over-reported leading to imprecise risk estimates and 
ultimately regression attenuation (178).  
 
In summary, null associations were observed for dietary vitamin D intake and all-cause 
mortality, cancer mortality and cause-specific mortality. Within EPIC, recorded dietary 
vitamin D intakes were low, dietary supplement intakes were not recorded, and 
endogenously produced vitamin D was not considered. Taken together, this suggests that 
within EPIC, the use of dietary intake as a surrogate measure of vitamin D status is 
inadequate. 
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4.2 Derivation and validation of predictor 25-hydroxyvitamin D scores 
 
In this analysis, a sample of participants with serum measurements available from the EPIC 
study were used to derive and validate circulating 25(OH)D predictor scores. Previously, 
predictor scores have been successfully derived and applied to assess cancer risk and type 
2 diabetes risk in the HPFS (52) and Framingham Offspring (165) cohorts respectively. The 
EPIC derived models were created by secondary analysing data from previous nested case-
control studies (colorectal cancer, prostate cancer, lymphoma and breast cancer). The final 
predictor scores provided poor estimates of absolute 25(OH)D values, but were reasonably 
successful at ranking participants into high and low predicted 25(OH)D categories. 
Consistent results were also yielded when actual and predicted circulating 25(OH)D 
measurements were used for analyses of colorectal cancer incidence and prostate cancer 
incidence. Taken together, this suggests that the derivation of predicted 25(OH)D scores 
may be a practical cost effective approach to be used in chronic disease epidemiological 
research, especially as the cost of measuring actual circulating 25(OH)D levels may be 
prohibitively expensive. 
 
4.2.1 Predictor circulating 25-hydroxyvitamin D score derivation 
 
The first stage in creating the EPIC based models was to assess which available variables 
correlated with circulating 25(OH)D as these would form the basis of the predictor scores. 
The correlates/determinants included within the predictor scores were: age at blood 
collection, dietary vitamin D intake, waist circumference, physical activity index, month of 
blood collection, country of residence, smoking status and intensity, ever use of menopausal 
hormone therapy, and source study and batch of serum samples. Overall the predictor 
scores explained 34% and 28% of the variance (R2) in circulating 25(OH)D amongst men 
and women respectively, therefore limiting their ability to classify participants’ absolute 
vitamin D status. However, these R2 values are consistent with previous studies which have 
investigated correlates of circulating 25(OH)D levels (ranging from 0.21 – 0.42) 
(50;164;165;179;180). 
 
Generally, the correlates/determinants included in the EPIC derived scores were similarly 
related to circulating 25(OH)D as per previous studies. Waist circumference (the marker of 
adiposity used) was inversely correlated with circulating 25(OH)D in both men and women 
(50). Dietary vitamin D intake was positively correlated with circulating 25(OH)D in both men 
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and women (49;52;165). The monthly variation in circulating 25(OH)D levels was consistent 
with previous analyses, with the highest levels found in the late summer/early autumn 
months and the lowest levels in late winter/early spring months (164;165).  
 
The relationships between mean circulating 25(OH)D and country indicated that latitude is a 
poor predictor of vitamin D status when making inter-country comparisons across Europe. 
For women, higher mean serum 25(OH)D levels were found amongst participants from 
Denmark (latitude ~56°N), with women from Greece (37°N, Athens) and Italy (36°N - 45°N) 
having among the lowest levels. Men from Italy were found to have the highest mean levels 
of circulating 25(OH)D, but individuals from the UK (51°N - 52°N) and the Netherlands 
(52°N) had higher mean 25(OH)D concentrations than participants from Spain (37°N - 
43°N). This positive association between latitude and 25(OH)D levels across European 
countries has been observed in previous analyses. One study of European populations 
reported that people from Scandinavian countries had the highest mean levels of serum 
25(OH)D (181). Similarly, a recent systematic review of elderly participants across Europe 
calculated a mean increase in serum 25(OH)D of 11.8 nmol/L was associated with a 10 
degree increase in latitude of country of residence (47). Potential explanations for this 
seemingly counter-intuitive relationship between vitamin D status and latitude are that 
dietary supplement intakes are higher amongst northern European populations (177). 
Another potential reason may be that northern European populations with lighter skin colour 
are more inclined to sun expose than southern European populations who have darker skin 
and less desire to be in the sun for long time periods (47).  
 
Physical activity index, included in the predictor models as a proxy measurement of sun 
exposure, was positively correlated with circulating 25(OH)D levels, and this was in line with 
previous research (50;52;164). Age at blood collection was inversely associated with 
circulating 25(OH)D for women, which is consistent with previous research (3;53;165); but 
unexpectedly, age was positively correlated with 25(OH)D for men. Current smokers had 
lower mean circulating 25(OH)D levels than never smokers (49;165). Both age at blood 
collection and smoking status and intensity were important correlates/determinants of 
circulating 25(OH)D levels, and as a consequence were included in the predictor scores as 
covariates; however, both are also prominent risk factors/confounders for chronic disease, 
so as a consequence, these variables were excluded from the predictor scores when applied 
to the validation datasets to minimise the risk of statistical over-adjustment. 
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4.2.2 Predictor circulating 25-hydroxyvitamin D score validations 
 
Correlations between predicted 25-hydroxyvitamin D and actual circulating 25-
hydroxyvitamin D 
For the EPIC derived predictor scores, relatively low Spearman and Pearson correlation 
coefficients (ranging from 0.19-0.21) were observed when levels of predicted and actual 
circulating 25(OH)D were compared in the independent validation datasets. The correlation 
coefficients from previous predictor scores, when predicted and actual serum levels of 
25(OH)D were compared in independent datasets, have ranged from 0.23 – 0.40 in the NHS 
and HPFS studies, to 0.45 in the WHI, and 0.51 in the Framingham Offspring cohort 
(50;164;165). 
 
Assessing the validity of predictor scores by calculating the correlation with single 
measurements of actual circulating 25(OH)D may not be appropriate. Single 25(OH)D 
measures are influenced by recent sun exposures and behaviours (e.g. beach holiday and 
sunbathing habits), and are therefore a better indicator of short-term exposures. Intra-class 
correlation coefficients between circulating 25(OH)D taken 2-3 years apart are around ~0.70 
(52;162); however, over longer time periods (5 years plus) the correlations have been shown 
to decrease ~0.50 (163;164). In chronic disease epidemiology, estimates of long term 
average exposures - rather than short-term - are required to assess associations. Due to the 
within-person variation in actual circulating 25(OH)D levels, the use of a single measure as 
the “gold standard” or “truth” to assess the validity of the predictor scores may not be 
optimal. The use of such an “alloyed” or imperfect “gold standard” may have meant that the 
correlation coefficients between predicted and actual circulating 25(OH)D levels in the 
validation datasets were underestimated by the random within-person error intrinsic to both 
of these measures (164;182;183). 
 
Actual 25-hydroxyvitaminD measurements by decile of predicted 25-hydroxyvitamin D 
An alternative approach to assess the performance of predictor scores is to compare the 
actual mean circulating 25(OH)D levels by decile of predicted 25(OH)D. While single 
measures of circulating 25(OH)D are subject to random within-person error, the average of 
these measurements in each decile should be unbiased and provide population level means 
(164;178). Within the EPIC validation datasets, mean circulating 25(OH)D levels generally 
grew with increasing decile of predicted 25(OH)D scores (P-trends <0.0001). In men and 
women, the differences in actual 25(OH)D levels between the extreme deciles were 23.3 
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nmol/L and 15.2 nmol/L respectively. Within the NHS and HPFS cohorts similar differences 
(ranging from 21.7-30.7 nmol/L) were reported (52;164). 
 
Cross-classifications of participants by predicted and actual circulating 25-
hydroxyvitamin D categories 
For both sexes, the ability of the models to classify men and women in the validation 
datasets into equivalent clinically defined actual and predicted 25(OH)D categories was 
poor. When three categories of 25(OH)D were used (<50 nmol/L deficient, 50-<75 nmol/L 
insufficient, and 75+ nmol/L sufficient), the predictor scores cross-classified the vast majority 
of men in the actual ‘deficient’ category into the equivalent predictor score derived group 
(85.4%). However, the predictor score was far less successful at classifying men with higher 
levels of actual circulating 25(OH)D into corresponding categories, and did not classify any 
individuals with actual 25(OH)D levels over 75 nmol/L (the optimal level for bone health) into 
the equivalent predicted category. For women, the predictor score was also poor at cross-
classifying into equivalent actual and predicted clinically defined categories. Once more, at 
actual levels over 75 nmol/L, just 2.4% of women were classified into the corresponding 
predicted 25(OH)D category. That the predictor scores performed so poorly when estimating 
absolute vitamin D levels and classifying participants into clinically relevant categories is 
unsurprising as 66% and 72% of variance in circulating 25(OH)D levels were unexplained for 
men and women respectively. The WHI derived predictor score also performed poorly when 
classifying women into clinically defined 25(OH)D categories (50).This indicates that 
25(OH)D predictor scores would not have utility in a clinical setting as absolute levels cannot 
be estimated. Similarly, the predicted scores could not be used in epidemiological studies 
when clinically defined exposure categories are used. Thus, they are not useful when 
investigating the elevated risks of all-cause mortality (and other cancer incidence end-points) 
previously observed at circulating 25(OH)D levels ranging from >93-140 nmol/L when 
compared against the mid-range reference categories (33-35).  
 
However, within epidemiological studies, rather than absolute values, ranking participants 
into high and low exposure categories is usually of interest (178). For quintiles, the predictor 
scores performed better at classifying individuals into equivalent predicted and actual 
circulating 25(OH)D categories. Across all quintiles, 27% of men and 24% of women were 
classified into identical predicted and actual 25(OH)D categories. Just under half of men 
(46.3%) and women (45.8%) were classified into equivalent or parallel quintiles of actual and 
predicted 25(OH)D. Within the NHS and HPFS derived predictor scores similar proportions 
of participants were classified into corresponding actual and predicted 25(OH)D quintiles 
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(164). Also, similarly to these cohorts, the EPIC derived scores classified just 5% of all 
participants into the extreme opposite quintiles according to actual and predicted 25(OH)D 
levels (164). 
 
Assessment of colorectal cancer and prostate cancer risk using the predictor 
circulating 25-hydroxyvitamin D scores 
The final validation stage for the EPIC derived predictor scores was to use them to assess 
risks of colorectal cancer incidence (in the nested case-control and full EPIC datasets) and 
prostate cancer incidence (in the full EPIC dataset). For both cancers nested case-control 
studies have been published which measured actual circulating 25(OH)D levels (67;97).  
 
Firstly, the predictor scores were applied to the colorectal cancer nested case-control 
dataset. Importantly, to ensure independence, the predictor scores for this particular 
validation stage were derived excluding the actual 25(OH)D samples sourced from the 
published colorectal cancer analysis (67). In the multivariable model of the earlier published 
EPIC analysis which measured actual 25(OH)D measurements, a 38% reduced colorectal 
cancer incidence risk (OR 0.62, 95% CI: 0.47-0.81) was observed when the highest and 
lowest quintiles were compared (67). When quintiles of predicted 25(OH)D were inputted 
into the multivariable model, a similar, albeit slightly stronger inverse association was 
observed (Q5 vs. Q1, OR 0.50, 95% CI: 0.26-0.97; P-trend 0.03). This inverse association 
ceased to be significant when the multivariable model was additionally adjusted for physical 
activity index, although a significant inverse association remained in the continuous model. 
Physical activity index was an important correlate/determinant of circulating 25(OH)D 
included in the predictor scores. Therefore predicted 25(OH)D levels would already have 
taken into account participant physical activity levels, and including again in the multivariable 
models when assessing disease risk relationships may be statistical over-adjustment. 
However, for information purposes, risk estimates for the multivariable models plus physical 
activity adjustment are presented. Similarly, the multivariable model is also presented minus 
BMI adjustment. Waist circumference was included as the marker of adiposity in the 
predictor scores, but due to its close correlation with BMI (r =0.78), additionally adjusting for 
BMI within the multivariable models when assessing disease risk may also be deemed as 
statistical over-adjustment. However, it is arguable that biologically these measures are 
different indicators of adiposity: with waist circumference a better measurement of central 
obesity which impacts most upon metabolic disorders; while BMI is a more suitable 
measurement of whole body adiposity. For colorectal cancer incidence, when the 
multivariable model was not adjusted for BMI, a slightly stronger inverse association was 
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observed. Colorectal cancer is a suitable end-point to test the sensitivities of these potential 
over-adjustments as physical activity index and BMI are accepted risk factors for the disease 
(184-187).  
 
Next, the predictor scores were applied to assess colorectal cancer incidence and prostate 
cancer incidence in the full EPIC cohort. For colorectal cancer incidence, in the sexes 
combined multivariable model, once more a significant inverse association was observed 
(Q5 vs. Q1, HR 0.75, 95% CI: 0.62-0.91; P-trend 0.009). For prostate cancer incidence, a 
previous EPIC nested case-control study reported a non-significant positive association in 
the multivariable model (Q5 vs. Q1, OR 1.28, 95% CI: 0.88-1.88; P-trend 0.19) (97). When 
the men’s predictor 25(OH)D score was applied to the full EPIC cohort, a non-significant 
positive association was also observed (Q5 vs. Q1, HR 1.08, 95% CI: 0.90-1.39; P-trend 
0.70). 
 
Overall, encouragingly consistent colorectal cancer and prostate cancer associations were 
observed between models which used actual and predicted 25(OH)D measurements. 
Likewise in the NHS and HPFS cohorts, similar results were yielded between analyses using 
predicted and actual circulating 25(OH)D measurements for endpoints, including colorectal 
cancer incidence and mortality, pancreatic cancer incidence, prostate cancer incidence, and 
hypertension (164). For instance, in a joint NHS and HPFS nested case-control analysis for 
colorectal cancer incidence, risk estimates of 0.82 and 0.78 were yielded per increment of 25 
nmol/L for models using actual and predicted 25(OH)D respectively (52;130;164). This 
evidence from EPIC and the U.S. cohorts suggests that predicted 25(OH)D may be an 
acceptable surrogate indicator of actual 25(OH)D levels for epidemiological studies. 
 
Validation of the Health Professionals Follow-Up Study predicted 25-hydroxyvitamin D 
score 
The adaptation and application of the HPFS derived 25(OH)D predictor score (52) within 
men in EPIC was unsuccessful. In the validation dataset, the correlation coefficients 
between actual and HPFS predicted 25(OH)D score was just 0.05. Importantly, where the 
EPIC derived scores performed well (actual mean per decile of predicted 25(OH)D and the 
duplication of the previous inverse colorectal cancer incidence association), the HPFS 
predictor scores performed poorly. For instance, when the adapted HPFS score was applied 
to the men’s EPIC dataset, a non-significant positive association was observed when the 
highest and lowest quintiles of predicted 25(OH)D were compared (HR 1.23, 95% CI: 0.76-
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1.99). Bertrand et al., (164) had proposed that 25(OH)D prediction scores may be used 
across different cohorts as long as participants within each population were relatively 
homogenous for characteristics, demographics and residential latitude locations. HPFS 
participants were not located at latitudes above 47°N which meant that EPIC participants in 
northern France, Germany, the Netherlands, UK, and Denmark had to be excluded when the 
predictor score was adapted. Men within the HPFS are, due to all working within the same 
sector, probably similarly educated and from the same or similar social class. In contrast, the 
EPIC cohort is heterogeneous with regards to occupations and social class (as assessed by 
the proxy measurement of highest educational level attained). Finally, inter-cohort 
differences in exposure measurement instruments, and the associated systematic and 
random measurement error, may have also contributed to the failed adaption of the HPFS 
predictor score within EPIC. However, although the adaptation and application of the HPFS 
derived 25(OH)D score within EPIC was unsuccessful in this instance, predictor scores may 
be transferable where inter-cohort differences are minimal. 
 
 
4.2.3 Strengths and limitations of using predictor circulating 25-hydroxyvitamin D 
scores  
 
Strengths of using predictor circulating 25-hydroxyvitamin D scores 
 
Practical and cost effective analytical approach 
Within epidemiological studies, 25(OH)D prediction scores are a practical and cost effective 
alternative to investigate vitamin D-chronic disease associations. Actual 25(OH)D 
measurements are required from a sample of a cohort and then, providing the information on 
correlates/determinants is available, can be used to derive predictor scores. While using 
actual circulating 25(OH)D measurements to assess disease risk is viewed as the “gold 
standard” approach, the high laboratory costs often mean that this is prohibitively expensive. 
Instead the larger cohort studies have generally used the nested case-control study design 
to investigate vitamin D-chronic diseases associations. Although costs are minimised by 
analyses including a subset of cohort participants, the nested case-control datasets created 
are specific for a disease or disease subtype; as the control participants, usually selected 
using incidence density sampling, are uniquely matched to cases by follow-up time, time of 
year of blood collection, age, and other criteria. This means that the relationships between 
vitamin D and other disease end-points cannot be carried out without creating a new 
disease-specific nested case-control dataset. The advantage of using predicted 25(OH)D 
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scores is that the disease risk analyses can include all cohort participants (minus those who 
were used in the derivation of the predictor score) and multiple end-points can be studied. A 
further advantage is that the scores can be re-derived to provide updated predicted 25(OH)D 
estimates as additional exposure information is collected participants during the follow-up 
period.  
 
 
Limitations of using predictor circulating 25-hydroxyvitamin D scores 
 
Large amount of variability in circulating 25-hydroxyvitamin D unexplained 
For both men and women’s 25(OH)D predictor scores 66% and 72% of variability in 
circulating 25(OH)D was unexplained respectively. This was probably due to measurement 
error in the correlates/determinants of 25(OH)D included in the predictor scores, plus known 
determinants of vitamin D status - which were unmeasured within EPIC – excluded from the 
predictor scores. For instance, vitamin D supplement intakes were unknown, and the 
European inter-country positive association between latitude and vitamin D status suggests 
that this is an important correlate/determinant of 25(OH)D levels. Additionally, information on 
race/ethnicity of EPIC participants, an important determinant of vitamin D status (9), has not 
been collected. Although the assumption is that the vast majority of participants are 
Caucasian, accurately capturing this information may have explained more variance in the 
predictor model. The inclusion of genetic information within the predictor scores may also 
have explained more variance as results from twin studies are suggestive of a significant 
hereditable component in circulating 25(OH)D levels (188). In particular, certain SNPs 
related to vitamin D binding protein (VDP) gene, such as rs4588 and rs7041 have been 
consistently associated with circulating 25(OH)D levels (180;189).  
 
Within the predictor scores, physical activity index was used as a proxy measurement for 
actual UV exposure. The physical activity index variable measured walking, cycling, 
gardening, sports, DIY, stair climbing, and occupational activity. Many of these activities may 
be performed indoors, so physical activity in the EPIC models is probably an inadequate 
proxy variable of sun related behaviour. Also, the amount of vitamin D endogenously 
produced while outside is dependent on many factors, including time spent outside, clothing 
worn, sunscreen use, and time of day and season of exposure. All of this important 
information has not been captured within the physical activity index variable and 
consequently the predictor models.  
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Different laboratories and 25-hydroxyvitamin D assays used 
The actual circulating 25(OH)D samples used to derive and validate the predictor scores 
were sourced from four different nested case-control studies (colorectal cancer, prostate 
cancer, lymphoma, or breast cancer). This meant that 25(OH)D levels were assessed at 
different times and in four different laboratories. Furthermore, across the four studies, two 
different assays were used. This may have introduced extraneous inter-study laboratory and 
batch variation into the circulating 25(OH)D measurements. In an attempt to partially adjust 
for this methodological limitation, a variable for which study and batch the circulating 
25(OH)D data were sourced from was additionally included in the predictor scores. Inclusion 
of this source study-batch variable explained 7% of the circulating 25(OH)D variance in men 
and women. Lips et al., (181) recommend that the optimal method of control would be to 
cross-calibrate samples by analysing a selection of the same serum data at different 
laboratories. This was not possible in this EPIC study as the serum samples had been 
measured prior to this current analysis. 
 
Confounding and over-adjustment by the correlates/determinants of 25-hydroxyvitamin D 
An objection raised to the use of vitamin D predictor scores is that of confounding and/or 
statistical over-adjustment, as some of the correlates/determinants of 25(OH)D are also 
important chronic disease risk factors (e.g. age, smoking status, waist circumference and 
physical activity) (50;164). This limitation is also applicable to actual circulating 25(OH)D 
measurements which intrinsically incorporate these factors. For instance, within EPIC, higher 
levels of actual circulating 25(OH)D were correlated with being physically ‘active’, not 
smoking and being slimmer. An advantage of predictor 25(OH)D scores is that sensitivity 
analyses can be performed to assess the influence of possible statistical over-adjustment. 
During the current study’s validation stage sensitivity analyses, no evidence of statistical 
over-adjustment was revealed; although this does not mean that this bias can be entirely 
discounted. For prudence, to evaluate the impact of possible statistical over-adjustment, 
multivariable risk estimates minus BMI adjustment, and with additional adjustment for 
physical activity index are presented. 
 
Lack of generalizability to other populations 
As the analysis of the HPFS predictor score within EPIC demonstrated, 25(OH)D predictor 
scores created within a particular population may only be valid for use within the same 
population. However, this lack of external generalizability should not affect the internal 
validity of the predictors score creation, validations and application to assess disease risk. 
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Small amount of circulating 25-hydroxyvitamin D samples available for predictor score 
development and validation 
EPIC is a large and heterogeneous cohort including 521,448 participants from 23 centres in 
10 European countries. This current study used serum samples from just 6,118 participants 
(1.2%) to derive and validate the 25(OH)D predictor scores. Additional 25(OH)D samples 
may better capture the heterogeneity of EPIC participants and ultimately improve the 
performance of the predictor scores. As additional samples do become available from future 
nested case-control analyses, the predictor scores could be re-derived and validated once 
more. 
 
 
4.2.4 Conclusion 
 
For the first time in a European population predicted circulating 25(OH)D scores were 
derived and validated. Consistent with previous studies in the U.S. the predictor scores 
provided a poor indication of absolute vitamin D status and would therefore not be useful in a 
clinical setting or when clinically relevant categories are used in observational research. 
However, for epidemiological research, where ranking of participants is often sufficient, the 
predictor scores may have utility. Encouragingly, the predictor scores were able to replicate 
results from previous colorectal cancer incidence and prostate cancer incidence nested 
case-control studies which used actual circulating 25(OH)D measurements. This suggests 
that predicted 25(OH)D scores may be a practical cost-effective alternative to measuring 
actual vitamin D levels. However, when using predictor scores, sensitivity analyses should 
always be undertaken to ensure that bias is not introduced due to confounding and statistical 
over-adjustment by the correlates/determinants of 25(OH)D also being confounders in the 
disease risk analyses. 
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4.3 Predicted 25-hydroxyvitamin D levels and cancer incidence and 
mortality, all-cause mortality and cause-specific mortality 
 
In this prospective analysis within the EPIC cohort, the validated predicted 25(OH)D scores 
were applied to assess the relationships with cancer incidence and mortality, circulatory 
disease mortality, respiratory disease mortality, digestive disease mortality, and all-cause 
mortality. This was the first time that predictor 25(OH)D scores have been used in European 
populations to assess disease incidence and mortality risks. As was revealed during the 
predictor scores validation stage, an inverse association was observed for colorectal cancer 
incidence, a result consistent with the majority of previous studies. Additionally, inverse 
predicted 25(OH)D score associations were observed for: overall cancer incidence and 
mortality; lung cancer incidence and mortality; kidney cancer incidence; stomach and 
oesophageal cancer incidence; pancreatic cancer incidence and mortality; thyroid cancer 
incidence; prostate cancer mortality; all-cause mortality; circulatory disease mortality; 
respiratory disease mortality; and digestive disease mortality. Many of these end-points have 
not previously been associated with vitamin D. The observed results were generally 
consistent across strata of other chronic disease risk factors and stable when cases/deaths 
recorded within the first 5 years of follow-up were excluded. However, due to the 
methodological limitations of 25(OH)D predictor scores, and observational epidemiology in 
general, it is important to acknowledge that alternative explanations may explain some or all 
of these observed relationships. 
 
4.3.1 Cancer incidence and mortality 
 
Overall cancer  
To date, only a handful of prospective studies have investigated the vitamin D-cancer 
incidence relationship. The inverse relationship observed in this current EPIC analysis is 
consistent with a HPFS analysis which also used predicted 25(OH)D levels (52). Of the 
studies which measured actual circulating 25(OH)D levels, a recent German cohort analysis 
observed a reduced cancer incidence risk amongst men in the highest exposure group of 
actual circulating 25(OH)D when compared with the lowest group; although no association 
was observed for women (57). Similarly, a small Swedish cohort also observed increased 
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cancer incidence risk at lower levels; however, this analysis also revealed an elevated risk 
amongst individuals with actual 25(OH)D levels >98 nmol/L when compared against the mid-
range reference category (vs. 46-93 nmol/L, RR 1.68, 95% CI: 1.06-2.65) (35). Due to the 
predictor scores estimating absolute 25(OH)D levels so poorly (i.e. being unable to 
adequately classify individuals with actual circulating 25(OH)D levels >75 nmol/L into the 
equivalent predicted 25(OH)D category), an investigation of the elevated cancer incidence 
risk observed amongst individuals with higher 25(OH)D levels was not possible.  
 
When the predicted 25(OH)D levels-overall cancer incidence association was analysed by 
strata of lifestyle, demographic, anthropometric, and dietary variables, non-significant 
interactions were observed for all of the various factors considered. However, no association 
was observed amongst never smokers, which suggests that residual confounding may have 
influenced the vitamin D-overall cancer incidence relationship. To further investigate this 
possible bias, cancer incidence and mortality cases were split into smoking and non-
smoking related cancer cases. For smoking related cancer incidence, a stronger inverse 
association was observed than for overall cancer incidence (a 35% lower risk per 25 nmol/L 
increment in predicted 25(OH)D vs. 13% lower risk for overall cancer incidence). Importantly, 
significant inverse associations for smoking related cancer incidence were observed across 
all strata of smoking status, including for never smokers. Despite this, residual confounding 
by smoking habits cannot be ruled out as an explanation for the inverse cancer incidence 
and mortality associations observed as tobacco consumption is a major cause of cancer. 
 
For cancer mortality, a stronger inverse relationship was observed than for overall cancer 
incidence (35% lower risk per 25 nmol/L increment in predicted 25(OH)D vs. 13% lower 
risk). In the HPFS study, Giovannucci et al., (52) reported similar cancer incidence and 
mortality associations to those observed within EPIC. However, mixed results have been 
reported in the previous studies which measured actual circulating 25(OH)D levels to assess 
cancer mortality risk. Three previous studies have reported elevated risks in the highest 
exposure group when compared against the mid-range or lowest group (35;36;54). 
Freedman et al., (36) in an NHANES III analysis reported an increased cancer mortality risk 
(1.9-fold) amongst men with actual 25(OH)D levels >100 nmol/L when compared against the 
<37.5 nmol/L exposure group. While, the aforementioned Swedish cohort, observed a 2.5-
fold increased cancer mortality risk (similarly to what they observed for cancer incidence) 
amongst the >93 nmol/L actual 25(OH)D group compared to the mid-range group (<39 
nmol/L) (35). From the remainder of previous studies, some reported inverse associations 
(59-61), but most reported non-significant relationships (62-65;156). Overall, whether vitamin 
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D has a beneficial biological role for overall cancer incidence and mortality remains unclear. 
Heterogeneous results have been observed, with unexpected positive associations observed 
amongst individuals with actual circulating 25(OH)D levels >93/100 nmol/L. The lack of 
consistency between individual studies of overall cancer incidence and mortality may be a 
consequence of the considerable aetiological heterogeneity of individual cancers (and 
indeed within subtypes of the same cancers). 
 
Giovannucci et al., (52), based upon ecological data, hypothesised that any biological role 
for vitamin D on cancer would be stronger for tumours sited in digestive tract. Results from 
the HPFS study were supportive of this with a 48% and 55% lower digestive tract cancer 
incidence and mortality association observed respectively per 25 nmol/L increment of 
predicted 25(OH)D level (52). Similarly to this result, within EPIC, stronger associations were 
observed for digestive system cancer incidence than for non-digestive system cancer 
incidence, although significant risk estimates were observed for the latter. The 
characteristics of digestive system cancers that may make them more responsive to the 
biological effects of vitamin D are currently unknown. 
 
Colorectal cancer 
As was revealed during the predictor score validation stage, an inverse association was 
observed for colorectal cancer incidence. This result is consistent with the vast majority of 
prospective research (67;70;71;77). Of all the cancers, only for colorectal cancer does an 
anti-carcinogenic role for vitamin D seem persuasive. However, as these results are all 
observational, intervention studies are required to determine if this relationship is causal. 
Previous research investigating the relationships between circulating 25(OH)D and 
colorectal cancer mortality have only occasionally been conducted. In two of these studies 
(one from EPIC), which included individuals with colorectal cancer only, higher pre-diagnosis 
levels of actual circulating 25(OH)D were associated with lower risks of colorectal cancer 
deaths (83;85). Within this current EPIC analysis, which included all participants (rather than 
solely individuals with colorectal cancer), an inverse relationship was observed, although this 
was non-significant. Whether actual or predicted pre-diagnosis estimates of circulating 
25(OH)D are the optimal measure for assessing mortality is uncertain. This is because 
behaviours may change after a cancer diagnosis, and such modifications would impact upon 
the correlates/determinants of vitamin D and ultimately predicted/actual 25(OH)D levels. 
Within EPIC, post-diagnosis lifestyle, anthropometric and dietary information has not been 
collected from participants. If in the future this information becomes available, the predictor 
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scores could be re-derived to estimate post-diagnosis 25(OH)D levels and use this to re-
assess mortality risks. 
 
Lung cancer 
The inverse association observed for lung cancer incidence was stronger and only 
significant among women. Previous prospective analyses of actual or predicted 25(OH)D 
have reported non-significant associations (52;126;127). The observed inverse association 
should, however, be interpreted with caution due to the sensitivity of adjusting for BMI in the 
multivariable models. When BMI was removed from the model, the previously inverse 
association became null (HR per 25 nmol/L increment in predicted 25(OH)D, 1.01, 95% CI: 
0.81-1.26). For predicted 25(OH)D levels and lung cancer mortality, a significant inverse 
association was observed in the sexes combined categorical model. A previous NHANES III 
analysis observed no association for actual 25(OH)D and lung cancer mortality (128). 
Similarly, to the lung cancer incidence results, this inverse association with lung cancer 
mortality was no longer present when the multivariable model was not adjusted for BMI. 
Overall, more large studies investigating the vitamin D-lung cancer relationship are 
warranted. In particular, studies which are suitably powered to investigate the association by 
smoking status are required.  
 
Kidney cancer 
This was the largest prospective study to date (in terms of cases) to investigate the vitamin 
D-kidney cancer incidence relationship. The significant inverse association observed was 
contrary to the null results observed in the VDPP nested case-control analysis which 
measured actual circulating 25(OH)D levels (129). However, the result was consistent with a 
recent HPFS/NHS analysis, in which a 25 nmol/L increment in predicted 25(OH)D was 
associated with a 44% lower kidney cancer risk (versus a 53% lower risk within EPIC) (130). 
In the HPFS/NHS analysis similar strength inverse associations were observed amongst 
men and women. Within EPIC, the inverse association was stronger for men; however, 
although non-significant, an inverse association was also observed for women. The 
inconsistent results between the VDPP analysis which measured actual levels of 25(OH)D, 
and the NHS/HPFS and EPIC analyses which used predicted 25(OH)D levels, could be 
because single actual 25(OH)D measurements may not reflect long-term exposure due to 
the within-person variation in vitamin D levels. However, whether predicted 25(OH)D 
estimates provide a more stable long-term indicator of vitamin D status than actual 
measurements in EPIC is unknown. 
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Stomach and oesophageal cancers 
The 40% lower risk observed per 25 nmol/L increment in predicted 25(OH)D should be 
interpreted cautiously as this association weakened and became non-significant when the 
multivariable model was not adjusted for BMI. This suggests that the association may be an 
artefact of confounding and/or statistical over-adjustment. Prospective studies investigating 
the vitamin D-stomach and oesophageal cancer relationship are rare. In the HPFS study, a 
significant inverse associations was observed for predicted 25(OH)D with oesophageal 
cancer, with a non-significant relationship observed for stomach cancer (52). In a VDPP 
nested case-control study, null results were reported for oesophageal and gastric cancer 
when analysed together (131).  
 
Bladder cancer 
The null result observed for bladder cancer incidence is consistent with all but one previous 
prospective study (52;134). Only in the ATBC study was an inverse association observed 
(133); that participants within this analysis were all men who smoked could have been a 
factor influencing this result. However as only four prospective studies have been carried out 
to date, more data for the vitamin D-bladder cancer relationship are required. 
 
Pancreatic cancer 
The inverse association observed for predicted 25(OH)D levels with pancreatic cancer 
incidence is similar to a recent joint HPFS, NHS, PHS, WHI, and WHS nested case-control 
analysis which measured actual circulating 25(OH)D levels (125). However, this is contrary 
to the VDPP nested case-control analysis which included data from eight prospective 
cohorts and reported a twofold elevated pancreatic cancer risk at actual 25(OH)D levels over 
≥100 nmol/L when compared against the mid-range category (50-<75 nmol/L) (40). 
Unfortunately, investigating whether individuals with 25(OH)D levels ≥100 nmol/L was not 
possible in this current EPIC analysis as the predicted scores were unable to provide 
adequate estimates of absolute vitamin D levels. For pancreatic cancer mortality, 
unsurprisingly due to the poor prognosis of patients with the disease, an inverse predicted 
25(OH)D association of similar strength was also observed. In general, more research is 
required to understand role of vitamin D on pancreatic carcinogenesis. In particular, other 
prospective studies which measure actual 25(OH)D levels are required to further investigate 
the possible elevated risk at high concentrations. 
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Liver cancer 
To date, no previous prospective studies investigating the vitamin D-liver cancer incidence 
relationship have been carried out. Within this current analysis, a non-significant inverse 
association was observed in the multivariable model. However, when the multivariable 
model was not adjusted for BMI, the inverse association strengthened and became 
significant. This result is indicative of a possible beneficial role for vitamin D on liver cancer 
incidence, even though the strength, and whether this relationship was significant, was 
sensitive to BMI adjustment. Either way, the result highlights a possible novel vitamin D-
cancer relationship which warrants further investigation; specifically, with prospective studies 
which measure actual circulating 25(OH)D levels. 
 
Non-Hodgkin’s lymphoma 
No association was observed for predicted 25(OH)D and overall NHL incidence. This null 
result for overall NHL risk is consistent with all previous published analyses, including an 
EPIC nested case-control study (52;135;136). However, NHL is a heterogeneous disease 
with multiple subtypes which may have varying aetiologies (190). Within the aforementioned 
EPIC analysis, a positive B-NHL association was observed amongst those individuals with 
actual 25(OH)D levels over ≥75 nmol (vs. 50-<75 nmol/L, OR 1.36, 95% CI: 1.00-1.83; P-
trend 0.007) (136). As the predicted scores were unable to classify individuals with 25(OH)D 
levels ≥75 nmol, this association could not be investigated in the current analysis. 
 
Brain cancer 
A suggestive inverse association was observed for predicted 25(OH)D and brain cancer 
incidence, with a near significance inverse trend (P-trend 0.05) observed for women. The 
only previous prospective study reported a non-significant positive association using a 
predicted 25(OH)D score in the HPFS study (52). For brain cancer mortality, no association 
was observed. 
 
Skin cancer 
The positive association observed between predicted 25(OH)D and skin cancer incidence 
was consistent with a HPFS analysis which also used predicted 25(OH)D levels (52). The 
vitamin D-skin cancer relationship is likely to be confounded by sun exposure habits. 
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Detailed information on sun exposure behaviours was not available within EPIC. As sun 
exposure habits/behaviours would likely be a positive confounder, the observed positive skin 
cancer association would be expected to disappear or attenuate after adjustment for these 
factors. However, that a positive association was observed suggests that the predicted 
25(OH)D scores may be an acceptable surrogate measure of vitamin D status. 
 
Thyroid cancer 
No previous studies have investigated the relationship between vitamin D and thyroid 
cancer. Therefore the 50% lower thyroid cancer incidence risk (95% CI: 0.50-0.97) observed 
per 25 nmol/L increment in predicted 25(OH)D levels is a novel finding. However, this 
association in the sexes combined continuous model should be interpreted cautiously. 
Firstly, this analysis included just 325 thyroid cancer cases. Secondly, in sensitivity analyses, 
the association attenuated and became non-significant when the multivariable model was 
not adjusted for BMI; suggesting that the association may be an artefact of confounding 
and/or statistical over-adjustment. Despite this, the results highlight a possible role for 
vitamin D on thyroid carcinogenesis. In this scenario, the predictor scores have acted as a 
hypothesis generator and flagged up a possible exposure-endpoint relationship where future 
resources may be focussed; specifically, nested case-control studies which measure actual 
circulating 25(OH)D levels. 
 
Prostate cancer 
As was revealed during the predictor scores validation stage, a non-significant positive 
association was observed for prostate cancer incidence. The vast majority of prostate cancer 
nested case-control studies which measured circulating 25(OH)D have yielded null or non-
significant positive associations (86-95), although three recent Nordic nested case-control 
studies have observed significant positive associations (37-39). For prostate cancer 
mortality, the observed inverse association is consistent with a recent HPFS nested case-
control analysis which reported a 57% reduced risk (95% CI: 0.24-0.76) when the highest 
quartile of pre-diagnosis circulating 25(OH)D was compared with the lowest quartile (102). 
Within EPIC, a 50% reduced risk was observed for the equivalent comparison of pre-
diagnosis predicted 25(OH)D quintiles. However, this inverse association should be 
interpreted cautiously. First, only 228 prostate cancer deaths were included within the 
analysis, meaning that this association could be due to chance. Second, residual 
confounding from unmeasured factors may have impacted upon this association. 
Specifically, failure to control for screening from prostate-specific antigen (PSA) testing may 
have biased the results; however within the HPFS analysis, virtually unchanged associations 
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were observed even after adjustment for PSA screening occurrence and frequency (102). 
Overall, larger pooled studies with an increased number of recorded deaths, plus information 
on PSA screening and treatments, are required to confirm the potential beneficial role of 
vitamin D on prostate cancer mortality. 
 
Breast cancer 
Similarly to the recently published EPIC nested case-control analysis using actual circulating 
measurements (117), a null result was also observed for the predicted 25(OH)D-breast 
cancer incidence relationship. A similar null result was also observed for breast cancer 
mortality. All but two (110;111) previous prospective nested case-control studies which 
measured actual circulating 25(OH)D levels have similarly reported no association for breast 
cancer incidence (110;112-117). Although a meta-analysis of these studies (excluding the 
EPIC nested case-control study which was the largest to date) reported an inverse 
association which was of borderline significance (highest vs. lowest circulating 25(OH)D 
quintiles pooled OR 0.87, 95% CI: 0.77-0.99) (118). However, when updating the meta-
analysis calculation, the inclusion of the EPIC nested case-control study risk estimate 
(highest vs. lowest 25(OH)D quintiles pooled meta-analysis OR 0.92, 95% CI: 0.80-1.06) or 
the risk estimate using the predicted 25(OH)D score (highest vs. lowest 25(OH)D quintiles 
pooled meta-analysis OR 0.92, 95% CI: 0.82-1.02) resulted in this association weakening 
and losing significance. Overall, the largely null prospective evidence is contrary to case-
control evidence which have usually reported inverse associations, most likely due to 
reverse causality bias. The National Cancer Institute Cohort Consortium of more than 40 
studies, is currently undertaking a pooled analysis of the actual circulating 25(OH)D-breast 
cancer relationship. This analysis will have sufficient power to analyse the associations by 
breast cancer subtype (ER- and ER+) and by menopausal status, which may provide further 
insights into the relationship. 
 
Ovarian and endometrial cancers 
The null result observed between predicted 25(OH)D levels and incidence of ovarian cancer 
is consistent with previous prospective analyses (143;144). For endometrial cancer, no 
association was observed in the multivariable models (HR per 25 nmol/L increment in 
predicted 25(OH)D, 0.92, 95% CI: 0.63-1.35). However, in sensitivity analysis, when the 
multivariable model was not adjusted for BMI, a strong significant inverse association was 
observed (64% lower risk per 25 nmol/L increment in predicted 25(OH)D). BMI is an 
established risk factor for endometrial cancer with a recent meta-analysis of 24 studies 
reporting a 1.6-fold higher risk per 5 kg/m2 increment of BMI (191). This sensitivity of the 
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predicted 25(OH)D-endometrial cancer relationship to BMI adjustment suggests that the 
association may be an artefact of confounding and/or statistical over-adjustment. This 
association should therefore be interpreted cautiously. 
 
 
4.3.2 All-cause and cause-specific mortality 
 
All-cause mortality 
The inverse all-cause mortality association observed for predicted 25(OH)D is consistent 
with most previous research where similar linear associations have been observed 
(59;61;63;64;147;149-151). Within this current analysis, a significant linear inverse 
association was observed for men and women, for all countries, and across strata of all 
lifestyle, demographic, anthropometric, and dietary variables considered. The observational 
evidence indicating a beneficial role for vitamin D against deaths from all-causes has been 
supported by a meta-analysis of 18 smaller trials which reported a significant RR of 0.93 
(95% CI: 0.87-0.99) for participants who received vitamin D supplements (153).  
 
Despite this seemingly convincing evidence for a beneficial effect of vitamin D against all-
cause mortality, three recent prospective observational studies have reported J- or U-shaped 
25(OH)D-all-cause deaths relationships, with increased risks at higher levels (33-35). Within 
these analyses, elevated all-cause mortality risks were observed for those individuals with 
actual 25(OH)D levels ranging from >93-140 nmol/L, when compared against mid-range 
reference groups (33-35). Whether these associations are true or an artefact of other 
unmeasured criteria remains unclear. Due to the predicted scores yielding poor absolute 
25(OH)D estimates, this analysis was unable to investigate whether higher 25(OH)D levels 
were correlated with higher mortality risks. Larger observational studies which measure 
actual circulating 25(OH)D are required to investigate any possible adverse effects of higher 
levels of vitamin D.  
 
Circulatory disease mortality 
This was the largest study to date (n=3,641 deaths) to investigate the vitamin D-circulatory 
disease mortality relationship. Previous prospective studies, which measured actual 
circulating 25(OH)D levels, have been smaller, with only two having more than 1,000 
recorded circulatory disease deaths. Within these studies linear inverse associations have 
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usually been observed, with a recent meta-analysis of 18 prospective studies reporting a 
21% reduced vascular mortality risk when the highest and lowest quartiles of actual 
circulating 25(OH)D were compared (61). The inverse association observed in the current 
EPIC study was present for men and women, across all countries and strata of all lifestyle, 
demographic, anthropometric, and dietary variables considered. The inverse relationship 
was also similar for ischaemic heart disease and cerebrovascular disease deaths. The 
totality of the observational evidence is indicative of possible role for vitamin D in reducing 
circulatory disease deaths. However, these observed inverse correlations require verification 
in RCTs.  
 
Respiratory disease and digestive disease mortality 
Remarkably strong inverse associations were observed for respiratory disease and digestive 
disease mortality, especially in the continuous models (88% and 89% lower risks observed 
respectively per 25 nmol/L increment in predicted 25(OH)D). Although for respiratory 
disease, this association weakened but remained strong and significant when the 
multivariable model was not adjusted for BMI (62% lower risk per 25 nmol/L increment in 
predicted 25(OH)D). The inverse respiratory disease mortality relationship is consistent with 
the three previous prospective studies that have investigated the association using actual 
circulating 25(OH)D measurements (59;61;62). Similarly, for digestive disease mortality, the 
inverse association observed was consistent with the one previous prospective analysis, 
where a 72% reduced risk was observed when the highest and lowest quartiles of actual 
25(OH)D were compared (62). Plausible biological mechanisms for vitamin D on digestive 
and respiratory diseases include: acting as an anti-inflammatory and anti-fibrosis agent; plus 
elevated antiviral response (158;192).  
 
Despite this biological plausibility, other explanations for the inverse associations observed 
should be considered. For instance, reverse causality may explain part of the inverse 
associations observed. The results may be biased by pre-clinical disease at baseline 
influencing the correlates/determinants of 25(OH)D included within the predictor scores. The 
result of which may be an artificially elevated disease risk observed amongst individuals with 
lower predicted 25(OH)D levels. However, in sensitivity analyses, similar strength 
associations were observed when individuals whose follow-up time was less than 5 years 
were excluded. While when the analyses were limited to individuals who self-reported being 
in ‘excellent’ or ‘good’ health at baseline, similar inverse associations were observed. Thus, 
although part of the inverse associations may be caused by reverse causality, the sensitivity 
analyses conducted were unsupportive of this possibility. A further explanation for the 
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unrealistically strong inverse associations observed maybe that the predictor scores provide 
an indicator of ‘good general health’ rather than estimating vitamin D levels. This is because 
having higher predicted 25(OH)D levels was associated with having a lower BMI, drinking 
less alcohol, and being younger and physically active. However, this supposition is also 
relevant for actual 25(OH)D measurements which also intrinsically incorporate these factors.  
 
Overall, few previous studies have investigated the vitamin D-respiratory disease and 
digestive disease mortality associations. The results from this current analysis are indicative 
of strong biological roles for vitamin D on respiratory disease and digestive disease mortality. 
Further large studies with sufficient cases and longer follow-up times are required to validate 
and scrutinise these relationships.  
 
 
4.3.3 Strengths and limitations 
 
Strengths 
 
Large prospective cohort with low losses to follow-up 
This was the largest study to date to derive and apply predicted 25(OH)D scores to 
investigate the vitamin D-cancer incidence and mortality, all-cause mortality and cause-
specific mortality relationships. The large number of participants and recorded endpoints 
(cases/deaths) meant that these associations could be investigated thoroughly. Participants 
were predominantly sourced from the general population, and comprehensive cohort follow-
up by each of the participating study centres ensured low losses to follow-up (<2%) (193).   
 
Variability and detail of exposure information 
The current analysis contained participants from eight European countries, within which wide 
exposure ranges for dietary and lifestyle variables were recorded. Participants were resident 
in northern to southern European countries at differing latitudes, and with heterogeneous 
dietary and lifestyle habits. At baseline extensive dietary, lifestyle, demographic, health, and 
anthropometric information was collected from all participants (168). For this analysis it 
meant that thorough examination of all possible factors which may confound predicted 
25(OH)D levels and the multiple end-points considered could be investigated. 
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Limitations 
 
Reverse causality 
Participants experiencing pre-clinical disease symptoms at baseline may have had as a 
consequence a lower waist circumference/BMI, lower dietary intakes and physical activity 
levels. As a result, such individuals would have lower predicted 25(OH)D levels, thus 
artificially increasing the chronic disease incidence/mortality risks amongst these 
participants. However, participants who self-reported previous ill-health at baseline (i.e. 
cancer, heart disease, stroke, and diabetes) were excluded from the mortality analyses. 
Further, similar all-cause and cause-specific mortality associations were observed when the 
analyses were limited to those individuals who self-reported being in ‘excellent’ or ‘good’ 
health at baseline. Finally, all of the observed associations remained stable after 
cases/deaths recorded within the first five years of follow-up were excluded. Taken together, 
although reverse causality cannot be ruled out the sensitivity analyses revealed no evidence 
that the observed associations were caused by this. 
 
Residual confounding 
Although detailed information on possible confounding factors was collected from all 
participants at baseline, as with all epidemiological research, the observed relationships 
could be biased by residual confounding from unmeasured/poorly measured factors, or the 
inability of the statistical models to capture complex interrelationships between exposure 
variables. For instance, information on cancer screening was unavailable, which may have 
meant that the observed inverse cancer mortality associations are merely an artefact of 
individuals with higher predicted 25(OH)D levels undergoing screening earlier, and as a 
consequence early stage treatable tumours being identified.  
 
Predicted vitamin D scores may also be especially sensitive to residual confounding and/or 
statistical over-adjustment as the correlates/determinants of 25(OH)D used at the derivation 
stage may also be confounders when assessing the risks of chronic disease incidence and 
mortality. Within this analysis, separate risk estimates were presented for the multivariable 
model minus BMI adjustment, plus physical activity index adjustment. For the results where 
large disparity between models with or without these adjustments was identified (lung cancer 
incidence and mortality; stomach and oesophageal cancer incidence; liver cancer incidence; 
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thyroid cancer incidence; endometrial cancer incidence; and respiratory disease mortality), 
the observed associations should be interpreted with caution due to this instability. 
 
Different exposure assessment methods used 
The multi-centre design of EPIC meant that different exposure assessment methods were 
used. For instance, diet was measured face-to-face in Greece using a quantitative dietary 
assessment questionnaire with 254 food items (168). In contrast, in Norway diet, was 
measured by a self-administered semi-quantitative food frequency questionnaire containing 
88 food items (168). Similarly, there were differences between EPIC centres in the 
measurement of anthropometric measurements. In the majority of centres a similar protocol 
was used as anthropometric measurements were measured at baseline. However, in the 
France and Oxford (UK) centres these measurements were self-reported (168). Although 
substantial efforts have been undertaken to standardise exposures across countries/centres 
(170;194), the possibility exists that extraneous measurement error may have been 
introduced by the variable methods used.   
 
End-point information collected differently across countries/centres 
Cancer registries are used to identify cases during follow-up in Denmark, Italy, the 
Netherlands, Norway, Spain, Sweden and the UK (168). In the remaining countries (France, 
Germany and Greece) a combination of methods are used to identify cases, including: 
health insurance records, cancer and pathology registries and through active follow-up of 
participants and their next-of-kin (168). These differences in recording cancer cases may 
have meant that diagnoses may be underreported in some countries which may have 
influenced the observed results. 
 
Multiple end-points and chance associations 
Within this study 36 incidence and mortality end-points were considered (not including 
subgroup analyses across strata of other dietary, lifestyle, demographic and anthropometric 
factors). Due to these multiple analyses several false-positive or chance associations would 
be expected to be observed (P-value of <0.05). 
 
Generalizabilty to non-Caucasian populations 
Although this information was not formally collected, EPIC is thought to consist of Caucasian 
participants only. This means that the observed associations may not be applicable to other 
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racial/ethnic groups. However, this also means that the study results are unlikely to be 
confounded by ethnicity/race, which is an important determinant of vitamin D status. 
 
Post-diagnosis exposures unknown 
For the cause-specific mortality analyses, the derived scores were based on pre-diagnosis 
information, meaning that any post-diagnosis changes in dietary and lifestyle habits were 
unknown. Within the predictor scores, pre-diagnosis physical activity index (included in the 
predictor models as a proxy measurement of sun exposure) was an important 
correlate/determinant of circulating 25(OH)D levels. Evidence from the UK and U.S. has 
shown that physical activity levels reduce in cancer patients post-diagnosis (195;196). Such 
a reduction would be expected to lower predicted 25(OH)D levels, although whether such 
changes occurred within EPIC is unknown.  
 
Information on post-diagnosis therapeutic treatments is also unknown in EPIC. The 
possibility exists that individuals with higher predicted 25(OH)D levels may have been more 
likely to undergo effective treatment earlier, and as a consequence had better disease 
prognosis and a lower mortality risk. Within EPIC, higher predicted 25(OH)D levels were 
correlated with younger age and higher educational level attained (in women). For cancer, 
evidence has shown that the likelihood of individuals to accept screening and chemotherapy 
treatment is higher amongst those with higher incomes, educations and social class 
(197;198). Furthermore, older age has previously been associated as a risk factor for a 
poorer standard of cancer treatment (197).  
 
Across the multiple European countries included within EPIC, clinical practices and 
treatments may have differed which may have introduced bias into the observed results. In 
an attempt, to partially adjust for this inter-country heterogeneity, all models were stratified 
by study centre. Similarly, during the 12 years of follow-up time treatments may also have 
changed within countries; although the mortality associations observed were generally stable 
throughout the follow-up period. 
 
Subtypes of diseases not considered 
The endpoints considered were for overall incidence/mortality for a certain type of 
cancer/chronic disease. This is likely to be an oversimplification, as increasing aetiological 
heterogeneity has been identified between subtypes of the same cancer. For instance, 
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previous EPIC analyses have often reported heterogeneous associations with various risk 
factors by colorectal cancer sub-site. For example, reduced risk of proximal colon cancer 
has been observed amongst physically active participants when compared against inactive 
participants; but no association was observed for distal colon and rectal cancers (199). 
Similarly, an inverse dietary fibre association was observed for proximal colon and rectal 
cancers, but not distal colon cancers (200). For breast cancer, a recent pooled analysis 
which included just under 1 million women reported inverse fruit and vegetable associations 
for ER-, but not ER+ tumours (201). The analyses included within this current EPIC study 
should therefore be considered as hypothesis generating, with more thorough disease 
subtype investigations being undertaken in future analyses. 
 
 
4.3.3 Conclusion 
 
In this comprehensive prospective analysis, higher predicted circulating 25(OH)D levels 
were associated with lower risks of: overall cancer incidence and mortality; colorectal cancer 
incidence; lung cancer incidence and mortality; kidney cancer incidence; stomach and 
oesophageal cancer incidence; pancreatic cancer incidence and mortality; thyroid cancer 
incidence; prostate cancer mortality; all-cause mortality; circulatory disease mortality; 
respiratory disease mortality; and digestive disease mortality. Many of these end-points have 
not previously been correlated with vitamin D levels, so these results provide indicators for 
future research on these diseases. However, care should be taken when interpreting these 
results due to the methodological limitations of observational research and of using predicted 
25(OH)D scores.  
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4.4 Future research  
 
Despite biological plausibility and a substantial amount of research, whether vitamin D 
reduces the incidence and mortality of certain chronic diseases - in particular cancer - 
remains uncertain. The predictor score results within this study provide new lines of inquiry 
for possible biological roles, in particular the inverse associations observed for thyroid 
cancer incidence, kidney cancer incidence, respiratory disease mortality and digestive 
disease mortality. Further observational research where predicted or actual 25(OH)D levels 
are measured is warranted to investigate these relationships. Additional prospective 
research is also required to scrutinise the elevated risks of all-cause mortality (33-35), 
overall cancer incidence (35;36), prostate cancer incidence (37-39), and pancreatic cancer 
incidence (40) observed at higher levels of actual circulating 25(OH)D which have previously 
been reported. These future analyses should measure actual circulating 25(OH)D levels, as 
predicted 25(OH)D scores have been shown to be poor at estimating absolute vitamin D 
levels.  
 
The inverse associations observed for colorectal cancer incidence and circulatory disease 
mortality in this current analysis are consistent with the majority of previous prospective 
analyses. However, within an observational setting causality cannot be ascertained. A 
concern of measuring actual or predicted 25(OH)D levels is whether they are indicators of 
actual vitamin D levels or general “good health”. Within EPIC, higher 25(OH)D levels were 
correlated with having a lower BMI, being younger and physically active, and reporting lower 
intakes of alcohol. Despite multivariable adjustments, residual confounding by these or other 
unmeasured factors may have caused the observed inverse associations. 
 
Large RCTs are required to confirm these seemingly protective associations. In the U.S. one 
such intervention, called the VITamin D and OmegA-3 TriaL (VITAL) has just begun (202). 
For this double blind trial, 20,000 healthy men and women aged over 50 years have been 
recruited, half of whom will be receive 50 µg/day of vitamin D3, with the remainder of 
participants receiving a placebo. The expected mean treatment period will be for 5 years and 
primary end-points considered are cancer and cardiovascular disease. Although RCTs are 
viewed as the highest form of evidence to prove a causal relationship, they are not without 
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limitations. Firstly, the previous WHI RCT - in which the intervention group were 
administered 10 µg of vitamin D plus 1 g of elemental calcium each day – was criticised for 
the 7 year trial duration being too short a time period for vitamin D to influence colorectal 
cancer occurrence (79;80), suggesting that the 5 year intervention within the VITAL study 
may be inadequate. Secondly, as nutritional supplements are freely available, there is a risk 
of individuals within the placebo group taking non-study supplements, and as a 
consequence the contrast in vitamin D levels with the intervention group may be too low to 
detect any effect. Finally, rarer outcomes cannot be captured with enough frequency to 
deduce any possible vitamin D effect.  
 
An alternative approach, which may provide further indications of causal relationships, is to 
conduct suitably powered Mendelian randomisation analyses. Theodoratou et al., (203) 
carried out one such analysis for colorectal cancer in a Scottish study containing 2,001 
cases and 2,237 controls. In this analysis, as compared to homozygotes of the respective 
wild-type allele, carriers of a variant allele of the SNPs rs2282679 and rs12785878 were 
significantly associated with circulating 25(OH)D levels. The SNP rs2282679 is located in the 
gene which encodes a vitamin D binding protein that binds and transports vitamin D; while 
rs12785878 is located in a gene which encodes the enzyme 7-dehydrocholesterol 
reductase. Although neither of these SNPs (instrumental variables) was subsequently 
associated with colorectal cancer risk, this may have been the result of insufficient statistical 
power, which is a common pitfall of this study design (203). However, more recent evidence 
from a much larger pooled study of 10,061 cases and 12,768 controls from 13 studies also 
failed to observe relationships between these two SNPs and colorectal cancer risk (204). 
This analysis additionally investigated whether three other polymorphisms which have been 
associated with circulating 25(OH)D levels were related to colorectal cancer risk. These 
were the SNPs rs10741657 (located near the CYP2R1 gene), rs11234027 (located in a 
gene which encodes the enzyme 7-dehydrocholesterol reductase) and rs6013897 (located 
near the CYP24A1 gene). Similarly, none of these additional SNPs were associated with 
colorectal cancer risk. Within this pooled analysis just 5% of the variance in circulating 
25(OH)D levels was explained by these studied SNPs (204). Thus, the possibility exists that 
even this large pooling study may have been underpowered to detect an association. An 
alternative interpretation is that the vitamin D-colorectal cancer relationship reported in 
observational studies is non-causal. Overall, this recent evidence highlights the importance 
of ongoing RCTs to provide insights into whether the vitamin D-cancer relationship is more 
cause-effect than correlation. 
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5. CONCLUSION 
 
For the first time in a European population, predictor 25(OH)D scores were derived, 
validated and applied to the full EPIC cohort to assess the relationships with cancer 
incidence and mortality, circulatory disease mortality, respiratory disease mortality, digestive 
disease mortality and all-cause mortality. Significant inverse predicted 25(OH)D score 
associations were observed for: overall cancer incidence and mortality; colorectal cancer 
incidence; lung cancer incidence and mortality; kidney cancer incidence; stomach and 
oesophageal cancer incidence; pancreatic cancer incidence and mortality; thyroid cancer 
incidence; prostate cancer mortality; all-cause mortality; circulatory disease mortality; 
respiratory disease mortality; and digestive disease mortality. However, due to the 
methodological limitations specific to 25(OH)D predictor scores, and observational 
epidemiology in general, it is important to acknowledge that alternative explanations may 
explain some or all of these observed relationships. Nevertheless, the associations observed 
provide possible evidence for a beneficial role for vitamin D and the rarer outcomes have 
flagged up possible, previously unreported, relationships. Going forward, results from a 
recently begun VITAL RCT will hopefully provide insights into whether the vitamin D-
cancer/circulatory disease relationships are causal, rather than mere correlations. 
 
 
 
 
 
 
 
 
 
 
206 
 
 
6. APPENDIX 
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Table A1. Risk (hazard ratios) of cancer incidence amongst men and women with and 
without adjustment for body mass index associated with a 25 nmol/L increment in predicted 
25-hydroxyvitamin D level 
 
Multivariable Model Multivariable Model
Minus BMI adjustment
Men
Women
Overall cancer incidence
Both sexes
Multivariable model - HR (95% CI) ‡ 0.87 (0.80-0.92) 0.85 (0.80-0.91)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.92 (0.84-1.01) 0.89 (0.82-0.95)
Digestive system cancer incidence
Both sexes
Multivariable model - HR (95% CI) ‡ 0.63 (0.52-0.76) 0.63 (0.54-0.73)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.61 (0.48-0.77) 0.62 (0.51-0.74)
Non-digestive system cancer incidence
Both sexes
Multivariable model - HR (95% CI) ‡ 0.92 (0.85-0.99) 0.90 (0.84-0.96)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.99 (0.90-1.09) 0.94 (0.87-1.02)
Smoking related cancer incidence
Both sexes
Multivariable model - HR (95% CI) ‡ 0.65 (0.56-0.74) 0.71 (0.64-0.80)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.69 (0.58-0.82) 0.77 (0.68-0.89)
Non-smoking related cancer incidence
Both sexes
Multivariable model - HR (95% CI) ‡ 0.98 (0.89-1.07) 0.91 (0.84-0.98)
Multivariable model + physical activity adj - HR (95% CI) ɸ 1.03 (0.93-1.14) 0.92 (0.85-1.00)
Colorectal cancer  
Both sexes
Multivariable model - HR (95% CI) † ¥ 0.75 (0.57-0.97) 0.62 (0.50-0.78)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.83 (0.59-1.15) 0.63 (0.49-0.83)
Lung cancer
Both sexes
Multivariable model - HR (95% CI) † 0.64 (0.49-0.84) 1.01 (0.81-1.26)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.77 (0.55-1.08) 1.31 (1.02-1.68)
Kidney cancer
Both sexes
Multivariable model - HR (95% CI) † 0.47 (0.28-0.79) 0.42 (0.27-0.64)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.47 (0.24-0.92) 0.40 (0.24-0.67)
Stomach & oesophageal cancer
Both sexes
Multivariable model - HR (95% CI) † 0.60 (0.39-0.94) 0.74 (0.51-1.07)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.53 (0.30-0.94) 0.74 (0.48-1.16)
Bladder cancer
Both sexes
Multivariable model - HR (95% CI) † 0.89 (0.62-1.28) 0.83 (0.61-1.13)
Multivariable model + physical activity adj - HR (95% CI) ɸ 1.11 (0.70-1.75) 0.93 (0.63-1.36)
Pancreatic cancer
Both sexes
Multivariable model - HR (95% CI) † 0.52 (0.32-0.84) 0.51 (0.34-0.77)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.50 (0.27-0.94) 0.50 (0.31-0.81)
Liver cancer
Both sexes
Multivariable model - HR (95% CI) † 0.80 (0.41-1.43) 0.52 (0.31-0.87)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.69 (0.31-1.51) 0.42 (0.23-0.79)
Non-Hodgkin's lymphoma
Both sexes
Multivariable model - HR (95% CI) † 0.87 (0.54-1.43) 0.85 (0.57-1.28)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.81 (0.44-1.48) 0.80 (0.49-1.29)
Brain cancer
Both sexes
Multivariable model - HR (95% CI) † 0.77 (0.49-1.22) 0.72 (0.50-1.05)
Multivariable model + physical activity adj - HR (95% CI) ɸ 1.01 (0.59-1.72) 0.85 (0.55-1.32)
Skin cancer
Both sexes
Multivariable model - HR (95% CI) † 1.26 (1.00-1.60) 1.40 (1.16-1.69)
Multivariable model + physical activity adj - HR (95% CI) ɸ 1.20 (0.89-1.61) 1.39 (1.12-1.72)
Thyroid cancer
Both sexes
Multivariable model - HR (95% CI) † 0.50 (0.26-0.97) 0.69 (0.41-1.15)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.61 (0.27-1.36) 0.83 (0.46-1.51)
Prostate cancer
Men
Multivariable model - HR (95% CI) † 1.12 (0.86-1.47) 1.02 (0.80-1.30)
Multivariable model + physical activity adj - HR (95% CI) ɸ 1.30 (0.91-1.85) 1.08 (0.78-1.49)
Breast cancer
Women
N cases
Multivariable model - HR (95% CI) † ¶ 1.02 (0.89-1.17) 0.95 (0.85-1.06)
Multivariable model + physical activity adj - HR (95% CI) ɸ 1.12 (0.96-1.31) 0.99 (0.88-1.12)
Ovarian cancer
Women
N cases
Multivariable model - HR (95% CI) † ¶ 1.25 (0.85-1.85) 0.99 (0.71-1.36)
Multivariable model + physical activity adj - HR (95% CI) ɸ 1.22 (0.77-1.93) 0.93 (0.65-1.33)
Endometrial cancer
Women
N cases
Multivariable model - HR (95% CI) † ¶ 0.92 (0.63-1.35) 0.36 (0.27-0.49)
Multivariable model + physical activity adj - HR (95% CI) ɸ 0.83 (0.53-1.30) 0.28 (0.20-0.40)
Per 25 nmol/L increase Per 25 nmol/L increase
Both sexes
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†  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per 
day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary 
calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre.  
¥  Multivariable model – plus adjustment for cereal fibre intake (g/day). 
¶  Multivariable model – plus adjustment for age at first pregnancy (<21; 21-<30; 30+ years old; no children; or not specified); and age at 
menarche (<12; 12-<15; 15+ years old; or not specified). 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
BMI=body mass index. 
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Table A2. Risk (hazard ratios) of all-cause and cause-specific mortality amongst men and 
women with and without adjustment for body mass index associated with a 25 nmol/L 
increment in predicted 25-hydroxyvitamin D level 
 
†  Multivariable model - Cox regression using body mass index (<22; 22-<25; 25-<30; 30-<35; 35+ kg/m
2
), education status (none; primary school 
completed; technical/professional school; secondary school; longer education including university; or not specified), alcohol consumption (non-
consumers; <5; 5-<15; 15-<30; 30+ g/day), smoking status and intensity (never; current , 1-15 cigarettes per day; current, 16-25 cigarettes per 
day; current, 16+ cigarettes per day; former, quit ≤10 years; former, quit 11-20 years; former, quit 20+ years; current, pipe/cigar/occasional; 
current/former, missing; unknown); smoking duration (<10; 10-<20; 20-<30; 30-<40; 40+ years; smoking duration unknown); ever use of 
contraceptive pill (yes; no; or unknown), menopausal status (premenopausal; postmenopausal; perimenopausal/unknown menopausal status; or 
surgical postmenopausal), and intakes of total energy (kcal/day), red and processed meat (g/day), fruits and vegetables (g/day), and dietary 
calcium (mg/day) (all continuous), and stratified by age (1-year categories), sex, and centre.  
¥  Multivariable model – plus adjustment for cereal fibre intake (g/day). 
¶  Multivariable model – plus adjustment for age at first pregnancy (<21; 21-<30; 30+ years old; no children; or not specified); and age at 
menarche (<12; 12-<15; 15+ years old; or not specified). 
ɸ  Multivariable model - plus adjustment for physical activity index (inactive; moderately inactive; moderately active; active). 
BMI=body mass index. 
  
Multivariable Model Multivariable Model
Minus BMI adjustment
Men
Women
Total all-cause mortality
Both sexes
Multivariable model - HR (95% CI) † 0.48 (0.43-0.53) 0.52 (0.48-0.57)
Multivariable model + physical activity adj - HR (95% CI) 0.57 (0.50-0.64) 0.61 (0.56-0.67)
Cancer (C00-D48)
Both sexes
Multivariable model - HR (95% CI) † 0.65 (0.56-0.75) 0.72 (0.64-0.82)
Multivariable model + physical activity adj - HR (95% CI) 0.69 (0.57-0.83) 0.78 (0.68-0.91)
Circulatory diseases (I00-I99)
Both sexes
Multivariable model - HR (95% CI) † 0.39 (0.31-0.48) 0.30 (0.25-0.36)
Multivariable model + physical activity adj - HR (95% CI) 0.43 (0.33-0.58) 0.30 (0.24-0.38)
Respiratory diseases (J30-J98)
Both sexes
Multivariable model - HR (95% CI) † 0.12 (0.07-0.21) 0.38 (0.25-0.59)
Multivariable model + physical activity adj - HR (95% CI) 0.28 (0.14-0.55) 0.94 (0.57-1.56)
Digestive diseases (K00-K93)
Both sexes
Multivariable model - HR (95% CI) † 0.11 (0.06-0.20) 0.15 (0.09-0.24)
Multivariable model + physical activity adj - HR (95% CI) 0.19 (0.09-0.40) 0.24 (0.14-0.42)
External causes (S00-Y98)
Both sexes
Multivariable model - HR (95% CI) † 0.84 (0.53-1.33) 1.13 (0.77-1.65)
Multivariable model + physical activity adj - HR (95% CI) 0.75 (0.42-1.35) 1.17 (0.75-1.83)
Digestive system cancers *
Both sexes
Multivariable model - HR (95% CI) † 0.67 (0.49-0.91) 0.64 (0.49-0.82)
Multivariable model + physical activity adj - HR (95% CI) 0.70 (0.48-1.03) 0.65 (0.48-0.88)
Non-digestive system cancers *
Both sexes
Multivariable model - HR (95% CI) † 0.64 (0.54-0.76) 0.75 (0.65-0.87)
Multivariable model + physical activity adj - HR (95% CI) 0.68 (0.55-0.84) 0.83 (0.70-0.98)
Smoking related cancers *
Both sexes
Multivariable model - HR (95% CI) † 0.62 (0.51-0.77) 0.77 (0.65-0.91)
Multivariable model + physical activity adj - HR (95% CI) 0.67 (0.51-0.87) 0.86 (0.70-1.05)
Non-smoking related cancers *
Both sexes
Multivariable model - HR (95% CI) † 0.68 (0.55-0.85) 0.67 (0.56-0.80)
Multivariable model + physical activity adj - HR (95% CI) 0.72 (0.55-0.93) 0.70 (0.56-0.86)
Colorectal cancer (C18-C20)
Both sexes
Multivariable model - HR (95% CI) † ¥ 0.76 (0.44-1.32) 0.69 (0.43-1.09)
Multivariable model + physical activity adj - HR (95% CI) 1.00 (0.52-1.94) 0.81 (0.47-1.39)
Pancreatic cancer (C25)
Both sexes
Multivariable model - HR (95% CI) † 0.58 (0.34-0.99) 0.51 (0.33-0.79)
Multivariable model + physical activity adj - HR (95% CI) 0.65 (0.33-1.25) 0.52 (0.31-0.88)
Lung cancer (C34)
Both sexes
Multivariable model - HR (95% CI) † 0.76 (0.55-1.05) 1.22 (0.94-1.58)
Multivariable model + physical activity adj - HR (95% CI) 0.91 (0.61-1.36) 1.55 (1.17-2.07)
Prostate cancer (C61)
Both sexes
Multivariable model - HR (95% CI) † 0.32 (0.12-0.84) 0.31 (0.13-0.73)
Multivariable model + physical activity adj - HR (95% CI) 0.25 (0.05-1.18) 0.26 (0.08-0.89)
Breast cancer (C50)
Both sexes
Multivariable model - HR (95% CI) † ¶ 0.74 (0.46-1.19) 0.69 (0.41-1.09)
Multivariable model + physical activity adj - HR (95% CI) 0.95 (0.55-1.63) 0.77 (0.54-1.13)
Per 25 nmol/L increase Per 25 nmol/L increase
Both sexes
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